phbi_10q.htm

0001477932-21-005724.txt : 20210818 0001477932-21-005724.hdr.sgml : 20210818 20210818164636 ACCESSION NUMBER: 0001477932-21-005724 CONFORMED SUBMISSION TYPE: 10-Q PUBLIC DOCUMENT COUNT: 50 CONFORMED PERIOD OF REPORT: 20210630 FILED AS OF DATE: 20210818 DATE AS OF CHANGE: 20210818 FILER: COMPANY DATA: COMPANY CONFORMED NAME: Pharmagreen Biotech Inc. CENTRAL INDEX KEY: 0001435181 STANDARD INDUSTRIAL CLASSIFICATION: AIRPORTS, FLYING FIELDS & AIRPORT TERMINAL SERVICES [4581] IRS NUMBER: 980491567 STATE OF INCORPORATION: NV FISCAL YEAR END: 0930 FILING VALUES: FORM TYPE: 10-Q SEC ACT: 1934 Act SEC FILE NUMBER: 000-56090 FILM NUMBER: 211187189 BUSINESS ADDRESS: STREET 1: 2987 BLACKBEAR COURT CITY: COQUITLAM STATE: A1 ZIP: V3E3A2 BUSINESS PHONE: 702-803-9404 MAIL ADDRESS: STREET 1: 2987 BLACKBEAR COURT CITY: COQUITLAM STATE: A1 ZIP: V3E3A2 FORMER COMPANY: FORMER CONFORMED NAME: Air Transport Group Holdings, Inc. DATE OF NAME CHANGE: 20081106 FORMER COMPANY: FORMER CONFORMED NAME: Azure International, Inc. DATE OF NAME CHANGE: 20080515 10-Q 1 phbi_10q.htm FORM 10-Q phbi_10q.htm

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 10-Q

☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the quarterly period ended June 30, 2021

☐ TRANSITION REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the transition period from __________ to __________

000-56090

Commission File Number

PHARMAGREEN BIOTECH INC.

(Exact name of registrant as specified in its charter)

Nevada

98-0491567

(State or other jurisdiction of

incorporation or organization)

(I.R.S. Employer

Identification No.)

2987 Blackbear Court, Coquitlam, British Columbia BC		V3E 3A2
(Address of principal executive offices)		(Zip Code)

702-803-9404

(Registrant’s telephone number, including area code)

Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. ☒ Yes ☐ No

Indicate by check mark whether the registrant has submitted electronically and posted on its corporate Web site, if any, every Interactive Data File required to be submitted and posted pursuant to Rule 405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit and post such files). ☐ Yes ☐ No

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, or a smaller reporting company. See the definitions of “large accelerated filer,” “accelerated filer” and “smaller reporting company” in Rule 12b-2 of the Exchange Act:

Large accelerated filer	☐	Non-accelerated filer	☐
Accelerated filer	☐	Smaller reporting company	☒
		Emerging Growth	☒

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act ☒

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). ☐ Yes ☒ No

APPLICABLE ONLY TO ISSUERS INVOLVED IN BANKRUPTCY PROCEEDINGS DURING THE PRECEDING FIVE YEARS

Indicate by check mark whether the registrant has filed all documents and reports required to be filed by Sections 12, 13 or 15(d) of the Securities Exchange Act of 1934 subsequent to the distribution of securities under a plan confirmed by a court. ☐ Yes ☐ No

APPLICABLE ONLY TO CORPORATE ISSUERS:

Indicate the number of shares outstanding of each of the issuer’s classes of common stock, as of the latest practicable date. As of August 12, 2021, we had 355,831,269 shares of common stock issued and outstanding.

TABLE of CONTENTS

	PART I—FINANCIAL INFORMATION
Item 1.	Financial Statements.	3
Item 2.	Management’s Discussion and Analysis of Financial Condition and Results of Operations.	22
Item 3.	Quantitative and Qualitative Disclosures About Market Risk.	25
Item 4.	Controls and Procedures.	25

	PART II—OTHER INFORMATION
Item 1.	Legal Proceedings.	26
Item 1A.	Risk Factors.	26
Item 2.	Unregistered Sales of Securities and Use of Proceeds.	26
Item 3.	Defaults Upon Senior Securities.	26
Item 4.	Mine Safety Disclosure.	26
Item 5.	Other Information.	26
Item 6.	Exhibits.	27
	SIGNATURES	28

Table of Contents

PART I—FINANCIAL INFORMATION

Item 1. Financial Statements.

PHARMAGREEN BIOTECH INC.

Condensed Consolidated Financial Statements

For the Nine Months Ended June 30, 2021

(Expressed in U.S. Dollars)

(Unaudited)

Table of Contents

PHARMAGREEN BIOTECH INC.

Condensed Consolidated Balance Sheets

(Expressed in U.S. dollars)

	June 30, 2021			September 30, 2020
	$			$
	(Unaudited)
Assets

Current assets

Cash		19,218			12,196
Amounts receivable		88			295
Prepaid expenses and deposits		-			253,754
Total assets		19,306			266,245

Liabilities and Stockholders’ Deficit

Current liabilities

Accounts payable and accrued liabilities (Notes 3 and 7)		624,461			539,663
Advances from Alliance Growers Corp. (Note 11(a))		60,450			56,303
Due to related parties (Note 7)		607,827			508,874
Note payable (Note 4)		40,000			40,000
Convertible notes – current portion, net of unamortized discount of $Nil and $182,012, respectively (Note 5)		190,834			641,077
Derivative liabilities (Note 6)		298,301			1,380,957
Total current liabilities		1,821,873			3,166,874

Loan payable (Note 4)		32,240			30,028
Convertible notes, net of unamortized discount of $20,696 and $23,619, respectively (Note 5)		6,371			3,448
Total liabilities		1,860,484			3,200,350

Stockholders’ deficit

Preferred stock
Authorized: 1,000,000 shares, $0.001 par value; 10,000 and nil shares issued and outstanding, respectively		10			-
Common stock
Authorized: 2,000,000,000 shares, $0.001 par value; 355,129,269 and 95,806,289 shares issued and outstanding, respectively		355,129			95,806
Common stock issuable (Note 8)		121,500			180,000
Additional paid-in capital		8,628,541			3,967,261
Accumulated other comprehensive income (loss)		(31,735	)		36,679
Deficit		(10,867,990	)		(7,167,346	)
Total Pharmagreen Biotech Inc. stockholders’ deficit		(1,794,545	)		(2,887,600	)

Non-controlling interest		(46,633	)		(46,505	)

Total stockholders’ deficit		(1,841,178	)		(2,934,105	)

Total liabilities and stockholders’ deficit		19,306			266,245

Nature of business and continuance of operations (Note 1)

Commitments (Note 11)

Subsequent event (Note 12)

(The accompanying notes are an integral part of these condensed consolidated financial statements)

Table of Contents

PHARMAGREEN BIOTECH INC.

Condensed Consolidated Statements of Operations and Comprehensive Income (Loss)

(Expressed in U.S. dollars)

(Unaudited)

	Three months ended June 30, 2021 $			Three months ended June 30, 2020 $			Nine months ended June 30, 2021 $			Nine months ended June 30, 2020 $

Expenses

Consulting fees (Note 7)		190,794			30,108			296,987			153,999
Foreign exchange loss (gain)		(3,044	)		(15,824	)		(16,951	)		6,025
General and administrative		20,716			28,704			64,376			91,688
Professional fees		18,829			40,068			111,788			89,915
Salaries and wages		5,085			3,858			14,753			13,005
Total expenses		232,380			86,914			470,953			354,632

Net loss before other income (expense)		(232,380	)		(86,914	)		(470,953	)		(354,632	)

Other income (expense)

Accretion of discount on convertible notes (Note 5)		(1,179	)		(54,877	)		(86,801	)		(77,889	)
Gain (loss) on change in fair value of derivative liabilities (Note 6)		101,418			(1,187,033	)		(3,083,420	)		(1,347,031	)
Gain (loss) on settlement on convertible notes (Note 5)		-			(31,898	)		613,526			(38,411	)
Interest and finance costs (Note 5)		(10,087	)		-			(673,124	)		(45,000	)
Write-off of accounts payable		-			-			-			292,557

Total other income (expense)		90,152			(1,273,808	)		(3,229,819	)		(1,215,774	)

Net loss		(142,228	)		(1,360,722	)		(3,700,772	)		(1,570,406	)

Less: net loss attributable to non-controlling interest		83			8			128			161

Net loss attributable to Pharmagreen Biotech Inc.		(142,145	)		(1,360,714	)		(3,700,644	)		(1,570,245	)

Comprehensive income (loss)

Foreign currency translation gain (loss)		(13,215	)		(17,081	)		(68,414	)		2,045

Comprehensive loss attributable to Pharmagreen Biotech Inc.		(155,360	)		(1,377,795	)		(3,769,058	)		(1,568,200	)

Basic and diluted loss per share attributable to Pharmagreen Biotech Inc. stockholders		-			(0.02	)		(0.01	)		(0.02	)

Weighted average number of shares outstanding used in the calculation of net loss per share attributable to Pharmagreen Biotech Inc.		351,763,390			82,854,083			271,420,624			78,042,762

(The accompanying notes are an integral part of these condensed consolidated financial statements)

Table of Contents

PHARMAGREEN BIOTECH INC.

Condensed Consolidated Statements of Stockholders’ Deficit

(Expressed in U.S. dollars)

(Unaudited)

	Preferred stock				Common stock				Common stock		Additional paid-in		Accumulated other comprehensive						Non -controlling			Total stockholders’
	Number of shares		Amount $		Number of shares		Amount $		issuable $		capital $		income (loss) $			Deficit $			interest $			deficit $

Balance, September 30, 2019		–		-		75,646,835		75,647		-		3,772,781		47,824			(4,729,476	)		(1,274	)		(834,498	)

Foreign currency translation loss		–		-		–		-		-		-		(12,399	)		-			-			(12,399	)

Net loss for the period		–		-		–		-		-		-		-			(206,021	)		(36	)		(206,057	)

Balance, December 31, 2019		–		-		75,646,835		75,647		-		3,772,781		35,425			(4,935,497	)		(1,310	)		(1,052,954	)

Issuance of common stock pursuant to the conversion of convertible notes		–		-		78,064		78		-		20,999		-			-			-			21,077

Foreign currency translation gain		–		-		–		-		-		-		31,525			-			-			31,525

Net loss for the period		–		-		–		-		-		-		-			(3,510	)		(117	)		(3,627	)

Balance, March 31, 2020		–		-		75,724,899		75,725		-		3,793,780		66,950			(4,939,007	)		(1,427	)		(1,003,979	)

Issuance of common stock pursuant to the conversion of convertible notes		–		-		15,420,104		15,420		-		126,910		-			-			-			142,330

Foreign currency translation loss		–		-		–		-		-		-		(17,081	)		-			-			(17,081	)

Net loss for the period		–		-		–		-		-		-		-			(1,360,714	)		(8	)		(1,360,722	)

Balance, June 30, 2020		–		-		91,145,003		91,145		-		3,920,690		49,869			(6,299,721	)		(1,435	)		(2,239,452	)

(The accompanying notes are an integral part of these condensed consolidated financial statements)

Table of Contents

PHARMAGREEN BIOTECH INC.

Condensed Consolidated Statements of Stockholders’ Deficit (continued)

(Expressed in U.S. dollars)

(Unaudited)

	Preferred stock				Common stock				Common stock			Additional paid-in		Accumulated other comprehensive						Non -controlling			Total stockholders’
	Number of shares		Amount $		Number of shares		Amount $		issuable $			capital $		income (loss) $			Deficit $			interest $			deficit $

Balance, September 30, 2020		–		-		95,806,289		95,806		180,000			3,967,261		36,679			(7,167,346	)		(46,505	)		(2,934,105	)

Issuance of units for cash		–		-		5,400,000		5,400		-			21,600		-			-			-			27,000

Issuance of preferred shares for cash		10,000		10		–		-		-			-		-			-			-			10

Issuance of common stock pursuant to the conversion of convertible notes		–		-		144,315,380		144,316		(180,000	)		1,647,737		-			-			-			1,612,053

Issuance of common stock for services		–		-		90,000		90		-			1,265		-			-			-			1,355

Foreign currency translation loss		–		-		–		-		-			-		(42,455	)		-			-			(42,455	)

Net loss for the period		–		-		–		-		-			-		-			(417,109	)		(1	)		(417,110	)

Balance, December 31, 2020		10,000		10		245,611,669		245,612		-			5,637,863		(5,776	)		(7,584,455	)		(46,506	)		(1,753,252	)

Issuance of units for cash		–		-		17,411,250		17,411		6,113			72,701		-			-			-			96,225

Issuance of common stock pursuant to the conversion of convertible notes		–		-		84,845,100		84,845		-			2,848,372		-			-			-			2,933,217

Issuance of common stock for services		–		-		300,000		300		-			7,020		-			-			-			7,320

Foreign currency translation loss		–		-		–		-		-			-		(12,744	)		-			-			(12,744	)

Net loss for the period		–		-		–		-		-			-		-			(3,141,390	)		(44	)		(3,141,434	)

Balance, March 31, 2021		10,000		10		348,168,019		348,168		6,113			8,565,956		(18,520	)		(10,725,845	)		(46,550	)		(1,870,668	)

Issuance of units for cash		–		-		6,961,250		6,961		(6,113	)		62,585		-			-			-			63,433

Shares issuable for services		–		-		–		-		121,500			-		-			-			-			121,500

Foreign currency translation loss		–		-		–		-		-			-		(13,215	)		-			-			(13,215	)

Net loss for the period		–		-		–		-		-			-		-			(142,145	)		(83	)		(142,228	)

Balance, June 30, 2021		10,000		10		355,129,269		355,129		121,500			8,628,541		(31,735	)		(10,867,990	)		(46,633	)		(1,841,178	)

(The accompanying notes are an integral part of these condensed consolidated financial statements)

Table of Contents

PHARMAGREEN BIOTECH INC.

Condensed Consolidated Statements of Cash Flows

(Expressed in U.S. dollars)

(Unaudited)

	Nine months ended June 30, 2021 $			Nine months ended June 30, 2020 $

OPERATING ACTIVITIES

Net loss		(3,700,772	)		(1,570,406	)

Adjustments to reconcile net loss to net cash used in operating activities:
Accretion of discount on convertible notes		86,801			77,889
Financing fees and default penalties		673,124			45,000
Loss on change in fair value of derivative liabilities		3,083,420			1,347,031
Loss (gain) on settlement of convertible notes		(613,526	)		38,411
Shares issued or issuable for services		130,175			-
Write-off of accounts payable		-			(292,557	)

Changes in operating assets and liabilities:
Amounts receivable		207			9,849
Prepaid expenses and deposits		3,754			(236,798	)
Accounts payable and accrued liabilities		120,273			21,189
Due to related parties		65,307			13,840

Net cash used in operating activities		(151,237	)		(546,552	)

FINANCING ACTIVITIES

Proceeds from issuance of convertible notes		-			570,080
Proceeds from units issued and issuable for cash		186,725			-
Proceeds from issuance of preferred shares		10			-
Repayment of loans from related parties		-			(128,813	)
Proceeds from related party loans		33,646			64,981
Proceeds from loans payable		-			29,388
Financing costs		-			(5,000	)

Net cash provided by financing activities		220,381			530,636

Effect of foreign exchange rate changes on cash		(62,122	)		(12,184	)

Change in cash		7,022			(28,100	)

Cash, beginning of period		12,196			62,682

Cash, end of period		19,218			34,582

Non-cash investing and financing activities:

Original issue discount on convertible notes		-			532,594
Common shares issued for settlement of convertible notes		4,545,270			163,407
Issuance of promissory note as a financing fee		-			40,000

Supplemental disclosures:
Interest paid		-			4,601
Income taxes paid		-			-

(The accompanying notes are an integral part of these condensed consolidated financial statements)

Table of Contents

PHARMAGREEN BIOTECH INC.

Notes to the Condensed Consolidated Financial Statements

June 30, 2021

(Expressed in U.S. dollars)

(unaudited)

Nature of Business and Continuance of Operations

Pharmagreen Biotech Inc. (“the Company”) was incorporated under the laws of the State of Nevada, U.S. on November 26, 2007, under the name Azure International, Inc. On October 30, 2008, and effective as of the same date, the Company filed Articles of Merger (“Articles”) with the State of Nevada, to effect a merger by and between Air Transport Group Holdings, Inc., a Nevada corporation and Azure International, Inc. As a result of the merger, the Company changed its name to Air Transport Group Holdings, Inc. The Company was previously in the business of providing technical advisory and appraisals to the aircraft and aviation business as well as providing sourcing for aircraft leases and parts. Pursuant to a Share Exchange Agreement with WFS Pharmagreen Inc. (“WFS”) on May 2, 2018, the Company changed its name to Pharmagreen Biotech Inc. and changed its principal business to the production of starter plantlets for the North American high CBD hemp and medical cannabis industries through the application of the proprietary plant tissue culture in vitro process called “Chibafreen”. This proprietary process will produce plantlets that will be genetically identical and free of pests and disease free with consistent and certifiable constituent properties.

Going Concern

These condensed consolidated financial statements have been prepared on the going concern basis, which assumes that the Company will be able to realize its assets and discharge its liabilities in the normal course of business. As at June 30, 2021, the Company has not earned any revenues from operations, has a working capital deficit of $1,802,567, and has an accumulated deficit of $10,867,990. During the nine months ended June 30, 2021, the Company incurred a net loss of $3,700,644 and used cash flows for operations of $151,237. In addition, the Company filed voluntary petitions for reorganization under Chapter 11 of the United States Bankruptcy Code in the United States Bankruptcy Court for the District of Nevada on August 7, 2020. Refer to Note 11. As a result of the voluntary petition, various convertible note holders triggered default provisions on the Company’s outstanding convertible notes. On October 9, 2020, a stay order was lifted by a United States District Judge of the United States District Court for the Southern District of New York, on an action filed by a lender. This effectively removed the Company from its Chapter 11 bankruptcy proceedings and protection. Furthermore, the Company has defaulted on other convertible notes. These factors raise substantial doubt upon the Company’s ability to continue as a going concern. These condensed consolidated financial statements do not reflect any adjustments that may be necessary if the Company is unable to continue as a going concern.

The outbreak of the novel coronavirus COVID-19, which was declared a pandemic by the World Health Organization on March 11, 2020, has led to adverse impacts on the U.S. and global economies, disruptions of financial markets, and created uncertainty regarding potential impacts to the Company’s supply chain, operations, and customer demand. The COVID-19 pandemic has impacted and could further impact the Company’s operations and the operations of the Company’s suppliers and vendors as a result of quarantines, facility closures, and travel and logistics restrictions. Specifically, the Company attributes the pandemic to a delay in a planned financing which was to be used for the construction of the biotech complex, resulting in an impairment of the capitalized construction-in-progress at September 30, 2020. The extent to which the COVID-19 pandemic further impacts the Company’s business, results of operations and financial condition will depend on future developments, which are highly uncertain and cannot be predicted, including, but not limited to the duration, spread, severity, and impact of the COVID-19 pandemic, the effects of the COVID-19 pandemic on the Company’s customers, suppliers, and vendors and the remedial actions and stimulus measures adopted by local and federal governments, and to what extent normal economic and operating conditions can resume. The management team is closely following the progression of COVID-19 and its impact on the Company. Even after the COVID-19 pandemic has subsided, the Company may continue to experience adverse impacts to its business as a result of any economic recession or depression that has occurred or may occur in the future. Therefore, the Company cannot reasonably estimate the impact at this time our business, liquidity, capital resources, and financial results.

Table of Contents

PHARMAGREEN BIOTECH INC.

Notes to the Condensed Consolidated Financial Statements

June 30, 2021

(Expressed in U.S. dollars)

(unaudited)

2.	Significant Accounting Policies

	(a)	Interim Financial Statements

		These condensed consolidated financial statements have been prepared on the same basis as the annual consolidated financial statements and in the opinion of management, reflect all adjustments, which include only normal recurring adjustments, necessary to present fairly the Company’s financial position, results of operations and cash flows for the periods shown. The results of operations for such periods are not necessarily indicative of the results expected for a full year or for any future period.

	(b)	Basis of Presentation

		The accompanying condensed interim consolidated financial statements have been prepared in accordance with accounting principles generally accepted in the United States and are expressed in U.S. dollars. These condensed consolidated financial statements include the accounts of the Company and its wholly owned subsidiary, WFS Pharmagreen Inc. (“WFS”), and its 89.7% owned subsidiary 1155097 B.C. Ltd. (“115BC”), companies incorporated in British Columbia, Canada. All inter-company accounts and transactions have been eliminated. The Company’s fiscal year-end is September 30.

	(c)	Use of Estimates and Judgments

		The preparation of these condensed consolidated financial statements in conformity with U.S. generally accepted accounting principles requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. The Company regularly evaluates estimates and assumptions related to the recoverability of property and equipment, the equity component of convertible notes, fair value of derivative liabilities, fair value of share-based payments, and deferred income tax asset valuation allowances. The Company bases its estimates and assumptions on current facts, historical experience, and various other factors that it believes to be reasonable under the circumstances, the results of which form the basis for making judgments about the carrying values of assets and liabilities and the accrual of costs and expenses that are not readily apparent from other sources. The actual results experienced by the Company may differ materially and adversely from the Company’s estimates. To the extent there are material differences between the estimates and the actual results, future results of operations will be affected. The Company applies judgment in the application of the going concern assumption which requires management to take into account all available information about the future, which is at least, but not limited to, 12 months from the end of the reporting period and in the factors regarding the impairment of the property and equipment. The Company tests property and equipment for recoverability when events or changes in circumstances indicate that their carrying amount may not be recoverable. Circumstances which could trigger a review include, but are not limited to: significant decreases in the market price of the asset; significant adverse changes in the business climate or legal factors; accumulation of costs significantly in excess of the amount originally expected for the acquisition or construction of the asset; current period cash flow or operating losses combined with a history of losses or a forecast of continuing losses associated with the use of the asset; and current expectation that the asset will more likely than not be sold or disposed significantly before the end of its estimated useful life. Recoverability is assessed based on the carrying amount of the asset and its fair value, which is generally determined based on the sum of the undiscounted cash flows expected to result from the use and the eventual disposal of the asset, as well as specific appraisal in certain instances. An impairment loss is recognized when the carrying amount is not recoverable and exceeds fair value.

	(d)	Recently Adopted Accounting Pronouncements

		The Company has implemented all new accounting pronouncements that are in effect and that may impact its condensed consolidated financial statements and does not believe that there are any other new accounting pronouncements that have been issued that might have a material impact on its financial position or results of operations.

Table of Contents

PHARMAGREEN BIOTECH INC.

Notes to the Condensed Consolidated Financial Statements

June 30, 2021

(Expressed in U.S. dollars)

(unaudited)

3.	Accounts Payable and Accrued Liabilities

	Accounts payable and accrued liabilities consists of the following:

	June 30, 2021 $		September 30, 2020 $

Accounts payable (Note 7)		550,871		455,310
Accrued interest payable (Notes 4 and 5)		73,590		84,353

		624,461		539,663

4.	Note and Loan Payable

	(a)	On November 22, 2019, the Company entered into a promissory note with an unrelated party for $40,000 in connection with an equity purchase agreement (Refer to Note 11(b)). The promissory note is unsecured, was due on November 30, 2020, and bears interest on the unpaid principal balance at a rate of 10% per annum. At June 30, 2021, the Company has recorded accrued interest payable of $6,404 (September 30, 2020 - $3,421) and the promissory note is in default. On March 10, 2021, this noteholder filed a Notice of Motion for Summary Judgement in Lieu of Complaint (the “Notice”) with the State of New York Supreme Court, County of New York for $40,504 plus interest at the rate of 10% per annum from January 6, 2021 plus costs. On July 31, 2021, the Notice was dismissed without prejudice by the State of New York Supreme Court.

	(b)	On April 22, 2020, the Company received a loan for Cdn$40,000from the Government of Canada under the Canada Emergency Business Account program (“CEBA”). As at June 30, 2021, the balance owing is $32,240 (Cdn$40,000) (September 30, 2020 – $30,028 (Cdn$40,000)). These funds are interest free until December 31, 2022, at which time the remaining balance will convert to a 3-year term loan at an interest rate of 5% per annum. If the Company repays the loan prior to December 31, 2022, there will be loan forgiveness of 25% of the principal balance repaid, up to a maximum of Cdn$10,000.

5.	Convertible Notes

(a)

On April 4, 2018, the amount of $32,485 owed to related parties was converted to Series A convertible notes, which are unsecured, non-interest bearing, and due on April 4, 2023. These notes are convertible in whole or in part, at any time until maturity, to common shares of the Company at $0.0001 per share. The outstanding balance remaining at maturity shall bear interest at 12% per annum until fully paid. The Company evaluated the convertible notes for a beneficial conversion feature in accordance with ASC 470-20 Debt with Conversion and Other Options. The Company determined that the conversion price was below the closing stock price on the commitment date, and the convertible notes contained a beneficial conversion feature. The Company recognized the intrinsic value of the embedded beneficial conversion feature of $32,485 as additional paid-in capital and reduced the carrying value of the convertible note to $nil. The carrying value will be accreted over the term of the convertible notes up to their face value of $32,485.

During the year ended September 30, 2018, the Company issued 31,745,000 shares of common stock upon the conversion of $3,175 of Series A convertible notes, which included 18,000,000 common shares to the President of the Company and 5,320,000 common shares to family members of the President of the Company. Upon conversion, the Company immediately recognized the related remaining debt discount of $3,112 as accretion expense.

During the year ended September 30, 2019, the Company issued 3,900,000 shares of common stock upon the conversion of $390 of Series A convertible notes. Upon conversion, the Company immediately recognized the related remaining debt discount of $375 as accretion expense.

During the year ended September 30, 2020, the Company issued 18,525,000 shares of common stock upon the conversion of $1,853 of Series A convertible notes. Upon conversion, the Company immediately recognized the related remaining debt discount of $1,670 as accretion expense.

As at June 30, 2021, the carrying value of the convertible notes was $6,371 (September 30, 2020 – $3,448) and had an unamortized discount of $20,696 (September 30, 2020 - $23,619). During the nine months ended June 30, 2021, the Company recorded accretion expense of $2,923 (2020 - $1,358).

Table of Contents

PHARMAGREEN BIOTECH INC.

Notes to the Condensed Consolidated Financial Statements

June 30, 2021

(Expressed in U.S. dollars)

(unaudited)

5.	Convertible Notes (continued)

	(b)	On October 1, 2019, the Company entered into a convertible note with an unrelated party for $78,000, of which $3,255 was paid directly to third parties for financing costs, resulting in net proceeds to the Company of $74,745. The note is due on October 1, 2020, and bears interest on the unpaid principal balance at a rate of 10% per annum, which increases to 24% per annum upon default of the note.The note may be converted at any time after the date of issuance into shares of Company’s common stock at a conversion price equal to lower of: (i) the lowest trading price during the 10-trading day period prior to the issuance date; or (ii) 61% of the average 2 lowest trading prices during the 10-trading day period prior to the conversion date. In connection with the issuance of the above convertible note, the Company evaluated the conversion option for derivative treatment under ASC 815-15, Derivatives and Hedging, and determined the note and conversion feature qualified as derivatives. The Company classified the conversion feature as a derivative liability at fair value. The initial fair value of the conversion feature was determined to be $70,744. The Company recognized the maximum intrinsic value of the embedded beneficial conversion feature of $74,245 and reduced the carrying value of the convertible note to $500. The carrying value will be accreted over the term of the convertible note up to its face value of $78,000.

		On July 22, 2020, the Company received a preliminary statement of claim from the note holder for failure of the Company to deliver shares of common stock upon receipt of notices of conversion. Pursuant to the claim, the note holder requested receipt of all shares of common stock requested in the notices of conversion, and also damages in an amount to be determined at trial but in any event in excess of principal in the sum of $180,000, including without limitation the balance of any portion of the convertible note that ultimately is not converted into shares of common stock, along with default interest, liquidated damages, and damages as provided for in the convertible note. Upon default, the Company recognized the remaining debt discount of $46,904 as accretion expense. The financing costs were netted against the convertible note and were being amortized over the term using the effective interest rate method. During the year ended September 30, 2020, the Company recognized accretion expense of $77,500 and a default penalty of $85,864. During the nine months ended June 30, 2021, the Company recorded an additional $253,856 of default penalties. During the nine months ended June 30, 2021, the Company issued 133,226,100 shares of common stock upon the conversion of $417,719 of the convertible note and $11,000 of conversion fees. On March 12, 2021, the Company entered into a settlement agreement with the noteholder. Pursuant to the agreement, the Company was required to honour various conversion notices and the noteholder agreed to waive all principal, interest and penalties incurred. As at March 12, 2021, the carrying value of the convertible note was $nil (September 30, 2020 - $163,864) and the fair value of the derivative liability was $nil (September 30, 2020 - $485,863).

	(c)	On October 17, 2019, the Company entered into a convertible note with an unrelated party for $63,000, of which $3,000 was paid directly to third parties for financing costs, resulting in net cash proceeds to the Company of $60,000. The note is due on October 17, 2020, and bears interest on the unpaid principal balance at a rate of 10% per annum, which increases to 22% per annum upon default of the note. The note may be converted at any time after 180 days of the date of issuance into shares of Company’s common stock at a conversion price equal to 61% of the average 2 lowest trading prices during the 10-trading day period prior to the conversion date.

Table of Contents

PHARMAGREEN BIOTECH INC.

Notes to the Condensed Consolidated Financial Statements

June 30, 2021

(Expressed in U.S. dollars)

(unaudited)

5.	Convertible Notes (continued)

		On June 17, 2020, the Company entered into a settlement agreement with the lender, whereby the Company and the lender agreed on repayment terms for the remaining principal balance of $63,000, and accrued interest owing on the note of $5,775 which was due on September 30, 2020. Upon entering into the settlement agreement, the Company immediately recognized the remaining debt discount of $1,657. On September 30, 2020, the Company failed to meet the repayment terms within the settlement agreement which resulted in a default penalty of $63,000 and the resumption of the convertibility feature at a conversion price equal to 61% of the average 2 lowest trading prices during the 10-trading day period prior to the conversion date. On September 30, 2020, the Company evaluated the conversion option for derivative treatment under ASC 815-15, Derivatives and Hedging, and determined the note and conversion feature qualified as derivatives. The Company classified the conversion feature as a derivative liability at fair value. The initial fair value of the conversion feature was determined to be $112,822. The financing costs were netted against the convertible note and were being amortized over the term using the effective interest rate method. During the year ended September 30, 2020, the Company recognized accretion expense of $3,000 and a default penalty of $63,000. During the nine months ended June 30, 2021, the Company issued 7,730,486 shares of common stock upon the conversion of $126,000 of the convertible note. As at June 30, 2021, the carrying value of the convertible note was $nil (September 30, 2020 - $126,000) and the fair value of the derivative liability was $nil (September 30, 2020 - $112,822).

	(d)	On January 2, 2020, the Company entered into a convertible note with an unrelated party for $53,000, of which $3,000 was paid directly to third parties for financing costs, resulting in cash proceeds to the Company of $50,000. The note is due on January 2, 2021, and bears interest on the unpaid principal balance at a rate of 10% per annum, which increases to 22% per annum upon default of the note. The note may be converted at any time after 180 days of the date of issuance into shares of Company’s common stock at a conversion price equal to 61% of the average 2 lowest trading prices during the 10-trading day period prior to the conversion date.

		On June 17, 2020, the Company entered into a settlement agreement with the lender, whereby the Company and the lender agreed on repayment terms for the remaining principal of $53,000 and accrued interest owing on the note. Upon entering into the settlement agreement, the Company immediately recognized the remaining debt discount of $2,286. Effective September 30, 2020, the Company failed to meet the repayment terms of the settlement agreement and defaulted on the convertible note. On September 30, 2020, the Company evaluated the conversion option for derivative treatment under ASC 815-15, Derivatives and Hedging, and determined the note and conversion feature qualified as derivatives. The Company classified the conversion feature as a derivative liability at fair value. The initial fair value of the conversion feature was determined to be $139,702. The financing costs were netted against the convertible note and were being amortized over the term using the effective interest rate method. During the year ended September 30, 2020, the Company recognized accretion expense of $3,000 and a default penalty of $53,000. During the nine months ended June 30, 2021, the Company issued 16,994,905 shares of common stock upon the conversion of $106,000 of the convertible note. As at June 30, 2021, the carrying value of the convertible note was $nil (September 30, 2020 - $106,000) and the fair value of the derivative liability was $nil (September 30, 2020 - $139,702).

Table of Contents

PHARMAGREEN BIOTECH INC.

Notes to the Condensed Consolidated Financial Statements

June 30, 2021

(Expressed in U.S. dollars)

(unaudited)

5.	Convertible Notes (continued)

	(e)	On January 14, 2020, the Company entered into a convertible note with an unrelated party for $78,000, of which $3,000 was paid for financing costs, resulting in net proceeds to the Company of $75,000. The note is due on January 14, 2021, and bears interest on the unpaid principal balance at a rate of 12% per annum, which increases to 15% per annum upon default of the note. The note may be converted at any time after the date of issuance into shares of Company’s common stock at a conversion price equal to lower of: (i) 65% of the lowest trading price during the 20-trading day period prior to the issuance date; or (ii) 65% of the lowest trading price during the 20-trading day period prior to the conversion date. In connection with the issuance of the above convertible note, the Company evaluated the conversion option for derivative treatment under ASC 815-15, Derivatives and Hedging, and determined the note and conversion feature qualified as derivatives. The Company classified the conversion feature as a derivative liability at fair value. The initial fair value of the conversion feature was determined to be $76,330. The Company recognized the maximum intrinsic value of the embedded beneficial conversion feature of $74,500, resulting in a loss on change in fair value of derivative liabilities of $1,830, and reduced the carrying value of the convertible note to $500. The carrying value will be accreted over the term of the convertible note up to its face value of $78,000.

		The financing costs were netted against the convertible note and are being amortized over the term using the effective interest rate method. During the year ended September 30, 2020, the Company recognized accretion expense of $16,447. During the nine months ended June 30, 2021, the Company issued 2,600,000 shares of common stock upon the conversion of $18,923 of the convertible note and $4,500 of conversion fees. On January 14, 2021, the Company failed to repay the note upon maturity and recorded additional default principal of $53,007. As at June 30, 2021, the carrying value of the convertible note was $112,084 (September 30, 2020 - $16,947), net of an unamortized discount of $nil (September 30, 2020 - $61,053), and the fair value of the derivative liability was $170,586 (September 30, 2020 - $110,604).

	(f)	On January 15, 2020, the Company entered into a convertible note with an unrelated party for $61,000, of which $7,400 was paid directly to third parties for financing costs and an original issue discount of $3,000, resulting in proceeds to the Company of $50,600. The note is due on January 15, 2021, and bears interest on the unpaid principal balance at a rate of 10% per annum, payable in common stock, which increases to 24% per annum upon default of the note. The note may be converted at any time after the date of issuance into shares of Company’s common stock at a conversion price equal 65% of the lowest trading price during the 20-trading day period prior to the conversion date. In connection with the issuance of the above convertible note, the Company evaluated the conversion option for derivative treatment under ASC 815-15, Derivatives and Hedging, and determined the note and conversion feature qualified as derivatives. The Company classified the conversion feature as a derivative liability at fair value. The initial fair value of the conversion feature was determined to be $67,846.

		The Company recognized the maximum intrinsic value of the embedded beneficial conversion feature of $50,100, resulting in a loss on change in fair value of derivative liabilities of $17,746, and reduced the carrying value of the convertible note to $500. The carrying value will be accreted over the term of the convertible note up to its face value of $61,000. On July 23, 2020, the Company entered into a settlement agreement with the note holder, wherein the Company and the lender agreed to settle a convertible note and accrued interest for a total of $63,440 on a non-convertible basis, of which $15,000 was payable on or before July 24, 2020 (paid), followed by 6 monthly instalment payments of $8,073. Upon entering into the settlement agreement, the Company immediately recognized the remaining debt discount of $56,566. Effective August 24, 2020, the Company failed to meet the repayment terms and defaulted on the settlement agreement. The financing costs were netted against the convertible note and were being amortized over the term using the effective interest rate method. During the year ended September 30, 2020, the Company recognized accretion expense of $60,500. During the nine months ended June 30, 2021, the Company issued 3,601,718 shares of common stock upon the conversion of $46,000 of the convertible note, $5,586 of accrued interest and $500 of conversion fees. As at June 30, 2021, the carrying value of the convertible note was $nil (September 30, 2020 - $46,000) and the fair value of the derivative liability was $nil (September 30, 2020 - $69,320).

Table of Contents

PHARMAGREEN BIOTECH INC.

Notes to the Condensed Consolidated Financial Statements

June 30, 2021

(Expressed in U.S. dollars)

(unaudited)

5.	Convertible Notes (continued)

	(g)	On January 15, 2020, the Company entered into a convertible note with an unrelated party for $55,000, of which $2,500 was paid directly to third parties for financing costs, resulting in proceeds to the Company of $52,500. The note is due on January 15, 2021, and bears interest on the unpaid principal balance at a rate of 10% per annum, which increases to 24% per annum upon default of the note. The note may be converted at any time after the date of issuance into shares of Company’s common stock at a conversion price equal to lower of: (i) the lowest trading price during the 20-trading day period ending on the latest complete trading day prior to the issuance date; or (ii) 65% of the lowest trading price during the 20 consecutive trading day period on which at least 100 shares of common stock were traded prior to the conversion date. In connection with the issuance of the above convertible note, the Company evaluated the conversion option for derivative treatment under ASC 815-15, Derivatives and Hedging, and determined the note and conversion feature qualified as derivatives. The Company classified the conversion feature as a derivative liability at fair value. The initial fair value of the conversion feature was determined to be $61,173. The Company recognized the maximum intrinsic value of the embedded beneficial conversion feature of $52,000, resulting in a loss on change in fair value of derivative liabilities of $9,173, and reduced the carrying value of the convertible note to $500. The carrying value will be accreted over the term of the convertible note up to its face value of $55,000.

		During the year ended September 30, 2020, the Company defaulted on the convertible note which resulted in a default penalty of $27,500 and the amendment of the conversion rate from 65% to 50% of the lowest trading price during the 20 consecutive trading days prior to conversion. The Company recognized the remaining debt discount of $50,767 as accretion expense. The financing costs were netted against the convertible note and were being amortized over the term using the effective interest rate method. During the year ended September 30, 2020, the Company recognized accretion expense of $54,500 and a default penalty of $27,500. During the nine months ended June 30, 2021, the Company issued 17,557,925 shares of common stock upon the conversion of $82,500 of the convertible note, $7,693 of accrued interest and $3,000 of conversion fees. As at June 30, 2021, the carrying value of the convertible note was $nil (September 30, 2020 - $82,500) and the fair value of the derivative liability was $nil (September 30, 2020 - $146,272).

	(h)	On January 21, 2020, the Company entered into a convertible note with an unrelated party for $66,150, of which $7,800 was paid directly to third parties for financing costs and an original issue discount of $3,150, resulting in proceeds to the Company of $55,200. The note is due on January 21, 2021, and bears interest on the unpaid principal balance at a rate of 8% per annum, payable in common stock, which increases to 24% per annum upon default of the note. The note may be converted at any time after the date of issuance into shares of Company’s common stock at a conversion price equal 60% of the lowest trading price during the 20-trading day period prior to the conversion date. In connection with the issuance of the above convertible note, the Company evaluated the conversion option for derivative treatment under ASC 815-15, Derivatives and Hedging, and determined the note and conversion feature qualified as derivatives. The Company classified the conversion feature as a derivative liability at fair value. The initial fair value of the conversion feature was determined to be $71,278.

		The Company recognized the maximum intrinsic value of the embedded beneficial conversion feature of $54,700, resulting in a loss on change in fair value of derivative liabilities of $16,578, and reduced the carrying value of the convertible note to $500. The carrying value will be accreted over the term of the convertible note up to its face value of $66,150.

Table of Contents

PHARMAGREEN BIOTECH INC.

Notes to the Condensed Consolidated Financial Statements

June 30, 2021

(Expressed in U.S. dollars)

(unaudited)

5.	Convertible Notes (continued)

		The financing costs were netted against the convertible note and are being amortized over the term using the effective interest rate method. During the year ended September 30, 2020, the Company recognized accretion expense of $13,202. During the nine months ended June 30, 2021, the Company issued 4,431,963 shares of common stock upon the conversion of $66,150of the convertible note and $3,907 of accrued interest. As at June 30, 2021, the carrying value of the convertible note was $nil (September 30, 2020 - $13,702), net of an unamortized discount of $nil (September 30, 2020 - $52,448), and the fair value of the derivative liability was $nil (September 30, 2020 - $98,579).

	(i)	On January 22, 2020, the Company entered into a convertible note with an unrelated party for $78,750, of which $9,750 was paid directly to third parties for financing costs, resulting in proceeds to the Company of $69,000. The note is due on January 22, 2021, and bears interest on the unpaid principal balance at a rate of 10% per annum, payable in common stock, which increases to 24% per annum upon default of the note. The note may be converted at any time after the date of issuance into shares of Company’s common stock at a conversion price equal to 65% of the lowest trading price during the 20-trading day period ending on the latest complete trading day prior to the conversion date. In connection with the issuance of the above convertible note, the Company evaluated the conversion option for derivative treatment under ASC 815-15, Derivatives and Hedging, and determined the note and conversion feature qualified as derivatives. The Company classified the conversion feature as a derivative liability at fair value. The initial fair value of the conversion feature was determined to be $75,179. The Company recognized the maximum intrinsic value of the embedded beneficial conversion feature of $68,500, resulting in a loss on change in fair value of derivative liabilities of $6,679, and reduced the carrying value of the convertible note to $500. The carrying value will be accreted over the term of the convertible note up to its face value of $78,750.

		The financing costs were netted against the convertible note and are being amortized over the term using the effective interest rate method. During the year ended September 30, 2020, the Company defaulted on the convertible note and recognized accretion expense of $78,250. On January 22, 2021, the Company failed to repay the note upon maturity. As at June 30, 2021, the carrying value of the convertible note was $78,750 (September 30, 2020 - $78,750) and the fair value of the derivative liability was $127,715 (September 30, 2020 - $107,660).

	(j)	On February 4, 2020, the Company entered into a convertible note with an unrelated party for $100,000, of which $16,970 was paid directly to third parties for financing costs, resulting in proceeds to the Company of $83,030. The note is due on February 4, 2021, and bears interest on the unpaid principal balance at a rate of 12% per annum, which increases to 24% per annum upon default of the note. The note may be converted at any time after the date of issuance into shares of Company’s common stock at a conversion price equal to lower of: (i) the lowest trading price during the 10-trading day period ending on the latest complete trading day prior to the issuance date; or (ii) 60% of the average of the two lowest trading prices during the 10-trading day period prior to the conversion date. In connection with the issuance of the above convertible note, the Company evaluated the conversion option for derivative treatment under ASC 815-15, Derivatives and Hedging, and determined the note and conversion feature qualified as derivatives. The Company classified the conversion feature as a derivative liability at fair value. The initial fair value of the conversion feature was determined to be $125,640. The Company recognized the maximum intrinsic value of the embedded beneficial conversion feature of $82,530, resulting in a loss on change in fair value of derivative liabilities of $43,110, and reduced the carrying value of the convertible note to $500. The carrying value will be accreted over the term of the convertible note up to its face value of $100,000.

		During the year ended September 30, 2020, the noteholder converted $24,175 of the convertible note for 2,000,000 common shares with a fair value of $180,000 and was issued on October 20, 2020. Upon the notice of conversion, the Company immediately recognized the related remaining debt discount of $23,136 as accretion expense. The financing costs were netted against the convertible note and are being amortized over the term using the effective interest rate method. During the year ended September 30, 2020, the Company recognized accretion expense of $7,854.

Table of Contents

PHARMAGREEN BIOTECH INC.

Notes to the Condensed Consolidated Financial Statements

June 30, 2021

(Expressed in U.S. dollars)

(unaudited)

5.	Convertible Notes (continued)

During the nine months ended June 30, 2021, the Company issued 41,017,383 shares of common stock upon the conversion of $75,825 of the convertible note, $2,154 of accrued interest and $18,750 of fees. As at June 30, 2021, the carrying value of the convertible note was $nil (September 30, 2020 - $7,314), net of an unamortized discount of $nil (September 30, 2020 - $68,511), and the fair value of the derivative liability was $nil (September 30, 2020 - $110,135).

6.	Derivative Liabilities

	The embedded conversion option of certain of the Company’s convertible notes described in Note 5 contain a conversion feature that qualifies for embedded derivative classification. The fair value of this liability will be re-measured at the end of every reporting period and the change in fair value will be reported in the statement of operations as a gain or loss on change in fair value of derivative liabilities. The table below sets forth a summary of changes in the fair value of the Company’s Level 3 financial liabilities:

	$
Balance, September 30, 2020	1,380,957

Conversion of convertible notes	(4,166,076	)
Change in fair value	3,083,420

Balance, June 30, 2021	298,301

The Company uses Level 3 inputs for its valuation methodology for the embedded conversion option liabilities as their fair values were determined by using a binomial model based on various assumptions. Significant changes in any of these inputs in isolation would result in a significant change in the fair value measurement. As required, these are classified based on the lowest level of input that is significant to the fair value measurement. The following table shows the weighted-average assumptions used in the calculations:

Expected

volatility

Risk-free interest

rate

Expected dividend

yield

Expected life

(in years)

As at June 30, 2021

256

0.1

0.5

7.	Related Party Transactions

	(a)	As at June 30, 2021, the Company owed $548,586 (Cdn$680,628) (September 30, 2020 - $453,697(Cdn$604,366)) to the President of the Company, which is non-interest bearing, unsecured, and due on demand. During the nine months ended June 30, 2021, the Company incurred consulting fees of $72,171 (2020 - $63,044) to the President of the Company.

	(b)	As at June 30, 2021, the Company owed $59,241 (Cdn$73,500) (September 30, 2020 - $55,177 (Cdn$73,500)) to the father of the President of the Company, which is non-interest bearing, unsecured, and due on demand.

	(c)	As at June 30, 2021, the Company owed $27,565 (Cdn$34,200) (September 30, 2020 – $25,674 (Cdn$34,000)) to a company owned by the father of the President of the Company, which is included in accounts payable and accrued liabilities. The amount due is non-interest bearing, unsecured, and due on demand.

	(d)	As at June 30, 2021, the Company owed $431,105 (Cdn$534,870) (September 30, 2020 – $347,229 (Cdn$462,540)) to a company controlled by the Chief Financial Officer of WFS, which is included in accounts payable and accrued liabilities. The amount due is non-interest bearing, unsecured, and due on demand. During the nine months ended June 30, 2021, the Company incurred consulting fees of $72,171 (2020 - $63,044) to the company controlled by the Chief Financial Officer of WFS.

	(e)	On October 14, 2020, the Company issued 10,000 shares of Series A Super Voting Preferred Stock to a director of the Company for proceeds of $10.

Table of Contents

PHARMAGREEN BIOTECH INC.

Notes to the Condensed Consolidated Financial Statements

June 30, 2021

(Expressed in U.S. dollars)

(unaudited)

8.	Common Stock

	Nine months ended June 30, 2021

	(a)	In December 2020, the Company issued 5,400,000 units at $0.005 per unit for proceeds of $27,000 in a private placement. Each unit is comprised of one share of common stock and one share purchase warrant exercisable into an additional share of common stock at an exercise price of $0.05 per share for a period of 24 months.

	(b)	Between January 11 to February 16, 2021, the Company issued 16,800,000 units at $0.005 per unit for proceeds of $84,000 in a private placement. Each unit is comprised of one share of common stock and one share purchase warrant exercisable into an additional share of common stock at an exercise price of $0.05 per share for a period of 24 months.

	(c)	On March 1, 2021, the Company issued 611,250 units at $0.01 per unit for proceeds of $6,112 in a private placement. Each unit is comprised of one share of common stock and one share purchase warrant exercisable into an additional share of common stock at an exercise price of $0.05 per share for a period of 24 months.

	(d)	During the nine months ended June 30, 2021, the Company issued 133,226,100 shares of common stock upon the conversion of $417,719 of the convertible note and $11,000 of conversion fees (Note 5(b)).

	(e)	During the nine months ended June 30, 2021, the Company issued 7,730,486 shares of common stock upon the conversion of $126,000 of the convertible note and $3,150 of accrued interest (Note 5(c)).

	(f)	During the nine months ended June 30, 2021, the Company issued 16,994,905 shares of common stock upon the conversion of $106,000 of the convertible note and $2,650 of accrued interest (Note 5(d)).

	(g)	During the nine months ended June 30, 2021, the Company issued 2,600,000 shares of common stock upon the conversion of $18,923 of the convertible note and $4,500 of conversion fees (Note 5(e)).

	(h)	During the nine months ended June 30, 2021, the Company issued 3,601,718 shares of common stock upon the conversion of $46,000 of the convertible note, $5,586 of accrued interest and $500 of conversion fees (Note 5(f)).

	(i)	During the nine months ended June 30, 2021, the Company issued 17,557,925 shares of common stock upon the conversion of $82,500 of the convertible note, $7,693 of accrued interest and $3,000 of conversion fees (Note 5(g)).

	(j)	During the nine months ended June 30, 2021, the Company issued 4,431,963 shares of common stock upon the conversion of $66,150 of the convertible note, $3,907 of accrued interest (Note 5(h)).

	(k)	During the nine months ended June 30, 2021, the Company issued 41,017,383 shares of common stock upon the conversion of $75,825 of the convertible note, $2,154 of accrued interest and $18,750 of fees (Note 5(j)).

	(l)	On November 1, 2020, the Company issued 22,500 shares of common stock with a fair value of $401 for management consulting and strategic business advisory services.

	(m)	On November 26, 2020, the Company issued 45,000 shares of common stock with a fair value of $733 for management consulting and strategic business advisory services.

	(n)	On December 11, 2020, the Company issued 22,500 shares of common stock with a fair value of $221 for management consulting and strategic business advisory services.

	(o)	On February 2, 2021, the Company issued 150,000 shares of common stock with a fair value of $2,700 for management consulting and strategic business advisory services.

	(p)	On March 29, 2021, the Company issued 150,000 shares of common stock with a fair value of $4,620 for management consulting and strategic business advisory services.

	(q)	As at September 30, 2020, the Company received a conversion notice for 2,000,000 shares of common stock with a fair value of $180,000 pursuant to the conversion of $30,750 of a convertible note (see Note 5(j)). The common shares were issued on October 20, 2020.

Table of Contents

PHARMAGREEN BIOTECH INC.

Notes to the Condensed Consolidated Financial Statements

June 30, 2021

(Expressed in U.S. dollars)

(unaudited)

8.	Common Stock (continued)

	Nine months ended June 30, 2021 (continued)

	(r)	On May 14, 2021, the Company issued 611,250 units at $0.01 per unit for proceeds of $6,113 in a private placement. Each unit is comprised of one share of common stock and one share purchase warrant exercisable into an additional share of common stock at an exercise price of $0.05 per share for a period of 24 months.

	(s)	On May 14, 2021, the Company issued 6,350,000 units at $0.01 per unit for proceeds of $63,500. Each unit is comprised of one share of common stock and one share purchase warrant exercisable at $0.05 per share of common stock expiring 24 months from the date of issuance.

	(t)	As at June 30, 2021, the Company agreed to issue 6,750,000 shares of common stock with a fair value of $121,500, which has been included in shares issuable, pursuant to a production agreement (Note 11(d)).

Preferred Stock

On October 13, 2020, the Company filed a certificate of amendment to its articles of incorporation, whereby it increased the authorized capital to 2,000,000,000 shares of common stock with a par value of $0.001 per share and 1,000,000 preferred shares with a par value of $0.001. On October 14, 2020, the Company designated 10,000 preferred shares as Series A Super Voting Preferred Stock.

The Series A Super Voting Preferred Stock has the following rights and restrictions:

Dividends - Initially, there will be no dividends due or payable on the Series A Super Voting Preferred Stock. Any future terms with respect to dividends shall be determined by the Board consistent with the Corporation’s Certificate of Incorporation. Any and all such future terms concerning dividends shall be reflected in an amendment to this Certificate, which the Board shall promptly file or cause to be filed.

Liquidation and Redemption Rights - Upon the occurrence of a Liquidation Event, the holders of Series A Super Voting Preferred Stock are entitled to receive net assets on a pro-rata basis. Each holder of Series A Super Voting Preferred Stock is entitled to receive ratably any dividends declared by the Board, if any, out of funds legally available for the payment of dividends.

Rank - All shares of the Series A Super Voting Preferred Stock shall rank (i) senior to the Corporation’s (A) Common Stock, par value $0.001 per share ( “Common Stock” ), and any other class or series of capital stock of the Corporation hereafter created, except as otherwise provided in clauses (ii) and (iii) of this Section 4, (ii) pari passu with any class or series of capital stock of the Corporation hereafter created and specifically ranking, by its terms, on par with the Series A Super Voting Preferred-Stock and (iii) junior to any class or series of capital stock of the Corporation hereafter created specifically ranking, by its terms, senior to the Series A Preferred Stock, in each case as to distribution of assets upon liquidation, dissolution or winding up of the Corporation, whether voluntary or involuntary.

Voting Rights - If at least one share of Series A Super Voting Preferred Stock is issued and outstanding, then the total aggregate issued shares of Series A Super Voting Preferred Stock at any given time, regardless of their number, shall have voting rights equal to 20 times the sum of: i) the total number of shares of Common stock which are issued and outstanding at the time of voting, plus ii) the total number of shares of all Series of Preferred stocks which are issued and outstanding at the time of voting.

Each individual share of Series A Super Voting Preferred Stock shall have the voting rights equal to:

· [twenty times the sum of: {all shares of Common stock issued and outstanding at the time of voting + all shares of Series A, Series A and any newly designated Preferred stock issued and outstanding at the time of voting}] Divided by:

· [the number of shares of Series A Super Voting Preferred Stock issued and outstanding at the time of voting]

With respect to all matters upon which stockholders are entitled to vote or to which stockholders are entitled to give consent, the holders of the outstanding shares of Series A Super Voting Preferred Stock shall vote together with the holders of Common Stock without regard to class, except as to those matters on which separate class voting is required by applicable law or the Certificate of Incorporation or By-laws.

Table of Contents

PHARMAGREEN BIOTECH INC.

Notes to the Condensed Consolidated Financial Statements

June 30, 2021

(Expressed in U.S. dollars)

(unaudited)

Preferred Stock (continued)

Protective Provisions - So long as any shares of Series A Super Voting Preferred Stock are outstanding, the Corporation shall not, without first obtaining the unanimous written consent of the holders of Series A Super Voting Preferred Stock, alter or change the rights, preferences or privileges of the Series A Super Voting Preferred so as to affect adversely the holders of Series A Super Voting Preferred Stock.

On October 14, 2020, the Company issued 10,000 shares of Series A Super Voting Preferred Stock to a Director of the Company for proceeds of $10. In connection with the issuance of the Series A Super Voting Preferred Stock, the Company evaluated whether the preferred stock should be classified as a liability based on the guidance under ASC 480, Distinguishing Liabilities from Equity. The Series A Super Voting Preferred Stock are not considered mandatorily redeemable, are not settleable in a variable number of shares, and do not contain any features embedded that required a separate assessment. As a result, the Company determined the Series A Super Voting Preferred Stock were not a liability and classified the preferred stock within equity in the amount of the aggregate par value of the issued shares of preferred stock, with any excess attributed to additional paid-in capital.

10.	Share Purchase Warrants

	The following table summarizes the continuity of the Company’s share purchase warrants:

	Number of warrants		Weighted average exercise price $

Balance, September 30, 2020		114,286		0.55

Issued		29,772,500		0.05

Balance, June 30, 2021		29,886,786		0.05

As at June 30, 2021, the following share purchase warrants were outstanding:

Number of warrants		Exercise price		Expiry date

	114,286	$	0.55	July 16, 2022
	400,000	$	0.05	December 2, 2022
	3,000,000	$	0.05	December 11, 2022
	2,000,000	$	0.05	December 30, 2022
	2,300,000	$	0.05	January 11, 2023
	13,500,000	$	0.05	January 30, 2023
	1,000,000	$	0.05	February 16, 2023
	611,250	$	0.05	March 1, 2023
	6,961,250	$	0.05	May 14, 2023

	29,886,786

Table of Contents

PHARMAGREEN BIOTECH INC.

Notes to the Condensed Consolidated Financial Statements

June 30, 2021

(Expressed in U.S. dollars)

(unaudited)

11.

Commitments

	(a)	Effective December 11, 2017, the Company entered into a binding Letter of Intent (“LOI”) with Alliance Growers Corp. (“Alliance”), whereby the Company will build a new cannabis biotech complex located in Deroche, British Columbia, through their subsidiary, 115BC. On January 25, 2019, the Company’s subsidiaries WFS and 115BC entered into an option agreement with Alliance, which superseded the LOI entered into on December 11, 2017. The option agreement grants an option to Alliance to purchase 10% equity interest in 115BC for Cdn$1,350,000 and previously granted a second option to purchase an additional 20% equity interest in 115BC for funding of 30% of the total construction and equipment costs for the biotech complex less Cdn$1,350,000. On January 25, 2019, 115BC issued 8 shares of common stock to Alliance upon exercise of the first option for consideration of $1,018,182 (Cdn$1,350,008), which was recognized as additional paid-in capital. The second option expired unexercised. As at June 30, 2021, the Company received advances of $60,450 (Cdn$75,000) (September 30, 2020 - $56,303 (Cdn$75,000)) from Alliance, which is unsecured, non-interest bearing, and due on demand.

	(b)	On November 22, 2019, the Company entered into an equity purchase agreement with an unrelated party, whereby the third party is to purchase up to $10,000,000 of the Company’s common stock. The equity purchase agreement is effective for a term of 2 years from the effective date of the registration statement. The purchase price would be 85% of the market price. In return, the Company issued a promissory note of $40,000 (Refer to Note 4(a)). In addition, the third party is required to pay an additional commitment fee of $10,000, of which $5,000 was paid upon signing the term sheet and the remaining $5,000 is due upon completion of the first tranche of the financing.

	(c)	On December 13, 2020, the Company entered into a consulting agreement with a six month term. Pursuant to the agreement, the Company will 75,000 shares of common stock per month in exchange for consulting services. On June 13, 2021, the Company extended the consulting agreement for an additional six month term for the issuance of 117,000 common shares per month. Refer to Note 12(a).

	(d)	Effective May 13, 2021, the Company entered into a production agreement with New to the Street Group LLC. Pursuant to the terms of the agreement, New to the Street Group LLC will provide investor relations and consulting services for a period of six months. Pursuant to the agreement,the Company agreed to pay New to the Street Group LLC $3,500 upon signing, $3,500 per month and 6,750,000 restricted shares of the Company’s common stock. At June 30, 2021, the 6,750,000 restricted shares of common stock have not been issued.

	(e)	Effective May 14, 2021, the Company entered into a Software as a Service Agreement with Novation Solutions Inc. (“DealMaker”) to effect the Company’s planned Regulation A offering, including the set-up of an automated tracking, signing, and reconciliation portal. The Company will pay DealMaker $3,000 upon signing the agreement, $7,000 payable within 30 days of launching the portal, and a post launch monthly fee of $1,000.

12.

Subsequent Events

	(a)	On July 13, 2021, the Company issued 702,000 common shares for consulting services. Refer to Note 11(c).

	(b)	Subsequent to the nine months ended June 30, 2021, the Company received common stock subscriptions totaling $56,000 in connection with the proposed issuance of 5,600,000 shares of common stock at $0.01 per unit. Each unit will be comprised of one share of common stock and one share purchase warrant exercisable into an additional share of common stock at an exercise price of $0.05 per share for a period of 24 months.

Table of Contents

Item 2. Management’s Discussion and Analysis of Financial Condition and Results of Operations.

Forward-Looking Statements

This section of the Form 10-Q includes a number of forward-looking statements that reflect our current views with respect to future events and financial performance. Forward-looking statements are often identified by words like believe, expect, estimate, anticipate, intend, project and similar expressions, or words which, by their nature, refer to future events. You should not place undue certainty on these forward-looking statements. These forward-looking statements are subject to certain risks and uncertainties that could cause actual results to differ materially from our predictions.

Company History Overview

Pharmagreen Biotech Inc. (“the Company”) was incorporated under the laws of Nevada, U.S. on November 26, 2007 under the name Azure International, Inc. On October 30, 2008 and effective as of the same date, the Company filed Articles of Merger with the Secretary of the State of Nevada, to effect a merger by and between Air Transport Group Holdings, Inc., a Nevada corporation incorporated on October 16, 2008, and Azure International, Inc. As a result of the merger, the Company changed its name to Air Transport Group Holdings, Inc.

On April 12, 2018, the Company entered into a share exchange agreement with WFS Pharmagreen Inc., a private company incorporated under the laws of British Columbia, Canada, whereby the Company acquired all of the issued and outstanding shares of WFS Pharmagreen Inc. in exchange for 37,704,500 shares of common stock of the Company. Upon completion of this transaction, the shareholders of WFS Pharmagreen hold 95.5% of voting control of the Company.

Immediately prior to closing of the Agreement, the majority shareholder of the Company was also the majority shareholder of WFS. As a result of the common ownership upon closing of the transaction, the acquisition was considered a common-control transaction and was outside the scope of the business combination guidance in ASC 805-50. The entities are deemed to be under common control as of February 27, 2018, which was the date that the majority shareholder acquired control of the Company and, therefore, held control over both companies. On May 2, 2018, the Share Exchange Agreement was effected. In connection with this transaction, the Company changed its name on May 8, 2018 to Pharmagreen Biotech Inc. and changed its year end from April 30th to September 30th.

Our principal executive offices are temporarily located at 2987 Blackbear Court, Coquitlam, British Columbia, Canada. Our telephone number is (702-803-9404). Our internet address is www.pharmagreen.ca.

On August 7, 2020, our company (including our subsidiaries) filed voluntary petitions under Chapter 11 of the United States Bankruptcy Code in the United States Bankruptcy Court for the District of Nevada, Case No. 20-13886.

We expect to continue to incur losses for at least the next 12 months. We do not expect to generate revenue that is sufficient to cover our expenses, and we do not have sufficient cash and cash equivalents to execute our plan of operations for at least the next twelve months. We will need to obtain additional financing, through equity security sales, debt instruments and private financing, to conduct our day-to-day operations, and to fully execute our business plan. We plan to raise the capital necessary to fund our business through the sale of equity securities, debt instruments or private financing. These factors raise substantial doubt upon the Company’s ability to continue as a going concern. This report does not reflect all the adjustments that may be necessary if the Company is unable to continue as a going concern.

Table of Contents

Our Current Business

Pharmagreen Biotech Inc. (the “Company”) was incorporated under the laws of the State of Nevada on November 26, 2007. The Company is headquartered in Coquitlam, British Columbia. The Company’s mission is to advance the technology of tissue culture science and to provide the highest quality 100% germ free, disease free and all genetically the same plantlets of high CBD hemp and other flora and offering full spectrum DNA testing for plant identification, live genetics preservation using low temperature storage for various cannabis and horticulture plants; extraction of botanical oils mainly CBD oil, and to deliver laboratory based services to the North American high CBD hemp, Cannabis and agriculture sectors.

Management cannot provide assurance that the Company will ultimately achieve profitable operations or become cash flow positive, or raise additional debt and/or equity capital. However, if the Company is unable to raise additional capital in the near future, due to the Company’s liquidity problems, management expects that the Company will need to curtail operations, liquidate assets, seek additional capital on less favourable terms and/or pursue other remedial measures. These consolidated financial statements do not include any adjustments related to the recoverability and classification of assets or the amounts and classification of liabilities that might be necessary should the Company be unable to continue as a going concern.

The Company has decided that immediate business development in the hemp and cannabis industries provides a much greater opportunity in the United States. The project at Deroche has been placed on hold while the Company moves forward to build out a similar infrastructure planned for Deroche within the United States.

Subsequent to June 30, 2021, more specifically July 25th 2021, the Company entered into a Memorandum of Understanding to acquire all the assets and cannabis business operation (includes 12 acres property, structure and cannabis licenses, existing sales channels and distribution networks) from a private company situated in Northern California. Upon reaching a definitive agreement, the Company intends to further develop a state-of-the-art flowering greenhouse of approximately 12,000 square feet or the maximum allowed by California State and Regional County. The acquisition price is $2.4 million to be paid through a combination of cash and shares. The Company also has an option from the seller to acquire an additional 120 acres or more of land for business expansion and development. The Company currently lacks funds with which to consummate the contemplated transaction and has not negotiated a definitive agreement with respect to the contemplated transaction. Thus, there is no assurance that the Company will ever enter into, and consummate, a definitive agreement with respect to the contemplated transaction.

Capital Resources and Liquidity

Our auditors have issued a “going concern” opinion for our year ended September 30, 2020, meaning that there is substantial doubt if we can continue as an on-going business unless we obtain additional capital. No substantial revenues from our planned business model are anticipated until we have completed financing the Company. As at June 30, 2021, we had a working capital deficit of $1,802,567, and an accumulated deficit of $10,867,990. During the nine months ended June 30, 2021, we have not earned any revenues from our operations and used cash of $151,237 for our operating activities.

Table of Contents

We need to seek capital from resources such as the sale of private placements in the Company’s common stock or debt financing, which may not even be available to the Company. However, if such financing were available, because we are a, early-stage company with no or limited operations to date, it would likely have to pay additional costs associated with such financing and in the case of high risk loans be subject to an above market interest rate. At such time these funds are required, management would evaluate the terms of such financing. If the Company cannot raise additional proceeds via such financing, it may be required to cease business operations.

As of June 30, 2021, we had $19,218 in cash as compared to $12,196 in cash and prepaid expenses and deposits of $253,754 as of September 30, 2020. As of the date of this Form 10-Q, the current funds available to the Company will not be sufficient to fund the expenses related to maintaining our planned operations. We are in the process of seeking additional equity financing in the form of private placements, loans and registration statements to fund our intended business operations.

Management believes that if subsequent private placements are successful or we are successful in raising funds from registered securities, we will generate sales revenue within twelve months thereof. However, additional equity financing may not be available to us on acceptable terms or at all, and thus we could fail to satisfy our future cash requirements.

We do not anticipate researching any further products nor the purchase or sale of any significant equipment. We also do not expect any significant additions to the number of employees.

Results of Operations

Three Months Ended June 30, 2021

We had $nil in revenue for the three months ended June 30, 2021 and 2020.

Total expenses in the three months ended June 30, 2021 were $232,380 as compared to total expenses for the three months ended June 30, 2020 of $86,914. The net increase in expenses during the current period is mainly due to an increase in consulting fees from $30,108 in 2020 to $190,794 in 2021, which was mainly related to a production agreement entered into with New to the Street Group LLC on May 13, 2021.

We incurred a comprehensive loss of $1,377,795 during the three months ended June 30, 2020, compared to a comprehensive loss of $155,360 during the three months ended June 30, 2021. The decrease in comprehensive loss in 2021 was mainly attributable to a change in fair value of derivative liabilities from a loss of $1,187,033 in 2020 to a gain of $101,418 in 2021, as the Company had significantly more convertible debt in the prior year which resulted in more fluctuations of the derivative liability due to the floating rates attached to the conversion rights to the convertible debt.

During the three months ended June 30, 2021 and 2020, we incurred a net loss of $nil and $0.02 per share respectively.

Nine Months Ended June 30, 2021

We had $nil in revenue for the nine months ended June 30, 2021 and 2020.

Total expenses in the nine months ended June 30, 2021 were $470,953 as compared to total expenses for the nine months ended June 30, 2020 of $354,632. The net increase in expenses during the current period is mainly due to an increase in consulting fees from $153,999 in 2020 to $296,987 in 2021, which was mainly related to a production agreement entered into with New to the Street Group LLC on May 13, 2021.

We incurred a comprehensive loss of $3,769,058 during the nine months ended June 30, 2021, compared to a comprehensive loss of $1,568,200 during the nine months ended June 30, 2020. The increase in comprehensive loss during 2021 was mainly attributable to interest and finance costs of $673,124 compared to $45,000 in 2020, and a loss on change in fair value of derivative liabilities from $1,347,031 in 2020 to $3,083,420 in 2021, offset by a loss on settlement of convertible notes from $38,411 in 2020 to a gain of $613,526 in 2021.

During the nine months ended June 30, 2021, and 2020, we incurred a net loss of $0.01 and $0.02 per share, respectively.

Table of Contents

Off-balance Sheet Arrangements

The Company has no off-balance sheet arrangements that have or are reasonably likely to have a current or future effect or change on the company’s financial condition, revenues or expenses, results of operations, liquidity, capital expenditures or capital resources that are material to investors. The term “off-balance sheet arrangement” generally means any transaction, agreement or other contractual arrangement to which an entity unconsolidated with the company is a party, under which the company has (i) any obligation arising under a guarantee contract, derivative instrument or variable interest; or (ii) a retained or contingent interest in assets transferred to such entity or similar arrangement that serves as credit, liquidity or market risk support for such assets.

Item 3. Quantitative and Qualitative Disclosures About Market Risk.

We are a smaller reporting company as defined by Rule 12b-2 of the Exchange Act and are not required to provide the information required under this item.

Item 4. Controls and Procedures.

Evaluation of Disclosure Controls and Procedures

Disclosure controls and procedures are controls and other procedures that are designed to ensure that information required to be disclosed in our reports filed or submitted under the Securities Exchange Act of 1934 is recorded, processed, summarized and reported, within the time period specified in the SEC’s rules and forms. Disclosure controls and procedures include, without limitation, controls and procedures designed to ensure that information required to be disclosed in our reports filed or submitted under the Securities Exchange Act of 1934 is accumulated and communicated to management including our principal executive officer and principal financial officer as appropriate, to allow timely decisions regarding required disclosure.

In connection with this quarterly report, as required by Rule 15d-15 under the Securities Exchange Act of 1934, we have carried out an evaluation of the effectiveness of the design and operation of our company’s disclosure controls and procedures. This evaluation was carried out under the supervision and with the participation of our company’s management, including our company’s principal executive officer and principal financial officer. Based upon that evaluation, our company’s principal executive officer and principal financial officer concluded that as of June 30, 2021 our disclosure controls and procedures were not effective due to the existence of material weaknesses in our internal controls over financial reporting.

Changes in Internal Control Over Financial Reporting

There were no changes in our internal control over financial reporting (as defined in Rule 13a-15(f) or 15d-15(f)) during the quarter ended June 30, 2021 that have materially affected, or are reasonably likely to materially affect, our internal controls over financial reporting.

Saturna Group Chartered Professional Accountants LLP, our independent auditors, are not required to and have not performed an assessment of our internal controls over financial reporting.

Table of Contents

PART II—OTHER INFORMATION

Item 1. Legal Proceedings.

On July 22, 2020, the Company received a preliminary statement of claim from a convertible note holder for failure of the Company to deliver shares of common stock upon receipt of notices of conversion. Pursuant to the claim, the plaintiff has requested receipt of all shares of common stock requested in the notices of conversion, and also damages in an amount to be determined at trial but in any event in excess of principal amount of $78,000 for a total sum of $180,000, including without limitation the balance of any portion of the convertible note that ultimately is not converted into shares of common stock, along with default interest, liquidated damages, and damages as provided for in the convertible note.

On October 9, 2020, a stay order was lifted by a United States District Judge of the United States District Court for the Southern District of New York, on an action filed by a lender. This effectively removed the Company from its Chapter 11 bankruptcy proceedings and protection. The lifting of the stay order further allowed the convertible note holders to convert thereby increasing the number of shares issued and outstanding.

On October 29, 2020 a second note holder filed a statement of claim. This lender, as of December 24, 2020, has completely converted the full amount of the note of $100,000, interest of $8,689.80 and penalty and fees aggregating $19,500.

Also, as mentioned above, the Company filed voluntary petitions for reorganization under chapter 11 of the United States Bankruptcy Code in the United States Bankruptcy Court for the District of Nevada on August 7, 2020. The Company’s filing with the Court was designated as Case No. 20-13886. During the pendency of this matter, the Company has also filed motions with the Court seeking authorization to continue to operate its businesses as “debtors-in-possession” under the jurisdiction of the Court and in accordance with the applicable provisions of the Bankruptcy Code and orders of the Court. Due to the stay order mentioned, the Company did not file a plan of reorganization with the Court for approval.

On March 12, 2021, the Company entered into a settlement agreement with the convertible noteholder that had filed a preliminary statement of claim on July 22, 2020. Pursuant to the agreement the Company was required to honor various conversion notices and the noteholder agreed to wave all principal, interest and penalties incurred.

On March 10, 2021, the promissory note holder referred to in Note 4 (a) of the accompanying financial statements filed a Notice of Motion For Summary Judgement in Lieu of Complaint (the “Notice”) with the State of New York Supreme Court, County of New York for $40,504 plus interest at the rate of 10% per annum from January 6, 2021 plus costs. On July 31, 2021, the Notice was dismissed without prejudice by the State of New York Supreme Court.

Except as mentioned in the preceding paragraphs, there are no pending legal proceedings to which the Company is a party or in which any director, officer or affiliate of the Company, any owner of record or beneficially of more than 5% of any class of voting securities of the Company, or stockholder is a party adverse to the Company or has a material interest adverse to the Company.

Item 1A. Risk Factors.

As a “smaller reporting company,” as defined in Rule 12b-2 of the Exchange Act, we are not required to provide the information called for by this Item.

Item 2. Unregistered Sales of Securities and Use of Proceeds.

During the three months ended June 30, 2021, we issued a total of 6,961,250 units of our securities (each unit is comprised of one share of common stock and one warrant purchase an additional share of common stock at an exercise price of $0.05 per share for a period of 24 months) for a total of $69,613 in cash. These funds were used for operating expenses.

Item 3. Defaults Upon Senior Securities.

The commencement of the Chapter 11 Cases discussed above constituted an event of default under certain of the Company’s debt instruments, including various convertible notes, which resulted in automatic acceleration of the Company’s obligations under such debt instruments. As of the date of this Quarterly Report, we are in default under two separate convertible debt instruments.

Item 4. Mine Safety Disclosure.

N/A

Item 5. Other Information.

None

Table of Contents

Item 6. Exhibits.

The following documents are filed as a part of this report or are incorporated by reference to previous filings, if so indicated:

Exhibit Number		Description

2.1		Articles of Incorporation and Bylaws dated November 26, 2007 as previously filed with the SEC on March 20, 2019

2.2		Articles of Merger dated, October 30, 2008 (Azure International, Inc./ Air Transport Group Holding, Inc. as previously filed with the SEC on March 20, 2019

2.10		Equity Purchase Agreement with Oscaleta Partners LLC as previously filed with the SEC on December 2, 2019

2.11		Registration Rights Agreement with Oscaleta Partners LLC as previously filed with the SEC on December 2, 2019

31.1		Certification of Principal Financial Officer Pursuant to Rule 13a-14(a) or 15d-14(a) of the Securities Exchange Act of 1934*

31.2		Certification of Chief Executive Officer Pursuant to Rule 13a–14(a) or 15d-14(a) of the Securities Exchange Act of 1934**

32.1		Certification of Chief Executive Officer under Section 1350 as Adopted Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002

32.2		Certification of Principal Financial Officer under Section 1350 as Adopted Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002**

* Included in Exhibit 31.1

** Included in Exhibit 32.1

Table of Contents

SIGNATURES*

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.

	Pharmagreen Biotech Inc.

Dated August 16, 2021	By:	/s/ Peter Wojcik
		Peter Wojcik
		President and Director Principal Executive Officer

	By:	/s/ Terry Kwan
		Terry Kwan
		Principal Accounting Officer

EX-31.1 2 phbi_ex311.htm CERTIFICATION phbi_ex311.htm

EXHIBIT 31.1

CERTIFICATION

Peter Wojcik and Terry Kwan, certify that:

1.	We have reviewed this quarterly report on Form 10-Q of Pharmagreen Biotech Inc. for the quarter ended June 30, 2021;

2.	Based on our knowledge, this quarterly report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this quarterly report;

3.	Based on our knowledge, the financial statements, and other financial information included in report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this quarterly report;

4.	We are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:

	(a)	Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;

	(b)	Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;

	(c)	Evaluated the effectiveness of the registrant’s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation;

	(d)	Disclosed in this report any change in the registrant’s internal control over financial reporting that occurred during the registrant’s most recent fiscal quarter (the registrant’s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant’s internal control over financial reporting; and

5.	We have disclosed, based on our most recent evaluation, to the registrant's auditors and the audit committee of registrant's board of directors (or persons performing the equivalent functions):

	(a)	All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant’s ability to record, process, summarize and report financial information; and

	(b)	Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant's internal controls over financial reporting.

August 16, 2021

By:	/s/ Peter Wojcik
	Peter Wojcik
	President and Director
	Principal Executive Officer

By:	/s/ Terry Kwan
	Terry Kwan
	Principal Accounting Officer

EX-32.1 3 phbi_ex321.htm CERTIFICATION phbi_ex321.htm

EXHIBIT 32.1

CERTIFICATION PURSUANT TO 18 U.S.C. 1350 AS ADOPTED

PURSUANT TO SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002

In connection with the Quarterly Report on Form 10-Q of Pharmagreen Biotech Inc. (the “Company”) for the quarter ended June 30, 2021 as filed with the Securities and Exchange Commission on the date hereof (the Report), we, Peter Wojcik, Principal Executive Officer of the Company and Terry Kwan, Principal Financial Officer of the Company certify, pursuant to 18 U.S.C. 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that:

	1.	The Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934; and

	2.	The information contained in the Report fairly presents, in all material respects the financial condition and results of operations of the Company.

August 16, 2021

/s/ Peter Wojcik
Peter Wojcik
President and Director Principal Executive Officer

/s/ Terry Kwan
Terry Kwan Principal Accounting Officer

EX-101.SCH 4 phbi-20210630.xsd XBRL TAXONOMY EXTENSION SCHEMA 000001 - Document - Cover link:presentationLink link:calculationLink link:definitionLink 000002 - Statement - Condensed Consolidated Balance Sheets link:presentationLink link:calculationLink link:definitionLink 000003 - Statement - Condensed Consolidated Balance Sheets (Parenthetical) link:presentationLink link:calculationLink link:definitionLink 000004 - Statement - Condensed Consolidated Statements of Operations and Comprehensive Income (Loss) (Unaudited) link:presentationLink link:calculationLink link:definitionLink 000005 - Statement - Condensed Consolidated Statements of Stockholders' Deficit (Unaudited) link:presentationLink link:calculationLink link:definitionLink 000006 - Statement - Condensed Consolidated Statements of Cash Flows (Unaudited) link:presentationLink link:calculationLink link:definitionLink 000007 - Disclosure - Nature of Business and Continuance of Operations link:presentationLink link:calculationLink link:definitionLink 000008 - Disclosure - Summary of Significant Accounting Policies link:presentationLink link:calculationLink link:definitionLink 000009 - Disclosure - Accounts Payable and Accrued Liabilities link:presentationLink link:calculationLink link:definitionLink 000010 - Disclosure - Note and Loan Payable link:presentationLink link:calculationLink link:definitionLink 000011 - Disclosure - Convertible Notes link:presentationLink link:calculationLink link:definitionLink 000012 - Disclosure - Derivative Liabilities link:presentationLink link:calculationLink link:definitionLink 000013 - Disclosure - Related Party Transactions link:presentationLink link:calculationLink link:definitionLink 000014 - Disclosure - Common Stock link:presentationLink link:calculationLink link:definitionLink 000015 - Disclosure - Preferred Stock link:presentationLink link:calculationLink link:definitionLink 000016 - Disclosure - Share Purchase Warrants link:presentationLink link:calculationLink link:definitionLink 000017 - Disclosure - Commitments link:presentationLink link:calculationLink link:definitionLink 000018 - Disclosure - Subsequent Events link:presentationLink link:calculationLink link:definitionLink 000019 - Disclosure - Summary of Significant Accounting Policies (Policies) link:presentationLink link:calculationLink link:definitionLink 000020 - Disclosure - Accounts Payable and Accrued Liabilities (Tables) link:presentationLink link:calculationLink link:definitionLink 000021 - Disclosure - Derivative Liabilities (Tables) link:presentationLink link:calculationLink link:definitionLink 000022 - Disclosure - Share Purchase Warrants (Tables) link:presentationLink link:calculationLink link:definitionLink 000023 - Disclosure - Nature of Business and Continuance of Operations (Details Narrative) link:presentationLink link:calculationLink link:definitionLink 000024 - Disclosure - Accounts Payable and Accrued Liabilities (Details) link:presentationLink link:calculationLink link:definitionLink 000025 - Disclosure - Note and Loan Payable (Details Narrative) link:presentationLink link:calculationLink link:definitionLink 000026 - Disclosure - Convertible Notes (Details Narrative) link:presentationLink link:calculationLink link:definitionLink 000027 - Disclosure - Derivative Liabilities (Details) link:presentationLink link:calculationLink link:definitionLink 000028 - Disclosure - Derivative Liabilities (Details 1) link:presentationLink link:calculationLink link:definitionLink 000029 - Disclosure - Related Party Transactions (Details Narrative) link:presentationLink link:calculationLink link:definitionLink 000030 - Disclosure - Common Stock (Details Narrative) link:presentationLink link:calculationLink link:definitionLink 000031 - Disclosure - Preferred Stock (Details Narrative) link:presentationLink link:calculationLink link:definitionLink 000032 - Disclosure - Share Purchase Warrants (Details) link:presentationLink link:calculationLink link:definitionLink 000033 - Disclosure - Share Purchase Warrants (Details 1) link:presentationLink link:calculationLink link:definitionLink 000034 - Disclosure - Commitments (Details Narrative) link:presentationLink link:calculationLink link:definitionLink 000035 - Disclosure - Subsequent Events (Details Narrative) link:presentationLink link:calculationLink link:definitionLink EX-101.LAB 5 phbi-20210630_lab.xml XBRL TAXONOMY EXTENSION LABEL LINKBASE Cover [Abstract] Entity Registrant Name Entity Central Index Key Document Type Amendment Flag Current Fiscal Year End Date Entity Small Business Entity Shell Company Entity Emerging Growth Company Entity Current Reporting Status Document Period End Date Entity Filer Category Document Fiscal Period Focus Document Fiscal Year Focus Entity Ex Transition Period Entity Common Stock Shares Outstanding Document Quarterly Report Document Transition Report Entity File Number Entity Incorporation State Country Code Entity Tax Identification Number Entity Address Address Line 1 Entity Address City Or Town Entity Address State Or Province Entity Address Postal Zip Code City Area Code Local Phone Number Entity Interactive Data Current Condensed Consolidated Balance Sheets Assets Current assets Cash Amounts receivable Prepaid expenses and deposits Total assets [Assets] Liabilities and Stockholders' Deficit Current liabilities Accounts payable and accrued liabilities (Notes 3 and 7) Advances from Alliance Growers Corp. (Note 11(a)) Due to related parties (Note 7) Note payable (Note 4) Convertible notes - current portion, net of unamortized discount of $Nil and $182,012, respectively (Note 5) Derivative liabilities (Note 6) Total current liabilities [Liabilities, Current] Loan payable (Note 4) Convertible notes, net of unamortized discount of $20,696 and $23,619, respectively (Note 5) Total liabilities [Liabilities] Stockholders' deficit Preferred stock Authorized: 1,000,000 shares, $0.001 par value; 10,000 and nil shares issued and outstanding, respectively Common stock Authorized: 2,000,000,000 shares, $0.001 par value; 355,129,269 and 95,806,289 shares issued and outstanding, respectively Common stock issuable (Note 8) Additional paid-in capital Accumulated other comprehensive income (loss) Deficit Total Pharmagreen Biotech Inc. stockholders' deficit Non-controlling interest Total stockholders' deficit [Stockholders' Equity Attributable to Parent] Total liabilities and stockholders' deficit Convertible Notes, Unamortized Discount, Current Convertible Notes, Unamortized Discount, Noncurrent Preferred Stock, Par Value Preferred Stock, Shared Authorized Preferred Stock, Shares Issued Preferred Stock, Shares Outstanding Common Stock, Par Value Common Stock, Shares Authorized Common Stock, Shares Issued Common Stock, Shares Outstanding Condensed Consolidated Statements of Operations and Comprehensive Income (Loss) (Unaudited) Expenses Consulting fees (Note 7) Foreign exchange loss (gain) General and administrative Professional fees Salaries and wages Total expenses [Operating Expenses] Net loss before other income (expense) Other income (expense) Accretion of discount on convertible notes (Note 5) [Accretion (Amortization) of Discounts and Premiums, Investments] Gain (loss) on change in fair value of derivative liabilities (Note 6) Gain (loss) on settlement on convertible notes (Note 5) Interest and finance costs (Note 5) [Interest Expense] Write-off of accounts payable Total other income (expense) [Nonoperating Income (Expense)] Net loss [Net Income (Loss) Attributable to Parent] Less: net loss attributable to non-controlling interest Net loss attributable to Pharmagreen Biotech Inc. Comprehensive income (loss) Foreign currency translation gain (loss) Comprehensive loss attributable to Pharmagreen Biotech Inc. Basic and diluted loss per share attributable to Pharmagreen Biotech Inc. stockholders Weighted average number of shares outstanding used in the calculation of net loss per share attributable to Pharmagreen Biotech Inc. Condensed Consolidated Statements of Stockholders' Deficit (Unaudited) Statement [Table] Statement [Line Items] Statement Equity Components [Axis] Preferred Stock Preferred Stock [Member] Common Stock Common Stock [Member] Common Stock Issuable [Member] Additional Paid-In Capital Accumulated other comprehensive loss Retained Earnings (Accumulated Deficit) Noncontrolling Interest Balance, shares [Shares, Issued] Balance, amount Foreign currency translation loss Net loss for the period Issuance of common stock pursuant to the conversion of convertible notes, shares Issuance of common stock pursuant to the conversion of convertible notes, amount Issuance of units for cash, shares Issuance of units for cash, amount Issuance of preferred shares for cash, shares Issuance of preferred shares for cash, amount Issuance of common stock for services, shares Issuance of common stock for services, amount Shares issuable for services Balance, shares Balance, amount Condensed Consolidated Statements of Cash Flows (Unaudited) OPERATING ACTIVITIES Net loss Adjustments to reconcile net loss to net cash used in operating activities: Accretion of discount on convertible notes Financing fees and default penalties Loss on change in fair value of derivative liabilities Loss (gain) on settlement of convertible notes Shares issued or issuable for services Write-off of accounts payable Changes in operating assets and liabilities: Amounts receivable [Increase (Decrease) in Accounts and Other Receivables] Prepaid expenses and deposits [Increase (Decrease) in Prepaid Expense] Accounts payable and accrued liabilities Due to related parties Net cash used in operating activities [Net Cash Provided by (Used in) Operating Activities] FINANCING ACTIVITIES Proceeds from issuance of convertible notes Proceeds from units issued and issuable for cash Proceeds from issuance of preferred shares Repayment of loans from related parties [Repayment of loans from related parties] Proceeds from related party loans Proceeds from loans payable Financing costs [Payment of Financing and Stock Issuance Costs] Net cash provided by financing activities [Net Cash Provided by (Used in) Financing Activities] Effect of foreign exchange rate changes on cash Change in cash [Cash, Period Increase (Decrease)] Cash, beginning of period Cash, end of period Non-cash investing and financing activities: Original issue discount on convertible notes Common shares issued for settlement of convertible notes Issuance of promissory note as a financing fee Supplemental disclosures: Interest paid Income taxes paid Nature of Business and Continuance of Operations 1. Nature of Business and Continuance of Operations Summary of Significant Accounting Policies 2. Summary of Significant Accounting Policies Accounts Payable and Accrued Liabilities 3. Accounts Payable and Accrued Liabilities Note and Loan Payable 4. Note and Loan Payable Convertible Notes 5. Convertible Notes Derivative Liabilities 6. Derivative Liabilities Related Party Transactions 7. Related Party Transactions Common Stock 8. Common Stock Preferred Stock 9. Preferred Stock Share Purchase Warrants 10. Share Purchase Warrants Commitments 11. Commitments Subsequent Events 12. Subsequent Events Interim Financial Statements Basis of Presentation Use of Estimates and Judgments Recently Adopted Accounting Pronouncements Schedule of Accounts Payable and Accrued Liabilities Schedule of Derivative Liability Schedule of weighted-average assumptions used in the calculations EX-101.CAL 6 phbi-20210630_cal.xml XBRL TAXONOMY EXTENSION CALCULATION LINKBASE EX-101.PRE 7 phbi-20210630_pre.xml XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE EX-101.DEF 8 phbi-20210630_def.xml XBRL TAXONOMY EXTENSION DEFINITION LINKBASE XML 9 phbi_10q_htm.xml IDEA: XBRL DOCUMENT 0001435181 2020-10-01 2021-06-30 0001435181 phbi:CAMember phbi:AllianceGrowersCorpMember 2020-09-30 0001435181 phbi:CAMember phbi:AllianceGrowersCorpMember 2021-06-30 0001435181 phbi:CAMember phbi:AllianceGrowersCorpMember 2019-01-24 2019-01-25 0001435181 phbi:AllianceGrowersCorpMember 2021-06-30 0001435181 phbi:AllianceGrowersCorpMember 2019-01-24 2019-01-25 0001435181 phbi:AllianceGrowersCorpMember 2020-09-30 0001435181 phbi:NovationSolutionsIncMember 2021-05-01 2021-05-14 0001435181 phbi:NewToTheStreetGroupLLCMember 2021-06-30 0001435181 2021-06-13 0001435181 2020-12-13 0001435181 phbi:EquityPurchaseAgreementMember 2019-11-01 2019-11-22 0001435181 phbi:EquityPurchaseAgreementMember 2019-11-22 0001435181 phbi:NewToTheStreetGroupLLCMember 2021-05-01 2021-05-13 0001435181 phbi:EquityPurchaseAgreementMember 2021-06-30 0001435181 phbi:ConsultingAgreementMember 2021-06-01 2021-06-13 0001435181 phbi:WarrantsThreeMember 2020-10-01 2021-06-30 0001435181 phbi:WarrantsTwoMember 2020-10-01 2021-06-30 0001435181 phbi:WarrantsNineMember 2020-10-01 2021-06-30 0001435181 phbi:WarrantsEightMember 2020-10-01 2021-06-30 0001435181 phbi:WarrantsSevenMember 2020-10-01 2021-06-30 0001435181 phbi:WarrantsSixMember 2020-10-01 2021-06-30 0001435181 phbi:WarrantsFiveMember 2020-10-01 2021-06-30 0001435181 phbi:WarrantsFourMember 2020-10-01 2021-06-30 0001435181 phbi:WarrantsOneMember 2020-10-01 2021-06-30 0001435181 phbi:WarrantsMember 2021-06-30 0001435181 phbi:WarrantsMember 2020-10-01 2021-06-30 0001435181 phbi:WarrantsMember 2020-09-30 0001435181 2020-10-13 0001435181 us-gaap:PrivatePlacementMember 2020-12-31 0001435181 us-gaap:PrivatePlacementMember 2020-12-01 2020-12-31 0001435181 us-gaap:PrivatePlacementMember 2021-02-28 2021-03-01 0001435181 us-gaap:PrivatePlacementMember 2021-01-01 2021-01-11 0001435181 us-gaap:PrivatePlacementMember 2021-01-11 0001435181 us-gaap:PrivatePlacementMember 2021-05-14 0001435181 us-gaap:PrivatePlacementMember 2021-05-01 2021-05-14 0001435181 us-gaap:PrivatePlacementMember 2021-03-01 0001435181 phbi:MayFourteenTwoThousandTwentyOneMember 2021-05-14 0001435181 2020-09-01 2020-09-30 0001435181 phbi:MarchTwentyNineTwoThousandTwentyOneMember 2020-10-01 2021-06-30 0001435181 phbi:FebruaryTwoTwoThousandTwentyOneMember 2020-10-01 2021-06-30 0001435181 phbi:DecemberElevenTwoThousandTwentyMember 2020-10-01 2021-06-30 0001435181 phbi:NovemberTwentySixTwoThousandTwentyMember 2020-10-01 2021-06-30 0001435181 phbi:NovemberOneTwoThousandTwentyMember 2020-10-01 2021-06-30 0001435181 phbi:ConvertibleNotesPayableSevenMember 2020-10-01 2021-06-30 0001435181 phbi:ConvertibleNotesPayableSixMember 2020-10-01 2021-06-30 0001435181 phbi:MayFourteenTwoThousandTwentyOneMember 2021-05-01 2021-05-14 0001435181 phbi:ConvertibleNotesPayableFiveMember 2020-10-01 2021-06-30 0001435181 phbi:ConvertibleNotesPayableFourMember 2020-10-01 2021-06-30 0001435181 phbi:ConvertibleNotesPayableThreeMember 2020-10-01 2021-06-30 0001435181 phbi:ConvertibleNotesPayableOneMember 2020-10-01 2021-06-30 0001435181 phbi:ConvertibleNotesPayableTwoMember 2020-10-01 2021-06-30 0001435181 us-gaap:ConvertibleNotesPayableMember 2020-10-01 2021-06-30 0001435181 srt:DirectorMember 2020-10-01 2020-10-14 0001435181 phbi:CAMember srt:ChiefFinancialOfficerMember 2020-09-30 0001435181 phbi:CAMember srt:ChiefFinancialOfficerMember 2021-06-30 0001435181 phbi:CAMember phbi:CompanyOwnedByTheFatherofPresidentMember 2020-09-30 0001435181 phbi:CAMember phbi:CompanyOwnedByTheFatherofPresidentMember 2021-06-30 0001435181 phbi:CAMember phbi:FatherOfPresidentMember 2020-09-30 0001435181 phbi:CAMember phbi:FatherOfPresidentMember 2021-06-30 0001435181 phbi:CAMember 2020-10-01 2021-06-30 0001435181 phbi:CompanyOwnedByTheFatherOfPresidentMember 2020-09-30 0001435181 phbi:CompanyOwnedByTheFatherOfPresidentMember 2021-06-30 0001435181 phbi:PresidentFatherMember 2020-09-30 0001435181 phbi:PresidentFatherMember 2021-06-30 0001435181 srt:ChiefFinancialOfficerMember 2021-06-30 0001435181 srt:PresidentMember 2021-06-30 0001435181 srt:ChiefFinancialOfficerMember 2019-10-01 2020-06-30 0001435181 srt:ChiefFinancialOfficerMember 2020-10-01 2021-06-30 0001435181 srt:ChiefFinancialOfficerMember 2020-09-30 0001435181 srt:PresidentMember 2019-10-01 2020-06-30 0001435181 srt:PresidentMember 2020-10-01 2021-06-30 0001435181 srt:PresidentMember 2020-09-30 0001435181 phbi:CAMember 2020-09-30 0001435181 phbi:CAMember 2021-06-30 0001435181 phbi:DerivativeLiabilityMember 2020-10-01 2021-06-30 0001435181 phbi:SeriesAConvertibleNotesMember phbi:FamilyMemberOfThePresidentMember 2017-10-01 2018-09-30 0001435181 phbi:SeriesAConvertibleNotesMember phbi:CompanyPresidentMember 2017-10-01 2018-09-30 0001435181 phbi:SeriesAConvertibleNotesMember 2018-09-30 0001435181 phbi:SeriesAConvertibleNotesMember 2020-09-30 0001435181 phbi:SeriesAConvertibleNotesMember 2019-09-30 0001435181 phbi:SeriesAConvertibleNotesMember 2017-10-01 2018-09-30 0001435181 phbi:SeriesAConvertibleNotesMember 2019-10-01 2020-09-30 0001435181 phbi:SeriesAConvertibleNotesMember 2018-10-01 2019-09-30 0001435181 phbi:ConvertibleNoteMember 2018-04-03 2018-04-04 0001435181 phbi:OctoberSeventeenTwoThousandNineteenMember phbi:UnrelatedPartyMember 2020-10-01 2021-06-30 0001435181 phbi:OctoberSeventeenTwoThousandNineteenMember phbi:UnrelatedPartyMember 2021-06-30 0001435181 phbi:SettlementAgreementWithNoteholderMember 2020-09-30 0001435181 phbi:SettlementAgreementWithNoteholderMember 2021-03-12 0001435181 phbi:JulyTwentyTwoTwoThousandTwentyMember phbi:ConvertibleNoteMember 2020-09-30 0001435181 phbi:JulyTwentyTwoTwoThousandTwentyMember phbi:ConvertibleNoteMember 2020-10-01 2021-06-30 0001435181 phbi:JulyTwentyTwoTwoThousandTwentyMember phbi:ConvertibleNoteMember 2019-10-01 2020-09-30 0001435181 2020-07-01 2020-07-22 0001435181 phbi:OctoberFirstTwoThousandNineteenMember phbi:UnrelatedPartyMember 2021-06-30 0001435181 phbi:OctoberFirstTwoThousandNineteenMember phbi:UnrelatedPartyMember 2020-10-01 2021-06-30 0001435181 phbi:AprilFourTwoThousandEighteenMember phbi:ConvertibleNoteMember 2020-07-01 2020-07-22 0001435181 phbi:AprilFourTwoThousandEighteenMember phbi:ConvertibleNoteMember 2020-10-01 2021-06-30 0001435181 phbi:AprilFourTwoThousandEighteenMember phbi:ConvertibleNoteMember 2019-10-01 2020-09-30 0001435181 2019-10-01 2020-09-30 0001435181 phbi:ConvertibleNoteMember 2018-04-04 0001435181 phbi:FebruaryFourTwoThousandTwentyMember phbi:UnrelatedPartyMember 2020-09-01 2020-09-30 0001435181 phbi:FebruaryFourTwoThousandTwentyMember phbi:UnrelatedPartyMember 2020-09-30 0001435181 phbi:FebruaryFourTwoThousandTwentyMember phbi:UnrelatedPartyMember 2020-10-20 0001435181 phbi:FebruaryFourTwoThousandTwentyMember phbi:UnrelatedPartyMember 2019-10-01 2020-09-30 0001435181 phbi:FebruaryFourTwoThousandTwentyMember phbi:UnrelatedPartyMember 2020-10-01 2021-06-30 0001435181 phbi:FebruaryFourTwoThousandTwentyMember phbi:UnrelatedPartyMember 2021-06-30 0001435181 phbi:JanuaryTwentyTwoThousandTwentyMember phbi:UnrelatedPartyMember 2020-09-30 0001435181 phbi:JanuaryTwentyTwoThousandTwentyMember phbi:UnrelatedPartyMember 2019-10-01 2020-09-30 0001435181 phbi:JanuaryTwentyTwoThousandTwentyMember phbi:UnrelatedPartyMember 2020-10-01 2021-06-30 0001435181 phbi:JanuaryTwentyTwoThousandTwentyMember phbi:UnrelatedPartyMember 2021-06-30 0001435181 phbi:JanuaryTwentyOneThousandTwentyMember phbi:UnrelatedPartyMember 2020-09-30 0001435181 phbi:JanuaryTwentyOneThousandTwentyMember phbi:UnrelatedPartyMember 2019-10-01 2020-09-30 0001435181 phbi:JanuaryTwentyOneThousandTwentyMember phbi:UnrelatedPartyMember 2020-10-01 2021-06-30 0001435181 phbi:JanuaryTwentyOneThousandTwentyMember phbi:UnrelatedPartyMember 2021-06-30 0001435181 phbi:JanuaryFifteenTwoThousandTwentyMember phbi:UnrelatedPartyMember phbi:NoteTwoMember 2020-09-30 0001435181 phbi:JanuaryFifteenTwoThousandTwentyMember phbi:UnrelatedPartyMember phbi:NoteTwoMember 2019-10-01 2020-09-30 0001435181 phbi:JulyTwentyThreeTwoThousandTwentyMember phbi:ConvertibleNoteMember 2020-09-01 2020-09-30 0001435181 phbi:JulyTwentyThreeTwoThousandTwentyMember phbi:ConvertibleNoteMember 2020-07-01 2020-07-24 0001435181 phbi:JulyTwentyThreeTwoThousandTwentyMember phbi:ConvertibleNoteMember 2020-07-24 0001435181 phbi:JanuaryFifteenTwoThousandTwentyMember phbi:UnrelatedPartyMember phbi:NoteTwoMember 2020-10-01 2021-06-30 0001435181 phbi:JanuaryFifteenTwoThousandTwentyMember phbi:UnrelatedPartyMember phbi:NoteTwoMember 2021-06-30 0001435181 phbi:JulyTwentyThreeTwoThousandTwentyMember phbi:ConvertibleNoteMember 2020-09-30 0001435181 phbi:JulyTwentyThreeTwoThousandTwentyMember phbi:ConvertibleNoteMember 2020-10-01 2021-06-30 0001435181 phbi:JulyTwentyThreeTwoThousandTwentyMember phbi:ConvertibleNoteMember 2021-06-30 0001435181 phbi:JanuaryFifteenTwoThousandTwentyMember phbi:UnrelatedPartyMember 2020-10-01 2021-06-30 0001435181 phbi:JanuaryFifteenTwoThousandTwentyMember phbi:UnrelatedPartyMember 2021-06-30 0001435181 phbi:JanuaryFourteenTwoThousandTwentyMember phbi:UnrelatedPartyMember 2020-09-30 0001435181 phbi:JanuaryFourteenTwoThousandTwentyMember phbi:UnrelatedPartyMember 2021-01-14 0001435181 phbi:JanuaryFourteenTwoThousandTwentyMember phbi:UnrelatedPartyMember 2019-10-01 2020-09-30 0001435181 phbi:JanuaryFourteenTwoThousandTwentyMember phbi:UnrelatedPartyMember 2021-06-30 0001435181 phbi:JanuaryFourteenTwoThousandTwentyMember phbi:UnrelatedPartyMember 2020-10-01 2021-06-30 0001435181 phbi:JuneSeventeenTwoThousandTwentyMember 2020-09-30 0001435181 phbi:JuneSeventeenTwoThousandTwentyMember 2020-10-01 2021-06-30 0001435181 phbi:JuneSeventeenTwoThousandTwentyMember 2021-06-30 0001435181 phbi:JanuarySecondTwoThousandTwentyMember phbi:UnrelatedPartyMember 2020-01-01 2020-01-02 0001435181 phbi:JanuarySecondTwoThousandTwentyMember phbi:UnrelatedPartyMember 2020-09-30 0001435181 phbi:JuneSeventeenTwoThousandTwentyMember phbi:ConvertibleNoteMember 2020-10-01 2021-06-30 0001435181 phbi:JuneSeventeenTwoThousandTwentyMember phbi:ConvertibleNoteMember 2019-10-01 2020-09-30 0001435181 phbi:JuneSeventeenTwoThousandTwentyMember phbi:ConvertibleNoteMember 2020-09-30 0001435181 phbi:JuneSeventeenTwoThousandTwentyMember phbi:ConvertibleNoteMember 2021-06-30 0001435181 phbi:LoansPayable1Member 2020-09-30 0001435181 phbi:CAMember phbi:LoansPayable2Member 2020-09-30 0001435181 phbi:CAMember phbi:LoansPayable2Member 2021-06-30 0001435181 phbi:LoansPayable2Member 2020-09-30 0001435181 phbi:LoansPayable2Member 2021-06-30 0001435181 phbi:LoansPayable2Member 2020-10-01 2021-06-30 0001435181 phbi:LoansPayable1Member 2020-10-01 2021-06-30 0001435181 phbi:LoansPayable1Member 2021-06-30 0001435181 us-gaap:NoncontrollingInterestMember 2021-06-30 0001435181 us-gaap:RetainedEarningsMember 2021-06-30 0001435181 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2021-06-30 0001435181 us-gaap:AdditionalPaidInCapitalMember 2021-06-30 0001435181 phbi:CommonStockIssuableMember 2021-06-30 0001435181 us-gaap:CommonStockMember 2021-06-30 0001435181 us-gaap:PreferredStockMember 2021-06-30 0001435181 us-gaap:NoncontrollingInterestMember 2021-04-01 2021-06-30 0001435181 us-gaap:RetainedEarningsMember 2021-04-01 2021-06-30 0001435181 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2021-04-01 2021-06-30 0001435181 us-gaap:AdditionalPaidInCapitalMember 2021-04-01 2021-06-30 0001435181 phbi:CommonStockIssuableMember 2021-04-01 2021-06-30 0001435181 us-gaap:CommonStockMember 2021-04-01 2021-06-30 0001435181 us-gaap:PreferredStockMember 2021-04-01 2021-06-30 0001435181 2021-03-31 0001435181 us-gaap:NoncontrollingInterestMember 2021-03-31 0001435181 us-gaap:RetainedEarningsMember 2021-03-31 0001435181 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2021-03-31 0001435181 us-gaap:AdditionalPaidInCapitalMember 2021-03-31 0001435181 phbi:CommonStockIssuableMember 2021-03-31 0001435181 us-gaap:CommonStockMember 2021-03-31 0001435181 us-gaap:PreferredStockMember 2021-03-31 0001435181 2021-01-01 2021-03-31 0001435181 us-gaap:NoncontrollingInterestMember 2021-01-01 2021-03-31 0001435181 us-gaap:RetainedEarningsMember 2021-01-01 2021-03-31 0001435181 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2021-01-01 2021-03-31 0001435181 us-gaap:AdditionalPaidInCapitalMember 2021-01-01 2021-03-31 0001435181 phbi:CommonStockIssuableMember 2021-01-01 2021-03-31 0001435181 us-gaap:CommonStockMember 2021-01-01 2021-03-31 0001435181 us-gaap:PreferredStockMember 2021-01-01 2021-03-31 0001435181 2020-12-31 0001435181 us-gaap:NoncontrollingInterestMember 2020-12-31 0001435181 us-gaap:RetainedEarningsMember 2020-12-31 0001435181 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2020-12-31 0001435181 us-gaap:AdditionalPaidInCapitalMember 2020-12-31 0001435181 phbi:CommonStockIssuableMember 2020-12-31 0001435181 us-gaap:CommonStockMember 2020-12-31 0001435181 us-gaap:PreferredStockMember 2020-12-31 0001435181 2020-10-01 2020-12-31 0001435181 us-gaap:NoncontrollingInterestMember 2020-10-01 2020-12-31 0001435181 us-gaap:RetainedEarningsMember 2020-10-01 2020-12-31 0001435181 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2020-10-01 2020-12-31 0001435181 us-gaap:AdditionalPaidInCapitalMember 2020-10-01 2020-12-31 0001435181 phbi:CommonStockIssuableMember 2020-10-01 2020-12-31 0001435181 us-gaap:CommonStockMember 2020-10-01 2020-12-31 0001435181 us-gaap:PreferredStockMember 2020-10-01 2020-12-31 0001435181 us-gaap:NoncontrollingInterestMember 2020-09-30 0001435181 us-gaap:RetainedEarningsMember 2020-09-30 0001435181 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2020-09-30 0001435181 us-gaap:AdditionalPaidInCapitalMember 2020-09-30 0001435181 phbi:CommonStockIssuableMember 2020-09-30 0001435181 us-gaap:CommonStockMember 2020-09-30 0001435181 us-gaap:PreferredStockMember 2020-09-30 0001435181 2020-06-30 0001435181 us-gaap:NoncontrollingInterestMember 2020-06-30 0001435181 us-gaap:RetainedEarningsMember 2020-06-30 0001435181 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2020-06-30 0001435181 us-gaap:AdditionalPaidInCapitalMember 2020-06-30 0001435181 phbi:CommonStockIssuableMember 2020-06-30 0001435181 us-gaap:CommonStockMember 2020-06-30 0001435181 us-gaap:PreferredStockMember 2020-06-30 0001435181 us-gaap:NoncontrollingInterestMember 2020-04-01 2020-06-30 0001435181 us-gaap:RetainedEarningsMember 2020-04-01 2020-06-30 0001435181 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2020-04-01 2020-06-30 0001435181 us-gaap:AdditionalPaidInCapitalMember 2020-04-01 2020-06-30 0001435181 phbi:CommonStockIssuableMember 2020-04-01 2020-06-30 0001435181 us-gaap:CommonStockMember 2020-04-01 2020-06-30 0001435181 us-gaap:PreferredStockMember 2020-04-01 2020-06-30 0001435181 2020-03-31 0001435181 us-gaap:NoncontrollingInterestMember 2020-03-31 0001435181 us-gaap:RetainedEarningsMember 2020-03-31 0001435181 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2020-03-31 0001435181 us-gaap:AdditionalPaidInCapitalMember 2020-03-31 0001435181 phbi:CommonStockIssuableMember 2020-03-31 0001435181 us-gaap:CommonStockMember 2020-03-31 0001435181 us-gaap:PreferredStockMember 2020-03-31 0001435181 2020-01-01 2020-03-31 0001435181 us-gaap:NoncontrollingInterestMember 2020-01-01 2020-03-31 0001435181 us-gaap:RetainedEarningsMember 2020-01-01 2020-03-31 0001435181 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2020-01-01 2020-03-31 0001435181 us-gaap:AdditionalPaidInCapitalMember 2020-01-01 2020-03-31 0001435181 phbi:CommonStockIssuableMember 2020-01-01 2020-03-31 0001435181 us-gaap:CommonStockMember 2020-01-01 2020-03-31 0001435181 us-gaap:PreferredStockMember 2020-01-01 2020-03-31 0001435181 2019-12-31 0001435181 us-gaap:NoncontrollingInterestMember 2019-12-31 0001435181 us-gaap:RetainedEarningsMember 2019-12-31 0001435181 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2019-12-31 0001435181 us-gaap:AdditionalPaidInCapitalMember 2019-12-31 0001435181 phbi:CommonStockIssuableMember 2019-12-31 0001435181 us-gaap:CommonStockMember 2019-12-31 0001435181 us-gaap:PreferredStockMember 2019-12-31 0001435181 2019-10-01 2019-12-31 0001435181 us-gaap:NoncontrollingInterestMember 2019-10-01 2019-12-31 0001435181 us-gaap:RetainedEarningsMember 2019-10-01 2019-12-31 0001435181 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2019-10-01 2019-12-31 0001435181 us-gaap:AdditionalPaidInCapitalMember 2019-10-01 2019-12-31 0001435181 phbi:CommonStockIssuableMember 2019-10-01 2019-12-31 0001435181 us-gaap:CommonStockMember 2019-10-01 2019-12-31 0001435181 us-gaap:PreferredStockMember 2019-10-01 2019-12-31 0001435181 2019-09-30 0001435181 us-gaap:NoncontrollingInterestMember 2019-09-30 0001435181 us-gaap:RetainedEarningsMember 2019-09-30 0001435181 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2019-09-30 0001435181 us-gaap:AdditionalPaidInCapitalMember 2019-09-30 0001435181 phbi:CommonStockIssuableMember 2019-09-30 0001435181 us-gaap:CommonStockMember 2019-09-30 0001435181 us-gaap:PreferredStockMember 2019-09-30 0001435181 2019-10-01 2020-06-30 0001435181 2020-04-01 2020-06-30 0001435181 2021-04-01 2021-06-30 0001435181 2020-09-30 0001435181 2021-06-30 0001435181 2021-08-12 iso4217:USD shares iso4217:USD shares iso4217:CAD 0001435181 false --09-30 Non-accelerated Filer Q3 2021 false

36679

0.001

1000000

10000

0.001

2000000000

95806289

355129269

23136

453697

462540

December 30, 2022 6750000

0.01

10-Q true 2021-06-30 false 000-56090 PHARMAGREEN BIOTECH INC. NV 98-0491567 2987 Blackbear Court Coquitlam BC V3E 3A2 702 803-9404 Yes No true true false 355831269

19218

12196

295

253754

19306

266245

624461

539663

60450 56303

607827

508874

40000

182012

190834

641077

298301

1380957

1821873

3166874

32240

30028

20696

23619

6371

3448

1860484

3200350

1000000

0.001

10000

2000000000

0.001

355129269

95806289

355129

95806

121500 180000

8628541

-3967261

-31735

-10867990

-7167346

-1794545

-2887600

-46633

-46505

-1841178

-2934105

19306

266245

190794

30108

296987

153999

-3044 -15824 -16951 6025

20716

28704

64376

91688

18829

40068

111788

89915

5085

3858

14753

13005

232380

86914

470953

354632

-232380

-86914

-470953

-354632

1179

54877

86801

77889

101418

-1187033

-3083420

-1347031

-31898

613526

-38411

10087

673124

45000

0 0 0 292557

90152

-1273808

-3229819

-1215774

-142228

-1360722

-3700772

-1570406

128

161

-142145

-1360714

-3700644

-1570245

-13215

-17081

-68414

2045

-155360

-1377795

-3769058

-1568200

-0.02

-0.01

-0.02

351763390

82854083

271420624

78042762

75646835

75647

3772781

47824

-4729476

-1274

-834498

-12399

-206021

-36

-206057

75646835

75647

3772781

35425

-4935497

-1310

-1052954

0 78064 78 0 20999 0 0 0 21077

31525

-3510

-117

-3627

75724899

75725

3793780

66950

-4939007

-1427

-1003979

0 15420104 15420 0 126910 0 0 0 142330

-17081

-1360714

-8

-1360722

91145003

91145

3920690

49869

-6299721

-1435

-2239452

95806289

95806

180000

3967261

36679

-7167346

-46505

-2934105

5400000

5400

21600

27000

10000 10 0 0 0 0 0 0 10 0 144315380 144316 -180000 1647737 0 0 0 1612053 0 90000 90 0 1265 0 0 0 1355

-42455

-417109

-1

-417110

10000

245611669

245612

5637863

-5776

-7584455

-46506

-1753252

17411250

17411

6113

72701

96225

0 84845100 84845 0 2848372 0 0 0 2933217 0 300000 300 0 7020 0 0 0 7320

-12744

-3141390

-44

-3141434

10000

348168019

348168

6113

8565956

-18520

-10725845

-46550

-1870668

6961250

6961

-6113

62585

63433

0 0 121500 0 0 0 0 121500

-13215

-142145

-83

-142228

10000

355129269

355129

121500

8628541

-31735

-10867990

-46633

-1841178

-3700772

-1570406

86801 77889 673124 45000

3083420

1347031

-613526 38411

130175

0 292557

207

9849

3754

-236798

120273

21189

65307

13840

-151237

-546552

570080

186725

128813

33646

64981

29388

5000

220381

530636

-62122

-12184

7022

-28100

12196

62682

19218

34582

0 532594

4545270

163407

0 40000

4601

<table cellpadding="0" style="border-spacing:0;font-size:10pt;font-variant:normal;font-weight:normal;font-style:normal;text-align:justify;margin-left:auto;line-height:normal;margin-right:auto;width:100%"><tbody><tr style="height:15px"><td style="width:4%;vertical-align:top;">1. </td><td style="vertical-align:top;">Nature of Business and Continuance of Operations</td></tr><tr style="height:15px"><td> </td><td> </td></tr><tr style="height:15px"><td> </td><td>Pharmagreen Biotech Inc. (“the Company”) was incorporated under the laws of the State of Nevada, U.S. on November 26, 2007, under the name Azure International, Inc. On October 30, 2008, and effective as of the same date, the Company filed Articles of Merger (“Articles”) with the State of Nevada, to effect a merger by and between Air Transport Group Holdings, Inc., a Nevada corporation and Azure International, Inc. As a result of the merger, the Company changed its name to Air Transport Group Holdings, Inc. The Company was previously in the business of providing technical advisory and appraisals to the aircraft and aviation business as well as providing sourcing for aircraft leases and parts. Pursuant to a Share Exchange Agreement with WFS Pharmagreen Inc. (“WFS”) on May 2, 2018, the Company changed its name to Pharmagreen Biotech Inc. and changed its principal business to the production of starter plantlets for the North American high CBD hemp and medical cannabis industries through the application of the proprietary plant tissue culture in vitro process called “Chibafreen”. This proprietary process will produce plantlets that will be genetically identical and free of pests and disease free with consistent and certifiable constituent properties. Going Concern These condensed consolidated financial statements have been prepared on the going concern basis, which assumes that the Company will be able to realize its assets and discharge its liabilities in the normal course of business. As at June 30, 2021, the Company has not earned any revenues from operations, has a working capital deficit of $1,802,567, and has an accumulated deficit of $10,867,990. During the nine months ended June 30, 2021, the Company incurred a net loss of $3,700,644 and used cash flows for operations of $151,237. In addition, the Company filed voluntary petitions for reorganization under Chapter 11 of the United States Bankruptcy Code in the United States Bankruptcy Court for the District of Nevada on August 7, 2020. Refer to Note 11. As a result of the voluntary petition, various convertible note holders triggered default provisions on the Company’s outstanding convertible notes. On October 9, 2020, a stay order was lifted by a United States District Judge of the United States District Court for the Southern District of New York, on an action filed by a lender. This effectively removed the Company from its Chapter 11 bankruptcy proceedings and protection. Furthermore, the Company has defaulted on other convertible notes. These factors raise substantial doubt upon the Company’s ability to continue as a going concern. These condensed consolidated financial statements do not reflect any adjustments that may be necessary if the Company is unable to continue as a going concern. The outbreak of the novel coronavirus COVID-19, which was declared a pandemic by the World Health Organization on March 11, 2020, has led to adverse impacts on the U.S. and global economies, disruptions of financial markets, and created uncertainty regarding potential impacts to the Company’s supply chain, operations, and customer demand. The COVID-19 pandemic has impacted and could further impact the Company’s operations and the operations of the Company’s suppliers and vendors as a result of quarantines, facility closures, and travel and logistics restrictions. Specifically, the Company attributes the pandemic to a delay in a planned financing which was to be used for the construction of the biotech complex, resulting in an impairment of the capitalized construction-in-progress at September 30, 2020. The extent to which the COVID-19 pandemic further impacts the Company’s business, results of operations and financial condition will depend on future developments, which are highly uncertain and cannot be predicted, including, but not limited to the duration, spread, severity, and impact of the COVID-19 pandemic, the effects of the COVID-19 pandemic on the Company’s customers, suppliers, and vendors and the remedial actions and stimulus measures adopted by local and federal governments, and to what extent normal economic and operating conditions can resume. The management team is closely following the progression of COVID-19 and its impact on the Company. Even after the COVID-19 pandemic has subsided, the Company may continue to experience adverse impacts to its business as a result of any economic recession or depression that has occurred or may occur in the future. Therefore, the Company cannot reasonably estimate the impact at this time our business, liquidity, capital resources, and financial results.</td></tr></tbody></table>

1802567

-10867990

-3700644

-151237

These condensed consolidated financial statements have been prepared on the same basis as the annual consolidated financial statements and in the opinion of management, reflect all adjustments, which include only normal recurring adjustments, necessary to present fairly the Company’s financial position, results of operations and cash flows for the periods shown. The results of operations for such periods are not necessarily indicative of the results expected for a full year or for any future period.

The accompanying condensed interim consolidated financial statements have been prepared in accordance with accounting principles generally accepted in the United States and are expressed in U.S. dollars. These condensed consolidated financial statements include the accounts of the Company and its wholly owned subsidiary, WFS Pharmagreen Inc. (“WFS”), and its 89.7% owned subsidiary 1155097 B.C. Ltd. (“115BC”), companies incorporated in British Columbia, Canada. All inter-company accounts and transactions have been eliminated. The Company’s fiscal year-end is September 30.

The preparation of these condensed consolidated financial statements in conformity with U.S. generally accepted accounting principles requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. The Company regularly evaluates estimates and assumptions related to the recoverability of property and equipment, the equity component of convertible notes, fair value of derivative liabilities, fair value of share-based payments, and deferred income tax asset valuation allowances. The Company bases its estimates and assumptions on current facts, historical experience, and various other factors that it believes to be reasonable under the circumstances, the results of which form the basis for making judgments about the carrying values of assets and liabilities and the accrual of costs and expenses that are not readily apparent from other sources. The actual results experienced by the Company may differ materially and adversely from the Company’s estimates. To the extent there are material differences between the estimates and the actual results, future results of operations will be affected. The Company applies judgment in the application of the going concern assumption which requires management to take into account all available information about the future, which is at least, but not limited to, 12 months from the end of the reporting period and in the factors regarding the impairment of the property and equipment. The Company tests property and equipment for recoverability when events or changes in circumstances indicate that their carrying amount may not be recoverable. Circumstances which could trigger a review include, but are not limited to: significant decreases in the market price of the asset; significant adverse changes in the business climate or legal factors; accumulation of costs significantly in excess of the amount originally expected for the acquisition or construction of the asset; current period cash flow or operating losses combined with a history of losses or a forecast of continuing losses associated with the use of the asset; and current expectation that the asset will more likely than not be sold or disposed significantly before the end of its estimated useful life. Recoverability is assessed based on the carrying amount of the asset and its fair value, which is generally determined based on the sum of the undiscounted cash flows expected to result from the use and the eventual disposal of the asset, as well as specific appraisal in certain instances. An impairment loss is recognized when the carrying amount is not recoverable and exceeds fair value.

The Company has implemented all new accounting pronouncements that are in effect and that may impact its condensed consolidated financial statements and does not believe that there are any other new accounting pronouncements that have been issued that might have a material impact on its financial position or results of operations.

<table cellpadding="0" style="border-spacing:0;font-size:10pt;text-align:left;width:100%"><tbody><tr style="height:15px"><td style="width:4%;">3.</td><td>Accounts Payable and Accrued Liabilities</td></tr><tr style="height:15px"><td> </td><td> </td></tr><tr style="height:15px"><td> </td><td>Accounts payable and accrued liabilities consists of the following:</td></tr></tbody></table> <table cellpadding="0" style="border-spacing:0;text-align:left;font:10pt times new roman;margin-left:auto;margin-right:auto;width:92%"><tbody><tr style="height:15px"><td> </td><td style="white-space: nowrap;"> </td><td class="hdcell" colspan="2" style="BORDER-BOTTOM: #000000 1px solid;width:9%;vertical-align:bottom;text-align:center;">June 30,2021$</td><td style="white-space: nowrap;"> </td><td style="white-space: nowrap;"> </td><td class="hdcell" colspan="2" style="BORDER-BOTTOM: #000000 1px solid;width:9%;vertical-align:bottom;text-align:center;">September 30,2020$</td><td style="white-space: nowrap;"> </td></tr><tr style="height:15px"><td> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" colspan="2" style="width:9%;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" colspan="2" style="width:9%;"> </td><td style="width:1%;white-space: nowrap;"> </td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;">Accounts payable (Note 7) </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">550,871</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">455,310</td><td style="width:1%;white-space: nowrap;"> </td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;">Accrued interest payable (Notes 4 and 5)</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">73,590</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">84,353</td><td style="width:1%;white-space: nowrap;"> </td></tr><tr style="height:15px;background-color:#cceeff"><td> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;"> </td><td style="width:1%;white-space: nowrap;"> </td></tr><tr style="height:15px;background-color:#ffffff"><td> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">624,461</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">539,663</td><td style="width:1%;white-space: nowrap;"> </td></tr></tbody></table>

<table cellpadding="0" style="border-spacing:0;text-align:left;font:10pt times new roman;margin-left:auto;margin-right:auto;width:92%"><tbody><tr style="height:15px"><td> </td><td style="white-space: nowrap;"> </td><td class="hdcell" colspan="2" style="BORDER-BOTTOM: #000000 1px solid;width:9%;vertical-align:bottom;text-align:center;">June 30,2021$</td><td style="white-space: nowrap;"> </td><td style="white-space: nowrap;"> </td><td class="hdcell" colspan="2" style="BORDER-BOTTOM: #000000 1px solid;width:9%;vertical-align:bottom;text-align:center;">September 30,2020$</td><td style="white-space: nowrap;"> </td></tr><tr style="height:15px"><td> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" colspan="2" style="width:9%;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" colspan="2" style="width:9%;"> </td><td style="width:1%;white-space: nowrap;"> </td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;">Accounts payable (Note 7) </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">550,871</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">455,310</td><td style="width:1%;white-space: nowrap;"> </td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;">Accrued interest payable (Notes 4 and 5)</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">73,590</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">84,353</td><td style="width:1%;white-space: nowrap;"> </td></tr><tr style="height:15px;background-color:#cceeff"><td> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;"> </td><td style="width:1%;white-space: nowrap;"> </td></tr><tr style="height:15px;background-color:#ffffff"><td> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">624,461</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">539,663</td><td style="width:1%;white-space: nowrap;"> </td></tr></tbody></table>

550871

455310

73590

84353

624461

539663

40000

6404

3421

On March 10, 2021, this noteholder filed a Notice of Motion for Summary Judgement in Lieu of Complaint (the “Notice”) with the State of New York Supreme Court, County of New York for $40,504 plus interest at the rate of 10% per annum from January 6, 2021 plus costs. On July 31, 2021

40000

32240

40000

30028

40000

5 If the Company repays the loan prior to December 31, 2022, there will be loan forgiveness of 25% of the principal balance repaid, up to a maximum of Cdn$10,000

<table cellpadding="0" style="border-spacing:0;font-size:10pt;font-variant:normal;font-weight:normal;font-style:normal;text-align:left;line-height:normal;width:100%"><tbody><tr style="height:15px"><td style="width:4%;vertical-align:top;">5. </td><td style="vertical-align:top;">Convertible Notes </td></tr></tbody></table> <table cellpadding="0" style="border-spacing:0;font-size:10pt;text-align:justify;margin-left:auto;margin-right:auto;width:100%"><tbody><tr style="height:15px"><td style="width:4%;"> </td><td style="width:4%;vertical-align:top;">(a)</td><td>On April 4, 2018, the amount of $32,485 owed to related parties was converted to Series A convertible notes, which are unsecured, non-interest bearing, and due on April 4, 2023. These notes are convertible in whole or in part, at any time until maturity, to common shares of the Company at $0.0001 per share. The outstanding balance remaining at maturity shall bear interest at 12% per annum until fully paid. The Company evaluated the convertible notes for a beneficial conversion feature in accordance with ASC 470-20 Debt with Conversion and Other Options. The Company determined that the conversion price was below the closing stock price on the commitment date, and the convertible notes contained a beneficial conversion feature. The Company recognized the intrinsic value of the embedded beneficial conversion feature of $32,485 as additional paid-in capital and reduced the carrying value of the convertible note to $nil. The carrying value will be accreted over the term of the convertible notes up to their face value of $32,485. </td></tr><tr style="height:15px"><td> </td><td> </td><td> </td></tr><tr style="height:15px"><td> </td><td> </td><td>During the year ended September 30, 2018, the Company issued 31,745,000 shares of common stock upon the conversion of $3,175 of Series A convertible notes, which included 18,000,000 common shares to the President of the Company and 5,320,000 common shares to family members of the President of the Company. Upon conversion, the Company immediately recognized the related remaining debt discount of $3,112 as accretion expense. During the year ended September 30, 2019, the Company issued 3,900,000 shares of common stock upon the conversion of $390 of Series A convertible notes. Upon conversion, the Company immediately recognized the related remaining debt discount of $375 as accretion expense. During the year ended September 30, 2020, the Company issued 18,525,000 shares of common stock upon the conversion of $1,853 of Series A convertible notes. Upon conversion, the Company immediately recognized the related remaining debt discount of $1,670 as accretion expense. As at June 30, 2021, the carrying value of the convertible notes was $6,371 (September 30, 2020 – $3,448) and had an unamortized discount of $20,696 (September 30, 2020 - $23,619). During the nine months ended June 30, 2021, the Company recorded accretion expense of $2,923 (2020 - $1,358).</td></tr></tbody></table><table cellpadding="0" style="border-spacing:0;font-size:10pt;text-align:left;width:100%"><tbody><tr style="height:15px"><td style="width:4%;">5. </td><td>Convertible Notes (continued)</td></tr></tbody></table> <table cellpadding="0" style="border-spacing:0;font-size:10pt;text-align:justify;margin-left:auto;margin-right:auto;width:100%"><tbody><tr style="height:15px"><td style="width:4%;"> </td><td style="width:4%;vertical-align:top;">(b)</td><td>On October 1, 2019, the Company entered into a convertible note with an unrelated party for $78,000, of which $3,255 was paid directly to third parties for financing costs, resulting in net proceeds to the Company of $74,745. The note is due on October 1, 2020, and bears interest on the unpaid principal balance at a rate of 10% per annum, which increases to 24% per annum upon default of the note.The note may be converted at any time after the date of issuance into shares of Company’s common stock at a conversion price equal to lower of: (i) the lowest trading price during the 10-trading day period prior to the issuance date; or (ii) 61% of the average 2 lowest trading prices during the 10-trading day period prior to the conversion date. In connection with the issuance of the above convertible note, the Company evaluated the conversion option for derivative treatment under ASC 815-15, Derivatives and Hedging, and determined the note and conversion feature qualified as derivatives. The Company classified the conversion feature as a derivative liability at fair value. The initial fair value of the conversion feature was determined to be $70,744. The Company recognized the maximum intrinsic value of the embedded beneficial conversion feature of $74,245 and reduced the carrying value of the convertible note to $500. The carrying value will be accreted over the term of the convertible note up to its face value of $78,000. </td></tr><tr style="height:15px"><td> </td><td> </td><td> </td></tr><tr style="height:15px"><td> </td><td> </td><td>On July 22, 2020, the Company received a preliminary statement of claim from the note holder for failure of the Company to deliver shares of common stock upon receipt of notices of conversion. Pursuant to the claim, the note holder requested receipt of all shares of common stock requested in the notices of conversion, and also damages in an amount to be determined at trial but in any event in excess of principal in the sum of $180,000, including without limitation the balance of any portion of the convertible note that ultimately is not converted into shares of common stock, along with default interest, liquidated damages, and damages as provided for in the convertible note. Upon default, the Company recognized the remaining debt discount of $46,904 as accretion expense. The financing costs were netted against the convertible note and were being amortized over the term using the effective interest rate method. During the year ended September 30, 2020, the Company recognized accretion expense of $77,500 and a default penalty of $85,864. During the nine months ended June 30, 2021, the Company recorded an additional $253,856 of default penalties. During the nine months ended June 30, 2021, the Company issued 133,226,100 shares of common stock upon the conversion of $417,719 of the convertible note and $11,000 of conversion fees. On March 12, 2021, the Company entered into a settlement agreement with the noteholder. Pursuant to the agreement, the Company was required to honour various conversion notices and the noteholder agreed to waive all principal, interest and penalties incurred. As at March 12, 2021, the carrying value of the convertible note was $nil (September 30, 2020 - $163,864) and the fair value of the derivative liability was $nil (September 30, 2020 - $485,863).</td></tr><tr style="height:15px"><td> </td><td> </td><td> </td></tr><tr style="height:15px"><td> </td><td style="vertical-align:top;">(c)</td><td>On October 17, 2019, the Company entered into a convertible note with an unrelated party for $63,000, of which $3,000 was paid directly to third parties for financing costs, resulting in net cash proceeds to the Company of $60,000. The note is due on October 17, 2020, and bears interest on the unpaid principal balance at a rate of 10% per annum, which increases to 22% per annum upon default of the note. The note may be converted at any time after 180 days of the date of issuance into shares of Company’s common stock at a conversion price equal to 61% of the average 2 lowest trading prices during the 10-trading day period prior to the conversion date. </td></tr></tbody></table><table cellpadding="0" style="border-spacing:0;font-size:10pt;font-variant:normal;font-weight:normal;font-style:normal;text-align:left;line-height:normal;width:100%"><tbody><tr style="height:15px"><td style="width:4%;vertical-align:top;">5. </td><td style="vertical-align:top;">Convertible Notes (continued)</td></tr></tbody></table> <table cellpadding="0" style="border-spacing:0;font-size:10pt;text-align:justify;margin-left:auto;margin-right:auto;width:100%"><tbody><tr style="height:15px"><td style="width:4%;"> </td><td style="width:4%;"> </td><td>On June 17, 2020, the Company entered into a settlement agreement with the lender, whereby the Company and the lender agreed on repayment terms for the remaining principal balance of $63,000, and accrued interest owing on the note of $5,775 which was due on September 30, 2020. Upon entering into the settlement agreement, the Company immediately recognized the remaining debt discount of $1,657. On September 30, 2020, the Company failed to meet the repayment terms within the settlement agreement which resulted in a default penalty of $63,000 and the resumption of the convertibility feature at a conversion price equal to 61% of the average 2 lowest trading prices during the 10-trading day period prior to the conversion date. On September 30, 2020, the Company evaluated the conversion option for derivative treatment under ASC 815-15, Derivatives and Hedging, and determined the note and conversion feature qualified as derivatives. The Company classified the conversion feature as a derivative liability at fair value. The initial fair value of the conversion feature was determined to be $112,822. The financing costs were netted against the convertible note and were being amortized over the term using the effective interest rate method. During the year ended September 30, 2020, the Company recognized accretion expense of $3,000 and a default penalty of $63,000. During the nine months ended June 30, 2021, the Company issued 7,730,486 shares of common stock upon the conversion of $126,000 of the convertible note. As at June 30, 2021, the carrying value of the convertible note was $nil (September 30, 2020 - $126,000) and the fair value of the derivative liability was $nil (September 30, 2020 - $112,822).</td></tr><tr style="height:15px"><td> </td><td> </td><td> </td></tr><tr style="height:15px"><td> </td><td style="vertical-align:top;">(d)</td><td>On January 2, 2020, the Company entered into a convertible note with an unrelated party for $53,000, of which $3,000 was paid directly to third parties for financing costs, resulting in cash proceeds to the Company of $50,000. The note is due on January 2, 2021, and bears interest on the unpaid principal balance at a rate of 10% per annum, which increases to 22% per annum upon default of the note. The note may be converted at any time after 180 days of the date of issuance into shares of Company’s common stock at a conversion price equal to 61% of the average 2 lowest trading prices during the 10-trading day period prior to the conversion date. </td></tr><tr style="height:15px"><td> </td><td> </td><td> </td></tr><tr style="height:15px"><td> </td><td> </td><td>On June 17, 2020, the Company entered into a settlement agreement with the lender, whereby the Company and the lender agreed on repayment terms for the remaining principal of $53,000 and accrued interest owing on the note. Upon entering into the settlement agreement, the Company immediately recognized the remaining debt discount of $2,286. Effective September 30, 2020, the Company failed to meet the repayment terms of the settlement agreement and defaulted on the convertible note. On September 30, 2020, the Company evaluated the conversion option for derivative treatment under ASC 815-15, Derivatives and Hedging, and determined the note and conversion feature qualified as derivatives. The Company classified the conversion feature as a derivative liability at fair value. The initial fair value of the conversion feature was determined to be $139,702. The financing costs were netted against the convertible note and were being amortized over the term using the effective interest rate method. During the year ended September 30, 2020, the Company recognized accretion expense of $3,000 and a default penalty of $53,000. During the nine months ended June 30, 2021, the Company issued 16,994,905 shares of common stock upon the conversion of $106,000 of the convertible note. As at June 30, 2021, the carrying value of the convertible note was $nil (September 30, 2020 - $106,000) and the fair value of the derivative liability was $nil (September 30, 2020 - $139,702).</td></tr></tbody></table><table cellpadding="0" style="border-spacing:0;font-size:10pt;font-variant:normal;font-weight:normal;font-style:normal;text-align:left;line-height:normal;width:100%"><tbody><tr style="height:15px"><td style="width:4%;vertical-align:top;">5. </td><td style="vertical-align:top;">Convertible Notes (continued)</td></tr></tbody></table> <table cellpadding="0" style="border-spacing:0;font-size:10pt;text-align:justify;margin-left:auto;margin-right:auto;width:100%"><tbody><tr style="height:15px"><td style="width:4%;"/><td style="width:4%;vertical-align:top;">(e)</td><td>On January 14, 2020, the Company entered into a convertible note with an unrelated party for $78,000, of which $3,000 was paid for financing costs, resulting in net proceeds to the Company of $75,000. The note is due on January 14, 2021, and bears interest on the unpaid principal balance at a rate of 12% per annum, which increases to 15% per annum upon default of the note. The note may be converted at any time after the date of issuance into shares of Company’s common stock at a conversion price equal to lower of: (i) 65% of the lowest trading price during the 20-trading day period prior to the issuance date; or (ii) 65% of the lowest trading price during the 20-trading day period prior to the conversion date. In connection with the issuance of the above convertible note, the Company evaluated the conversion option for derivative treatment under ASC 815-15, Derivatives and Hedging, and determined the note and conversion feature qualified as derivatives. The Company classified the conversion feature as a derivative liability at fair value. The initial fair value of the conversion feature was determined to be $76,330. The Company recognized the maximum intrinsic value of the embedded beneficial conversion feature of $74,500, resulting in a loss on change in fair value of derivative liabilities of $1,830, and reduced the carrying value of the convertible note to $500. The carrying value will be accreted over the term of the convertible note up to its face value of $78,000. </td></tr><tr style="height:15px"><td> </td><td> </td><td> </td></tr><tr style="height:15px"><td> </td><td> </td><td>The financing costs were netted against the convertible note and are being amortized over the term using the effective interest rate method. During the year ended September 30, 2020, the Company recognized accretion expense of $16,447. During the nine months ended June 30, 2021, the Company issued 2,600,000 shares of common stock upon the conversion of $18,923 of the convertible note and $4,500 of conversion fees. On January 14, 2021, the Company failed to repay the note upon maturity and recorded additional default principal of $53,007. As at June 30, 2021, the carrying value of the convertible note was $112,084 (September 30, 2020 - $16,947), net of an unamortized discount of $nil (September 30, 2020 - $61,053), and the fair value of the derivative liability was $170,586 (September 30, 2020 - $110,604).</td></tr><tr style="height:15px"><td> </td><td> </td><td> </td></tr><tr style="height:15px"><td> </td><td style="vertical-align:top;">(f)</td><td>On January 15, 2020, the Company entered into a convertible note with an unrelated party for $61,000, of which $7,400 was paid directly to third parties for financing costs and an original issue discount of $3,000, resulting in proceeds to the Company of $50,600. The note is due on January 15, 2021, and bears interest on the unpaid principal balance at a rate of 10% per annum, payable in common stock, which increases to 24% per annum upon default of the note. The note may be converted at any time after the date of issuance into shares of Company’s common stock at a conversion price equal 65% of the lowest trading price during the 20-trading day period prior to the conversion date. In connection with the issuance of the above convertible note, the Company evaluated the conversion option for derivative treatment under ASC 815-15, Derivatives and Hedging, and determined the note and conversion feature qualified as derivatives. The Company classified the conversion feature as a derivative liability at fair value. The initial fair value of the conversion feature was determined to be $67,846. </td></tr><tr style="height:15px"><td> </td><td> </td><td> </td></tr><tr style="height:15px"><td> </td><td> </td><td>The Company recognized the maximum intrinsic value of the embedded beneficial conversion feature of $50,100, resulting in a loss on change in fair value of derivative liabilities of $17,746, and reduced the carrying value of the convertible note to $500. The carrying value will be accreted over the term of the convertible note up to its face value of $61,000. On July 23, 2020, the Company entered into a settlement agreement with the note holder, wherein the Company and the lender agreed to settle a convertible note and accrued interest for a total of $63,440 on a non-convertible basis, of which $15,000 was payable on or before July 24, 2020 (paid), followed by 6 monthly instalment payments of $8,073. Upon entering into the settlement agreement, the Company immediately recognized the remaining debt discount of $56,566. Effective August 24, 2020, the Company failed to meet the repayment terms and defaulted on the settlement agreement. The financing costs were netted against the convertible note and were being amortized over the term using the effective interest rate method. During the year ended September 30, 2020, the Company recognized accretion expense of $60,500. During the nine months ended June 30, 2021, the Company issued 3,601,718 shares of common stock upon the conversion of $46,000 of the convertible note, $5,586 of accrued interest and $500 of conversion fees. As at June 30, 2021, the carrying value of the convertible note was $nil (September 30, 2020 - $46,000) and the fair value of the derivative liability was $nil (September 30, 2020 - $69,320).</td></tr></tbody></table><table cellpadding="0" style="border-spacing:0;font-size:10pt;font-variant:normal;font-weight:normal;font-style:normal;text-align:left;line-height:normal;width:100%"><tbody><tr style="height:15px"><td style="width:4%;vertical-align:top;">5. </td><td style="vertical-align:top;">Convertible Notes (continued)</td></tr></tbody></table> <table cellpadding="0" style="border-spacing:0;font-size:10pt;text-align:justify;margin-left:auto;margin-right:auto;width:100%"><tbody><tr style="height:15px"><td style="width:4%;"> </td><td style="width:4%;vertical-align:top;">(g)</td><td>On January 15, 2020, the Company entered into a convertible note with an unrelated party for $55,000, of which $2,500 was paid directly to third parties for financing costs, resulting in proceeds to the Company of $52,500. The note is due on January 15, 2021, and bears interest on the unpaid principal balance at a rate of 10% per annum, which increases to 24% per annum upon default of the note. The note may be converted at any time after the date of issuance into shares of Company’s common stock at a conversion price equal to lower of: (i) the lowest trading price during the 20-trading day period ending on the latest complete trading day prior to the issuance date; or (ii) 65% of the lowest trading price during the 20 consecutive trading day period on which at least 100 shares of common stock were traded prior to the conversion date. In connection with the issuance of the above convertible note, the Company evaluated the conversion option for derivative treatment under ASC 815-15, Derivatives and Hedging, and determined the note and conversion feature qualified as derivatives. The Company classified the conversion feature as a derivative liability at fair value. The initial fair value of the conversion feature was determined to be $61,173. The Company recognized the maximum intrinsic value of the embedded beneficial conversion feature of $52,000, resulting in a loss on change in fair value of derivative liabilities of $9,173, and reduced the carrying value of the convertible note to $500. The carrying value will be accreted over the term of the convertible note up to its face value of $55,000. </td></tr><tr style="height:15px"><td> </td><td> </td><td> </td></tr><tr style="height:15px"><td> </td><td> </td><td>During the year ended September 30, 2020, the Company defaulted on the convertible note which resulted in a default penalty of $27,500 and the amendment of the conversion rate from 65% to 50% of the lowest trading price during the 20 consecutive trading days prior to conversion. The Company recognized the remaining debt discount of $50,767 as accretion expense. The financing costs were netted against the convertible note and were being amortized over the term using the effective interest rate method. During the year ended September 30, 2020, the Company recognized accretion expense of $54,500 and a default penalty of $27,500. During the nine months ended June 30, 2021, the Company issued 17,557,925 shares of common stock upon the conversion of $82,500 of the convertible note, $7,693 of accrued interest and $3,000 of conversion fees. As at June 30, 2021, the carrying value of the convertible note was $nil (September 30, 2020 - $82,500) and the fair value of the derivative liability was $nil (September 30, 2020 - $146,272). </td></tr><tr style="height:15px"><td> </td><td> </td><td> </td></tr><tr style="height:15px"><td> </td><td style="vertical-align:top;">(h) </td><td>On January 21, 2020, the Company entered into a convertible note with an unrelated party for $66,150, of which $7,800 was paid directly to third parties for financing costs and an original issue discount of $3,150, resulting in proceeds to the Company of $55,200. The note is due on January 21, 2021, and bears interest on the unpaid principal balance at a rate of 8% per annum, payable in common stock, which increases to 24% per annum upon default of the note. The note may be converted at any time after the date of issuance into shares of Company’s common stock at a conversion price equal 60% of the lowest trading price during the 20-trading day period prior to the conversion date. In connection with the issuance of the above convertible note, the Company evaluated the conversion option for derivative treatment under ASC 815-15, Derivatives and Hedging, and determined the note and conversion feature qualified as derivatives. The Company classified the conversion feature as a derivative liability at fair value. The initial fair value of the conversion feature was determined to be $71,278. </td></tr><tr style="height:15px"><td> </td><td> </td><td> </td></tr><tr style="height:15px"><td> </td><td> </td><td>The Company recognized the maximum intrinsic value of the embedded beneficial conversion feature of $54,700, resulting in a loss on change in fair value of derivative liabilities of $16,578, and reduced the carrying value of the convertible note to $500. The carrying value will be accreted over the term of the convertible note up to its face value of $66,150.</td></tr></tbody></table><table cellpadding="0" style="border-spacing:0;font-size:10pt;font-variant:normal;font-weight:normal;font-style:normal;text-align:left;line-height:normal;width:100%"><tbody><tr style="height:15px"><td style="width:4%;vertical-align:top;">5. </td><td style="vertical-align:top;">Convertible Notes (continued)</td></tr></tbody></table> <table cellpadding="0" style="border-spacing:0;font-size:10pt;text-align:justify;margin-left:auto;margin-right:auto;width:100%"><tbody><tr style="height:15px"><td> </td><td> </td><td>The financing costs were netted against the convertible note and are being amortized over the term using the effective interest rate method. During the year ended September 30, 2020, the Company recognized accretion expense of $13,202. During the nine months ended June 30, 2021, the Company issued 4,431,963 shares of common stock upon the conversion of $66,150of the convertible note and $3,907 of accrued interest. As at June 30, 2021, the carrying value of the convertible note was $nil (September 30, 2020 - $13,702), net of an unamortized discount of $nil (September 30, 2020 - $52,448), and the fair value of the derivative liability was $nil (September 30, 2020 - $98,579).</td></tr><tr style="height:15px"><td> </td><td> </td><td> </td></tr><tr style="height:15px"><td style="width:4%;"> </td><td style="width:4%;vertical-align:top;">(i)</td><td>On January 22, 2020, the Company entered into a convertible note with an unrelated party for $78,750, of which $9,750 was paid directly to third parties for financing costs, resulting in proceeds to the Company of $69,000. The note is due on January 22, 2021, and bears interest on the unpaid principal balance at a rate of 10% per annum, payable in common stock, which increases to 24% per annum upon default of the note. The note may be converted at any time after the date of issuance into shares of Company’s common stock at a conversion price equal to 65% of the lowest trading price during the 20-trading day period ending on the latest complete trading day prior to the conversion date. In connection with the issuance of the above convertible note, the Company evaluated the conversion option for derivative treatment under ASC 815-15, Derivatives and Hedging, and determined the note and conversion feature qualified as derivatives. The Company classified the conversion feature as a derivative liability at fair value. The initial fair value of the conversion feature was determined to be $75,179. The Company recognized the maximum intrinsic value of the embedded beneficial conversion feature of $68,500, resulting in a loss on change in fair value of derivative liabilities of $6,679, and reduced the carrying value of the convertible note to $500. The carrying value will be accreted over the term of the convertible note up to its face value of $78,750. </td></tr><tr style="height:15px"><td> </td><td> </td><td> </td></tr><tr style="height:15px"><td> </td><td> </td><td>The financing costs were netted against the convertible note and are being amortized over the term using the effective interest rate method. During the year ended September 30, 2020, the Company defaulted on the convertible note and recognized accretion expense of $78,250. On January 22, 2021, the Company failed to repay the note upon maturity. As at June 30, 2021, the carrying value of the convertible note was $78,750 (September 30, 2020 - $78,750) and the fair value of the derivative liability was $127,715 (September 30, 2020 - $107,660).</td></tr><tr style="height:15px"><td> </td><td> </td><td> </td></tr><tr style="height:15px"><td> </td><td style="vertical-align:top;">(j)</td><td>On February 4, 2020, the Company entered into a convertible note with an unrelated party for $100,000, of which $16,970 was paid directly to third parties for financing costs, resulting in proceeds to the Company of $83,030. The note is due on February 4, 2021, and bears interest on the unpaid principal balance at a rate of 12% per annum, which increases to 24% per annum upon default of the note. The note may be converted at any time after the date of issuance into shares of Company’s common stock at a conversion price equal to lower of: (i) the lowest trading price during the 10-trading day period ending on the latest complete trading day prior to the issuance date; or (ii) 60% of the average of the two lowest trading prices during the 10-trading day period prior to the conversion date. In connection with the issuance of the above convertible note, the Company evaluated the conversion option for derivative treatment under ASC 815-15, Derivatives and Hedging, and determined the note and conversion feature qualified as derivatives. The Company classified the conversion feature as a derivative liability at fair value. The initial fair value of the conversion feature was determined to be $125,640. The Company recognized the maximum intrinsic value of the embedded beneficial conversion feature of $82,530, resulting in a loss on change in fair value of derivative liabilities of $43,110, and reduced the carrying value of the convertible note to $500. The carrying value will be accreted over the term of the convertible note up to its face value of $100,000. </td></tr><tr style="height:15px"><td> </td><td> </td><td> </td></tr><tr style="height:15px"><td> </td><td> </td><td>During the year ended September 30, 2020, the noteholder converted $24,175 of the convertible note for 2,000,000 common shares with a fair value of $180,000 and was issued on October 20, 2020. Upon the notice of conversion, the Company immediately recognized the related remaining debt discount of $23,136 as accretion expense. The financing costs were netted against the convertible note and are being amortized over the term using the effective interest rate method. During the year ended September 30, 2020, the Company recognized accretion expense of $7,854.</td></tr></tbody></table><table cellpadding="0" style="border-spacing:0;font-size:10pt;font-variant:normal;font-weight:normal;font-style:normal;text-align:left;line-height:normal;width:100%"><tbody><tr style="height:15px"><td style="width:4%;vertical-align:top;">5. </td><td style="vertical-align:top;">Convertible Notes (continued)</td></tr></tbody></table> <table cellpadding="0" style="border-spacing:0;font-size:10pt;text-align:left;width:100%"><tbody><tr style="height:15px"><td style="width:4%;"> </td><td style="width:4%;"> </td><td>During the nine months ended June 30, 2021, the Company issued 41,017,383 shares of common stock upon the conversion of $75,825 of the convertible note, $2,154 of accrued interest and $18,750 of fees. As at June 30, 2021, the carrying value of the convertible note was $nil (September 30, 2020 - $7,314), net of an unamortized discount of $nil (September 30, 2020 - $68,511), and the fair value of the derivative liability was $nil (September 30, 2020 - $110,135).</td></tr></tbody></table>

32485

April 4, 2023

0.0001

12%

32485

31745000

3175

18000000

5320000

3112

3900000

390

375

18525000

1853

1670

6371

3448

20696

23619

2923

1358

78000

3255

74745

October 1, 2020 10% 24% The note may be converted at any time after the date of issuance into shares of Company’s common stock at a conversion price equal to lower of: (i) the lowest trading price during the 10-trading day period prior to the issuance date; or (ii) 61% of the average 2 lowest trading prices during the 10-trading day period prior to the conversion date

70744

74245

500

78000

180000

46904

77500

85864 253856

133226100

417719

11000

163864

485863

63000

60000

October 17, 2020 10% 22% The note may be converted at any time after 180 days of the date of issuance into shares of Company’s common stock at a conversion price equal to 61% of the average 2 lowest trading prices during the 10-trading day period prior to the conversion date

63000

5775

1657

the convertibility feature at a conversion price equal to 61% of the average 2 lowest trading prices during the 10-trading day period prior to the conversion date

112822

3000

63000

7730486

126000

112822

53000

3000

50000

January 2, 2021 10% 22% The note may be converted at any time after 180 days of the date of issuance into shares of Company’s common stock at a conversion price equal to 61% of the average 2 lowest trading prices during the 10-trading day period prior to the conversion date

53000

2286

139702

3000

53000

16994905

106000

139702

78000

3000

75000

January 14, 2021 12% 15% The note may be converted at any time after the date of issuance into shares of Company’s common stock at a conversion price equal to lower of: (i) 65% of the lowest trading price during the 20-trading day period prior to the issuance date; or (ii) 65% of the lowest trading price during the 20-trading day period prior to the conversion date

76330

74500

1830

78000

16447

2600000

18923

4500 53007

112084

16947

61053

170586

110604

61000

7400

3000

50600

January 15, 2021 10% 24% The note may be converted at any time after the date of issuance into shares of Company’s common stock at a conversion price equal 65% of the lowest trading price during the 20-trading day period prior to the conversion date

67846

50100

17746

500

61000

63440

15000

6 monthly instalment

8073

56566

60500

3601718

46000

5586

500

46000

69320

55000

2500

52500

January 15, 2021 10% 24% The note may be converted at any time after the date of issuance into shares of Company’s common stock at a conversion price equal to lower of: (i) the lowest trading price during the 20-trading day period ending on the latest complete trading day prior to the issuance date; or (ii) 65% of the lowest trading price during the 20 consecutive trading day period on which at least 100 shares of common stock were traded prior to the conversion date

61173

52000

9173

55000

the conversion rate from 65% to 50% of the lowest trading price during the 20 consecutive trading days prior to conversion

50767

54500

27500

17557925

82500

7693

3000

82500

146272

66150

3150

55200

January 21, 2021 8% 24% The note may be converted at any time after the date of issuance into shares of Company’s common stock at a conversion price equal 60% of the lowest trading price during the 20-trading day period prior to the conversion date

71278

54700

16578

500

66150

13202

4431963

66150

3907

13702

52448

98579

78750

9750

69000

January 22, 2021 10% 24% The note may be converted at any time after the date of issuance into shares of Company’s common stock at a conversion price equal to 65% of the lowest trading price during the 20-trading day period ending on the latest complete trading day prior to the conversion date

75179

68500

6679

78750

78250

78750

127715

107660

100000

16970

83030

February 4, 2021 12% 24% (i) the lowest trading price during the 10-trading day period ending on the latest complete trading day prior to the issuance date; or (ii) 60% of the average of the two lowest trading prices during the 10-trading day period prior to the conversion date 82530

43110

500

100000

24175

2000000

180000

7854

41017383

75825

2154

18750

7314

68511

110135

<table cellpadding="0" style="border-spacing:0;text-align:left;font:10pt times new roman;margin-left:auto;margin-right:auto;width:92%"><tbody><tr style="height:15px"><td> </td><td> </td><td> </td><td class="ffcell" style="BORDER-BOTTOM: #000000 1px solid;">$</td><td> </td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;">Balance, September 30, 2020</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">1,380,957</td><td style="width:1%;white-space: nowrap;"> </td></tr><tr style="height:15px;background-color:#ffffff"><td> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;"> </td><td style="width:1%;white-space: nowrap;"> </td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;">Conversion of convertible notes</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">(4,166,076</td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">)</td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;">Change in fair value </td><td style="width:1%;white-space: nowrap;"> </td><td style="BORDER-BOTTOM: black 1px solid;width:1%;white-space: nowrap;"> </td><td class="ffcell" style="BORDER-BOTTOM: black 1px solid;width:9%;vertical-align:bottom;text-align:right;">3,083,420</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"> </td></tr><tr style="height:15px;background-color:#cceeff"><td> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;"> </td><td style="width:1%;white-space: nowrap;"> </td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;">Balance, June 30, 2021</td><td style="width:1%;white-space: nowrap;"> </td><td style="BORDER-BOTTOM: black 1px solid;width:1%;white-space: nowrap;"> </td><td class="ffcell" style="BORDER-BOTTOM: black 1px solid;width:9%;vertical-align:bottom;text-align:right;">298,301</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"> </td></tr></tbody></table>

1380957

-4166076

3083420

298301

<table cellpadding="0" style="border-spacing:0;text-align:left;font:10pt times new roman;margin-left:auto;margin-right:auto;width:92%"><tbody><tr style="height:15px"><td> </td><td style="white-space: nowrap;"> </td><td class="hdcell" colspan="2" style="BORDER-BOTTOM: #000000 1px solid;width:9%;vertical-align:bottom;text-align:center;">Expectedvolatility</td><td style="white-space: nowrap;"> </td><td style="white-space: nowrap;"> </td><td class="hdcell" colspan="2" style="BORDER-BOTTOM: #000000 1px solid;width:9%;vertical-align:bottom;text-align:center;">Risk-free interestrate</td><td style="white-space: nowrap;"> </td><td style="white-space: nowrap;"> </td><td class="hdcell" colspan="2" style="BORDER-BOTTOM: #000000 1px solid;width:9%;vertical-align:bottom;text-align:center;">Expected dividendyield</td><td style="white-space: nowrap;"> </td><td style="white-space: nowrap;"> </td><td class="hdcell" colspan="2" style="BORDER-BOTTOM: #000000 1px solid;width:9%;vertical-align:bottom;text-align:center;">Expected life(in years)</td><td style="white-space: nowrap;"> </td></tr><tr style="height:15px"><td> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" colspan="2" style="width:9%;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" colspan="2" style="width:9%;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" colspan="2" style="width:9%;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" colspan="2" style="width:9%;"> </td><td style="width:1%;white-space: nowrap;"> </td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;">As at June 30, 2021</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">256</td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">%</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">0.1</td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">%</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">0</td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">%</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">0.5</td><td style="width:1%;white-space: nowrap;"> </td></tr></tbody></table> 256 0.1 0 0.5

548586

680628

453697

604366

72171 63044

59241

73500

55177

73500

27565

34200

25674

34000

431105

534870

347229

72171 63044 10000 10

5400000

0.005

27000

16800000

0.005

84000

611250

0.01

6112

133226100

417719

11000

7730486

126000

3150

16994905

106000

2650

2600000

18923

4500

3601718

46000

5586 500

17557925

82500

7693 3000

4431963

66150

3907

41017383

75825

2154 18750

22500

401

45000

733

22500

221

150000

2700

150000

4620

2000000

180000

30750

611250

0.01

6113

0.05

6350000

0.01

63500

0.05

6750000

121500

2000000000

0.001

1000000

0.001

10000 10000 10 <table cellpadding="0" style="border-spacing:0;font-size:10pt;font-variant:normal;font-weight:normal;font-style:normal;text-align:justify;margin-left:auto;line-height:normal;margin-right:auto;width:100%"><tbody><tr style="height:15px"><td style="width:4%;">10. </td><td>Share Purchase Warrants</td></tr><tr style="height:15px"><td> </td><td> </td></tr><tr style="height:15px"><td> </td><td>The following table summarizes the continuity of the Company’s share purchase warrants: </td></tr></tbody></table> <table cellpadding="0" style="border-spacing:0;text-align:left;font:10pt times new roman;margin-left:auto;margin-right:auto;width:92%"><tbody><tr style="height:15px"><td> </td><td style="white-space: nowrap;"> </td><td class="hdcell" colspan="2" style="BORDER-BOTTOM: #000000 1px solid;width:9%;vertical-align:bottom;text-align:center;">Number ofwarrants</td><td style="white-space: nowrap;"> </td><td style="white-space: nowrap;"> </td><td class="hdcell" colspan="2" style="BORDER-BOTTOM: #000000 1px solid;width:9%;vertical-align:bottom;text-align:center;">Weighted average exercise price$</td><td style="white-space: nowrap;"> </td></tr><tr style="height:15px"><td> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" colspan="2" style="width:9%;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" colspan="2" style="width:9%;"> </td><td style="width:1%;white-space: nowrap;"> </td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;">Balance, September 30, 2020</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">114,286</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">0.55</td><td style="width:1%;white-space: nowrap;"> </td></tr><tr style="height:15px;background-color:#ffffff"><td> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;"> </td><td style="width:1%;white-space: nowrap;"> </td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;">Issued </td><td style="width:1%;white-space: nowrap;"> </td><td style="BORDER-BOTTOM: black 1px solid;width:1%;white-space: nowrap;"> </td><td class="ffcell" style="BORDER-BOTTOM: black 1px solid;width:9%;vertical-align:bottom;text-align:right;">29,772,500</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="BORDER-BOTTOM: black 1px solid;width:1%;white-space: nowrap;"> </td><td class="ffcell" style="BORDER-BOTTOM: black 1px solid;width:9%;vertical-align:bottom;text-align:right;">0.05</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"> </td></tr><tr style="height:15px;background-color:#ffffff"><td> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;"> </td><td style="width:1%;white-space: nowrap;"> </td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;">Balance, June 30, 2021</td><td style="width:1%;white-space: nowrap;"> </td><td style="BORDER-BOTTOM: black 3px double;width:1%;white-space: nowrap;"> </td><td class="ffcell" style="BORDER-BOTTOM: black 3px double;width:9%;vertical-align:bottom;text-align:right;">29,886,786</td><td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="BORDER-BOTTOM: black 3px double;width:1%;white-space: nowrap;"> </td><td class="ffcell" style="BORDER-BOTTOM: black 3px double;width:9%;vertical-align:bottom;text-align:right;">0.05</td><td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"> </td></tr></tbody></table> <table cellpadding="0" style="border-spacing:0;font-size:10pt;text-align:left;width:100%"><tbody><tr style="height:15px"><td style="width:4%;"> </td><td>As at June 30, 2021, the following share purchase warrants were outstanding:</td></tr></tbody></table> <table cellpadding="0" style="border-spacing:0;text-align:left;font:10pt times new roman;margin-left:auto;margin-right:auto;width:92%"><tbody><tr style="height:15px"><td colspan="2" style="BORDER-BOTTOM: #000000 1px solid;vertical-align:bottom;">Number of warrants</td><td style="white-space: nowrap;"> </td><td style="white-space: nowrap;"> </td><td class="hdcell" colspan="2" style="BORDER-BOTTOM: #000000 1px solid;vertical-align:bottom;text-align:center;">Exercise price </td><td style="white-space: nowrap;"> </td><td style="white-space: nowrap;"> </td><td class="hdcell" style="BORDER-BOTTOM: #000000 1px solid;vertical-align:bottom;text-align:center;">Expiry date</td><td> </td></tr><tr style="height:15px"><td colspan="2"> </td><td style="white-space: nowrap;"> </td><td style="white-space: nowrap;"> </td><td class="ffcell" colspan="2"> </td><td style="white-space: nowrap;"> </td><td style="white-space: nowrap;"> </td><td class="ffcell"> </td><td> </td></tr><tr style="height:15px;background-color:#cceeff"><td style="width:1%;white-space: nowrap;"> </td><td style="width:15%;">114,286</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">0.55</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:15%;">July 16, 2022</td><td style="width:1%;"> </td></tr><tr style="height:15px;background-color:#ffffff"><td style="white-space: nowrap;"> </td><td>400,000</td><td style="white-space: nowrap;"> </td><td style="white-space: nowrap;"> </td><td style="vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="vertical-align:bottom;text-align:right;">0.05</td><td style="white-space: nowrap;"> </td><td style="white-space: nowrap;"> </td><td>December 2, 2022</td><td> </td></tr><tr style="height:15px;background-color:#cceeff"><td style="white-space: nowrap;"> </td><td>3,000,000</td><td style="white-space: nowrap;"> </td><td style="white-space: nowrap;"> </td><td style="vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="vertical-align:bottom;text-align:right;">0.05</td><td style="white-space: nowrap;"> </td><td style="white-space: nowrap;"> </td><td>December 11, 2022</td><td> </td></tr><tr style="height:15px;background-color:#ffffff"><td style="white-space: nowrap;"> </td><td>2,000,000</td><td style="white-space: nowrap;"> </td><td style="white-space: nowrap;"> </td><td style="vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="vertical-align:bottom;text-align:right;">0.05</td><td style="white-space: nowrap;"> </td><td style="white-space: nowrap;"> </td><td>December 30, 2022</td><td> </td></tr><tr style="height:15px;background-color:#cceeff"><td style="white-space: nowrap;"> </td><td>2,300,000</td><td style="white-space: nowrap;"> </td><td style="white-space: nowrap;"> </td><td style="vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="vertical-align:bottom;text-align:right;">0.05</td><td style="white-space: nowrap;"> </td><td style="white-space: nowrap;"> </td><td>January 11, 2023</td><td> </td></tr><tr style="height:15px;background-color:#ffffff"><td style="white-space: nowrap;"> </td><td>13,500,000</td><td style="white-space: nowrap;"> </td><td style="white-space: nowrap;"> </td><td style="vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="vertical-align:bottom;text-align:right;">0.05</td><td style="white-space: nowrap;"> </td><td style="white-space: nowrap;"> </td><td>January 30, 2023</td><td> </td></tr><tr style="height:15px;background-color:#cceeff"><td style="white-space: nowrap;"> </td><td>1,000,000</td><td style="white-space: nowrap;"> </td><td style="white-space: nowrap;"> </td><td style="vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="vertical-align:bottom;text-align:right;">0.05</td><td style="white-space: nowrap;"> </td><td style="white-space: nowrap;"> </td><td>February 16, 2023</td><td> </td></tr><tr style="height:15px;background-color:#ffffff"><td style="white-space: nowrap;"> </td><td>611,250</td><td style="white-space: nowrap;"> </td><td style="white-space: nowrap;"> </td><td style="vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="vertical-align:bottom;text-align:right;">0.05</td><td style="white-space: nowrap;"> </td><td style="white-space: nowrap;"> </td><td>March 1, 2023</td><td> </td></tr><tr style="height:15px;background-color:#cceeff"><td style="BORDER-BOTTOM: black 1px solid;white-space: nowrap;"> </td><td style="BORDER-BOTTOM: black 1px solid;">6,961,250</td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"> </td><td style="white-space: nowrap;"> </td><td style="vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="vertical-align:bottom;text-align:right;">0.05</td><td style="white-space: nowrap;"> </td><td style="white-space: nowrap;"> </td><td>May 14, 2023</td><td> </td></tr><tr style="height:15px;background-color:#ffffff"><td style="white-space: nowrap;"> </td><td> </td><td style="white-space: nowrap;"> </td><td style="white-space: nowrap;"> </td><td style="white-space: nowrap;"> </td><td class="ffcell"> </td><td style="white-space: nowrap;"> </td><td style="white-space: nowrap;"> </td><td class="ffcell"> </td><td> </td></tr><tr style="height:15px;background-color:#cceeff"><td style="BORDER-BOTTOM: black 3px double;white-space: nowrap;"> </td><td style="BORDER-BOTTOM: black 3px double;">29,886,786</td><td style="PADDING-BOTTOM: 3px;white-space: nowrap;"> </td><td style="white-space: nowrap;"> </td><td style="white-space: nowrap;"> </td><td class="ffcell"> </td><td style="white-space: nowrap;"> </td><td style="white-space: nowrap;"> </td><td class="ffcell"> </td><td> </td></tr></tbody></table>

<table cellpadding="0" style="border-spacing:0;text-align:left;font:10pt times new roman;margin-left:auto;margin-right:auto;width:92%"><tbody><tr style="height:15px"><td> </td><td style="white-space: nowrap;"> </td><td class="hdcell" colspan="2" style="BORDER-BOTTOM: #000000 1px solid;width:9%;vertical-align:bottom;text-align:center;">Number ofwarrants</td><td style="white-space: nowrap;"> </td><td style="white-space: nowrap;"> </td><td class="hdcell" colspan="2" style="BORDER-BOTTOM: #000000 1px solid;width:9%;vertical-align:bottom;text-align:center;">Weighted average exercise price$</td><td style="white-space: nowrap;"> </td></tr><tr style="height:15px"><td> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" colspan="2" style="width:9%;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" colspan="2" style="width:9%;"> </td><td style="width:1%;white-space: nowrap;"> </td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;">Balance, September 30, 2020</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">114,286</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">0.55</td><td style="width:1%;white-space: nowrap;"> </td></tr><tr style="height:15px;background-color:#ffffff"><td> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;"> </td><td style="width:1%;white-space: nowrap;"> </td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;">Issued </td><td style="width:1%;white-space: nowrap;"> </td><td style="BORDER-BOTTOM: black 1px solid;width:1%;white-space: nowrap;"> </td><td class="ffcell" style="BORDER-BOTTOM: black 1px solid;width:9%;vertical-align:bottom;text-align:right;">29,772,500</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="BORDER-BOTTOM: black 1px solid;width:1%;white-space: nowrap;"> </td><td class="ffcell" style="BORDER-BOTTOM: black 1px solid;width:9%;vertical-align:bottom;text-align:right;">0.05</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"> </td></tr><tr style="height:15px;background-color:#ffffff"><td> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;"> </td><td style="width:1%;white-space: nowrap;"> </td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;">Balance, June 30, 2021</td><td style="width:1%;white-space: nowrap;"> </td><td style="BORDER-BOTTOM: black 3px double;width:1%;white-space: nowrap;"> </td><td class="ffcell" style="BORDER-BOTTOM: black 3px double;width:9%;vertical-align:bottom;text-align:right;">29,886,786</td><td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="BORDER-BOTTOM: black 3px double;width:1%;white-space: nowrap;"> </td><td class="ffcell" style="BORDER-BOTTOM: black 3px double;width:9%;vertical-align:bottom;text-align:right;">0.05</td><td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"> </td></tr></tbody></table>

114286

0.55

29772500

0.05

29886786

0.05

<table cellpadding="0" style="border-spacing:0;text-align:left;font:10pt times new roman;margin-left:auto;margin-right:auto;width:92%"><tbody><tr style="height:15px"><td colspan="2" style="BORDER-BOTTOM: #000000 1px solid;vertical-align:bottom;">Number of warrants</td><td style="white-space: nowrap;"> </td><td style="white-space: nowrap;"> </td><td class="hdcell" colspan="2" style="BORDER-BOTTOM: #000000 1px solid;vertical-align:bottom;text-align:center;">Exercise price </td><td style="white-space: nowrap;"> </td><td style="white-space: nowrap;"> </td><td class="hdcell" style="BORDER-BOTTOM: #000000 1px solid;vertical-align:bottom;text-align:center;">Expiry date</td><td> </td></tr><tr style="height:15px"><td colspan="2"> </td><td style="white-space: nowrap;"> </td><td style="white-space: nowrap;"> </td><td class="ffcell" colspan="2"> </td><td style="white-space: nowrap;"> </td><td style="white-space: nowrap;"> </td><td class="ffcell"> </td><td> </td></tr><tr style="height:15px;background-color:#cceeff"><td style="width:1%;white-space: nowrap;"> </td><td style="width:15%;">114,286</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">0.55</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:15%;">July 16, 2022</td><td style="width:1%;"> </td></tr><tr style="height:15px;background-color:#ffffff"><td style="white-space: nowrap;"> </td><td>400,000</td><td style="white-space: nowrap;"> </td><td style="white-space: nowrap;"> </td><td style="vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="vertical-align:bottom;text-align:right;">0.05</td><td style="white-space: nowrap;"> </td><td style="white-space: nowrap;"> </td><td>December 2, 2022</td><td> </td></tr><tr style="height:15px;background-color:#cceeff"><td style="white-space: nowrap;"> </td><td>3,000,000</td><td style="white-space: nowrap;"> </td><td style="white-space: nowrap;"> </td><td style="vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="vertical-align:bottom;text-align:right;">0.05</td><td style="white-space: nowrap;"> </td><td style="white-space: nowrap;"> </td><td>December 11, 2022</td><td> </td></tr><tr style="height:15px;background-color:#ffffff"><td style="white-space: nowrap;"> </td><td>2,000,000</td><td style="white-space: nowrap;"> </td><td style="white-space: nowrap;"> </td><td style="vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="vertical-align:bottom;text-align:right;">0.05</td><td style="white-space: nowrap;"> </td><td style="white-space: nowrap;"> </td><td>December 30, 2022</td><td> </td></tr><tr style="height:15px;background-color:#cceeff"><td style="white-space: nowrap;"> </td><td>2,300,000</td><td style="white-space: nowrap;"> </td><td style="white-space: nowrap;"> </td><td style="vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="vertical-align:bottom;text-align:right;">0.05</td><td style="white-space: nowrap;"> </td><td style="white-space: nowrap;"> </td><td>January 11, 2023</td><td> </td></tr><tr style="height:15px;background-color:#ffffff"><td style="white-space: nowrap;"> </td><td>13,500,000</td><td style="white-space: nowrap;"> </td><td style="white-space: nowrap;"> </td><td style="vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="vertical-align:bottom;text-align:right;">0.05</td><td style="white-space: nowrap;"> </td><td style="white-space: nowrap;"> </td><td>January 30, 2023</td><td> </td></tr><tr style="height:15px;background-color:#cceeff"><td style="white-space: nowrap;"> </td><td>1,000,000</td><td style="white-space: nowrap;"> </td><td style="white-space: nowrap;"> </td><td style="vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="vertical-align:bottom;text-align:right;">0.05</td><td style="white-space: nowrap;"> </td><td style="white-space: nowrap;"> </td><td>February 16, 2023</td><td> </td></tr><tr style="height:15px;background-color:#ffffff"><td style="white-space: nowrap;"> </td><td>611,250</td><td style="white-space: nowrap;"> </td><td style="white-space: nowrap;"> </td><td style="vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="vertical-align:bottom;text-align:right;">0.05</td><td style="white-space: nowrap;"> </td><td style="white-space: nowrap;"> </td><td>March 1, 2023</td><td> </td></tr><tr style="height:15px;background-color:#cceeff"><td style="BORDER-BOTTOM: black 1px solid;white-space: nowrap;"> </td><td style="BORDER-BOTTOM: black 1px solid;">6,961,250</td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"> </td><td style="white-space: nowrap;"> </td><td style="vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="vertical-align:bottom;text-align:right;">0.05</td><td style="white-space: nowrap;"> </td><td style="white-space: nowrap;"> </td><td>May 14, 2023</td><td> </td></tr><tr style="height:15px;background-color:#ffffff"><td style="white-space: nowrap;"> </td><td> </td><td style="white-space: nowrap;"> </td><td style="white-space: nowrap;"> </td><td style="white-space: nowrap;"> </td><td class="ffcell"> </td><td style="white-space: nowrap;"> </td><td style="white-space: nowrap;"> </td><td class="ffcell"> </td><td> </td></tr><tr style="height:15px;background-color:#cceeff"><td style="BORDER-BOTTOM: black 3px double;white-space: nowrap;"> </td><td style="BORDER-BOTTOM: black 3px double;">29,886,786</td><td style="PADDING-BOTTOM: 3px;white-space: nowrap;"> </td><td style="white-space: nowrap;"> </td><td style="white-space: nowrap;"> </td><td class="ffcell"> </td><td style="white-space: nowrap;"> </td><td style="white-space: nowrap;"> </td><td class="ffcell"> </td><td> </td></tr></tbody></table>

114286 0.55 July 16, 2022 400000 0.05 December 2, 2022 3000000 0.05 December 11, 2022 2000000 0.05 2300000 0.05 January 11, 2023 13500000 0.05 January 30, 2023 1000000 0.05 February 16, 2023 611250 0.05 March 1, 2 6961250 0.05 May 14, 2023 29886786

The option agreement grants an option to Alliance to purchase 10% equity interest in 115BC for Cdn$1,350,000 and previously granted a second option to purchase an additional 20% equity interest in 115BC for funding of 30% of the total construction and equipment costs for the biotech complex less Cdn$1,350,000.

1018182

1350008

60450 75000 56303 75000 10000000 The purchase price would be 85% of the market price

40000

the third party is required to pay an additional commitment fee of $10,000, of which $5,000 was paid upon signing the term sheet and the remaining $5,000 is due upon completion of the first tranche of the financing. 75000 the Company extended the consulting agreement for an additional six month term for the issuance of 117,000 common shares per month. the Company agreed to pay New to the Street Group LLC $3,500 upon signing, $3,500 per month and 6,750,000 restricted shares of the Company’s common stock. At June 30, 2021, the 6,750,000 restricted shares of common stock have not been issued. The Company will pay DealMaker $3,000 upon signing the agreement, $7,000 payable within 30 days of launching the portal, and a post launch monthly fee of $1,000

702000

56000

5600000 Each unit will be comprised of one share of common stock and one share purchase warrant exercisable into an additional share of common stock at an exercise price of $0.05 per share for a period of 24 months XML 10 R1.htm IDEA: XBRL DOCUMENT

Cover - shares	9 Months Ended
Cover - shares	Jun. 30, 2021	Aug. 12, 2021
Cover [Abstract]
Entity Registrant Name	PHARMAGREEN BIOTECH INC.
Entity Central Index Key	0001435181
Document Type	10-Q
Amendment Flag	false
Current Fiscal Year End Date	--09-30
Entity Small Business	true
Entity Shell Company	false
Entity Emerging Growth Company	true
Entity Current Reporting Status	Yes
Document Period End Date	Jun. 30, 2021
Entity Filer Category	Non-accelerated Filer
Document Fiscal Period Focus	Q3
Document Fiscal Year Focus	2021
Entity Ex Transition Period	false
Entity Common Stock Shares Outstanding		355,831,269
Document Quarterly Report	true
Document Transition Report	false
Entity File Number	000-56090
Entity Incorporation State Country Code	NV
Entity Tax Identification Number	98-0491567
Entity Address Address Line 1	2987 Blackbear Court
Entity Address City Or Town	Coquitlam
Entity Address State Or Province	BC
Entity Address Postal Zip Code	V3E 3A2
City Area Code	702
Local Phone Number	803-9404
Entity Interactive Data Current	No

XML 11 R2.htm IDEA: XBRL DOCUMENT

Condensed Consolidated Balance Sheets - USD ($)	Jun. 30, 2021	Sep. 30, 2020
Current assets
Cash	$ 19,218	$ 12,196
Amounts receivable	88	295
Prepaid expenses and deposits	0	253,754
Total assets	19,306	266,245
Current liabilities
Accounts payable and accrued liabilities (Notes 3 and 7)	624,461	539,663
Advances from Alliance Growers Corp. (Note 11(a))	60,450	56,303
Due to related parties (Note 7)	607,827	508,874
Note payable (Note 4)	40,000	40,000
Convertible notes - current portion, net of unamortized discount of $Nil and $182,012, respectively (Note 5)	190,834	641,077
Derivative liabilities (Note 6)	298,301	1,380,957
Total current liabilities	1,821,873	3,166,874
Loan payable (Note 4)	32,240	30,028
Convertible notes, net of unamortized discount of $20,696 and $23,619, respectively (Note 5)	6,371	3,448
Total liabilities	1,860,484	3,200,350
Stockholders' deficit
Preferred stock Authorized: 1,000,000 shares, $0.001 par value; 10,000 and nil shares issued and outstanding, respectively	10	0
Common stock Authorized: 2,000,000,000 shares, $0.001 par value; 355,129,269 and 95,806,289 shares issued and outstanding, respectively	355,129	95,806
Common stock issuable (Note 8)	121,500	180,000
Additional paid-in capital	8,628,541	(3,967,261)
Accumulated other comprehensive income (loss)	(31,735)	36,679
Deficit	(10,867,990)	(7,167,346)
Total Pharmagreen Biotech Inc. stockholders' deficit	(1,794,545)	(2,887,600)
Non-controlling interest	(46,633)	(46,505)
Total stockholders' deficit	(1,841,178)	(2,934,105)
Total liabilities and stockholders' deficit	$ 19,306	$ 266,245

XML 12 R3.htm IDEA: XBRL DOCUMENT

Condensed Consolidated Balance Sheets (Parenthetical) - USD ($)	Jun. 30, 2021	Sep. 30, 2020
Condensed Consolidated Balance Sheets
Convertible Notes, Unamortized Discount, Current	$ 0	$ 182,012
Convertible Notes, Unamortized Discount, Noncurrent	$ 20,696	$ 23,619
Preferred Stock, Par Value	$ 0.001	$ 0.001
Preferred Stock, Shared Authorized	1,000,000	1,000,000
Preferred Stock, Shares Issued	10,000	0
Preferred Stock, Shares Outstanding	10,000	0
Common Stock, Par Value	$ 0.001	$ 0.001
Common Stock, Shares Authorized	2,000,000,000	2,000,000,000
Common Stock, Shares Issued	355,129,269	95,806,289
Common Stock, Shares Outstanding	355,129,269	95,806,289

XML 13 R4.htm IDEA: XBRL DOCUMENT

Condensed Consolidated Statements of Operations and Comprehensive Income (Loss) (Unaudited) - USD ($)	3 Months Ended		9 Months Ended
	Jun. 30, 2021	Jun. 30, 2020	Jun. 30, 2021	Jun. 30, 2020
Expenses
Consulting fees (Note 7)	$ 190,794	$ 30,108	$ 296,987	$ 153,999
Foreign exchange loss (gain)	(3,044)	(15,824)	(16,951)	6,025
General and administrative	20,716	28,704	64,376	91,688
Professional fees	18,829	40,068	111,788	89,915
Salaries and wages	5,085	3,858	14,753	13,005
Total expenses	232,380	86,914	470,953	354,632
Net loss before other income (expense)	(232,380)	(86,914)	(470,953)	(354,632)
Other income (expense)
Accretion of discount on convertible notes (Note 5)	(1,179)	(54,877)	(86,801)	(77,889)
Gain (loss) on change in fair value of derivative liabilities (Note 6)	101,418	(1,187,033)	(3,083,420)	(1,347,031)
Gain (loss) on settlement on convertible notes (Note 5)	0	(31,898)	613,526	(38,411)
Interest and finance costs (Note 5)	(10,087)	0	(673,124)	(45,000)
Write-off of accounts payable	0	0	0	292,557
Total other income (expense)	90,152	(1,273,808)	(3,229,819)	(1,215,774)
Net loss	(142,228)	(1,360,722)	(3,700,772)	(1,570,406)
Less: net loss attributable to non-controlling interest	83	8	128	161
Net loss attributable to Pharmagreen Biotech Inc.	(142,145)	(1,360,714)	(3,700,644)	(1,570,245)
Comprehensive income (loss)
Foreign currency translation gain (loss)	(13,215)	(17,081)	(68,414)	2,045
Comprehensive loss attributable to Pharmagreen Biotech Inc.	$ (155,360)	$ (1,377,795)	$ (3,769,058)	$ (1,568,200)
Basic and diluted loss per share attributable to Pharmagreen Biotech Inc. stockholders	$ 0	$ (0.02)	$ (0.01)	$ (0.02)
Weighted average number of shares outstanding used in the calculation of net loss per share attributable to Pharmagreen Biotech Inc.	351,763,390	82,854,083	271,420,624	78,042,762

XML 14 R5.htm IDEA: XBRL DOCUMENT

Condensed Consolidated Statements of Stockholders' Deficit (Unaudited) - USD ($)	Total	Preferred Stock	Common Stock	Common Stock Issuable [Member]	Additional Paid-In Capital	Accumulated other comprehensive loss	Retained Earnings (Accumulated Deficit)	Noncontrolling Interest
Balance, shares at Sep. 30, 2019			75,646,835
Balance, amount at Sep. 30, 2019	$ (834,498)	$ 0	$ 75,647	$ 0	$ 3,772,781	$ 47,824	$ (4,729,476)	$ (1,274)
Foreign currency translation loss	(12,399)	0	0	0	0	(12,399)	0	0
Net loss for the period	(206,057)	0	$ 0	0	0	0	(206,021)	(36)
Balance, shares at Dec. 31, 2019			75,646,835
Balance, amount at Dec. 31, 2019	(1,052,954)	0	$ 75,647	0	3,772,781	35,425	(4,935,497)	(1,310)
Balance, shares at Sep. 30, 2019			75,646,835
Balance, amount at Sep. 30, 2019	(834,498)	0	$ 75,647	0	3,772,781	47,824	(4,729,476)	(1,274)
Net loss for the period	(1,570,406)
Balance, shares at Jun. 30, 2020			91,145,003
Balance, amount at Jun. 30, 2020	(2,239,452)	0	$ 91,145	0	3,920,690	49,869	(6,299,721)	(1,435)
Balance, shares at Dec. 31, 2019			75,646,835
Balance, amount at Dec. 31, 2019	(1,052,954)	0	$ 75,647	0	3,772,781	35,425	(4,935,497)	(1,310)
Foreign currency translation loss	31,525	0	0	0	0	31,525	0	0
Net loss for the period	(3,627)	0	$ 0	0	0	0	(3,510)	(117)
Issuance of common stock pursuant to the conversion of convertible notes, shares			78,064
Issuance of common stock pursuant to the conversion of convertible notes, amount	21,077	0	$ 78	0	20,999	0	0	0
Balance, shares at Mar. 31, 2020			75,724,899
Balance, amount at Mar. 31, 2020	(1,003,979)	0	$ 75,725	0	3,793,780	66,950	(4,939,007)	(1,427)
Foreign currency translation loss	(17,081)	0	0	0	0	(17,081)	0	0
Net loss for the period	(1,360,722)	0	$ 0	0	0	0	(1,360,714)	(8)
Issuance of common stock pursuant to the conversion of convertible notes, shares			15,420,104
Issuance of common stock pursuant to the conversion of convertible notes, amount	142,330	0	$ 15,420	0	126,910	0	0	0
Balance, shares at Jun. 30, 2020			91,145,003
Balance, amount at Jun. 30, 2020	(2,239,452)	0	$ 91,145	0	3,920,690	49,869	(6,299,721)	(1,435)
Balance, shares at Sep. 30, 2020			95,806,289
Balance, amount at Sep. 30, 2020	(2,934,105)	0	$ 95,806	180,000	3,967,261	36,679	(7,167,346)	(46,505)
Foreign currency translation loss	(42,455)	0	0	0	0	(42,455)	0	0
Net loss for the period	(417,110)	0	$ 0	0	0	0	(417,109)	(1)
Issuance of common stock pursuant to the conversion of convertible notes, shares			144,315,380
Issuance of common stock pursuant to the conversion of convertible notes, amount	1,612,053	0	$ 144,316	(180,000)	1,647,737	0	0	0
Issuance of units for cash, shares			5,400,000
Issuance of units for cash, amount	27,000	$ 0	$ 5,400	0	21,600	0	0	0
Issuance of preferred shares for cash, shares		10,000
Issuance of preferred shares for cash, amount	10	$ 10	$ 0	0	0	0	0	0
Issuance of common stock for services, shares			90,000
Issuance of common stock for services, amount	1,355	$ 0	$ 90	0	1,265	0	0	0
Balance, shares at Dec. 31, 2020		10,000	245,611,669
Balance, amount at Dec. 31, 2020	(1,753,252)	$ 10	$ 245,612	0	5,637,863	(5,776)	(7,584,455)	(46,506)
Balance, shares at Sep. 30, 2020			95,806,289
Balance, amount at Sep. 30, 2020	(2,934,105)	$ 0	$ 95,806	180,000	3,967,261	36,679	(7,167,346)	(46,505)
Net loss for the period	(3,700,772)
Balance, shares at Jun. 30, 2021		10,000	355,129,269
Balance, amount at Jun. 30, 2021	(1,841,178)	$ 10	$ 355,129	121,500	8,628,541	(31,735)	(10,867,990)	(46,633)
Balance, shares at Dec. 31, 2020		10,000	245,611,669
Balance, amount at Dec. 31, 2020	(1,753,252)	$ 10	$ 245,612	0	5,637,863	(5,776)	(7,584,455)	(46,506)
Foreign currency translation loss	(12,744)	0	0	0	0	(12,744)	0	0
Net loss for the period	(3,141,434)	0	$ 0	0	0	0	(3,141,390)	(44)
Issuance of common stock pursuant to the conversion of convertible notes, shares			84,845,100
Issuance of common stock pursuant to the conversion of convertible notes, amount	2,933,217	0	$ 84,845	0	2,848,372	0	0	0
Issuance of units for cash, shares			17,411,250
Issuance of units for cash, amount	96,225	0	$ 17,411	6,113	72,701	0	0	0
Issuance of common stock for services, shares			300,000
Issuance of common stock for services, amount	7,320	$ 0	$ 300	0	7,020	0	0	0
Balance, shares at Mar. 31, 2021		10,000	348,168,019
Balance, amount at Mar. 31, 2021	(1,870,668)	$ 10	$ 348,168	6,113	8,565,956	(18,520)	(10,725,845)	(46,550)
Foreign currency translation loss	(13,215)	0	0	0	0	(13,215)	0	0
Net loss for the period	(142,228)	0	$ 0	0	0	0	(142,145)	(83)
Issuance of units for cash, shares			6,961,250
Issuance of units for cash, amount	63,433	0	$ 6,961	(6,113)	62,585	0	0	0
Shares issuable for services	121,500	$ 0	$ 0	121,500	0	0	0	0
Balance, shares at Jun. 30, 2021		10,000	355,129,269
Balance, amount at Jun. 30, 2021	$ (1,841,178)	$ 10	$ 355,129	$ 121,500	$ 8,628,541	$ (31,735)	$ (10,867,990)	$ (46,633)

XML 15 R6.htm IDEA: XBRL DOCUMENT

Condensed Consolidated Statements of Cash Flows (Unaudited) - USD ($)	9 Months Ended
	Jun. 30, 2021	Jun. 30, 2020
OPERATING ACTIVITIES
Net loss	$ (3,700,772)	$ (1,570,406)
Adjustments to reconcile net loss to net cash used in operating activities:
Accretion of discount on convertible notes	86,801	77,889
Financing fees and default penalties	673,124	45,000
Loss on change in fair value of derivative liabilities	3,083,420	1,347,031
Loss (gain) on settlement of convertible notes	(613,526)	38,411
Shares issued or issuable for services	130,175	0
Write-off of accounts payable	0	(292,557)
Changes in operating assets and liabilities:
Amounts receivable	207	9,849
Prepaid expenses and deposits	3,754	(236,798)
Accounts payable and accrued liabilities	120,273	21,189
Due to related parties	65,307	13,840
Net cash used in operating activities	(151,237)	(546,552)
FINANCING ACTIVITIES
Proceeds from issuance of convertible notes	0	570,080
Proceeds from units issued and issuable for cash	186,725	0
Proceeds from issuance of preferred shares	10	0
Repayment of loans from related parties	0	(128,813)
Proceeds from related party loans	33,646	64,981
Proceeds from loans payable	0	29,388
Financing costs	0	(5,000)
Net cash provided by financing activities	220,381	530,636
Effect of foreign exchange rate changes on cash	(62,122)	(12,184)
Change in cash	7,022	(28,100)
Cash, beginning of period	12,196	62,682
Cash, end of period	19,218	34,582
Non-cash investing and financing activities:
Original issue discount on convertible notes	0	532,594
Common shares issued for settlement of convertible notes	4,545,270	163,407
Issuance of promissory note as a financing fee	0	40,000
Supplemental disclosures:
Interest paid	0	4,601
Income taxes paid	$ 0	$ 0

XML 16 R7.htm IDEA: XBRL DOCUMENT

Nature of Business and Continuance of Operations

9 Months Ended

Jun. 30, 2021

Nature of Business and Continuance of Operations

1. Nature of Business and Continuance of Operations

Nature of Business and Continuance of Operations

Going Concern

XML 17 R8.htm IDEA: XBRL DOCUMENT

Summary of Significant Accounting Policies

9 Months Ended

Jun. 30, 2021

Summary of Significant Accounting Policies

2. Summary of Significant Accounting Policies

2.	Significant Accounting Policies

	(a)	Interim Financial Statements

		These condensed consolidated financial statements have been prepared on the same basis as the annual consolidated financial statements and in the opinion of management, reflect all adjustments, which include only normal recurring adjustments, necessary to present fairly the Company’s financial position, results of operations and cash flows for the periods shown. The results of operations for such periods are not necessarily indicative of the results expected for a full year or for any future period.

	(b)	Basis of Presentation

		The accompanying condensed interim consolidated financial statements have been prepared in accordance with accounting principles generally accepted in the United States and are expressed in U.S. dollars. These condensed consolidated financial statements include the accounts of the Company and its wholly owned subsidiary, WFS Pharmagreen Inc. (“WFS”), and its 89.7% owned subsidiary 1155097 B.C. Ltd. (“115BC”), companies incorporated in British Columbia, Canada. All inter-company accounts and transactions have been eliminated. The Company’s fiscal year-end is September 30.

	(c)	Use of Estimates and Judgments

		The preparation of these condensed consolidated financial statements in conformity with U.S. generally accepted accounting principles requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. The Company regularly evaluates estimates and assumptions related to the recoverability of property and equipment, the equity component of convertible notes, fair value of derivative liabilities, fair value of share-based payments, and deferred income tax asset valuation allowances. The Company bases its estimates and assumptions on current facts, historical experience, and various other factors that it believes to be reasonable under the circumstances, the results of which form the basis for making judgments about the carrying values of assets and liabilities and the accrual of costs and expenses that are not readily apparent from other sources. The actual results experienced by the Company may differ materially and adversely from the Company’s estimates. To the extent there are material differences between the estimates and the actual results, future results of operations will be affected. The Company applies judgment in the application of the going concern assumption which requires management to take into account all available information about the future, which is at least, but not limited to, 12 months from the end of the reporting period and in the factors regarding the impairment of the property and equipment. The Company tests property and equipment for recoverability when events or changes in circumstances indicate that their carrying amount may not be recoverable. Circumstances which could trigger a review include, but are not limited to: significant decreases in the market price of the asset; significant adverse changes in the business climate or legal factors; accumulation of costs significantly in excess of the amount originally expected for the acquisition or construction of the asset; current period cash flow or operating losses combined with a history of losses or a forecast of continuing losses associated with the use of the asset; and current expectation that the asset will more likely than not be sold or disposed significantly before the end of its estimated useful life. Recoverability is assessed based on the carrying amount of the asset and its fair value, which is generally determined based on the sum of the undiscounted cash flows expected to result from the use and the eventual disposal of the asset, as well as specific appraisal in certain instances. An impairment loss is recognized when the carrying amount is not recoverable and exceeds fair value.

	(d)	Recently Adopted Accounting Pronouncements

		The Company has implemented all new accounting pronouncements that are in effect and that may impact its condensed consolidated financial statements and does not believe that there are any other new accounting pronouncements that have been issued that might have a material impact on its financial position or results of operations.

XML 18 R9.htm IDEA: XBRL DOCUMENT

Accounts Payable and Accrued Liabilities

9 Months Ended

Jun. 30, 2021

Accounts Payable and Accrued Liabilities

3. Accounts Payable and Accrued Liabilities

3.	Accounts Payable and Accrued Liabilities

	Accounts payable and accrued liabilities consists of the following:

	June 30, 2021 $		September 30, 2020 $

Accounts payable (Note 7)		550,871		455,310
Accrued interest payable (Notes 4 and 5)		73,590		84,353

		624,461		539,663

XML 19 R10.htm IDEA: XBRL DOCUMENT

Note and Loan Payable

9 Months Ended

Jun. 30, 2021

Note and Loan Payable

4. Note and Loan Payable

4.	Note and Loan Payable

	(a)	On November 22, 2019, the Company entered into a promissory note with an unrelated party for $40,000 in connection with an equity purchase agreement (Refer to Note 11(b)). The promissory note is unsecured, was due on November 30, 2020, and bears interest on the unpaid principal balance at a rate of 10% per annum. At June 30, 2021, the Company has recorded accrued interest payable of $6,404 (September 30, 2020 - $3,421) and the promissory note is in default. On March 10, 2021, this noteholder filed a Notice of Motion for Summary Judgement in Lieu of Complaint (the “Notice”) with the State of New York Supreme Court, County of New York for $40,504 plus interest at the rate of 10% per annum from January 6, 2021 plus costs. On July 31, 2021, the Notice was dismissed without prejudice by the State of New York Supreme Court.

	(b)	On April 22, 2020, the Company received a loan for Cdn$40,000from the Government of Canada under the Canada Emergency Business Account program (“CEBA”). As at June 30, 2021, the balance owing is $32,240 (Cdn$40,000) (September 30, 2020 – $30,028 (Cdn$40,000)). These funds are interest free until December 31, 2022, at which time the remaining balance will convert to a 3-year term loan at an interest rate of 5% per annum. If the Company repays the loan prior to December 31, 2022, there will be loan forgiveness of 25% of the principal balance repaid, up to a maximum of Cdn$10,000.

XML 20 R11.htm IDEA: XBRL DOCUMENT

Convertible Notes

9 Months Ended

Jun. 30, 2021

Convertible Notes

5. Convertible Notes

5.	Convertible Notes

(a)

5.	Convertible Notes (continued)

	(b)	On October 1, 2019, the Company entered into a convertible note with an unrelated party for $78,000, of which $3,255 was paid directly to third parties for financing costs, resulting in net proceeds to the Company of $74,745. The note is due on October 1, 2020, and bears interest on the unpaid principal balance at a rate of 10% per annum, which increases to 24% per annum upon default of the note.The note may be converted at any time after the date of issuance into shares of Company’s common stock at a conversion price equal to lower of: (i) the lowest trading price during the 10-trading day period prior to the issuance date; or (ii) 61% of the average 2 lowest trading prices during the 10-trading day period prior to the conversion date. In connection with the issuance of the above convertible note, the Company evaluated the conversion option for derivative treatment under ASC 815-15, Derivatives and Hedging, and determined the note and conversion feature qualified as derivatives. The Company classified the conversion feature as a derivative liability at fair value. The initial fair value of the conversion feature was determined to be $70,744. The Company recognized the maximum intrinsic value of the embedded beneficial conversion feature of $74,245 and reduced the carrying value of the convertible note to $500. The carrying value will be accreted over the term of the convertible note up to its face value of $78,000.

		On July 22, 2020, the Company received a preliminary statement of claim from the note holder for failure of the Company to deliver shares of common stock upon receipt of notices of conversion. Pursuant to the claim, the note holder requested receipt of all shares of common stock requested in the notices of conversion, and also damages in an amount to be determined at trial but in any event in excess of principal in the sum of $180,000, including without limitation the balance of any portion of the convertible note that ultimately is not converted into shares of common stock, along with default interest, liquidated damages, and damages as provided for in the convertible note. Upon default, the Company recognized the remaining debt discount of $46,904 as accretion expense. The financing costs were netted against the convertible note and were being amortized over the term using the effective interest rate method. During the year ended September 30, 2020, the Company recognized accretion expense of $77,500 and a default penalty of $85,864. During the nine months ended June 30, 2021, the Company recorded an additional $253,856 of default penalties. During the nine months ended June 30, 2021, the Company issued 133,226,100 shares of common stock upon the conversion of $417,719 of the convertible note and $11,000 of conversion fees. On March 12, 2021, the Company entered into a settlement agreement with the noteholder. Pursuant to the agreement, the Company was required to honour various conversion notices and the noteholder agreed to waive all principal, interest and penalties incurred. As at March 12, 2021, the carrying value of the convertible note was $nil (September 30, 2020 - $163,864) and the fair value of the derivative liability was $nil (September 30, 2020 - $485,863).

	(c)	On October 17, 2019, the Company entered into a convertible note with an unrelated party for $63,000, of which $3,000 was paid directly to third parties for financing costs, resulting in net cash proceeds to the Company of $60,000. The note is due on October 17, 2020, and bears interest on the unpaid principal balance at a rate of 10% per annum, which increases to 22% per annum upon default of the note. The note may be converted at any time after 180 days of the date of issuance into shares of Company’s common stock at a conversion price equal to 61% of the average 2 lowest trading prices during the 10-trading day period prior to the conversion date.

5.	Convertible Notes (continued)

		On June 17, 2020, the Company entered into a settlement agreement with the lender, whereby the Company and the lender agreed on repayment terms for the remaining principal balance of $63,000, and accrued interest owing on the note of $5,775 which was due on September 30, 2020. Upon entering into the settlement agreement, the Company immediately recognized the remaining debt discount of $1,657. On September 30, 2020, the Company failed to meet the repayment terms within the settlement agreement which resulted in a default penalty of $63,000 and the resumption of the convertibility feature at a conversion price equal to 61% of the average 2 lowest trading prices during the 10-trading day period prior to the conversion date. On September 30, 2020, the Company evaluated the conversion option for derivative treatment under ASC 815-15, Derivatives and Hedging, and determined the note and conversion feature qualified as derivatives. The Company classified the conversion feature as a derivative liability at fair value. The initial fair value of the conversion feature was determined to be $112,822. The financing costs were netted against the convertible note and were being amortized over the term using the effective interest rate method. During the year ended September 30, 2020, the Company recognized accretion expense of $3,000 and a default penalty of $63,000. During the nine months ended June 30, 2021, the Company issued 7,730,486 shares of common stock upon the conversion of $126,000 of the convertible note. As at June 30, 2021, the carrying value of the convertible note was $nil (September 30, 2020 - $126,000) and the fair value of the derivative liability was $nil (September 30, 2020 - $112,822).

	(d)	On January 2, 2020, the Company entered into a convertible note with an unrelated party for $53,000, of which $3,000 was paid directly to third parties for financing costs, resulting in cash proceeds to the Company of $50,000. The note is due on January 2, 2021, and bears interest on the unpaid principal balance at a rate of 10% per annum, which increases to 22% per annum upon default of the note. The note may be converted at any time after 180 days of the date of issuance into shares of Company’s common stock at a conversion price equal to 61% of the average 2 lowest trading prices during the 10-trading day period prior to the conversion date.

		On June 17, 2020, the Company entered into a settlement agreement with the lender, whereby the Company and the lender agreed on repayment terms for the remaining principal of $53,000 and accrued interest owing on the note. Upon entering into the settlement agreement, the Company immediately recognized the remaining debt discount of $2,286. Effective September 30, 2020, the Company failed to meet the repayment terms of the settlement agreement and defaulted on the convertible note. On September 30, 2020, the Company evaluated the conversion option for derivative treatment under ASC 815-15, Derivatives and Hedging, and determined the note and conversion feature qualified as derivatives. The Company classified the conversion feature as a derivative liability at fair value. The initial fair value of the conversion feature was determined to be $139,702. The financing costs were netted against the convertible note and were being amortized over the term using the effective interest rate method. During the year ended September 30, 2020, the Company recognized accretion expense of $3,000 and a default penalty of $53,000. During the nine months ended June 30, 2021, the Company issued 16,994,905 shares of common stock upon the conversion of $106,000 of the convertible note. As at June 30, 2021, the carrying value of the convertible note was $nil (September 30, 2020 - $106,000) and the fair value of the derivative liability was $nil (September 30, 2020 - $139,702).

5.	Convertible Notes (continued)

	(e)	On January 14, 2020, the Company entered into a convertible note with an unrelated party for $78,000, of which $3,000 was paid for financing costs, resulting in net proceeds to the Company of $75,000. The note is due on January 14, 2021, and bears interest on the unpaid principal balance at a rate of 12% per annum, which increases to 15% per annum upon default of the note. The note may be converted at any time after the date of issuance into shares of Company’s common stock at a conversion price equal to lower of: (i) 65% of the lowest trading price during the 20-trading day period prior to the issuance date; or (ii) 65% of the lowest trading price during the 20-trading day period prior to the conversion date. In connection with the issuance of the above convertible note, the Company evaluated the conversion option for derivative treatment under ASC 815-15, Derivatives and Hedging, and determined the note and conversion feature qualified as derivatives. The Company classified the conversion feature as a derivative liability at fair value. The initial fair value of the conversion feature was determined to be $76,330. The Company recognized the maximum intrinsic value of the embedded beneficial conversion feature of $74,500, resulting in a loss on change in fair value of derivative liabilities of $1,830, and reduced the carrying value of the convertible note to $500. The carrying value will be accreted over the term of the convertible note up to its face value of $78,000.

		The financing costs were netted against the convertible note and are being amortized over the term using the effective interest rate method. During the year ended September 30, 2020, the Company recognized accretion expense of $16,447. During the nine months ended June 30, 2021, the Company issued 2,600,000 shares of common stock upon the conversion of $18,923 of the convertible note and $4,500 of conversion fees. On January 14, 2021, the Company failed to repay the note upon maturity and recorded additional default principal of $53,007. As at June 30, 2021, the carrying value of the convertible note was $112,084 (September 30, 2020 - $16,947), net of an unamortized discount of $nil (September 30, 2020 - $61,053), and the fair value of the derivative liability was $170,586 (September 30, 2020 - $110,604).

	(f)	On January 15, 2020, the Company entered into a convertible note with an unrelated party for $61,000, of which $7,400 was paid directly to third parties for financing costs and an original issue discount of $3,000, resulting in proceeds to the Company of $50,600. The note is due on January 15, 2021, and bears interest on the unpaid principal balance at a rate of 10% per annum, payable in common stock, which increases to 24% per annum upon default of the note. The note may be converted at any time after the date of issuance into shares of Company’s common stock at a conversion price equal 65% of the lowest trading price during the 20-trading day period prior to the conversion date. In connection with the issuance of the above convertible note, the Company evaluated the conversion option for derivative treatment under ASC 815-15, Derivatives and Hedging, and determined the note and conversion feature qualified as derivatives. The Company classified the conversion feature as a derivative liability at fair value. The initial fair value of the conversion feature was determined to be $67,846.

		The Company recognized the maximum intrinsic value of the embedded beneficial conversion feature of $50,100, resulting in a loss on change in fair value of derivative liabilities of $17,746, and reduced the carrying value of the convertible note to $500. The carrying value will be accreted over the term of the convertible note up to its face value of $61,000. On July 23, 2020, the Company entered into a settlement agreement with the note holder, wherein the Company and the lender agreed to settle a convertible note and accrued interest for a total of $63,440 on a non-convertible basis, of which $15,000 was payable on or before July 24, 2020 (paid), followed by 6 monthly instalment payments of $8,073. Upon entering into the settlement agreement, the Company immediately recognized the remaining debt discount of $56,566. Effective August 24, 2020, the Company failed to meet the repayment terms and defaulted on the settlement agreement. The financing costs were netted against the convertible note and were being amortized over the term using the effective interest rate method. During the year ended September 30, 2020, the Company recognized accretion expense of $60,500. During the nine months ended June 30, 2021, the Company issued 3,601,718 shares of common stock upon the conversion of $46,000 of the convertible note, $5,586 of accrued interest and $500 of conversion fees. As at June 30, 2021, the carrying value of the convertible note was $nil (September 30, 2020 - $46,000) and the fair value of the derivative liability was $nil (September 30, 2020 - $69,320).

5.	Convertible Notes (continued)

	(g)	On January 15, 2020, the Company entered into a convertible note with an unrelated party for $55,000, of which $2,500 was paid directly to third parties for financing costs, resulting in proceeds to the Company of $52,500. The note is due on January 15, 2021, and bears interest on the unpaid principal balance at a rate of 10% per annum, which increases to 24% per annum upon default of the note. The note may be converted at any time after the date of issuance into shares of Company’s common stock at a conversion price equal to lower of: (i) the lowest trading price during the 20-trading day period ending on the latest complete trading day prior to the issuance date; or (ii) 65% of the lowest trading price during the 20 consecutive trading day period on which at least 100 shares of common stock were traded prior to the conversion date. In connection with the issuance of the above convertible note, the Company evaluated the conversion option for derivative treatment under ASC 815-15, Derivatives and Hedging, and determined the note and conversion feature qualified as derivatives. The Company classified the conversion feature as a derivative liability at fair value. The initial fair value of the conversion feature was determined to be $61,173. The Company recognized the maximum intrinsic value of the embedded beneficial conversion feature of $52,000, resulting in a loss on change in fair value of derivative liabilities of $9,173, and reduced the carrying value of the convertible note to $500. The carrying value will be accreted over the term of the convertible note up to its face value of $55,000.

		During the year ended September 30, 2020, the Company defaulted on the convertible note which resulted in a default penalty of $27,500 and the amendment of the conversion rate from 65% to 50% of the lowest trading price during the 20 consecutive trading days prior to conversion. The Company recognized the remaining debt discount of $50,767 as accretion expense. The financing costs were netted against the convertible note and were being amortized over the term using the effective interest rate method. During the year ended September 30, 2020, the Company recognized accretion expense of $54,500 and a default penalty of $27,500. During the nine months ended June 30, 2021, the Company issued 17,557,925 shares of common stock upon the conversion of $82,500 of the convertible note, $7,693 of accrued interest and $3,000 of conversion fees. As at June 30, 2021, the carrying value of the convertible note was $nil (September 30, 2020 - $82,500) and the fair value of the derivative liability was $nil (September 30, 2020 - $146,272).

	(h)	On January 21, 2020, the Company entered into a convertible note with an unrelated party for $66,150, of which $7,800 was paid directly to third parties for financing costs and an original issue discount of $3,150, resulting in proceeds to the Company of $55,200. The note is due on January 21, 2021, and bears interest on the unpaid principal balance at a rate of 8% per annum, payable in common stock, which increases to 24% per annum upon default of the note. The note may be converted at any time after the date of issuance into shares of Company’s common stock at a conversion price equal 60% of the lowest trading price during the 20-trading day period prior to the conversion date. In connection with the issuance of the above convertible note, the Company evaluated the conversion option for derivative treatment under ASC 815-15, Derivatives and Hedging, and determined the note and conversion feature qualified as derivatives. The Company classified the conversion feature as a derivative liability at fair value. The initial fair value of the conversion feature was determined to be $71,278.

		The Company recognized the maximum intrinsic value of the embedded beneficial conversion feature of $54,700, resulting in a loss on change in fair value of derivative liabilities of $16,578, and reduced the carrying value of the convertible note to $500. The carrying value will be accreted over the term of the convertible note up to its face value of $66,150.

5.	Convertible Notes (continued)

		The financing costs were netted against the convertible note and are being amortized over the term using the effective interest rate method. During the year ended September 30, 2020, the Company recognized accretion expense of $13,202. During the nine months ended June 30, 2021, the Company issued 4,431,963 shares of common stock upon the conversion of $66,150of the convertible note and $3,907 of accrued interest. As at June 30, 2021, the carrying value of the convertible note was $nil (September 30, 2020 - $13,702), net of an unamortized discount of $nil (September 30, 2020 - $52,448), and the fair value of the derivative liability was $nil (September 30, 2020 - $98,579).

	(i)	On January 22, 2020, the Company entered into a convertible note with an unrelated party for $78,750, of which $9,750 was paid directly to third parties for financing costs, resulting in proceeds to the Company of $69,000. The note is due on January 22, 2021, and bears interest on the unpaid principal balance at a rate of 10% per annum, payable in common stock, which increases to 24% per annum upon default of the note. The note may be converted at any time after the date of issuance into shares of Company’s common stock at a conversion price equal to 65% of the lowest trading price during the 20-trading day period ending on the latest complete trading day prior to the conversion date. In connection with the issuance of the above convertible note, the Company evaluated the conversion option for derivative treatment under ASC 815-15, Derivatives and Hedging, and determined the note and conversion feature qualified as derivatives. The Company classified the conversion feature as a derivative liability at fair value. The initial fair value of the conversion feature was determined to be $75,179. The Company recognized the maximum intrinsic value of the embedded beneficial conversion feature of $68,500, resulting in a loss on change in fair value of derivative liabilities of $6,679, and reduced the carrying value of the convertible note to $500. The carrying value will be accreted over the term of the convertible note up to its face value of $78,750.

		The financing costs were netted against the convertible note and are being amortized over the term using the effective interest rate method. During the year ended September 30, 2020, the Company defaulted on the convertible note and recognized accretion expense of $78,250. On January 22, 2021, the Company failed to repay the note upon maturity. As at June 30, 2021, the carrying value of the convertible note was $78,750 (September 30, 2020 - $78,750) and the fair value of the derivative liability was $127,715 (September 30, 2020 - $107,660).

	(j)	On February 4, 2020, the Company entered into a convertible note with an unrelated party for $100,000, of which $16,970 was paid directly to third parties for financing costs, resulting in proceeds to the Company of $83,030. The note is due on February 4, 2021, and bears interest on the unpaid principal balance at a rate of 12% per annum, which increases to 24% per annum upon default of the note. The note may be converted at any time after the date of issuance into shares of Company’s common stock at a conversion price equal to lower of: (i) the lowest trading price during the 10-trading day period ending on the latest complete trading day prior to the issuance date; or (ii) 60% of the average of the two lowest trading prices during the 10-trading day period prior to the conversion date. In connection with the issuance of the above convertible note, the Company evaluated the conversion option for derivative treatment under ASC 815-15, Derivatives and Hedging, and determined the note and conversion feature qualified as derivatives. The Company classified the conversion feature as a derivative liability at fair value. The initial fair value of the conversion feature was determined to be $125,640. The Company recognized the maximum intrinsic value of the embedded beneficial conversion feature of $82,530, resulting in a loss on change in fair value of derivative liabilities of $43,110, and reduced the carrying value of the convertible note to $500. The carrying value will be accreted over the term of the convertible note up to its face value of $100,000.

		During the year ended September 30, 2020, the noteholder converted $24,175 of the convertible note for 2,000,000 common shares with a fair value of $180,000 and was issued on October 20, 2020. Upon the notice of conversion, the Company immediately recognized the related remaining debt discount of $23,136 as accretion expense. The financing costs were netted against the convertible note and are being amortized over the term using the effective interest rate method. During the year ended September 30, 2020, the Company recognized accretion expense of $7,854.

5.	Convertible Notes (continued)

XML 21 R12.htm IDEA: XBRL DOCUMENT

Derivative Liabilities

9 Months Ended

Jun. 30, 2021

Derivative Liabilities

6. Derivative Liabilities

6.	Derivative Liabilities

	The embedded conversion option of certain of the Company’s convertible notes described in Note 5 contain a conversion feature that qualifies for embedded derivative classification. The fair value of this liability will be re-measured at the end of every reporting period and the change in fair value will be reported in the statement of operations as a gain or loss on change in fair value of derivative liabilities. The table below sets forth a summary of changes in the fair value of the Company’s Level 3 financial liabilities:

	$
Balance, September 30, 2020	1,380,957

Conversion of convertible notes	(4,166,076	)
Change in fair value	3,083,420

Balance, June 30, 2021	298,301

Expected

volatility

Risk-free interest

rate

Expected dividend

yield

Expected life

(in years)

As at June 30, 2021

256

0.1

0.5

XML 22 R13.htm IDEA: XBRL DOCUMENT

Related Party Transactions

9 Months Ended

Jun. 30, 2021

Related Party Transactions

7. Related Party Transactions

7.	Related Party Transactions

	(a)	As at June 30, 2021, the Company owed $548,586 (Cdn$680,628) (September 30, 2020 - $453,697(Cdn$604,366)) to the President of the Company, which is non-interest bearing, unsecured, and due on demand. During the nine months ended June 30, 2021, the Company incurred consulting fees of $72,171 (2020 - $63,044) to the President of the Company.

	(b)	As at June 30, 2021, the Company owed $59,241 (Cdn$73,500) (September 30, 2020 - $55,177 (Cdn$73,500)) to the father of the President of the Company, which is non-interest bearing, unsecured, and due on demand.

	(c)	As at June 30, 2021, the Company owed $27,565 (Cdn$34,200) (September 30, 2020 – $25,674 (Cdn$34,000)) to a company owned by the father of the President of the Company, which is included in accounts payable and accrued liabilities. The amount due is non-interest bearing, unsecured, and due on demand.

	(d)	As at June 30, 2021, the Company owed $431,105 (Cdn$534,870) (September 30, 2020 – $347,229 (Cdn$462,540)) to a company controlled by the Chief Financial Officer of WFS, which is included in accounts payable and accrued liabilities. The amount due is non-interest bearing, unsecured, and due on demand. During the nine months ended June 30, 2021, the Company incurred consulting fees of $72,171 (2020 - $63,044) to the company controlled by the Chief Financial Officer of WFS.

	(e)	On October 14, 2020, the Company issued 10,000 shares of Series A Super Voting Preferred Stock to a director of the Company for proceeds of $10.

XML 23 R14.htm IDEA: XBRL DOCUMENT

Common Stock

9 Months Ended

Jun. 30, 2021

Common Stock

8. Common Stock

8.	Common Stock

	Nine months ended June 30, 2021

	(a)	In December 2020, the Company issued 5,400,000 units at $0.005 per unit for proceeds of $27,000 in a private placement. Each unit is comprised of one share of common stock and one share purchase warrant exercisable into an additional share of common stock at an exercise price of $0.05 per share for a period of 24 months.

	(b)	Between January 11 to February 16, 2021, the Company issued 16,800,000 units at $0.005 per unit for proceeds of $84,000 in a private placement. Each unit is comprised of one share of common stock and one share purchase warrant exercisable into an additional share of common stock at an exercise price of $0.05 per share for a period of 24 months.

	(c)	On March 1, 2021, the Company issued 611,250 units at $0.01 per unit for proceeds of $6,112 in a private placement. Each unit is comprised of one share of common stock and one share purchase warrant exercisable into an additional share of common stock at an exercise price of $0.05 per share for a period of 24 months.

	(d)	During the nine months ended June 30, 2021, the Company issued 133,226,100 shares of common stock upon the conversion of $417,719 of the convertible note and $11,000 of conversion fees (Note 5(b)).

	(e)	During the nine months ended June 30, 2021, the Company issued 7,730,486 shares of common stock upon the conversion of $126,000 of the convertible note and $3,150 of accrued interest (Note 5(c)).

	(f)	During the nine months ended June 30, 2021, the Company issued 16,994,905 shares of common stock upon the conversion of $106,000 of the convertible note and $2,650 of accrued interest (Note 5(d)).

	(g)	During the nine months ended June 30, 2021, the Company issued 2,600,000 shares of common stock upon the conversion of $18,923 of the convertible note and $4,500 of conversion fees (Note 5(e)).

	(h)	During the nine months ended June 30, 2021, the Company issued 3,601,718 shares of common stock upon the conversion of $46,000 of the convertible note, $5,586 of accrued interest and $500 of conversion fees (Note 5(f)).

	(i)	During the nine months ended June 30, 2021, the Company issued 17,557,925 shares of common stock upon the conversion of $82,500 of the convertible note, $7,693 of accrued interest and $3,000 of conversion fees (Note 5(g)).

	(j)	During the nine months ended June 30, 2021, the Company issued 4,431,963 shares of common stock upon the conversion of $66,150 of the convertible note, $3,907 of accrued interest (Note 5(h)).

	(k)	During the nine months ended June 30, 2021, the Company issued 41,017,383 shares of common stock upon the conversion of $75,825 of the convertible note, $2,154 of accrued interest and $18,750 of fees (Note 5(j)).

	(l)	On November 1, 2020, the Company issued 22,500 shares of common stock with a fair value of $401 for management consulting and strategic business advisory services.

	(m)	On November 26, 2020, the Company issued 45,000 shares of common stock with a fair value of $733 for management consulting and strategic business advisory services.

	(n)	On December 11, 2020, the Company issued 22,500 shares of common stock with a fair value of $221 for management consulting and strategic business advisory services.

	(o)	On February 2, 2021, the Company issued 150,000 shares of common stock with a fair value of $2,700 for management consulting and strategic business advisory services.

	(p)	On March 29, 2021, the Company issued 150,000 shares of common stock with a fair value of $4,620 for management consulting and strategic business advisory services.

	(q)	As at September 30, 2020, the Company received a conversion notice for 2,000,000 shares of common stock with a fair value of $180,000 pursuant to the conversion of $30,750 of a convertible note (see Note 5(j)). The common shares were issued on October 20, 2020.

8.	Common Stock (continued)

	Nine months ended June 30, 2021 (continued)

	(r)	On May 14, 2021, the Company issued 611,250 units at $0.01 per unit for proceeds of $6,113 in a private placement. Each unit is comprised of one share of common stock and one share purchase warrant exercisable into an additional share of common stock at an exercise price of $0.05 per share for a period of 24 months.

	(s)	On May 14, 2021, the Company issued 6,350,000 units at $0.01 per unit for proceeds of $63,500. Each unit is comprised of one share of common stock and one share purchase warrant exercisable at $0.05 per share of common stock expiring 24 months from the date of issuance.

	(t)	As at June 30, 2021, the Company agreed to issue 6,750,000 shares of common stock with a fair value of $121,500, which has been included in shares issuable, pursuant to a production agreement (Note 11(d)).

XML 24 R15.htm IDEA: XBRL DOCUMENT

Preferred Stock

9 Months Ended

Jun. 30, 2021

Preferred Stock

9. Preferred Stock

Preferred Stock

The Series A Super Voting Preferred Stock has the following rights and restrictions:

Each individual share of Series A Super Voting Preferred Stock shall have the voting rights equal to:

· [the number of shares of Series A Super Voting Preferred Stock issued and outstanding at the time of voting]

Preferred Stock (continued)

XML 25 R16.htm IDEA: XBRL DOCUMENT

Share Purchase Warrants

9 Months Ended

Jun. 30, 2021

Share Purchase Warrants

10. Share Purchase Warrants

10.	Share Purchase Warrants

	The following table summarizes the continuity of the Company’s share purchase warrants:

	Number of warrants		Weighted average exercise price $

Balance, September 30, 2020		114,286		0.55

Issued		29,772,500		0.05

Balance, June 30, 2021		29,886,786		0.05

As at June 30, 2021, the following share purchase warrants were outstanding:

Number of warrants		Exercise price		Expiry date

	114,286	$	0.55	July 16, 2022
	400,000	$	0.05	December 2, 2022
	3,000,000	$	0.05	December 11, 2022
	2,000,000	$	0.05	December 30, 2022
	2,300,000	$	0.05	January 11, 2023
	13,500,000	$	0.05	January 30, 2023
	1,000,000	$	0.05	February 16, 2023
	611,250	$	0.05	March 1, 2023
	6,961,250	$	0.05	May 14, 2023

	29,886,786

XML 26 R17.htm IDEA: XBRL DOCUMENT

Commitments

9 Months Ended

Jun. 30, 2021

Commitments

11. Commitments

11.

Commitments

	(a)	Effective December 11, 2017, the Company entered into a binding Letter of Intent (“LOI”) with Alliance Growers Corp. (“Alliance”), whereby the Company will build a new cannabis biotech complex located in Deroche, British Columbia, through their subsidiary, 115BC. On January 25, 2019, the Company’s subsidiaries WFS and 115BC entered into an option agreement with Alliance, which superseded the LOI entered into on December 11, 2017. The option agreement grants an option to Alliance to purchase 10% equity interest in 115BC for Cdn$1,350,000 and previously granted a second option to purchase an additional 20% equity interest in 115BC for funding of 30% of the total construction and equipment costs for the biotech complex less Cdn$1,350,000. On January 25, 2019, 115BC issued 8 shares of common stock to Alliance upon exercise of the first option for consideration of $1,018,182 (Cdn$1,350,008), which was recognized as additional paid-in capital. The second option expired unexercised. As at June 30, 2021, the Company received advances of $60,450 (Cdn$75,000) (September 30, 2020 - $56,303 (Cdn$75,000)) from Alliance, which is unsecured, non-interest bearing, and due on demand.

	(b)	On November 22, 2019, the Company entered into an equity purchase agreement with an unrelated party, whereby the third party is to purchase up to $10,000,000 of the Company’s common stock. The equity purchase agreement is effective for a term of 2 years from the effective date of the registration statement. The purchase price would be 85% of the market price. In return, the Company issued a promissory note of $40,000 (Refer to Note 4(a)). In addition, the third party is required to pay an additional commitment fee of $10,000, of which $5,000 was paid upon signing the term sheet and the remaining $5,000 is due upon completion of the first tranche of the financing.

	(c)	On December 13, 2020, the Company entered into a consulting agreement with a six month term. Pursuant to the agreement, the Company will 75,000 shares of common stock per month in exchange for consulting services. On June 13, 2021, the Company extended the consulting agreement for an additional six month term for the issuance of 117,000 common shares per month. Refer to Note 12(a).

	(d)	Effective May 13, 2021, the Company entered into a production agreement with New to the Street Group LLC. Pursuant to the terms of the agreement, New to the Street Group LLC will provide investor relations and consulting services for a period of six months. Pursuant to the agreement,the Company agreed to pay New to the Street Group LLC $3,500 upon signing, $3,500 per month and 6,750,000 restricted shares of the Company’s common stock. At June 30, 2021, the 6,750,000 restricted shares of common stock have not been issued.

	(e)	Effective May 14, 2021, the Company entered into a Software as a Service Agreement with Novation Solutions Inc. (“DealMaker”) to effect the Company’s planned Regulation A offering, including the set-up of an automated tracking, signing, and reconciliation portal. The Company will pay DealMaker $3,000 upon signing the agreement, $7,000 payable within 30 days of launching the portal, and a post launch monthly fee of $1,000.

XML 27 R18.htm IDEA: XBRL DOCUMENT

Subsequent Events

9 Months Ended

Jun. 30, 2021

Subsequent Events

12. Subsequent Events

12.

Subsequent Events

	(a)	On July 13, 2021, the Company issued 702,000 common shares for consulting services. Refer to Note 11(c).

	(b)	Subsequent to the nine months ended June 30, 2021, the Company received common stock subscriptions totaling $56,000 in connection with the proposed issuance of 5,600,000 shares of common stock at $0.01 per unit. Each unit will be comprised of one share of common stock and one share purchase warrant exercisable into an additional share of common stock at an exercise price of $0.05 per share for a period of 24 months.

XML 28 R19.htm IDEA: XBRL DOCUMENT

Summary of Significant Accounting Policies (Policies)	9 Months Ended
Summary of Significant Accounting Policies (Policies)	Jun. 30, 2021
Summary of Significant Accounting Policies
Interim Financial Statements	These condensed consolidated financial statements have been prepared on the same basis as the annual consolidated financial statements and in the opinion of management, reflect all adjustments, which include only normal recurring adjustments, necessary to present fairly the Company’s financial position, results of operations and cash flows for the periods shown. The results of operations for such periods are not necessarily indicative of the results expected for a full year or for any future period.
Basis of Presentation	The accompanying condensed interim consolidated financial statements have been prepared in accordance with accounting principles generally accepted in the United States and are expressed in U.S. dollars. These condensed consolidated financial statements include the accounts of the Company and its wholly owned subsidiary, WFS Pharmagreen Inc. (“WFS”), and its 89.7% owned subsidiary 1155097 B.C. Ltd. (“115BC”), companies incorporated in British Columbia, Canada. All inter-company accounts and transactions have been eliminated. The Company’s fiscal year-end is September 30.
Use of Estimates and Judgments	The preparation of these condensed consolidated financial statements in conformity with U.S. generally accepted accounting principles requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. The Company regularly evaluates estimates and assumptions related to the recoverability of property and equipment, the equity component of convertible notes, fair value of derivative liabilities, fair value of share-based payments, and deferred income tax asset valuation allowances. The Company bases its estimates and assumptions on current facts, historical experience, and various other factors that it believes to be reasonable under the circumstances, the results of which form the basis for making judgments about the carrying values of assets and liabilities and the accrual of costs and expenses that are not readily apparent from other sources. The actual results experienced by the Company may differ materially and adversely from the Company’s estimates. To the extent there are material differences between the estimates and the actual results, future results of operations will be affected. The Company applies judgment in the application of the going concern assumption which requires management to take into account all available information about the future, which is at least, but not limited to, 12 months from the end of the reporting period and in the factors regarding the impairment of the property and equipment. The Company tests property and equipment for recoverability when events or changes in circumstances indicate that their carrying amount may not be recoverable. Circumstances which could trigger a review include, but are not limited to: significant decreases in the market price of the asset; significant adverse changes in the business climate or legal factors; accumulation of costs significantly in excess of the amount originally expected for the acquisition or construction of the asset; current period cash flow or operating losses combined with a history of losses or a forecast of continuing losses associated with the use of the asset; and current expectation that the asset will more likely than not be sold or disposed significantly before the end of its estimated useful life. Recoverability is assessed based on the carrying amount of the asset and its fair value, which is generally determined based on the sum of the undiscounted cash flows expected to result from the use and the eventual disposal of the asset, as well as specific appraisal in certain instances. An impairment loss is recognized when the carrying amount is not recoverable and exceeds fair value.
Recently Adopted Accounting Pronouncements	The Company has implemented all new accounting pronouncements that are in effect and that may impact its condensed consolidated financial statements and does not believe that there are any other new accounting pronouncements that have been issued that might have a material impact on its financial position or results of operations.

XML 29 R20.htm IDEA: XBRL DOCUMENT

Accounts Payable and Accrued Liabilities (Tables)

9 Months Ended

Jun. 30, 2021

Accounts Payable and Accrued Liabilities

Schedule of Accounts Payable and Accrued Liabilities

	June 30, 2021 $		September 30, 2020 $

Accounts payable (Note 7)		550,871		455,310
Accrued interest payable (Notes 4 and 5)		73,590		84,353

		624,461		539,663

XML 30 R21.htm IDEA: XBRL DOCUMENT

Derivative Liabilities (Tables)

9 Months Ended

Jun. 30, 2021

Derivative Liabilities

Schedule of Derivative Liability

	$
Balance, September 30, 2020	1,380,957

Conversion of convertible notes	(4,166,076	)
Change in fair value	3,083,420

Balance, June 30, 2021	298,301

Schedule of weighted-average assumptions used in the calculations

Expected

volatility

Risk-free interest

rate

Expected dividend

yield

Expected life

(in years)

As at June 30, 2021

256

0.1

0.5

XML 31 R22.htm IDEA: XBRL DOCUMENT

Share Purchase Warrants (Tables)

9 Months Ended

Jun. 30, 2021

Share Purchase Warrants

Schedule of Share Purchase Warrants

	Number of warrants		Weighted average exercise price $

Balance, September 30, 2020		114,286		0.55

Issued		29,772,500		0.05

Balance, June 30, 2021		29,886,786		0.05

Schedule of Warrants Outstanding

Number of warrants		Exercise price		Expiry date

	114,286	$	0.55	July 16, 2022
	400,000	$	0.05	December 2, 2022
	3,000,000	$	0.05	December 11, 2022
	2,000,000	$	0.05	December 30, 2022
	2,300,000	$	0.05	January 11, 2023
	13,500,000	$	0.05	January 30, 2023
	1,000,000	$	0.05	February 16, 2023
	611,250	$	0.05	March 1, 2023
	6,961,250	$	0.05	May 14, 2023

	29,886,786

XML 32 R23.htm IDEA: XBRL DOCUMENT

Nature of Business and Continuance of Operations (Details Narrative) - USD ($)	9 Months Ended
	Jun. 30, 2021	Jun. 30, 2020	Sep. 30, 2020
Related Party Transactions
Working Capital Deficit	$ 1,802,567
Accumulated Deficit	10,867,990		$ 7,167,346
Net loss	(3,700,644)
Net cash used in operating activities	$ 151,237	$ 546,552

- Definition

Amount after tax of income (loss) from continuing operations including portion attributable to the noncontrolling interest.

+ References

Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 323
-SubTopic 10
-Section 50
-Paragraph 3
-Subparagraph (c)
-URI http://asc.fasb.org/extlink&oid=114001798&loc=d3e33918-111571

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 32
-Subparagraph (c)
-URI http://asc.fasb.org/extlink&oid=120311839&loc=d3e8933-108599

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 32
-Subparagraph (f)
-URI http://asc.fasb.org/extlink&oid=120311839&loc=d3e8933-108599

Reference 4: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 235
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.4-08(g)(1)(ii))
-URI http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690

Reference 5: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 22
-URI http://asc.fasb.org/extlink&oid=120311839&loc=d3e8736-108599

Reference 6: http://www.xbrl.org/2003/role/exampleRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 31
-URI http://asc.fasb.org/extlink&oid=120311839&loc=d3e8924-108599

Reference 7: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 30
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=120311839&loc=d3e8906-108599

Reference 8: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 250
-SubTopic 10
-Section 50
-Paragraph 1
-Subparagraph (b)(2)
-URI http://asc.fasb.org/extlink&oid=109234566&loc=d3e22499-107794

Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 810
-SubTopic 10
-Section 45
-Paragraph 19
-URI http://asc.fasb.org/extlink&oid=108774443&loc=SL4569616-111683

Reference 10: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 825
-SubTopic 10
-Section 50
-Paragraph 28
-Subparagraph (f)
-URI http://asc.fasb.org/extlink&oid=75031198&loc=d3e14064-108612

+ Details

XML 33 R24.htm IDEA: XBRL DOCUMENT

Accounts Payable and Accrued Liabilities (Details) - USD ($)	Jun. 30, 2021	Sep. 30, 2020
Accounts Payable and Accrued Liabilities
Accounts payable	$ 550,871	$ 455,310
Accrued interest payable	73,590	84,353
Accounts Payable and Accrued Liabilities	$ 624,461	$ 539,663

XML 34 R25.htm IDEA: XBRL DOCUMENT

Note and Loan Payable (Details Narrative)	9 Months Ended
Note and Loan Payable (Details Narrative)	Jun. 30, 2021 USD ($)	Jun. 30, 2021 CAD ($)	Jun. 30, 2020 USD ($)	Jun. 30, 2021 CAD ($)	Sep. 30, 2020 USD ($)	Sep. 30, 2020 CAD ($)
Proceeds from loan	$ 0		$ 29,388
Promissory Note Nov. 22, 2019 [Member]
Promissory Note with unrelated party	$ 40,000
Interest rate	10	10
Accured Interest Payable	$ 6,404				$ 3,421
Motion for Summary Judgement, description	On March 10, 2021, this noteholder filed a Notice of Motion for Summary Judgement in Lieu of Complaint (the “Notice”) with the State of New York Supreme Court, County of New York for $40,504 plus interest at the rate of 10% per annum from January 6, 2021 plus costs. On July 31, 2021	On March 10, 2021, this noteholder filed a Notice of Motion for Summary Judgement in Lieu of Complaint (the “Notice”) with the State of New York Supreme Court, County of New York for $40,504 plus interest at the rate of 10% per annum from January 6, 2021 plus costs. On July 31, 2021
Loan Payable April 22, 2020 [Member]
Interest rate	5	5
Proceeds from loan		$ 40,000
Loans payable	$ 32,240				$ 30,028
Loan forgiveness description	If the Company repays the loan prior to December 31, 2022, there will be loan forgiveness of 25% of the principal balance repaid, up to a maximum of Cdn$10,000	If the Company repays the loan prior to December 31, 2022, there will be loan forgiveness of 25% of the principal balance repaid, up to a maximum of Cdn$10,000
Loan Payable April 22, 2020 [Member] \| CANADA
Loans payable				$ 40,000		$ 40,000

XML 35 R26.htm IDEA: XBRL DOCUMENT

Convertible Notes (Details Narrative) - USD ($)			1 Months Ended			9 Months Ended	12 Months Ended
Convertible Notes (Details Narrative) - USD ($)	Jan. 02, 2020	Apr. 04, 2018	Sep. 30, 2020	Jul. 24, 2020	Jul. 22, 2020	Jun. 30, 2021	Sep. 30, 2020	Sep. 30, 2019	Sep. 30, 2018	Mar. 12, 2021	Jan. 14, 2021	Oct. 20, 2020	Oct. 13, 2020
Carrying value of convertible notes			$ 3,448			$ 6,371	$ 3,448
Unamortized discount						20,696	$ 23,619
Principal amount converted into common stock					$ 180,000	$ (4,166,076)
Common Stock, Par Value			$ 0.001			$ 0.001	$ 0.001						$ 0.001
Settlement Agreement with Noteholder [Member]
Carrying value of convertible notes			$ 163,864				$ 163,864			$ 0
Fair value of the derivative liability			485,863				485,863			$ 0
June 17, 2020 [Member]
Carrying value of convertible notes			106,000				106,000
Unamortized discount						$ 2,286
Remaining value of convertible notes						53,000
Default penalty						53,000
Beneficial conversion feature						139,702
Accretion Expense						$ 3,000
Common stock, shares issued upon conversion of convertible shares						16,994,905
Convertible notes						$ 106,000
Fair value of the derivative liability			139,702				139,702
Convertible Note [Member]
Beneficial conversion feature		$ 32,485
Due date of note		April 4, 2023
Rate of interest		12%
Face value of convertible notes		$ 32,485
Amount Owed to Related Party		$ 32,485
Common Stock, Par Value		$ 0.0001
Convertible Note [Member] \| June 17, 2020 [Member]
Carrying value of convertible notes			126,000				126,000
Unamortized discount							1,657
Remaining value of convertible notes						$ 63,000
Accrued interest			5,775				5,775
Default penalty							$ 63,000
Description of conversion of convertible notes							the convertibility feature at a conversion price equal to 61% of the average 2 lowest trading prices during the 10-trading day period prior to the conversion date
Beneficial conversion feature							$ 112,822
Accretion Expense							3,000
Common stock, shares issued upon conversion of convertible shares						7,730,486
Convertible notes						$ 126,000
Fair value of the derivative liability			112,822				112,822
Convertible Note [Member] \| July 23, 2020 [Member]
Carrying value of convertible notes			46,000				46,000
Unamortized discount				$ 56,566
Principal amount converted into common stock						46,000
Accrued interest						$ 5,586
Accretion Expense			60,500
Common stock, shares issued upon conversion of convertible shares						3,601,718
Convertible notes				$ 15,000		$ 63,440
Fair value of the derivative liability			69,320				69,320
Conversion fees						500
Number of payment installments				6 monthly instalment
Monthly payment of convertible debt				$ 8,073
Convertible Note [Member] \| April 4, 2018 [Member]
Accretion Expense					$ 46,904	2,923	1,358
Convertible Note [Member] \| July 22, 2020 [Member]
Default penalty						$ 253,856	85,864
Accretion Expense							77,500
Common stock, shares issued upon conversion of convertible shares						133,226,100
Convertible notes			417,719				417,719
Conversion fees						$ 11,000
Unrelated party [Member] \| January 2, 2020 [Member]
Description of conversion of convertible notes	The note may be converted at any time after 180 days of the date of issuance into shares of Company’s common stock at a conversion price equal to 61% of the average 2 lowest trading prices during the 10-trading day period prior to the conversion date
Convertible notes			53,000				53,000
Directly paid to third party for financing			3,000				3,000
Proceeds from convertible debt	$ 50,000
Due date of note	January 2, 2021
Rate of interest	10%
Rate of interest on unpaid balance after default of note	22%
Unrelated party [Member] \| January 14, 2020 [Member]
Carrying value of convertible notes			16,947			112,084	16,947
Unamortized discount							61,053
Principal amount converted into common stock						$ 18,923
Description of conversion of convertible notes						The note may be converted at any time after the date of issuance into shares of Company’s common stock at a conversion price equal to lower of: (i) 65% of the lowest trading price during the 20-trading day period prior to the issuance date; or (ii) 65% of the lowest trading price during the 20-trading day period prior to the conversion date
Beneficial conversion feature						$ 76,330
Accretion Expense							16,447
Common stock, shares issued upon conversion of convertible shares						2,600,000
Convertible notes						$ 78,000
Fair value of the derivative liability			110,604			170,586	110,604
Proceeds from convertible debt						$ 75,000
Due date of note						January 14, 2021
Rate of interest						12%
Rate of interest on unpaid balance after default of note						15%
Maximum intrinsic value of the embedded beneficial conversion feature						$ 74,500
Loss on change in fair value of derivative						1,830
Face value of convertible notes						78,000
Financing cost of convertible note						3,000
Conversion fees						4,500
Principal default of convertible note											$ 53,007
Unrelated party [Member] \| January 15, 2020 [Member]
Carrying value of convertible notes						$ 500
Description of conversion of convertible notes						The note may be converted at any time after the date of issuance into shares of Company’s common stock at a conversion price equal 65% of the lowest trading price during the 20-trading day period prior to the conversion date
Beneficial conversion feature						$ 67,846
Convertible notes						61,000
Proceeds from convertible debt						$ 50,600
Due date of note						January 15, 2021
Rate of interest						10%
Rate of interest on unpaid balance after default of note						24%
Maximum intrinsic value of the embedded beneficial conversion feature						$ 50,100
Loss on change in fair value of derivative						17,746
Face value of convertible notes						61,000
Financing cost of convertible note						7,400
Original issuance discount on notes						3,000
Unrelated party [Member] \| January 15, 2020 [Member] \| Convertible note 2 [Member]
Carrying value of convertible notes						82,500
Unamortized discount							50,767
Principal amount converted into common stock						82,500
Accrued interest						$ 7,693
Default penalty							$ 27,500
Description of conversion of convertible notes						The note may be converted at any time after the date of issuance into shares of Company’s common stock at a conversion price equal to lower of: (i) the lowest trading price during the 20-trading day period ending on the latest complete trading day prior to the issuance date; or (ii) 65% of the lowest trading price during the 20 consecutive trading day period on which at least 100 shares of common stock were traded prior to the conversion date	the conversion rate from 65% to 50% of the lowest trading price during the 20 consecutive trading days prior to conversion
Beneficial conversion feature						$ 61,173
Accretion Expense							$ 54,500
Common stock, shares issued upon conversion of convertible shares						17,557,925
Convertible notes						$ 55,000
Fair value of the derivative liability			146,272				146,272
Directly paid to third party for financing						2,500
Proceeds from convertible debt						$ 52,500
Due date of note						January 15, 2021
Rate of interest						10%
Rate of interest on unpaid balance after default of note						24%
Maximum intrinsic value of the embedded beneficial conversion feature						$ 52,000
Loss on change in fair value of derivative						9,173
Face value of convertible notes						55,000
Conversion fees						3,000
Unrelated party [Member] \| January 21, 2020 [Member]
Carrying value of convertible notes			13,702			500	13,702
Unamortized discount							52,448
Principal amount converted into common stock						66,150
Accrued interest						$ 3,907
Description of conversion of convertible notes						The note may be converted at any time after the date of issuance into shares of Company’s common stock at a conversion price equal 60% of the lowest trading price during the 20-trading day period prior to the conversion date
Beneficial conversion feature						$ 71,278
Accretion Expense							13,202
Common stock, shares issued upon conversion of convertible shares						4,431,963
Convertible notes						$ 66,150
Fair value of the derivative liability			98,579				98,579
Directly paid to third party for financing						3,150
Proceeds from convertible debt						$ 55,200
Due date of note						January 21, 2021
Rate of interest						8%
Rate of interest on unpaid balance after default of note						24%
Maximum intrinsic value of the embedded beneficial conversion feature						$ 54,700
Loss on change in fair value of derivative						16,578
Face value of convertible notes						66,150
Unrelated party [Member] \| January 22, 2020 [Member]
Carrying value of convertible notes			78,750			$ 78,750	78,750
Description of conversion of convertible notes						The note may be converted at any time after the date of issuance into shares of Company’s common stock at a conversion price equal to 65% of the lowest trading price during the 20-trading day period ending on the latest complete trading day prior to the conversion date
Beneficial conversion feature						$ 75,179
Accretion Expense							78,250
Convertible notes						78,750
Fair value of the derivative liability			107,660			127,715	107,660
Directly paid to third party for financing						9,750
Proceeds from convertible debt						$ 69,000
Due date of note						January 22, 2021
Rate of interest						10%
Rate of interest on unpaid balance after default of note						24%
Maximum intrinsic value of the embedded beneficial conversion feature						$ 68,500
Loss on change in fair value of derivative						6,679
Face value of convertible notes						78,750
Unrelated party [Member] \| February 4, 2020 [Member]
Carrying value of convertible notes			7,314			500	7,314
Unamortized discount			68,511				23,136
Principal amount converted into common stock						75,825	24,175
Accrued interest						$ 2,154
Description of conversion of convertible notes						(i) the lowest trading price during the 10-trading day period ending on the latest complete trading day prior to the issuance date; or (ii) 60% of the average of the two lowest trading prices during the 10-trading day period prior to the conversion date
Beneficial conversion feature						$ 41,017,383
Accretion Expense							$ 7,854
Common stock, shares issued upon conversion of convertible shares							2,000,000
Convertible notes						100,000
Fair value of the derivative liability			110,135				$ 110,135
Directly paid to third party for financing						16,970
Proceeds from convertible debt						$ 83,030
Due date of note						February 4, 2021
Rate of interest						12%
Rate of interest on unpaid balance after default of note						24%
Maximum intrinsic value of the embedded beneficial conversion feature						$ 82,530
Loss on change in fair value of derivative						43,110
Face value of convertible notes						100,000
Conversion fees						18,750
Fair value of convertible notes												$ 180,000
Unrelated party [Member] \| October 1, 2019 [Member]
Carrying value of convertible notes						$ 500
Description of conversion of convertible notes						The note may be converted at any time after the date of issuance into shares of Company’s common stock at a conversion price equal to lower of: (i) the lowest trading price during the 10-trading day period prior to the issuance date; or (ii) 61% of the average 2 lowest trading prices during the 10-trading day period prior to the conversion date
Beneficial conversion feature						$ 74,245
Convertible notes						78,000
Proceeds from convertible debt						$ 74,745
Due date of note						October 1, 2020
Rate of interest						10%
Rate of interest on unpaid balance after default of note						24%
Face value of convertible notes						$ 78,000
Fair value of convertible notes						$ 70,744
Unrelated party [Member] \| October 17, 2019 [Member]
Description of conversion of convertible notes						The note may be converted at any time after 180 days of the date of issuance into shares of Company’s common stock at a conversion price equal to 61% of the average 2 lowest trading prices during the 10-trading day period prior to the conversion date
Convertible notes						$ 63,000
Directly paid to third party for financing						3,255
Proceeds from convertible debt						$ 60,000
Due date of note						October 17, 2020
Rate of interest						10%
Rate of interest on unpaid balance after default of note						22%
Series A Convertile Notes [Member]
Accretion Expense							$ 1,670	$ 375	$ 3,112
Common stock, shares issued upon conversion of convertible shares							18,525,000	3,900,000	31,745,000
Convertible notes			$ 1,853				$ 1,853	$ 390	$ 3,175
Series A Convertile Notes [Member] \| President
Common stock, shares issued upon conversion of convertible shares									18,000,000
Series A Convertile Notes [Member] \| Family Member of President [Member]
Common stock, shares issued upon conversion of convertible shares									5,320,000

XML 36 R27.htm IDEA: XBRL DOCUMENT

Derivative Liabilities (Details) - USD ($)	1 Months Ended	9 Months Ended
Derivative Liabilities (Details) - USD ($)	Jul. 22, 2020	Jun. 30, 2021
Derivative Liabilities
Derivative Liability		$ 1,380,957
Conversion of convertible notes	$ 180,000	(4,166,076)
Change in fair value		3,083,420
Derivative Liability		$ 298,301

XML 37 R28.htm IDEA: XBRL DOCUMENT

Derivative Liabilities (Details 1) - Derivative Liability [Member]	9 Months Ended
	Jun. 30, 2021
Expected volatility	256
Risk-free interest rate	0.1
Expected dividend yield	0
Expected life	0.5

XML 38 R29.htm IDEA: XBRL DOCUMENT

Related Party Transactions (Details Narrative)		9 Months Ended
Related Party Transactions (Details Narrative)	Oct. 14, 2020 USD ($) shares	Jun. 30, 2021 USD ($)	Jun. 30, 2020 USD ($)	Jun. 30, 2021 CAD ($)	Sep. 30, 2020 USD ($)	Sep. 30, 2020 CAD ($)
Due to Related Parties		$ 607,827			$ 508,874
President [Member]
Due to Related Parties		548,586			453,697
Consulting Fees		72,171	$ 63,044
Chief Financial Officer [Member]
Due to Related Parties		431,105			347,229
Consulting Fees		72,171	$ 63,044
Father of President [Member]
Due to Related Parties		59,241			55,177
Company Owned By The Father Of President [Member]
Due to Related Parties		27,565			$ 25,674
Director [Member]
Issuance of Series A Super Voting Preferred Stock \| shares	10,000
Proceeds from Issuance of Series A Super Voting Preferred Stock	$ 10
CANADA
Due to Related Parties				$ 680,628		$ 604,366
Consulting Fees		$ 453,697
CANADA \| Chief Financial Officer [Member]
Due to Related Parties				534,870		462,540
CANADA \| Father Of President [Member]
Due to Related Parties				73,500		73,500
CANADA \| Company Owned By The Father of President [Member]
Due to Related Parties				$ 34,200		$ 34,000

XML 39 R30.htm IDEA: XBRL DOCUMENT

Common Stock (Details Narrative) - USD ($)				1 Months Ended		9 Months Ended
Common Stock (Details Narrative) - USD ($)	May 14, 2021	Mar. 01, 2021	Jan. 11, 2021	Dec. 31, 2020	Sep. 30, 2020	Jun. 30, 2021	Jun. 30, 2020
Debt instrument converted amount					$ 30,750
Debt instrument converted amount, shares issued					2,000,000
Fair value of converted shares					$ 180,000
Common stock shares issued					6,750,000
Proceeds from issuance of common stock					$ 121,500	$ 186,725	$ 0
Common stock shares issued price per share						$ 0.01
Common stock shares issued for services, amount						$ 130,175	$ 0
Private Placement [Member]
Common stock shares issued	611,250	611,250	16,800,000	5,400,000
Proceeds from issuance of common stock	$ 6,113	$ 6,112	$ 84,000	$ 27,000
Exercise price	$ 0.05
Common stock shares issued price per share	$ 0.01	$ 0.01	$ 0.005	$ 0.005
May 14, 2021 [Member]
Common stock shares issued	6,350,000
Proceeds from issuance of common stock	$ 63,500
Exercise price	$ 0.05
Common stock shares issued price per share	$ 0.01
November 1, 2020 [Member]
Common stock shares issued for services, shares						22,500
Common stock shares issued for services, amount						$ 401
November 26, 2020 [Member]
Common stock shares issued for services, shares						45,000
Common stock shares issued for services, amount						$ 733
December 11, 2020 [Member]
Common stock shares issued for services, shares						22,500
Common stock shares issued for services, amount						$ 221
February 2, 2021 [Member]
Common stock shares issued for services, shares						150,000
Common stock shares issued for services, amount						$ 2,700
March 29, 2021 [Member]
Common stock shares issued for services, shares						150,000
Common stock shares issued for services, amount						$ 4,620
Convertible Notes Payable [Member]
Debt instrument converted amount						$ 417,719
Debt instrument converted amount, shares issued						133,226,100
Debt conversion fee						$ 11,000
Convertible Notes Payable Two [Member]
Debt instrument converted amount						$ 106,000
Debt instrument converted amount, shares issued						16,994,905
Debt instrument accrued interest converted amount						$ 2,650
Convertible Notes Payable One [Member]
Debt instrument converted amount						$ 126,000
Debt instrument converted amount, shares issued						7,730,486
Debt instrument accrued interest converted amount						$ 3,150
Convertible Notes Payable Three [Member]
Debt instrument converted amount						$ 18,923
Debt instrument converted amount, shares issued						2,600,000
Debt conversion fee						$ 4,500
Convertible Notes Payable Four [Member]
Debt instrument converted amount						$ 46,000
Debt instrument converted amount, shares issued						3,601,718
Debt conversion fee						$ 500
Debt instrument accrued interest converted amount						5,586
Convertible Notes Payable Five [Member]
Debt instrument converted amount						$ 82,500
Debt instrument converted amount, shares issued						17,557,925
Debt conversion fee						$ 3,000
Debt instrument accrued interest converted amount						7,693
Convertible Notes Payable Six [Member]
Debt instrument converted amount						$ 66,150
Debt instrument converted amount, shares issued						4,431,963
Debt instrument accrued interest converted amount						$ 3,907
Convertible Notes Payable Seven [Member]
Debt instrument converted amount						$ 75,825
Debt instrument converted amount, shares issued						41,017,383
Debt conversion fee						$ 18,750
Debt instrument accrued interest converted amount						$ 2,154

XML 40 R31.htm IDEA: XBRL DOCUMENT

Preferred Stock (Details Narrative) - USD ($)	Oct. 14, 2020	Jun. 30, 2021	Oct. 13, 2020	Sep. 30, 2020
Preferred stock authorized		1,000,000	1,000,000	1,000,000
Preferred stock par value		$ 0.001	$ 0.001	$ 0.001
Series A Super Voting Preferred Stock			10,000
Common Stock, Shares Authorized		2,000,000,000	2,000,000,000	2,000,000,000
Common Stock, Par Value		$ 0.001	$ 0.001	$ 0.001
Director [Member]
Issuance of Series A Super Voting Preferred Stock	10,000
Proceeds from Issuance of Series A Super Voting Preferred Stock	$ 10

XML 41 R32.htm IDEA: XBRL DOCUMENT

Share Purchase Warrants (Details) - Warrant [Member]	9 Months Ended
Share Purchase Warrants (Details) - Warrant [Member]	Jun. 30, 2021 $ / shares shares
Beginning Balance \| shares	114,286
Issued \| shares	29,772,500
Ending Balance \| shares	29,886,786
Weighted average exercise price, beginning \| $ / shares	$ 0.55
Weighted average exercise price, issued \| $ / shares	0.05
Weighted average exercise price, ending \| $ / shares	$ 0.05

XML 42 R33.htm IDEA: XBRL DOCUMENT

Share Purchase Warrants (Details 1)	9 Months Ended
Share Purchase Warrants (Details 1)	Jun. 30, 2021 $ / shares shares
Number of warrants	29,886,786
Warrant One [Member]
Number of warrants	114,286
Exercise price \| $ / shares	$ 0.55
Expiry date	July 16, 2022
Warrant Four [Member]
Number of warrants	2,000,000
Exercise price \| $ / shares	$ 0.05
Expiry date	December 30, 2022
Warrant Five [Member]
Number of warrants	2,300,000
Exercise price \| $ / shares	$ 0.05
Expiry date	January 11, 2023
Warrant Six [Member]
Number of warrants	13,500,000
Exercise price \| $ / shares	$ 0.05
Expiry date	January 30, 2023
Warrant Seven [Member]
Number of warrants	1,000,000
Exercise price \| $ / shares	$ 0.05
Expiry date	February 16, 2023
Warrant Eight [Member]
Number of warrants	611,250
Exercise price \| $ / shares	$ 0.05
Expiry date	March 1, 2
Warrant Nine [Member]
Number of warrants	6,961,250
Exercise price \| $ / shares	$ 0.05
Expiry date	May 14, 2023
Warrant Two [Member]
Number of warrants	400,000
Exercise price \| $ / shares	$ 0.05
Expiry date	December 2, 2022
Warrant Three [Member]
Number of warrants	3,000,000
Exercise price \| $ / shares	$ 0.05
Expiry date	December 11, 2022

XML 43 R34.htm IDEA: XBRL DOCUMENT

Commitments (Details Narrative)						1 Months Ended
Commitments (Details Narrative)	Jun. 13, 2021 shares	May 14, 2021	May 13, 2021	Jan. 25, 2019 USD ($) shares	Jan. 25, 2019 CAD ($) shares	Nov. 22, 2019 shares	Jun. 30, 2021 USD ($) shares	Jun. 30, 2021 CAD ($) shares	Dec. 13, 2020 shares	Sep. 30, 2020 USD ($)	Sep. 30, 2020 CAD ($)
Common stock shares issued for consulting services \| shares	702,000								75,000
New to the Street Group LLC [Member]
Production agreement fee payable description			the Company agreed to pay New to the Street Group LLC $3,500 upon signing, $3,500 per month and 6,750,000 restricted shares of the Company’s common stock. At June 30, 2021, the 6,750,000 restricted shares of common stock have not been issued.
Restricted shares, unissued \| shares							6,750,000	6,750,000
Novation Solutions Inc [Member]
Service agreement fee payable description		The Company will pay DealMaker $3,000 upon signing the agreement, $7,000 payable within 30 days of launching the portal, and a post launch monthly fee of $1,000
Alliance Growers Corp. [Member]
Advances from Alliance Growers Corp							$ 60,450			$ 56,303
Common Stock Issued upon exercise of the option, value				$ 1,018,182
Option agreement grants				The option agreement grants an option to Alliance to purchase 10% equity interest in 115BC for Cdn$1,350,000 and previously granted a second option to purchase an additional 20% equity interest in 115BC for funding of 30% of the total construction and equipment costs for the biotech complex less Cdn$1,350,000.	The option agreement grants an option to Alliance to purchase 10% equity interest in 115BC for Cdn$1,350,000 and previously granted a second option to purchase an additional 20% equity interest in 115BC for funding of 30% of the total construction and equipment costs for the biotech complex less Cdn$1,350,000.
Common Stock Issued upon exercise of the option (in Shares) \| shares				8	8
Alliance Growers Corp. [Member] \| CANADA
Advances from Alliance Growers Corp								$ 75,000			$ 75,000
Common Stock Issued upon exercise of the option, value					$ 1,350,008
Consulting Agreement [Member]
Agreement descriptions	the Company extended the consulting agreement for an additional six month term for the issuance of 117,000 common shares per month.
Equity Purchase Agreement [Member]
Promissory Note with unrelated party							$ 40,000
Maximun shares purchase under agreement \| shares						10,000,000
Purchase price description						The purchase price would be 85% of the market price
Additional commitment fee description						the third party is required to pay an additional commitment fee of $10,000, of which $5,000 was paid upon signing the term sheet and the remaining $5,000 is due upon completion of the first tranche of the financing.

XML 44 R35.htm IDEA: XBRL DOCUMENT

Subsequent Events (Details Narrative) - USD ($)	9 Months Ended
Subsequent Events (Details Narrative) - USD ($)	Jun. 30, 2021	Jun. 13, 2021	Dec. 13, 2020
Subsequent Events
Common stock shares issued for consulting services		702,000	75,000
Common stock subscriptions	$ 56,000
Common stock shares issued for subscription	5,600,000
Common stock price per share	$ 0.01
Warrant exercisable description	Each unit will be comprised of one share of common stock and one share purchase warrant exercisable into an additional share of common stock at an exercise price of $0.05 per share for a period of 24 months

EXCEL 45 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx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end XML 46 Show.js IDEA: XBRL DOCUMENT // Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission. Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105. var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0); e.removeAttribute('id');a.parentNode.appendChild(e)}} if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'} e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}} XML 47 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ ..report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } ..report table.authRefData a { display: block; font-weight: bold; } ..report table.authRefData p { margin-top: 0px; } ..report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } ..report table.authRefData .hide a:hover { background-color: #2F4497; } ..report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } ..report table.authRefData table{ font-size: 1em; } /* Report Styles */ ..pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ ..report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } ..report hr { border: 1px solid #acf; } /* Top labels */ ..report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } ..report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } ..report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; white-space: normal; /* word-wrap: break-word; */ } ..report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } ..report td.pl div.a { width: 200px; } ..report td.pl a:hover { background-color: #ffc; } /* Header rows... */ ..report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ ..report .rc { background-color: #f0f0f0; } /* Even rows... */ ..report .re, .report .reu { background-color: #def; } ..report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ ..report .ro, .report .rou { background-color: white; } ..report .rou td { border-bottom: 1px solid black; } ..report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ ..report .fn { white-space: nowrap; } /* styles for numeric types */ ..report .num, .report .nump { text-align: right; white-space: nowrap; } ..report .nump { padding-left: 2em; } ..report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ ..report .text { text-align: left; white-space: normal; } ..report .text .big { margin-bottom: 1em; width: 17em; } ..report .text .more { display: none; } ..report .text .note { font-style: italic; font-weight: bold; } ..report .text .small { width: 10em; } ..report sup { font-style: italic; } ..report .outerFootnotes { font-size: 1em; } XML 48 FilingSummary.xml IDEA: XBRL DOCUMENT 3.21.2 html 262 285 1 false 67 0 false 4 false false R1.htm 000001 - Document - Cover Sheet http://phbi.com/role/Cover Cover Cover 1 false false R2.htm 000002 - Statement - Condensed Consolidated Balance Sheets Sheet http://phbi.com/role/CondensedConsolidatedBalanceSheets Condensed Consolidated Balance Sheets Statements 2 false false R3.htm 000003 - Statement - Condensed Consolidated Balance Sheets (Parenthetical) Sheet http://phbi.com/role/CondensedConsolidatedBalanceSheetsParenthetical Condensed Consolidated Balance Sheets (Parenthetical) Statements 3 false false R4.htm 000004 - Statement - Condensed Consolidated Statements of Operations and Comprehensive Income (Loss) (Unaudited) Sheet http://phbi.com/role/CondensedConsolidatedStatementsOfOperationsAndComprehensiveIncomeLossUnaudited Condensed Consolidated Statements of Operations and Comprehensive Income (Loss) (Unaudited) Statements 4 false false R5.htm 000005 - Statement - Condensed Consolidated Statements of Stockholders' Deficit (Unaudited) Sheet http://phbi.com/role/CondensedConsolidatedStatementsOfStockholdersDeficitUnaudited Condensed Consolidated Statements of Stockholders' Deficit (Unaudited) Statements 5 false false R6.htm 000006 - Statement - Condensed Consolidated Statements of Cash Flows (Unaudited) Sheet http://phbi.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited Condensed Consolidated Statements of Cash Flows (Unaudited) Statements 6 false false R7.htm 000007 - Disclosure - Nature of Business and Continuance of Operations Sheet http://phbi.com/role/NatureOfBusinessAndContinuanceOfOperations Nature of Business and Continuance of Operations Notes 7 false false R8.htm 000008 - Disclosure - Summary of Significant Accounting Policies Sheet http://phbi.com/role/SummaryOfSignificantAccountingPolicies Summary of Significant Accounting Policies Notes 8 false false R9.htm 000009 - Disclosure - Accounts Payable and Accrued Liabilities Sheet http://phbi.com/role/AccountsPayableAndAccruedLiabilities Accounts Payable and Accrued Liabilities Notes 9 false false R10.htm 000010 - Disclosure - Note and Loan Payable Sheet http://phbi.com/role/NoteAndLoanPayable Note and Loan Payable Notes 10 false false R11.htm 000011 - Disclosure - Convertible Notes Notes http://phbi.com/role/ConvertibleNotes Convertible Notes Notes 11 false false R12.htm 000012 - Disclosure - Derivative Liabilities Sheet http://phbi.com/role/DerivativeLiabilities Derivative Liabilities Notes 12 false false R13.htm 000013 - Disclosure - Related Party Transactions Sheet http://phbi.com/role/RelatedPartyTransactions Related Party Transactions Notes 13 false false R14.htm 000014 - Disclosure - Common Stock Sheet http://phbi.com/role/CommonStock Common Stock Notes 14 false false R15.htm 000015 - Disclosure - Preferred Stock Sheet http://phbi.com/role/PreferredStock Preferred Stock Notes 15 false false R16.htm 000016 - Disclosure - Share Purchase Warrants Sheet http://phbi.com/role/SharePurchaseWarrants Share Purchase Warrants Notes 16 false false R17.htm 000017 - Disclosure - Commitments Sheet http://phbi.com/role/Commitments Commitments Notes 17 false false R18.htm 000018 - Disclosure - Subsequent Events Sheet http://phbi.com/role/SubsequentEvents Subsequent Events Notes 18 false false R19.htm 000019 - Disclosure - Summary of Significant Accounting Policies (Policies) Sheet http://phbi.com/role/SummaryOfSignificantAccountingPoliciesPolicies Summary of Significant Accounting Policies (Policies) Policies http://phbi.com/role/SummaryOfSignificantAccountingPolicies 19 false false R20.htm 000020 - Disclosure - Accounts Payable and Accrued Liabilities (Tables) Sheet http://phbi.com/role/AccountsPayableAndAccruedLiabilitiesTables Accounts Payable and Accrued Liabilities (Tables) Tables http://phbi.com/role/AccountsPayableAndAccruedLiabilities 20 false false R21.htm 000021 - Disclosure - Derivative Liabilities (Tables) Sheet http://phbi.com/role/DerivativeLiabilitiesTables Derivative Liabilities (Tables) Tables http://phbi.com/role/DerivativeLiabilities 21 false false R22.htm 000022 - Disclosure - Share Purchase Warrants (Tables) Sheet http://phbi.com/role/SharePurchaseWarrantsTables Share Purchase Warrants (Tables) Tables http://phbi.com/role/SharePurchaseWarrants 22 false false R23.htm 000023 - Disclosure - Nature of Business and Continuance of Operations (Details Narrative) Sheet http://phbi.com/role/NatureOfBusinessAndContinuanceOfOperationsDetailsNarrative Nature of Business and Continuance of Operations (Details Narrative) Details http://phbi.com/role/NatureOfBusinessAndContinuanceOfOperations 23 false false R24.htm 000024 - Disclosure - Accounts Payable and Accrued Liabilities (Details) Sheet http://phbi.com/role/AccountsPayableAndAccruedLiabilitiesDetails Accounts Payable and Accrued Liabilities (Details) Details http://phbi.com/role/AccountsPayableAndAccruedLiabilitiesTables 24 false false R25.htm 000025 - Disclosure - Note and Loan Payable (Details Narrative) Sheet http://phbi.com/role/NoteAndLoanPayableDetailsNarrative Note and Loan Payable (Details Narrative) Details http://phbi.com/role/NoteAndLoanPayable 25 false false R26.htm 000026 - Disclosure - Convertible Notes (Details Narrative) Notes http://phbi.com/role/ConvertibleNotesDetailsNarrative Convertible Notes (Details Narrative) Details http://phbi.com/role/ConvertibleNotes 26 false false R27.htm 000027 - Disclosure - Derivative Liabilities (Details) Sheet http://phbi.com/role/DerivativeLiabilitiesDetails Derivative Liabilities (Details) Details http://phbi.com/role/DerivativeLiabilitiesTables 27 false false R28.htm 000028 - Disclosure - Derivative Liabilities (Details 1) Sheet http://phbi.com/role/DerivativeLiabilitiesDetails1 Derivative Liabilities (Details 1) Details http://phbi.com/role/DerivativeLiabilitiesTables 28 false false R29.htm 000029 - Disclosure - Related Party Transactions (Details Narrative) Sheet http://phbi.com/role/RelatedPartyTransactionsDetailsNarrative Related Party Transactions (Details Narrative) Details http://phbi.com/role/RelatedPartyTransactions 29 false false R30.htm 000030 - Disclosure - Common Stock (Details Narrative) Sheet http://phbi.com/role/CommonStockDetailsNarrative Common Stock (Details Narrative) Details http://phbi.com/role/CommonStock 30 false false R31.htm 000031 - Disclosure - Preferred Stock (Details Narrative) Sheet http://phbi.com/role/PreferredStockDetailsNarrative Preferred Stock (Details Narrative) Details http://phbi.com/role/PreferredStock 31 false false R32.htm 000032 - Disclosure - Share Purchase Warrants (Details) Sheet http://phbi.com/role/SharePurchaseWarrantsDetails Share Purchase Warrants (Details) Details http://phbi.com/role/SharePurchaseWarrantsTables 32 false false R33.htm 000033 - Disclosure - Share Purchase Warrants (Details 1) Sheet http://phbi.com/role/SharePurchaseWarrantsDetails1 Share Purchase Warrants (Details 1) Details http://phbi.com/role/SharePurchaseWarrantsTables 33 false false R34.htm 000034 - Disclosure - Commitments (Details Narrative) Sheet http://phbi.com/role/CommitmentsDetailsNarrative Commitments (Details Narrative) Details http://phbi.com/role/Commitments 34 false false R35.htm 000035 - Disclosure - Subsequent Events (Details Narrative) Sheet http://phbi.com/role/SubsequentEventsDetailsNarrative Subsequent Events (Details Narrative) Details http://phbi.com/role/SubsequentEvents 35 false false All Reports Book All Reports phbi_10q.htm phbi-20210630.xsd phbi-20210630_cal.xml phbi-20210630_def.xml phbi-20210630_lab.xml phbi-20210630_pre.xml phbi_ex311.htm phbi_ex321.htm http://fasb.org/us-gaap/2020-01-31 http://xbrl.sec.gov/dei/2020-01-31 http://fasb.org/srt/2020-01-31 true true JSON 51 MetaLinks.json IDEA: XBRL DOCUMENT { "instance": { "phbi_10q.htm": { "axisCustom": 0, "axisStandard": 11, "contextCount": 262, "dts": { "calculationLink": { "local": [ "phbi-20210630_cal.xml" ] }, "definitionLink": { "local": [ "phbi-20210630_def.xml" ], "remote": [ "http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-eedm-def-2020-01-31.xml", "http://xbrl.fasb.org/srt/2020/elts/srt-eedm1-def-2020-01-31.xml" ] }, "inline": { "local": [ "phbi_10q.htm" ] }, "labelLink": { "local": [ "phbi-20210630_lab.xml" ], "remote": [ "https://xbrl.sec.gov/dei/2020/dei-doc-2020-01-31.xml", "http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-doc-2020-01-31.xml" ] }, "presentationLink": { "local": [ "phbi-20210630_pre.xml" ] }, "referenceLink": { "remote": [ "http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-ref-2020-01-31.xml", "https://xbrl.sec.gov/dei/2020/dei-ref-2020-01-31.xml" ] }, "schema": { "local": [ "phbi-20210630.xsd" ], "remote": [ "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd", "http://www.xbrl.org/2003/xl-2003-12-31.xsd", "http://www.xbrl.org/2003/xlink-2003-12-31.xsd", "https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd", "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd", "http://www.xbrl.org/2005/xbrldt-2005.xsd", "http://www.xbrl.org/dtr/type/nonNumeric-2009-12-16.xsd", "http://www.xbrl.org/dtr/type/numeric-2009-12-16.xsd", "http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd", "http://xbrl.fasb.org/us-gaap/2020/elts/us-roles-2020-01-31.xsd", "http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd", "http://www.xbrl.org/2006/ref-2006-02-27.xsd", "http://xbrl.fasb.org/srt/2020/elts/srt-types-2020-01-31.xsd", "http://xbrl.fasb.org/srt/2020/elts/srt-roles-2020-01-31.xsd", "https://xbrl.sec.gov/country/2020/country-2020-01-31.xsd", "http://xbrl.fasb.org/us-gaap/2020/elts/us-types-2020-01-31.xsd", "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd", "https://xbrl.sec.gov/currency/2020/currency-2020-01-31.xsd", "https://xbrl.sec.gov/exch/2020/exch-2020-01-31.xsd", "http://www.xbrl.org/lrr/arcrole/factExplanatory-2009-12-16.xsd", "https://xbrl.sec.gov/naics/2017/naics-2017-01-31.xsd", "https://xbrl.sec.gov/sic/2020/sic-2020-01-31.xsd", "https://xbrl.sec.gov/stpr/2018/stpr-2018-01-31.xsd", "http://www.xbrl.org/lrr/role/reference-2009-12-16.xsd", "http://xbrl.fasb.org/us-gaap/2020/elts/us-parts-codification-2020-01-31.xsd", "http://www.xbrl.org/lrr/role/deprecated-2009-12-16.xsd" ] } }, "elementCount": 339, "entityCount": 1, "hidden": { "http://fasb.org/us-gaap/2020-01-31": 17, "http://phbi.com/20210630": 2, "http://xbrl.sec.gov/dei/2020-01-31": 7, "total": 26 }, "keyCustom": 65, "keyStandard": 220, "memberCustom": 56, "memberStandard": 11, "nsprefix": "phbi", "nsuri": "http://phbi.com/20210630", "report": { "R1": { "firstAnchor": { "ancestors": [ "strong", "span", "p", "td", "tr", "tbody", "table", "body", "html" ], "baseRef": "phbi_10q.htm", "contextRef": "From2020-10-01to2021-06-30", "decimals": null, "first": true, "lang": "en-US", "name": "dei:EntityRegistrantName", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "document", "isDefault": "true", "longName": "000001 - Document - Cover", "role": "http://phbi.com/role/Cover", "shortName": "Cover", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "strong", "span", "p", "td", "tr", "tbody", "table", "body", "html" ], "baseRef": "phbi_10q.htm", "contextRef": "From2020-10-01to2021-06-30", "decimals": null, "first": true, "lang": "en-US", "name": "dei:EntityRegistrantName", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R10": { "firstAnchor": { "ancestors": [ "body", "html" ], "baseRef": "phbi_10q.htm", "contextRef": "From2020-10-01to2021-06-30", "decimals": null, "first": true, "lang": "en-US", "name": "phbi:PromissoryNoteTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "000010 - Disclosure - Note and Loan Payable", "role": "http://phbi.com/role/NoteAndLoanPayable", "shortName": "Note and Loan Payable", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "body", "html" ], "baseRef": "phbi_10q.htm", "contextRef": "From2020-10-01to2021-06-30", "decimals": null, "first": true, "lang": "en-US", "name": "phbi:PromissoryNoteTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R11": { "firstAnchor": { "ancestors": [ "body", "html" ], "baseRef": "phbi_10q.htm", "contextRef": "From2020-10-01to2021-06-30", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:DebtDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "000011 - Disclosure - Convertible Notes", "role": "http://phbi.com/role/ConvertibleNotes", "shortName": "Convertible Notes", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "body", "html" ], "baseRef": "phbi_10q.htm", "contextRef": "From2020-10-01to2021-06-30", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:DebtDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R12": { "firstAnchor": { "ancestors": [ "body", "html" ], "baseRef": "phbi_10q.htm", "contextRef": "From2020-10-01to2021-06-30", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "000012 - Disclosure - Derivative Liabilities", "role": "http://phbi.com/role/DerivativeLiabilities", "shortName": "Derivative Liabilities", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "body", "html" ], "baseRef": "phbi_10q.htm", "contextRef": "From2020-10-01to2021-06-30", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R13": { "firstAnchor": { "ancestors": [ "body", "html" ], "baseRef": "phbi_10q.htm", "contextRef": "From2020-10-01to2021-06-30", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:RelatedPartyTransactionsDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "000013 - Disclosure - Related Party Transactions", "role": "http://phbi.com/role/RelatedPartyTransactions", "shortName": "Related Party Transactions", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "body", "html" ], "baseRef": "phbi_10q.htm", "contextRef": "From2020-10-01to2021-06-30", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:RelatedPartyTransactionsDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R14": { "firstAnchor": { "ancestors": [ "body", "html" ], "baseRef": "phbi_10q.htm", "contextRef": "From2020-10-01to2021-06-30", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "000014 - Disclosure - Common Stock", "role": "http://phbi.com/role/CommonStock", "shortName": "Common Stock", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "body", "html" ], "baseRef": "phbi_10q.htm", "contextRef": "From2020-10-01to2021-06-30", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R15": { "firstAnchor": { "ancestors": [ "body", "html" ], "baseRef": "phbi_10q.htm", "contextRef": "From2020-10-01to2021-06-30", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:PreferredStockTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "000015 - Disclosure - Preferred Stock", "role": "http://phbi.com/role/PreferredStock", "shortName": "Preferred Stock", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "body", "html" ], "baseRef": "phbi_10q.htm", "contextRef": "From2020-10-01to2021-06-30", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:PreferredStockTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R16": { "firstAnchor": { "ancestors": [ "body", "html" ], "baseRef": "phbi_10q.htm", "contextRef": "From2020-10-01to2021-06-30", "decimals": null, "first": true, "lang": "en-US", "name": "phbi:SharePurchaseWarrantsTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "000016 - Disclosure - Share Purchase Warrants", "role": "http://phbi.com/role/SharePurchaseWarrants", "shortName": "Share Purchase Warrants", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "body", "html" ], "baseRef": "phbi_10q.htm", "contextRef": "From2020-10-01to2021-06-30", "decimals": null, "first": true, "lang": "en-US", "name": "phbi:SharePurchaseWarrantsTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R17": { "firstAnchor": { "ancestors": [ "body", "html" ], "baseRef": "phbi_10q.htm", "contextRef": "From2020-10-01to2021-06-30", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "000017 - Disclosure - Commitments", "role": "http://phbi.com/role/Commitments", "shortName": "Commitments", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "body", "html" ], "baseRef": "phbi_10q.htm", "contextRef": "From2020-10-01to2021-06-30", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R18": { "firstAnchor": { "ancestors": [ "body", "html" ], "baseRef": "phbi_10q.htm", "contextRef": "From2020-10-01to2021-06-30", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:SubsequentEventsTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "000018 - Disclosure - Subsequent Events", "role": "http://phbi.com/role/SubsequentEvents", "shortName": "Subsequent Events", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "body", "html" ], "baseRef": "phbi_10q.htm", "contextRef": "From2020-10-01to2021-06-30", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:SubsequentEventsTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R19": { "firstAnchor": { "ancestors": [ "td", "tr", "tbody", "table", "us-gaap:SignificantAccountingPoliciesTextBlock", "body", "html" ], "baseRef": "phbi_10q.htm", "contextRef": "From2020-10-01to2021-06-30", "decimals": null, "first": true, "lang": "en-US", "name": "phbi:InterimFinancialStatementsPolicyTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "000019 - Disclosure - Summary of Significant Accounting Policies (Policies)", "role": "http://phbi.com/role/SummaryOfSignificantAccountingPoliciesPolicies", "shortName": "Summary of Significant Accounting Policies (Policies)", "subGroupType": "policies", "uniqueAnchor": { "ancestors": [ "td", "tr", "tbody", "table", "us-gaap:SignificantAccountingPoliciesTextBlock", "body", "html" ], "baseRef": "phbi_10q.htm", "contextRef": "From2020-10-01to2021-06-30", "decimals": null, "first": true, "lang": "en-US", "name": "phbi:InterimFinancialStatementsPolicyTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R2": { "firstAnchor": { "ancestors": [ "td", "tr", "tbody", "table", "body", "html" ], "baseRef": "phbi_10q.htm", "contextRef": "AsOf2021-06-30", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:Cash", "reportCount": 1, "unitRef": "USD", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "000002 - Statement - Condensed Consolidated Balance Sheets", "role": "http://phbi.com/role/CondensedConsolidatedBalanceSheets", "shortName": "Condensed Consolidated Balance Sheets", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "td", "tr", "tbody", "table", "body", "html" ], "baseRef": "phbi_10q.htm", "contextRef": "AsOf2021-06-30", "decimals": "0", "lang": null, "name": "us-gaap:AccountsAndOtherReceivablesNetCurrent", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" } }, "R20": { "firstAnchor": { "ancestors": [ "us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock", "body", "html" ], "baseRef": "phbi_10q.htm", "contextRef": "From2020-10-01to2021-06-30", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "000020 - Disclosure - Accounts Payable and Accrued Liabilities (Tables)", "role": "http://phbi.com/role/AccountsPayableAndAccruedLiabilitiesTables", "shortName": "Accounts Payable and Accrued Liabilities (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock", "body", "html" ], "baseRef": "phbi_10q.htm", "contextRef": "From2020-10-01to2021-06-30", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R21": { "firstAnchor": { "ancestors": [ "us-gaap:DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock", "body", "html" ], "baseRef": "phbi_10q.htm", "contextRef": "From2020-10-01to2021-06-30", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfDerivativeLiabilitiesAtFairValueTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "000021 - Disclosure - Derivative Liabilities (Tables)", "role": "http://phbi.com/role/DerivativeLiabilitiesTables", "shortName": "Derivative Liabilities (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "us-gaap:DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock", "body", "html" ], "baseRef": "phbi_10q.htm", "contextRef": "From2020-10-01to2021-06-30", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfDerivativeLiabilitiesAtFairValueTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R22": { "firstAnchor": { "ancestors": [ "phbi:SharePurchaseWarrantsTextBlock", "body", "html" ], "baseRef": "phbi_10q.htm", "contextRef": "From2020-10-01to2021-06-30", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfProductWarrantyLiabilityTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "000022 - Disclosure - Share Purchase Warrants (Tables)", "role": "http://phbi.com/role/SharePurchaseWarrantsTables", "shortName": "Share Purchase Warrants (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "phbi:SharePurchaseWarrantsTextBlock", "body", "html" ], "baseRef": "phbi_10q.htm", "contextRef": "From2020-10-01to2021-06-30", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfProductWarrantyLiabilityTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R23": { "firstAnchor": { "ancestors": [ "p", "td", "tr", "tbody", "table", "us-gaap:NatureOfOperations", "body", "html" ], "baseRef": "phbi_10q.htm", "contextRef": "AsOf2021-06-30", "decimals": "0", "first": true, "lang": null, "name": "phbi:WorkingCapitalDeficit", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "000023 - Disclosure - Nature of Business and Continuance of Operations (Details Narrative)", "role": "http://phbi.com/role/NatureOfBusinessAndContinuanceOfOperationsDetailsNarrative", "shortName": "Nature of Business and Continuance of Operations (Details Narrative)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "p", "td", "tr", "tbody", "table", "us-gaap:NatureOfOperations", "body", "html" ], "baseRef": "phbi_10q.htm", "contextRef": "AsOf2021-06-30", "decimals": "0", "first": true, "lang": null, "name": "phbi:WorkingCapitalDeficit", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" } }, "R24": { "firstAnchor": { "ancestors": [ "td", "tr", "tbody", "table", "us-gaap:ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock", "us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock", "body", "html" ], "baseRef": "phbi_10q.htm", "contextRef": "AsOf2021-06-30", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:AccountsPayableCurrent", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "000024 - Disclosure - Accounts Payable and Accrued Liabilities (Details)", "role": "http://phbi.com/role/AccountsPayableAndAccruedLiabilitiesDetails", "shortName": "Accounts Payable and Accrued Liabilities (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "td", "tr", "tbody", "table", "us-gaap:ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock", "us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock", "body", "html" ], "baseRef": "phbi_10q.htm", "contextRef": "AsOf2021-06-30", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:AccountsPayableCurrent", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" } }, "R25": { "firstAnchor": { "ancestors": [ "td", "tr", "tbody", "table", "body", "html" ], "baseRef": "phbi_10q.htm", "contextRef": "From2020-10-01to2021-06-30", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:ProceedsFromLoanOriginations1", "reportCount": 1, "unitRef": "USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "000025 - Disclosure - Note and Loan Payable (Details Narrative)", "role": "http://phbi.com/role/NoteAndLoanPayableDetailsNarrative", "shortName": "Note and Loan Payable (Details Narrative)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "p", "td", "tr", "tbody", "table", "phbi:PromissoryNoteTextBlock", "body", "html" ], "baseRef": "phbi_10q.htm", "contextRef": "AsOf2021-06-30_phbi_LoansPayable1Member", "decimals": "0", "lang": null, "name": "us-gaap:SecuredDebtCurrent", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" } }, "R26": { "firstAnchor": { "ancestors": [ "p", "td", "tr", "tbody", "table", "us-gaap:DebtDisclosureTextBlock", "body", "html" ], "baseRef": "phbi_10q.htm", "contextRef": "AsOf2020-09-30", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:ConvertibleNotesPayable", "reportCount": 1, "unitRef": "USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "000026 - Disclosure - Convertible Notes (Details Narrative)", "role": "http://phbi.com/role/ConvertibleNotesDetailsNarrative", "shortName": "Convertible Notes (Details Narrative)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "p", "td", "tr", "tbody", "table", "us-gaap:DebtDisclosureTextBlock", "body", "html" ], "baseRef": "phbi_10q.htm", "contextRef": "AsOf2021-06-30", "decimals": "0", "lang": null, "name": "us-gaap:ConvertibleNotesPayable", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" } }, "R27": { "firstAnchor": { "ancestors": [ "td", "tr", "tbody", "table", "us-gaap:ScheduleOfDerivativeLiabilitiesAtFairValueTableTextBlock", "us-gaap:DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock", "body", "html" ], "baseRef": "phbi_10q.htm", "contextRef": "AsOf2020-09-30", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:DerivativeLiabilitiesCurrent", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "000027 - Disclosure - Derivative Liabilities (Details)", "role": "http://phbi.com/role/DerivativeLiabilitiesDetails", "shortName": "Derivative Liabilities (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "td", "tr", "tbody", "table", "us-gaap:ScheduleOfDerivativeLiabilitiesAtFairValueTableTextBlock", "us-gaap:DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock", "body", "html" ], "baseRef": "phbi_10q.htm", "contextRef": "AsOf2020-09-30", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:DerivativeLiabilitiesCurrent", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" } }, "R28": { "firstAnchor": { "ancestors": [ "td", "tr", "tbody", "table", "phbi:ScheduleOfWeightedAverageAssumptionsUsedInTheCalculationsTableTextblock", "us-gaap:DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock", "body", "html" ], "baseRef": "phbi_10q.htm", "contextRef": "From2020-10-01to2021-06-30_phbi_DerivativeLiabilityMember", "decimals": null, "first": true, "lang": "en-US", "name": "phbi:ExpectedVolatility", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "000028 - Disclosure - Derivative Liabilities (Details 1)", "role": "http://phbi.com/role/DerivativeLiabilitiesDetails1", "shortName": "Derivative Liabilities (Details 1)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "td", "tr", "tbody", "table", "phbi:ScheduleOfWeightedAverageAssumptionsUsedInTheCalculationsTableTextblock", "us-gaap:DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock", "body", "html" ], "baseRef": "phbi_10q.htm", "contextRef": "From2020-10-01to2021-06-30_phbi_DerivativeLiabilityMember", "decimals": null, "first": true, "lang": "en-US", "name": "phbi:ExpectedVolatility", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R29": { "firstAnchor": { "ancestors": [ "td", "tr", "tbody", "table", "body", "html" ], "baseRef": "phbi_10q.htm", "contextRef": "AsOf2021-06-30", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:DueToRelatedPartiesCurrent", "reportCount": 1, "unitRef": "USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "000029 - Disclosure - Related Party Transactions (Details Narrative)", "role": "http://phbi.com/role/RelatedPartyTransactionsDetailsNarrative", "shortName": "Related Party Transactions (Details Narrative)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "p", "td", "tr", "tbody", "table", "us-gaap:RelatedPartyTransactionsDisclosureTextBlock", "body", "html" ], "baseRef": "phbi_10q.htm", "contextRef": "AsOf2021-06-30_srt_PresidentMember", "decimals": "0", "lang": null, "name": "us-gaap:DueToRelatedPartiesCurrent", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" } }, "R3": { "firstAnchor": { "ancestors": [ "p", "td", "tr", "tbody", "table", "body", "html" ], "baseRef": "phbi_10q.htm", "contextRef": "AsOf2020-09-30", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:DebtInstrumentUnamortizedDiscountCurrent", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "000003 - Statement - Condensed Consolidated Balance Sheets (Parenthetical)", "role": "http://phbi.com/role/CondensedConsolidatedBalanceSheetsParenthetical", "shortName": "Condensed Consolidated Balance Sheets (Parenthetical)", "subGroupType": "parenthetical", "uniqueAnchor": { "ancestors": [ "p", "td", "tr", "tbody", "table", "body", "html" ], "baseRef": "phbi_10q.htm", "contextRef": "AsOf2020-09-30", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:DebtInstrumentUnamortizedDiscountCurrent", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" } }, "R30": { "firstAnchor": { "ancestors": [ "p", "td", "tr", "tbody", "table", "us-gaap:StockholdersEquityNoteDisclosureTextBlock", "body", "html" ], "baseRef": "phbi_10q.htm", "contextRef": "From2020-09-01to2020-09-30", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:DebtConversionConvertedInstrumentAmount1", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "000030 - Disclosure - Common Stock (Details Narrative)", "role": "http://phbi.com/role/CommonStockDetailsNarrative", "shortName": "Common Stock (Details Narrative)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "p", "td", "tr", "tbody", "table", "us-gaap:StockholdersEquityNoteDisclosureTextBlock", "body", "html" ], "baseRef": "phbi_10q.htm", "contextRef": "From2020-09-01to2020-09-30", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:DebtConversionConvertedInstrumentAmount1", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" } }, "R31": { "firstAnchor": { "ancestors": [ "p", "td", "tr", "tbody", "table", "body", "html" ], "baseRef": "phbi_10q.htm", "contextRef": "AsOf2021-06-30", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:PreferredStockSharesAuthorized", "reportCount": 1, "unitRef": "Shares", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "000031 - Disclosure - Preferred Stock (Details Narrative)", "role": "http://phbi.com/role/PreferredStockDetailsNarrative", "shortName": "Preferred Stock (Details Narrative)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "p", "td", "tr", "tbody", "table", "us-gaap:PreferredStockTextBlock", "body", "html" ], "baseRef": "phbi_10q.htm", "contextRef": "AsOf2020-10-13", "decimals": "0", "lang": null, "name": "us-gaap:PreferredStockSharesAuthorized", "reportCount": 1, "unique": true, "unitRef": "Shares", "xsiNil": "false" } }, "R32": { "firstAnchor": { "ancestors": [ "td", "tr", "tbody", "table", "us-gaap:ScheduleOfProductWarrantyLiabilityTableTextBlock", "phbi:SharePurchaseWarrantsTextBlock", "body", "html" ], "baseRef": "phbi_10q.htm", "contextRef": "AsOf2020-09-30_phbi_WarrantsMember", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber", "reportCount": 1, "unique": true, "unitRef": "Shares", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "000032 - Disclosure - Share Purchase Warrants (Details)", "role": "http://phbi.com/role/SharePurchaseWarrantsDetails", "shortName": "Share Purchase Warrants (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "td", "tr", "tbody", "table", "us-gaap:ScheduleOfProductWarrantyLiabilityTableTextBlock", "phbi:SharePurchaseWarrantsTextBlock", "body", "html" ], "baseRef": "phbi_10q.htm", "contextRef": "AsOf2020-09-30_phbi_WarrantsMember", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber", "reportCount": 1, "unique": true, "unitRef": "Shares", "xsiNil": "false" } }, "R33": { "firstAnchor": { "ancestors": [ "p", "td", "tr", "tbody", "table", "us-gaap:ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock", "phbi:SharePurchaseWarrantsTextBlock", "body", "html" ], "baseRef": "phbi_10q.htm", "contextRef": "From2020-10-01to2021-06-30", "decimals": "0", "first": true, "lang": null, "name": "phbi:NumberOfWarrants", "reportCount": 1, "unique": true, "unitRef": "Shares", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "000033 - Disclosure - Share Purchase Warrants (Details 1)", "role": "http://phbi.com/role/SharePurchaseWarrantsDetails1", "shortName": "Share Purchase Warrants (Details 1)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "p", "td", "tr", "tbody", "table", "us-gaap:ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock", "phbi:SharePurchaseWarrantsTextBlock", "body", "html" ], "baseRef": "phbi_10q.htm", "contextRef": "From2020-10-01to2021-06-30", "decimals": "0", "first": true, "lang": null, "name": "phbi:NumberOfWarrants", "reportCount": 1, "unique": true, "unitRef": "Shares", "xsiNil": "false" } }, "R34": { "firstAnchor": { "ancestors": [ "p", "td", "tr", "tbody", "table", "us-gaap:SubsequentEventsTextBlock", "body", "html" ], "baseRef": "phbi_10q.htm", "contextRef": "AsOf2021-06-13", "decimals": "0", "first": true, "lang": null, "name": "phbi:CommonStockSharesIssuedForConsultingServices", "reportCount": 1, "unitRef": "Shares", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "000034 - Disclosure - Commitments (Details Narrative)", "role": "http://phbi.com/role/CommitmentsDetailsNarrative", "shortName": "Commitments (Details Narrative)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "p", "td", "tr", "tbody", "table", "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock", "body", "html" ], "baseRef": "phbi_10q.htm", "contextRef": "From2021-05-01to2021-05-13_phbi_NewToTheStreetGroupLLCMember", "decimals": null, "lang": "en-US", "name": "phbi:ProductionAgreementFeePayableDescription", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R35": { "firstAnchor": { "ancestors": [ "p", "td", "tr", "tbody", "table", "us-gaap:SubsequentEventsTextBlock", "body", "html" ], "baseRef": "phbi_10q.htm", "contextRef": "AsOf2021-06-13", "decimals": "0", "first": true, "lang": null, "name": "phbi:CommonStockSharesIssuedForConsultingServices", "reportCount": 1, "unitRef": "Shares", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "000035 - Disclosure - Subsequent Events (Details Narrative)", "role": "http://phbi.com/role/SubsequentEventsDetailsNarrative", "shortName": "Subsequent Events (Details Narrative)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "p", "td", "tr", "tbody", "table", "us-gaap:SubsequentEventsTextBlock", "body", "html" ], "baseRef": "phbi_10q.htm", "contextRef": "AsOf2021-06-30", "decimals": "0", "lang": null, "name": "us-gaap:CommonStockSharesSubscriptions", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" } }, "R4": { "firstAnchor": { "ancestors": [ "td", "tr", "tbody", "table", "body", "html" ], "baseRef": "phbi_10q.htm", "contextRef": "From2021-04-01to2021-06-30", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:LegalFees", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "000004 - Statement - Condensed Consolidated Statements of Operations and Comprehensive Income (Loss) (Unaudited)", "role": "http://phbi.com/role/CondensedConsolidatedStatementsOfOperationsAndComprehensiveIncomeLossUnaudited", "shortName": "Condensed Consolidated Statements of Operations and Comprehensive Income (Loss) (Unaudited)", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "td", "tr", "tbody", "table", "body", "html" ], "baseRef": "phbi_10q.htm", "contextRef": "From2021-04-01to2021-06-30", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:LegalFees", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" } }, "R5": { "firstAnchor": { "ancestors": [ "td", "tr", "tbody", "table", "body", "html" ], "baseRef": "phbi_10q.htm", "contextRef": "AsOf2019-09-30_us-gaap_CommonStockMember", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:SharesIssued", "reportCount": 1, "unitRef": "Shares", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "000005 - Statement - Condensed Consolidated Statements of Stockholders' Deficit (Unaudited)", "role": "http://phbi.com/role/CondensedConsolidatedStatementsOfStockholdersDeficitUnaudited", "shortName": "Condensed Consolidated Statements of Stockholders' Deficit (Unaudited)", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "td", "tr", "tbody", "table", "body", "html" ], "baseRef": "phbi_10q.htm", "contextRef": "From2019-10-01to2019-12-31", "decimals": "0", "lang": null, "name": "us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" } }, "R6": { "firstAnchor": { "ancestors": [ "td", "tr", "tbody", "table", "body", "html" ], "baseRef": "phbi_10q.htm", "contextRef": "From2020-10-01to2021-06-30", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:NetIncomeLoss", "reportCount": 1, "unitRef": "USD", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "000006 - Statement - Condensed Consolidated Statements of Cash Flows (Unaudited)", "role": "http://phbi.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited", "shortName": "Condensed Consolidated Statements of Cash Flows (Unaudited)", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "td", "tr", "tbody", "table", "body", "html" ], "baseRef": "phbi_10q.htm", "contextRef": "From2020-10-01to2021-06-30", "decimals": "0", "lang": null, "name": "phbi:AccretionOfDiscountOnConvertibleNotes", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" } }, "R7": { "firstAnchor": { "ancestors": [ "body", "html" ], "baseRef": "phbi_10q.htm", "contextRef": "From2020-10-01to2021-06-30", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:NatureOfOperations", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "000007 - Disclosure - Nature of Business and Continuance of Operations", "role": "http://phbi.com/role/NatureOfBusinessAndContinuanceOfOperations", "shortName": "Nature of Business and Continuance of Operations", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "body", "html" ], "baseRef": "phbi_10q.htm", "contextRef": "From2020-10-01to2021-06-30", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:NatureOfOperations", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R8": { "firstAnchor": { "ancestors": [ "body", "html" ], "baseRef": "phbi_10q.htm", "contextRef": "From2020-10-01to2021-06-30", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:SignificantAccountingPoliciesTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "000008 - Disclosure - Summary of Significant Accounting Policies", "role": "http://phbi.com/role/SummaryOfSignificantAccountingPolicies", "shortName": "Summary of Significant Accounting Policies", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "body", "html" ], "baseRef": "phbi_10q.htm", "contextRef": "From2020-10-01to2021-06-30", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:SignificantAccountingPoliciesTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R9": { "firstAnchor": { "ancestors": [ "body", "html" ], "baseRef": "phbi_10q.htm", "contextRef": "From2020-10-01to2021-06-30", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "000009 - Disclosure - Accounts Payable and Accrued Liabilities", "role": "http://phbi.com/role/AccountsPayableAndAccruedLiabilities", "shortName": "Accounts Payable and Accrued Liabilities", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "body", "html" ], "baseRef": "phbi_10q.htm", "contextRef": "From2020-10-01to2021-06-30", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } } }, "segmentCount": 67, "tag": { "dei_AmendmentFlag": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.", "label": "Amendment Flag" } } }, "localname": "AmendmentFlag", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://phbi.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_CityAreaCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Area code of city", "label": "City Area Code" } } }, "localname": "CityAreaCode", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://phbi.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_CoverAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Cover page.", "label": "Cover [Abstract]" } } }, "localname": "CoverAbstract", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "xbrltype": "stringItemType" }, "dei_CurrentFiscalYearEndDate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "End date of current fiscal year in the format --MM-DD.", "label": "Current Fiscal Year End Date" } } }, "localname": "CurrentFiscalYearEndDate", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://phbi.com/role/Cover" ], "xbrltype": "gMonthDayItemType" }, "dei_DocumentFiscalPeriodFocus": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Fiscal period values are FY, Q1, Q2, and Q3. 1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.", "label": "Document Fiscal Period Focus" } } }, "localname": "DocumentFiscalPeriodFocus", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://phbi.com/role/Cover" ], "xbrltype": "fiscalPeriodItemType" }, "dei_DocumentFiscalYearFocus": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.", "label": "Document Fiscal Year Focus" } } }, "localname": "DocumentFiscalYearFocus", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://phbi.com/role/Cover" ], "xbrltype": "gYearItemType" }, "dei_DocumentPeriodEndDate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The end date of the period reflected on the cover page if a periodic report. For all other reports and registration statements containing historical data, it is the date up through which that historical data is presented. If there is no historical data in the report, use the filing date. The format of the date is YYYY-MM-DD.", "label": "Document Period End Date" } } }, "localname": "DocumentPeriodEndDate", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://phbi.com/role/Cover" ], "xbrltype": "dateItemType" }, "dei_DocumentQuarterlyReport": { "auth_ref": [ "r272" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a form used as an quarterly report.", "label": "Document Quarterly Report" } } }, "localname": "DocumentQuarterlyReport", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://phbi.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_DocumentTransitionReport": { "auth_ref": [ "r273" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a form used as a transition report.", "label": "Document Transition Report" } } }, "localname": "DocumentTransitionReport", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://phbi.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_DocumentType": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.", "label": "Document Type" } } }, "localname": "DocumentType", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://phbi.com/role/Cover" ], "xbrltype": "submissionTypeItemType" }, "dei_EntityAddressAddressLine1": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Address Line 1 such as Attn, Building Name, Street Name", "label": "Entity Address Address Line 1" } } }, "localname": "EntityAddressAddressLine1", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://phbi.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressCityOrTown": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Name of the City or Town", "label": "Entity Address City Or Town" } } }, "localname": "EntityAddressCityOrTown", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://phbi.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressPostalZipCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Code for the postal or zip code", "label": "Entity Address Postal Zip Code" } } }, "localname": "EntityAddressPostalZipCode", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://phbi.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressStateOrProvince": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Name of the state or province.", "label": "Entity Address State Or Province" } } }, "localname": "EntityAddressStateOrProvince", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://phbi.com/role/Cover" ], "xbrltype": "stateOrProvinceItemType" }, "dei_EntityCentralIndexKey": { "auth_ref": [ "r274" ], "lang": { "en-us": { "role": { "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.", "label": "Entity Central Index Key" } } }, "localname": "EntityCentralIndexKey", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://phbi.com/role/Cover" ], "xbrltype": "centralIndexKeyItemType" }, "dei_EntityCommonStockSharesOutstanding": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.", "label": "Entity Common Stock Shares Outstanding" } } }, "localname": "EntityCommonStockSharesOutstanding", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://phbi.com/role/Cover" ], "xbrltype": "sharesItemType" }, "dei_EntityCurrentReportingStatus": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.", "label": "Entity Current Reporting Status" } } }, "localname": "EntityCurrentReportingStatus", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://phbi.com/role/Cover" ], "xbrltype": "yesNoItemType" }, "dei_EntityEmergingGrowthCompany": { "auth_ref": [ "r274" ], "lang": { "en-us": { "role": { "documentation": "Indicate if registrant meets the emerging growth company criteria.", "label": "Entity Emerging Growth Company" } } }, "localname": "EntityEmergingGrowthCompany", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://phbi.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_EntityExTransitionPeriod": { "auth_ref": [ "r276" ], "lang": { "en-us": { "role": { "documentation": "Indicate if an emerging growth company has elected not to use the extended transition period for complying with any new or revised financial accounting standards.", "label": "Entity Ex Transition Period" } } }, "localname": "EntityExTransitionPeriod", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://phbi.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_EntityFileNumber": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.", "label": "Entity File Number" } } }, "localname": "EntityFileNumber", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://phbi.com/role/Cover" ], "xbrltype": "fileNumberItemType" }, "dei_EntityFilerCategory": { "auth_ref": [ "r274" ], "lang": { "en-us": { "role": { "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.", "label": "Entity Filer Category" } } }, "localname": "EntityFilerCategory", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://phbi.com/role/Cover" ], "xbrltype": "filerCategoryItemType" }, "dei_EntityIncorporationStateCountryCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Two-character EDGAR code representing the state or country of incorporation.", "label": "Entity Incorporation State Country Code" } } }, "localname": "EntityIncorporationStateCountryCode", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://phbi.com/role/Cover" ], "xbrltype": "edgarStateCountryItemType" }, "dei_EntityInteractiveDataCurrent": { "auth_ref": [ "r275" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).", "label": "Entity Interactive Data Current" } } }, "localname": "EntityInteractiveDataCurrent", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://phbi.com/role/Cover" ], "xbrltype": "yesNoItemType" }, "dei_EntityRegistrantName": { "auth_ref": [ "r274" ], "lang": { "en-us": { "role": { "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.", "label": "Entity Registrant Name" } } }, "localname": "EntityRegistrantName", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://phbi.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityShellCompany": { "auth_ref": [ "r274" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.", "label": "Entity Shell Company" } } }, "localname": "EntityShellCompany", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://phbi.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_EntitySmallBusiness": { "auth_ref": [ "r274" ], "lang": { "en-us": { "role": { "documentation": "Indicates that the company is a Smaller Reporting Company (SRC).", "label": "Entity Small Business" } } }, "localname": "EntitySmallBusiness", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://phbi.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_EntityTaxIdentificationNumber": { "auth_ref": [ "r274" ], "lang": { "en-us": { "role": { "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.", "label": "Entity Tax Identification Number" } } }, "localname": "EntityTaxIdentificationNumber", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://phbi.com/role/Cover" ], "xbrltype": "employerIdItemType" }, "dei_LocalPhoneNumber": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Local phone number for entity.", "label": "Local Phone Number" } } }, "localname": "LocalPhoneNumber", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://phbi.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "phbi_AccretionOfDiscountOnConvertibleNotes": { "auth_ref": [], "calculation": { "http://phbi.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited": { "order": 11.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Accretion of discount on convertible notes", "label": "Accretion of discount on convertible notes" } } }, "localname": "AccretionOfDiscountOnConvertibleNotes", "nsuri": "http://phbi.com/20210630", "presentation": [ "http://phbi.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited" ], "xbrltype": "monetaryItemType" }, "phbi_AdditionalCommitmentFeeDescription": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Additional commitment fee description" } } }, "localname": "AdditionalCommitmentFeeDescription", "nsuri": "http://phbi.com/20210630", "presentation": [ "http://phbi.com/role/CommitmentsDetailsNarrative" ], "xbrltype": "stringItemType" }, "phbi_AdvancesFromAllianceGrowersCorp": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "label": "Advances from Alliance Growers Corp" } } }, "localname": "AdvancesFromAllianceGrowersCorp", "nsuri": "http://phbi.com/20210630", "presentation": [ "http://phbi.com/role/CommitmentsDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "phbi_AdvancesFromAllianceGrowersCorpNote11A": { "auth_ref": [], "calculation": { "http://phbi.com/role/CondensedConsolidatedBalanceSheets": { "order": 9.0, "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "label": "Advances from Alliance Growers Corp. (Note 11(a))" } } }, "localname": "AdvancesFromAllianceGrowersCorpNote11A", "nsuri": "http://phbi.com/20210630", "presentation": [ "http://phbi.com/role/CondensedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "phbi_AgreementDescriptions": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Agreement descriptions" } } }, "localname": "AgreementDescriptions", "nsuri": "http://phbi.com/20210630", "presentation": [ "http://phbi.com/role/CommitmentsDetailsNarrative" ], "xbrltype": "stringItemType" }, "phbi_AllianceGrowersCorpMember": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Alliance Growers Corp. [Member]" } } }, "localname": "AllianceGrowersCorpMember", "nsuri": "http://phbi.com/20210630", "presentation": [ "http://phbi.com/role/CommitmentsDetailsNarrative" ], "xbrltype": "domainItemType" }, "phbi_AprilFourTwoThousandEighteenMember": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "April 4, 2018 [Member]" } } }, "localname": "AprilFourTwoThousandEighteenMember", "nsuri": "http://phbi.com/20210630", "presentation": [ "http://phbi.com/role/ConvertibleNotesDetailsNarrative" ], "xbrltype": "domainItemType" }, "phbi_CAMember": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "CANADA", "verboseLabel": "CANADA" } } }, "localname": "CAMember", "nsuri": "http://phbi.com/20210630", "presentation": [ "http://phbi.com/role/CommitmentsDetailsNarrative", "http://phbi.com/role/NoteAndLoanPayableDetailsNarrative", "http://phbi.com/role/RelatedPartyTransactionsDetailsNarrative" ], "xbrltype": "domainItemType" }, "phbi_ChangeInFairValueOfEmbeddedConversionOption": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "label": "Change in fair value" } } }, "localname": "ChangeInFairValueOfEmbeddedConversionOption", "nsuri": "http://phbi.com/20210630", "presentation": [ "http://phbi.com/role/DerivativeLiabilitiesDetails" ], "xbrltype": "monetaryItemType" }, "phbi_CommonStockIssuableMember": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Common Stock Issuable [Member]" } } }, "localname": "CommonStockIssuableMember", "nsuri": "http://phbi.com/20210630", "presentation": [ "http://phbi.com/role/CondensedConsolidatedStatementsOfStockholdersDeficitUnaudited" ], "xbrltype": "domainItemType" }, "phbi_CommonStockIssuableNote8": { "auth_ref": [], "calculation": { "http://phbi.com/role/CondensedConsolidatedBalanceSheets": { "order": 16.0, "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "label": "Common stock issuable (Note 8)" } } }, "localname": "CommonStockIssuableNote8", "nsuri": "http://phbi.com/20210630", "presentation": [ "http://phbi.com/role/CondensedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "phbi_CommonStockSharesIssuedForConsultingServices": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Common stock shares issued for consulting services", "verboseLabel": "Common stock shares issued for consulting services" } } }, "localname": "CommonStockSharesIssuedForConsultingServices", "nsuri": "http://phbi.com/20210630", "presentation": [ "http://phbi.com/role/CommitmentsDetailsNarrative", "http://phbi.com/role/SubsequentEventsDetailsNarrative" ], "xbrltype": "sharesItemType" }, "phbi_CommonStockSharesIssuedForSubscription": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Common stock shares issued for subscription" } } }, "localname": "CommonStockSharesIssuedForSubscription", "nsuri": "http://phbi.com/20210630", "presentation": [ "http://phbi.com/role/SubsequentEventsDetailsNarrative" ], "xbrltype": "sharesItemType" }, "phbi_CompanyOwnedByTheFatherOfPresidentMember": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Company Owned By The Father Of President [Member]" } } }, "localname": "CompanyOwnedByTheFatherOfPresidentMember", "nsuri": "http://phbi.com/20210630", "presentation": [ "http://phbi.com/role/RelatedPartyTransactionsDetailsNarrative" ], "xbrltype": "domainItemType" }, "phbi_CompanyOwnedByTheFatherofPresidentMember": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Company Owned By The Father of President [Member]" } } }, "localname": "CompanyOwnedByTheFatherofPresidentMember", "nsuri": "http://phbi.com/20210630", "presentation": [ "http://phbi.com/role/RelatedPartyTransactionsDetailsNarrative" ], "xbrltype": "domainItemType" }, "phbi_CompanyPresidentMember": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "President" } } }, "localname": "CompanyPresidentMember", "nsuri": "http://phbi.com/20210630", "presentation": [ "http://phbi.com/role/ConvertibleNotesDetailsNarrative" ], "xbrltype": "domainItemType" }, "phbi_ConsultingAgreementMember": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Consulting Agreement [Member]" } } }, "localname": "ConsultingAgreementMember", "nsuri": "http://phbi.com/20210630", "presentation": [ "http://phbi.com/role/CommitmentsDetailsNarrative" ], "xbrltype": "domainItemType" }, "phbi_ConsultingFees": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Consulting Fees", "label": "Consulting Fees" } } }, "localname": "ConsultingFees", "nsuri": "http://phbi.com/20210630", "presentation": [ "http://phbi.com/role/RelatedPartyTransactionsDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "phbi_ConversionFees": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of fees and commissions from financial services and banking activities and correspondent clearing. Includes fees from depositor accounts, credit cards, merchant discounts, and fiduciary and trust activities, guarantee fees, investment advisory, man", "label": "Conversion fees" } } }, "localname": "ConversionFees", "nsuri": "http://phbi.com/20210630", "presentation": [ "http://phbi.com/role/ConvertibleNotesDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "phbi_ConvertibleNoteMember": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Convertible Note [Member]" } } }, "localname": "ConvertibleNoteMember", "nsuri": "http://phbi.com/20210630", "presentation": [ "http://phbi.com/role/ConvertibleNotesDetailsNarrative" ], "xbrltype": "domainItemType" }, "phbi_ConvertibleNotesPayableFiveMember": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Convertible Notes Payable Five [Member]" } } }, "localname": "ConvertibleNotesPayableFiveMember", "nsuri": "http://phbi.com/20210630", "presentation": [ "http://phbi.com/role/CommonStockDetailsNarrative" ], "xbrltype": "domainItemType" }, "phbi_ConvertibleNotesPayableFourMember": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Convertible Notes Payable Four [Member]" } } }, "localname": "ConvertibleNotesPayableFourMember", "nsuri": "http://phbi.com/20210630", "presentation": [ "http://phbi.com/role/CommonStockDetailsNarrative" ], "xbrltype": "domainItemType" }, "phbi_ConvertibleNotesPayableOneMember": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Convertible Notes Payable One [Member]" } } }, "localname": "ConvertibleNotesPayableOneMember", "nsuri": "http://phbi.com/20210630", "presentation": [ "http://phbi.com/role/CommonStockDetailsNarrative" ], "xbrltype": "domainItemType" }, "phbi_ConvertibleNotesPayableSevenMember": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Convertible Notes Payable Seven [Member]" } } }, "localname": "ConvertibleNotesPayableSevenMember", "nsuri": "http://phbi.com/20210630", "presentation": [ "http://phbi.com/role/CommonStockDetailsNarrative" ], "xbrltype": "domainItemType" }, "phbi_ConvertibleNotesPayableSixMember": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Convertible Notes Payable Six [Member]" } } }, "localname": "ConvertibleNotesPayableSixMember", "nsuri": "http://phbi.com/20210630", "presentation": [ "http://phbi.com/role/CommonStockDetailsNarrative" ], "xbrltype": "domainItemType" }, "phbi_ConvertibleNotesPayableThreeMember": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Convertible Notes Payable Three [Member]" } } }, "localname": "ConvertibleNotesPayableThreeMember", "nsuri": "http://phbi.com/20210630", "presentation": [ "http://phbi.com/role/CommonStockDetailsNarrative" ], "xbrltype": "domainItemType" }, "phbi_ConvertibleNotesPayableTwoMember": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Convertible Notes Payable Two [Member]" } } }, "localname": "ConvertibleNotesPayableTwoMember", "nsuri": "http://phbi.com/20210630", "presentation": [ "http://phbi.com/role/CommonStockDetailsNarrative" ], "xbrltype": "domainItemType" }, "phbi_DebtConversionFee": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "label": "Debt conversion fee" } } }, "localname": "DebtConversionFee", "nsuri": "http://phbi.com/20210630", "presentation": [ "http://phbi.com/role/CommonStockDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "phbi_DebtInstrumentAccruedInterestConvertedAmount": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "label": "Debt instrument accrued interest converted amount" } } }, "localname": "DebtInstrumentAccruedInterestConvertedAmount", "nsuri": "http://phbi.com/20210630", "presentation": [ "http://phbi.com/role/CommonStockDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "phbi_DecemberElevenTwoThousandTwentyMember": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "December 11, 2020 [Member]" } } }, "localname": "DecemberElevenTwoThousandTwentyMember", "nsuri": "http://phbi.com/20210630", "presentation": [ "http://phbi.com/role/CommonStockDetailsNarrative" ], "xbrltype": "domainItemType" }, "phbi_DefaultPenalty": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "label": "Default penalty" } } }, "localname": "DefaultPenalty", "nsuri": "http://phbi.com/20210630", "presentation": [ "http://phbi.com/role/ConvertibleNotesDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "phbi_DerivativeLiabilityMember": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Derivative Liability [Member]" } } }, "localname": "DerivativeLiabilityMember", "nsuri": "http://phbi.com/20210630", "presentation": [ "http://phbi.com/role/DerivativeLiabilitiesDetails1" ], "xbrltype": "domainItemType" }, "phbi_DescriptionOfConversionOfConvertibleNotes": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Description of conversion of convertible notes" } } }, "localname": "DescriptionOfConversionOfConvertibleNotes", "nsuri": "http://phbi.com/20210630", "presentation": [ "http://phbi.com/role/ConvertibleNotesDetailsNarrative" ], "xbrltype": "stringItemType" }, "phbi_DirectlyPaidToThirdPartyForFinancing": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "label": "Directly paid to third party for financing" } } }, "localname": "DirectlyPaidToThirdPartyForFinancing", "nsuri": "http://phbi.com/20210630", "presentation": [ "http://phbi.com/role/ConvertibleNotesDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "phbi_DueDateOfNote": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Due date of note" } } }, "localname": "DueDateOfNote", "nsuri": "http://phbi.com/20210630", "presentation": [ "http://phbi.com/role/ConvertibleNotesDetailsNarrative" ], "xbrltype": "stringItemType" }, "phbi_EquityPurchaseAgreementMember": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Equity Purchase Agreement [Member]" } } }, "localname": "EquityPurchaseAgreementMember", "nsuri": "http://phbi.com/20210630", "presentation": [ "http://phbi.com/role/CommitmentsDetailsNarrative" ], "xbrltype": "domainItemType" }, "phbi_ExercisePrice": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Exercise price", "verboseLabel": "Exercise price" } } }, "localname": "ExercisePrice", "nsuri": "http://phbi.com/20210630", "presentation": [ "http://phbi.com/role/CommonStockDetailsNarrative", "http://phbi.com/role/SharePurchaseWarrantsDetails1" ], "xbrltype": "perShareItemType" }, "phbi_ExpectedDividendYield": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Expected dividend yield" } } }, "localname": "ExpectedDividendYield", "nsuri": "http://phbi.com/20210630", "presentation": [ "http://phbi.com/role/DerivativeLiabilitiesDetails1" ], "xbrltype": "stringItemType" }, "phbi_ExpectedLife": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Expected life" } } }, "localname": "ExpectedLife", "nsuri": "http://phbi.com/20210630", "presentation": [ "http://phbi.com/role/DerivativeLiabilitiesDetails1" ], "xbrltype": "stringItemType" }, "phbi_ExpectedVolatility": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Expected volatility" } } }, "localname": "ExpectedVolatility", "nsuri": "http://phbi.com/20210630", "presentation": [ "http://phbi.com/role/DerivativeLiabilitiesDetails1" ], "xbrltype": "stringItemType" }, "phbi_ExpiryDate": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Expiry date" } } }, "localname": "ExpiryDate", "nsuri": "http://phbi.com/20210630", "presentation": [ "http://phbi.com/role/SharePurchaseWarrantsDetails1" ], "xbrltype": "stringItemType" }, "phbi_FairValueOfConvertedShares": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "label": "Fair value of converted shares" } } }, "localname": "FairValueOfConvertedShares", "nsuri": "http://phbi.com/20210630", "presentation": [ "http://phbi.com/role/CommonStockDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "phbi_FamilyMemberOfThePresidentMember": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Family Member of President [Member]" } } }, "localname": "FamilyMemberOfThePresidentMember", "nsuri": "http://phbi.com/20210630", "presentation": [ "http://phbi.com/role/ConvertibleNotesDetailsNarrative" ], "xbrltype": "domainItemType" }, "phbi_FatherOfPresidentMember": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Father Of President [Member]" } } }, "localname": "FatherOfPresidentMember", "nsuri": "http://phbi.com/20210630", "presentation": [ "http://phbi.com/role/RelatedPartyTransactionsDetailsNarrative" ], "xbrltype": "domainItemType" }, "phbi_FebruaryFourTwoThousandTwentyMember": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "February 4, 2020 [Member]" } } }, "localname": "FebruaryFourTwoThousandTwentyMember", "nsuri": "http://phbi.com/20210630", "presentation": [ "http://phbi.com/role/ConvertibleNotesDetailsNarrative" ], "xbrltype": "domainItemType" }, "phbi_FebruaryTwoTwoThousandTwentyOneMember": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "February 2, 2021 [Member]" } } }, "localname": "FebruaryTwoTwoThousandTwentyOneMember", "nsuri": "http://phbi.com/20210630", "presentation": [ "http://phbi.com/role/CommonStockDetailsNarrative" ], "xbrltype": "domainItemType" }, "phbi_FinancingFees": { "auth_ref": [], "calculation": { "http://phbi.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited": { "order": 10.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Financing Fees", "label": "Financing fees and default penalties" } } }, "localname": "FinancingFees", "nsuri": "http://phbi.com/20210630", "presentation": [ "http://phbi.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited" ], "xbrltype": "monetaryItemType" }, "phbi_ForeignExchangeLossGain": { "auth_ref": [], "calculation": { "http://phbi.com/role/CondensedConsolidatedStatementsOfOperationsAndComprehensiveIncomeLossUnaudited": { "order": 6.0, "parentTag": "us-gaap_OperatingExpenses", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "label": "Foreign exchange loss (gain)" } } }, "localname": "ForeignExchangeLossGain", "nsuri": "http://phbi.com/20210630", "presentation": [ "http://phbi.com/role/CondensedConsolidatedStatementsOfOperationsAndComprehensiveIncomeLossUnaudited" ], "xbrltype": "monetaryItemType" }, "phbi_InterestRate": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Interest rate" } } }, "localname": "InterestRate", "nsuri": "http://phbi.com/20210630", "presentation": [ "http://phbi.com/role/NoteAndLoanPayableDetailsNarrative" ], "xbrltype": "stringItemType" }, "phbi_InterimFinancialStatementsPolicyTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Interim Financial Statements [Policy Text Block]", "label": "Interim Financial Statements" } } }, "localname": "InterimFinancialStatementsPolicyTextBlock", "nsuri": "http://phbi.com/20210630", "presentation": [ "http://phbi.com/role/SummaryOfSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "phbi_IssuanceOfCommonStockForServicesAmount": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "label": "Issuance of common stock for services, amount" } } }, "localname": "IssuanceOfCommonStockForServicesAmount", "nsuri": "http://phbi.com/20210630", "presentation": [ "http://phbi.com/role/CondensedConsolidatedStatementsOfStockholdersDeficitUnaudited" ], "xbrltype": "monetaryItemType" }, "phbi_IssuanceOfCommonStockForServicesShares": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Issuance of common stock for services, shares" } } }, "localname": "IssuanceOfCommonStockForServicesShares", "nsuri": "http://phbi.com/20210630", "presentation": [ "http://phbi.com/role/CondensedConsolidatedStatementsOfStockholdersDeficitUnaudited" ], "xbrltype": "sharesItemType" }, "phbi_IssuanceOfCommonStockPursuantToTheConversionOfConvertibleNotesAmount": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "label": "Issuance of common stock pursuant to the conversion of convertible notes, amount" } } }, "localname": "IssuanceOfCommonStockPursuantToTheConversionOfConvertibleNotesAmount", "nsuri": "http://phbi.com/20210630", "presentation": [ "http://phbi.com/role/CondensedConsolidatedStatementsOfStockholdersDeficitUnaudited" ], "xbrltype": "monetaryItemType" }, "phbi_IssuanceOfCommonStockPursuantToTheConversionOfConvertibleNotesShares": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Issuance of common stock pursuant to the conversion of convertible notes, shares" } } }, "localname": "IssuanceOfCommonStockPursuantToTheConversionOfConvertibleNotesShares", "nsuri": "http://phbi.com/20210630", "presentation": [ "http://phbi.com/role/CondensedConsolidatedStatementsOfStockholdersDeficitUnaudited" ], "xbrltype": "sharesItemType" }, "phbi_IssuanceOfPreferredSharesForCashAmount": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "label": "Issuance of preferred shares for cash, amount" } } }, "localname": "IssuanceOfPreferredSharesForCashAmount", "nsuri": "http://phbi.com/20210630", "presentation": [ "http://phbi.com/role/CondensedConsolidatedStatementsOfStockholdersDeficitUnaudited" ], "xbrltype": "monetaryItemType" }, "phbi_IssuanceOfPreferredSharesForCashShares": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Issuance of preferred shares for cash, shares" } } }, "localname": "IssuanceOfPreferredSharesForCashShares", "nsuri": "http://phbi.com/20210630", "presentation": [ "http://phbi.com/role/CondensedConsolidatedStatementsOfStockholdersDeficitUnaudited" ], "xbrltype": "sharesItemType" }, "phbi_IssuanceOfPromissoryNoteAsFinancingFee": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Issuance of Promissory Note as Financing Fees", "label": "Issuance of promissory note as a financing fee" } } }, "localname": "IssuanceOfPromissoryNoteAsFinancingFee", "nsuri": "http://phbi.com/20210630", "presentation": [ "http://phbi.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited" ], "xbrltype": "monetaryItemType" }, "phbi_IssuanceOfSeriesASuperVotingPreferredStock": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Issuance of Series A Super Voting Preferred Stock", "verboseLabel": "Issuance of Series A Super Voting Preferred Stock" } } }, "localname": "IssuanceOfSeriesASuperVotingPreferredStock", "nsuri": "http://phbi.com/20210630", "presentation": [ "http://phbi.com/role/PreferredStockDetailsNarrative", "http://phbi.com/role/RelatedPartyTransactionsDetailsNarrative" ], "xbrltype": "sharesItemType" }, "phbi_JanuaryFifteenTwoThousandTwentyMember": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "January 15, 2020 [Member]" } } }, "localname": "JanuaryFifteenTwoThousandTwentyMember", "nsuri": "http://phbi.com/20210630", "presentation": [ "http://phbi.com/role/ConvertibleNotesDetailsNarrative" ], "xbrltype": "domainItemType" }, "phbi_JanuaryFourteenTwoThousandTwentyMember": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "January 14, 2020 [Member]" } } }, "localname": "JanuaryFourteenTwoThousandTwentyMember", "nsuri": "http://phbi.com/20210630", "presentation": [ "http://phbi.com/role/ConvertibleNotesDetailsNarrative" ], "xbrltype": "domainItemType" }, "phbi_JanuarySecondTwoThousandTwentyMember": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "January 2, 2020 [Member]" } } }, "localname": "JanuarySecondTwoThousandTwentyMember", "nsuri": "http://phbi.com/20210630", "presentation": [ "http://phbi.com/role/ConvertibleNotesDetailsNarrative" ], "xbrltype": "domainItemType" }, "phbi_JanuaryTwentyOneThousandTwentyMember": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "January 21, 2020 [Member]" } } }, "localname": "JanuaryTwentyOneThousandTwentyMember", "nsuri": "http://phbi.com/20210630", "presentation": [ "http://phbi.com/role/ConvertibleNotesDetailsNarrative" ], "xbrltype": "domainItemType" }, "phbi_JanuaryTwentyTwoThousandTwentyMember": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "January 22, 2020 [Member]" } } }, "localname": "JanuaryTwentyTwoThousandTwentyMember", "nsuri": "http://phbi.com/20210630", "presentation": [ "http://phbi.com/role/ConvertibleNotesDetailsNarrative" ], "xbrltype": "domainItemType" }, "phbi_JulyTwentyThreeTwoThousandTwentyMember": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "July 23, 2020 [Member]" } } }, "localname": "JulyTwentyThreeTwoThousandTwentyMember", "nsuri": "http://phbi.com/20210630", "presentation": [ "http://phbi.com/role/ConvertibleNotesDetailsNarrative" ], "xbrltype": "domainItemType" }, "phbi_JulyTwentyTwoTwoThousandTwentyMember": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "July 22, 2020 [Member]" } } }, "localname": "JulyTwentyTwoTwoThousandTwentyMember", "nsuri": "http://phbi.com/20210630", "presentation": [ "http://phbi.com/role/ConvertibleNotesDetailsNarrative" ], "xbrltype": "domainItemType" }, "phbi_JuneSeventeenTwoThousandTwentyMember": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "June 17, 2020 [Member]" } } }, "localname": "JuneSeventeenTwoThousandTwentyMember", "nsuri": "http://phbi.com/20210630", "presentation": [ "http://phbi.com/role/ConvertibleNotesDetailsNarrative" ], "xbrltype": "domainItemType" }, "phbi_LoanForgivenessDescription": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Loan forgiveness description" } } }, "localname": "LoanForgivenessDescription", "nsuri": "http://phbi.com/20210630", "presentation": [ "http://phbi.com/role/NoteAndLoanPayableDetailsNarrative" ], "xbrltype": "stringItemType" }, "phbi_LoansPayable1Member": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Promissory Note Nov. 22, 2019 [Member]" } } }, "localname": "LoansPayable1Member", "nsuri": "http://phbi.com/20210630", "presentation": [ "http://phbi.com/role/NoteAndLoanPayableDetailsNarrative" ], "xbrltype": "domainItemType" }, "phbi_LoansPayable2Member": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Loan Payable April 22, 2020 [Member]" } } }, "localname": "LoansPayable2Member", "nsuri": "http://phbi.com/20210630", "presentation": [ "http://phbi.com/role/NoteAndLoanPayableDetailsNarrative" ], "xbrltype": "domainItemType" }, "phbi_LossGainOnSettlementOfConvertibleNotes": { "auth_ref": [], "calculation": { "http://phbi.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited": { "order": 8.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "label": "Loss (gain) on settlement of convertible notes" } } }, "localname": "LossGainOnSettlementOfConvertibleNotes", "nsuri": "http://phbi.com/20210630", "presentation": [ "http://phbi.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited" ], "xbrltype": "monetaryItemType" }, "phbi_MarchTwentyNineTwoThousandTwentyOneMember": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "March 29, 2021 [Member]" } } }, "localname": "MarchTwentyNineTwoThousandTwentyOneMember", "nsuri": "http://phbi.com/20210630", "presentation": [ "http://phbi.com/role/CommonStockDetailsNarrative" ], "xbrltype": "domainItemType" }, "phbi_MaximumIntrinsicValueOfTheEmbeddedBeneficialConversionFeature": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "label": "Maximum intrinsic value of the embedded beneficial conversion feature" } } }, "localname": "MaximumIntrinsicValueOfTheEmbeddedBeneficialConversionFeature", "nsuri": "http://phbi.com/20210630", "presentation": [ "http://phbi.com/role/ConvertibleNotesDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "phbi_MaximunSharesPurchaseUnderAgreement": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Maximun shares purchase under agreement" } } }, "localname": "MaximunSharesPurchaseUnderAgreement", "nsuri": "http://phbi.com/20210630", "presentation": [ "http://phbi.com/role/CommitmentsDetailsNarrative" ], "xbrltype": "sharesItemType" }, "phbi_MayFourteenTwoThousandTwentyOneMember": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "May 14, 2021 [Member]" } } }, "localname": "MayFourteenTwoThousandTwentyOneMember", "nsuri": "http://phbi.com/20210630", "presentation": [ "http://phbi.com/role/CommonStockDetailsNarrative" ], "xbrltype": "domainItemType" }, "phbi_MotionForSummaryJudgementDescription": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Motion for Summary Judgement, description" } } }, "localname": "MotionForSummaryJudgementDescription", "nsuri": "http://phbi.com/20210630", "presentation": [ "http://phbi.com/role/NoteAndLoanPayableDetailsNarrative" ], "xbrltype": "stringItemType" }, "phbi_NewToTheStreetGroupLLCMember": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "New to the Street Group LLC [Member]" } } }, "localname": "NewToTheStreetGroupLLCMember", "nsuri": "http://phbi.com/20210630", "presentation": [ "http://phbi.com/role/CommitmentsDetailsNarrative" ], "xbrltype": "domainItemType" }, "phbi_NoteTwoMember": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Convertible note 2 [Member]" } } }, "localname": "NoteTwoMember", "nsuri": "http://phbi.com/20210630", "presentation": [ "http://phbi.com/role/ConvertibleNotesDetailsNarrative" ], "xbrltype": "domainItemType" }, "phbi_NovationSolutionsIncMember": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Novation Solutions Inc [Member]" } } }, "localname": "NovationSolutionsIncMember", "nsuri": "http://phbi.com/20210630", "presentation": [ "http://phbi.com/role/CommitmentsDetailsNarrative" ], "xbrltype": "domainItemType" }, "phbi_NovemberOneTwoThousandTwentyMember": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "November 1, 2020 [Member]" } } }, "localname": "NovemberOneTwoThousandTwentyMember", "nsuri": "http://phbi.com/20210630", "presentation": [ "http://phbi.com/role/CommonStockDetailsNarrative" ], "xbrltype": "domainItemType" }, "phbi_NovemberTwentySixTwoThousandTwentyMember": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "November 26, 2020 [Member]" } } }, "localname": "NovemberTwentySixTwoThousandTwentyMember", "nsuri": "http://phbi.com/20210630", "presentation": [ "http://phbi.com/role/CommonStockDetailsNarrative" ], "xbrltype": "domainItemType" }, "phbi_NumberOfPaymentInstallments": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Number of payment installments" } } }, "localname": "NumberOfPaymentInstallments", "nsuri": "http://phbi.com/20210630", "presentation": [ "http://phbi.com/role/ConvertibleNotesDetailsNarrative" ], "xbrltype": "stringItemType" }, "phbi_NumberOfWarrants": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Number of warrants" } } }, "localname": "NumberOfWarrants", "nsuri": "http://phbi.com/20210630", "presentation": [ "http://phbi.com/role/SharePurchaseWarrantsDetails1" ], "xbrltype": "sharesItemType" }, "phbi_OctoberFirstTwoThousandNineteenMember": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "October 1, 2019 [Member]" } } }, "localname": "OctoberFirstTwoThousandNineteenMember", "nsuri": "http://phbi.com/20210630", "presentation": [ "http://phbi.com/role/ConvertibleNotesDetailsNarrative" ], "xbrltype": "domainItemType" }, "phbi_OctoberSeventeenTwoThousandNineteenMember": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "October 17, 2019 [Member]" } } }, "localname": "OctoberSeventeenTwoThousandNineteenMember", "nsuri": "http://phbi.com/20210630", "presentation": [ "http://phbi.com/role/ConvertibleNotesDetailsNarrative" ], "xbrltype": "domainItemType" }, "phbi_OptionAgreementGrants": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Option agreement grants" } } }, "localname": "OptionAgreementGrants", "nsuri": "http://phbi.com/20210630", "presentation": [ "http://phbi.com/role/CommitmentsDetailsNarrative" ], "xbrltype": "stringItemType" }, "phbi_OriginalIssueDiscountOnConvertibleNotes": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "label": "Original issue discount on convertible notes" } } }, "localname": "OriginalIssueDiscountOnConvertibleNotes", "nsuri": "http://phbi.com/20210630", "presentation": [ "http://phbi.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited" ], "xbrltype": "monetaryItemType" }, "phbi_PresidentFatherMember": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Father of President [Member]" } } }, "localname": "PresidentFatherMember", "nsuri": "http://phbi.com/20210630", "presentation": [ "http://phbi.com/role/RelatedPartyTransactionsDetailsNarrative" ], "xbrltype": "domainItemType" }, "phbi_PrincipalDefaultOfConvertibleNote": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "label": "Principal default of convertible note" } } }, "localname": "PrincipalDefaultOfConvertibleNote", "nsuri": "http://phbi.com/20210630", "presentation": [ "http://phbi.com/role/ConvertibleNotesDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "phbi_ProceedsFromIssuanceOfSeriesASuperVotingPreferredStock": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "label": "Proceeds from Issuance of Series A Super Voting Preferred Stock", "verboseLabel": "Proceeds from Issuance of Series A Super Voting Preferred Stock" } } }, "localname": "ProceedsFromIssuanceOfSeriesASuperVotingPreferredStock", "nsuri": "http://phbi.com/20210630", "presentation": [ "http://phbi.com/role/PreferredStockDetailsNarrative", "http://phbi.com/role/RelatedPartyTransactionsDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "phbi_ProductionAgreementFeePayableDescription": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Production agreement fee payable description" } } }, "localname": "ProductionAgreementFeePayableDescription", "nsuri": "http://phbi.com/20210630", "presentation": [ "http://phbi.com/role/CommitmentsDetailsNarrative" ], "xbrltype": "stringItemType" }, "phbi_PromissoryNoteTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Promissory Note [Text Block]", "label": "4. Note and Loan Payable" } } }, "localname": "PromissoryNoteTextBlock", "nsuri": "http://phbi.com/20210630", "presentation": [ "http://phbi.com/role/NoteAndLoanPayable" ], "xbrltype": "textBlockItemType" }, "phbi_PurchasePriceDescription": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Purchase price description" } } }, "localname": "PurchasePriceDescription", "nsuri": "http://phbi.com/20210630", "presentation": [ "http://phbi.com/role/CommitmentsDetailsNarrative" ], "xbrltype": "stringItemType" }, "phbi_RateOfInterestOnUnpaidBalance": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Rate of interest" } } }, "localname": "RateOfInterestOnUnpaidBalance", "nsuri": "http://phbi.com/20210630", "presentation": [ "http://phbi.com/role/ConvertibleNotesDetailsNarrative" ], "xbrltype": "stringItemType" }, "phbi_RateOfInterestOnUnpaidBalanceAfterDefaultOfNote": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Rate of interest on unpaid balance after default of note" } } }, "localname": "RateOfInterestOnUnpaidBalanceAfterDefaultOfNote", "nsuri": "http://phbi.com/20210630", "presentation": [ "http://phbi.com/role/ConvertibleNotesDetailsNarrative" ], "xbrltype": "stringItemType" }, "phbi_RepaymentOfLoansFromRelatedParties": { "auth_ref": [], "calculation": { "http://phbi.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited": { "order": 15.0, "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Repayment of loans from related parties", "label": "[Repayment of loans from related parties]", "negatedLabel": "Repayment of loans from related parties" } } }, "localname": "RepaymentOfLoansFromRelatedParties", "nsuri": "http://phbi.com/20210630", "presentation": [ "http://phbi.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited" ], "xbrltype": "monetaryItemType" }, "phbi_RestrictedSharesUnissued": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Restricted shares, unissued" } } }, "localname": "RestrictedSharesUnissued", "nsuri": "http://phbi.com/20210630", "presentation": [ "http://phbi.com/role/CommitmentsDetailsNarrative" ], "xbrltype": "sharesItemType" }, "phbi_RiskFreeInterestRate": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Risk-free interest rate" } } }, "localname": "RiskFreeInterestRate", "nsuri": "http://phbi.com/20210630", "presentation": [ "http://phbi.com/role/DerivativeLiabilitiesDetails1" ], "xbrltype": "stringItemType" }, "phbi_ScheduleOfWeightedAverageAssumptionsUsedInTheCalculationsTableTextblock": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Schedule of weighted-average assumptions used in the calculations" } } }, "localname": "ScheduleOfWeightedAverageAssumptionsUsedInTheCalculationsTableTextblock", "nsuri": "http://phbi.com/20210630", "presentation": [ "http://phbi.com/role/DerivativeLiabilitiesTables" ], "xbrltype": "textBlockItemType" }, "phbi_SeriesAConvertibleNotesMember": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Series A Convertile Notes [Member]" } } }, "localname": "SeriesAConvertibleNotesMember", "nsuri": "http://phbi.com/20210630", "presentation": [ "http://phbi.com/role/ConvertibleNotesDetailsNarrative" ], "xbrltype": "domainItemType" }, "phbi_SeriesASuperVotingPreferredStock": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Series A Super Voting Preferred Stock" } } }, "localname": "SeriesASuperVotingPreferredStock", "nsuri": "http://phbi.com/20210630", "presentation": [ "http://phbi.com/role/PreferredStockDetailsNarrative" ], "xbrltype": "sharesItemType" }, "phbi_ServiceAgreementFeePayableDescription": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Service agreement fee payable description" } } }, "localname": "ServiceAgreementFeePayableDescription", "nsuri": "http://phbi.com/20210630", "presentation": [ "http://phbi.com/role/CommitmentsDetailsNarrative" ], "xbrltype": "stringItemType" }, "phbi_SettlementAgreementWithNoteholderMember": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Settlement Agreement with Noteholder [Member]" } } }, "localname": "SettlementAgreementWithNoteholderMember", "nsuri": "http://phbi.com/20210630", "presentation": [ "http://phbi.com/role/ConvertibleNotesDetailsNarrative" ], "xbrltype": "domainItemType" }, "phbi_SharePurchaseWarrantsTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Share Purchase Warrant [Text block]", "label": "10. Share Purchase Warrants" } } }, "localname": "SharePurchaseWarrantsTextBlock", "nsuri": "http://phbi.com/20210630", "presentation": [ "http://phbi.com/role/SharePurchaseWarrants" ], "xbrltype": "textBlockItemType" }, "phbi_SharesIssuableForServices": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "label": "Shares issuable for services" } } }, "localname": "SharesIssuableForServices", "nsuri": "http://phbi.com/20210630", "presentation": [ "http://phbi.com/role/CondensedConsolidatedStatementsOfStockholdersDeficitUnaudited" ], "xbrltype": "monetaryItemType" }, "phbi_UnrelatedPartyMember": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Unrelated party [Member]" } } }, "localname": "UnrelatedPartyMember", "nsuri": "http://phbi.com/20210630", "presentation": [ "http://phbi.com/role/ConvertibleNotesDetailsNarrative" ], "xbrltype": "domainItemType" }, "phbi_WarrantExercisableDescription": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Warrant exercisable description" } } }, "localname": "WarrantExercisableDescription", "nsuri": "http://phbi.com/20210630", "presentation": [ "http://phbi.com/role/SubsequentEventsDetailsNarrative" ], "xbrltype": "stringItemType" }, "phbi_WarrantsEightMember": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Warrant Eight [Member]" } } }, "localname": "WarrantsEightMember", "nsuri": "http://phbi.com/20210630", "presentation": [ "http://phbi.com/role/SharePurchaseWarrantsDetails1" ], "xbrltype": "domainItemType" }, "phbi_WarrantsFiveMember": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Warrant Five [Member]" } } }, "localname": "WarrantsFiveMember", "nsuri": "http://phbi.com/20210630", "presentation": [ "http://phbi.com/role/SharePurchaseWarrantsDetails1" ], "xbrltype": "domainItemType" }, "phbi_WarrantsFourMember": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Warrant Four [Member]" } } }, "localname": "WarrantsFourMember", "nsuri": "http://phbi.com/20210630", "presentation": [ "http://phbi.com/role/SharePurchaseWarrantsDetails1" ], "xbrltype": "domainItemType" }, "phbi_WarrantsMember": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Warrant [Member]" } } }, "localname": "WarrantsMember", "nsuri": "http://phbi.com/20210630", "presentation": [ "http://phbi.com/role/SharePurchaseWarrantsDetails" ], "xbrltype": "domainItemType" }, "phbi_WarrantsNineMember": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Warrant Nine [Member]" } } }, "localname": "WarrantsNineMember", "nsuri": "http://phbi.com/20210630", "presentation": [ "http://phbi.com/role/SharePurchaseWarrantsDetails1" ], "xbrltype": "domainItemType" }, "phbi_WarrantsOneMember": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Warrant One [Member]" } } }, "localname": "WarrantsOneMember", "nsuri": "http://phbi.com/20210630", "presentation": [ "http://phbi.com/role/SharePurchaseWarrantsDetails1" ], "xbrltype": "domainItemType" }, "phbi_WarrantsSevenMember": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Warrant Seven [Member]" } } }, "localname": "WarrantsSevenMember", "nsuri": "http://phbi.com/20210630", "presentation": [ "http://phbi.com/role/SharePurchaseWarrantsDetails1" ], "xbrltype": "domainItemType" }, "phbi_WarrantsSixMember": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Warrant Six [Member]" } } }, "localname": "WarrantsSixMember", "nsuri": "http://phbi.com/20210630", "presentation": [ "http://phbi.com/role/SharePurchaseWarrantsDetails1" ], "xbrltype": "domainItemType" }, "phbi_WarrantsThreeMember": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Warrant Three [Member]" } } }, "localname": "WarrantsThreeMember", "nsuri": "http://phbi.com/20210630", "presentation": [ "http://phbi.com/role/SharePurchaseWarrantsDetails1" ], "xbrltype": "domainItemType" }, "phbi_WarrantsTwoMember": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Warrant Two [Member]" } } }, "localname": "WarrantsTwoMember", "nsuri": "http://phbi.com/20210630", "presentation": [ "http://phbi.com/role/SharePurchaseWarrantsDetails1" ], "xbrltype": "domainItemType" }, "phbi_WeightedAverageExercisePriceBeginning": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Weighted average exercise price, beginning" } } }, "localname": "WeightedAverageExercisePriceBeginning", "nsuri": "http://phbi.com/20210630", "presentation": [ "http://phbi.com/role/SharePurchaseWarrantsDetails" ], "xbrltype": "perShareItemType" }, "phbi_WeightedAverageExercisePriceEnding": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Weighted average exercise price, ending" } } }, "localname": "WeightedAverageExercisePriceEnding", "nsuri": "http://phbi.com/20210630", "presentation": [ "http://phbi.com/role/SharePurchaseWarrantsDetails" ], "xbrltype": "perShareItemType" }, "phbi_WeightedAverageExercisePriceIssued": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Weighted average exercise price, issued" } } }, "localname": "WeightedAverageExercisePriceIssued", "nsuri": "http://phbi.com/20210630", "presentation": [ "http://phbi.com/role/SharePurchaseWarrantsDetails" ], "xbrltype": "perShareItemType" }, "phbi_WorkingCapitalDeficit": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Working Capital Deficit", "label": "Working Capital Deficit" } } }, "localname": "WorkingCapitalDeficit", "nsuri": "http://phbi.com/20210630", "presentation": [ "http://phbi.com/role/NatureOfBusinessAndContinuanceOfOperationsDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "phbi_WriteoffOfAccountsPayable": { "auth_ref": [], "calculation": { "http://phbi.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited": { "order": 6.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 }, "http://phbi.com/role/CondensedConsolidatedStatementsOfOperationsAndComprehensiveIncomeLossUnaudited": { "order": 7.0, "parentTag": "us-gaap_NonoperatingIncomeExpense", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "label": "Write-off of accounts payable", "negatedLabel": "Write-off of accounts payable" } } }, "localname": "WriteoffOfAccountsPayable", "nsuri": "http://phbi.com/20210630", "presentation": [ "http://phbi.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited", "http://phbi.com/role/CondensedConsolidatedStatementsOfOperationsAndComprehensiveIncomeLossUnaudited" ], "xbrltype": "monetaryItemType" }, "srt_ChiefFinancialOfficerMember": { "auth_ref": [ "r104" ], "lang": { "en-us": { "role": { "label": "Chief Financial Officer [Member]" } } }, "localname": "ChiefFinancialOfficerMember", "nsuri": "http://fasb.org/srt/2020-01-31", "presentation": [ "http://phbi.com/role/RelatedPartyTransactionsDetailsNarrative" ], "xbrltype": "domainItemType" }, "srt_DirectorMember": { "auth_ref": [ "r104" ], "lang": { "en-us": { "role": { "label": "Director [Member]", "verboseLabel": "Director [Member]" } } }, "localname": "DirectorMember", "nsuri": "http://fasb.org/srt/2020-01-31", "presentation": [ "http://phbi.com/role/PreferredStockDetailsNarrative", "http://phbi.com/role/RelatedPartyTransactionsDetailsNarrative" ], "xbrltype": "domainItemType" }, "srt_PresidentMember": { "auth_ref": [ "r104" ], "lang": { "en-us": { "role": { "label": "President [Member]" } } }, "localname": "PresidentMember", "nsuri": "http://fasb.org/srt/2020-01-31", "presentation": [ "http://phbi.com/role/RelatedPartyTransactionsDetailsNarrative" ], "xbrltype": "domainItemType" }, "srt_SegmentGeographicalDomain": { "auth_ref": [ "r102", "r103", "r135", "r136", "r250", "r263", "r264", "r265", "r266", "r267", "r268", "r269", "r270" ], "localname": "SegmentGeographicalDomain", "nsuri": "http://fasb.org/srt/2020-01-31", "presentation": [ "http://phbi.com/role/CommitmentsDetailsNarrative", "http://phbi.com/role/NoteAndLoanPayableDetailsNarrative", "http://phbi.com/role/RelatedPartyTransactionsDetailsNarrative" ], "xbrltype": "domainItemType" }, "srt_StatementGeographicalAxis": { "auth_ref": [ "r102", "r103", "r135", "r136", "r250", "r262", "r263", "r264", "r265", "r266", "r267", "r268", "r269", "r270", "r271" ], "lang": { "en-us": { "role": { "label": "Statement Geographical Axis" } } }, "localname": "StatementGeographicalAxis", "nsuri": "http://fasb.org/srt/2020-01-31", "presentation": [ "http://phbi.com/role/CommitmentsDetailsNarrative", "http://phbi.com/role/NoteAndLoanPayableDetailsNarrative", "http://phbi.com/role/RelatedPartyTransactionsDetailsNarrative" ], "xbrltype": "stringItemType" }, "us-gaap_AccountingPoliciesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Summary of Significant Accounting Policies" } } }, "localname": "AccountingPoliciesAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "xbrltype": "stringItemType" }, "us-gaap_AccountsAndOtherReceivablesNetCurrent": { "auth_ref": [], "calculation": { "http://phbi.com/role/CondensedConsolidatedBalanceSheets": { "order": 3.0, "parentTag": "us-gaap_Assets", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount, after allowance, receivable from customers, clients, or other third-parties, and receivables classified as other due within one year or the normal operating cycle, if longer.", "label": "Amounts receivable" } } }, "localname": "AccountsAndOtherReceivablesNetCurrent", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://phbi.com/role/CondensedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent": { "auth_ref": [ "r18" ], "calculation": { "http://phbi.com/role/CondensedConsolidatedBalanceSheets": { "order": 10.0, "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Sum of the carrying values as of the balance sheet date of obligations incurred through that date and due within one year (or the operating cycle, if longer), including liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received, taxes, interest, rent and utilities, accrued salaries and bonuses, payroll taxes and fringe benefits.", "label": "Accounts payable and accrued liabilities (Notes 3 and 7)", "verboseLabel": "Accounts Payable and Accrued Liabilities" } } }, "localname": "AccountsPayableAndAccruedLiabilitiesCurrent", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://phbi.com/role/AccountsPayableAndAccruedLiabilitiesDetails", "http://phbi.com/role/CondensedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock": { "auth_ref": [ "r16" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for accounts payable and accrued liabilities at the end of the reporting period.", "label": "3. Accounts Payable and Accrued Liabilities" } } }, "localname": "AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://phbi.com/role/AccountsPayableAndAccruedLiabilities" ], "xbrltype": "textBlockItemType" }, "us-gaap_AccountsPayableCurrent": { "auth_ref": [ "r15" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).", "label": "Accounts payable" } } }, "localname": "AccountsPayableCurrent", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://phbi.com/role/AccountsPayableAndAccruedLiabilitiesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments": { "auth_ref": [ "r58" ], "calculation": { "http://phbi.com/role/CondensedConsolidatedStatementsOfOperationsAndComprehensiveIncomeLossUnaudited": { "order": 11.0, "parentTag": "us-gaap_NonoperatingIncomeExpense", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The sum of the periodic adjustments of the differences between securities' face values and purchase prices that are charged against earnings. This is called accretion if the security was purchased at a discount and amortization if it was purchased at premium. As a noncash item, this element is an adjustment to net income when calculating cash provided by or used in operations using the indirect method.", "label": "[Accretion (Amortization) of Discounts and Premiums, Investments]", "negatedLabel": "Accretion of discount on convertible notes (Note 5)" } } }, "localname": "AccretionAmortizationOfDiscountsAndPremiumsInvestments", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://phbi.com/role/CondensedConsolidatedStatementsOfOperationsAndComprehensiveIncomeLossUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_AccretionExpense": { "auth_ref": [ "r119", "r120" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount recognized for the passage of time, typically for liabilities, that have been discounted to their net present values. Excludes accretion associated with asset retirement obligations.", "label": "Accretion Expense" } } }, "localname": "AccretionExpense", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://phbi.com/role/ConvertibleNotesDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "us-gaap_AccruedLiabilitiesCurrent": { "auth_ref": [ "r20" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).", "label": "Accrued interest" } } }, "localname": "AccruedLiabilitiesCurrent", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://phbi.com/role/ConvertibleNotesDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax": { "auth_ref": [ "r10", "r33", "r34", "r35", "r245", "r255", "r256" ], "calculation": { "http://phbi.com/role/CondensedConsolidatedBalanceSheets": { "order": 14.0, "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Accumulated change in equity from transactions and other events and circumstances from non-owner sources, net of tax effect, at period end. Excludes Net Income (Loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners. Includes foreign currency translation items, certain pension adjustments, unrealized gains and losses on certain investments in debt and equity securities, other than temporary impairment (OTTI) losses related to factors other than credit losses on available-for-sale and held-to-maturity debt securities that an entity does not intend to sell and it is not more likely than not that the entity will be required to sell before recovery of the amortized cost basis, as well as changes in the fair value of derivatives related to the effective portion of a designated cash flow hedge.", "label": "Accumulated other comprehensive income (loss)" } } }, "localname": "AccumulatedOtherComprehensiveIncomeLossNetOfTax", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://phbi.com/role/CondensedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_AccumulatedOtherComprehensiveIncomeMember": { "auth_ref": [ "r32", "r35", "r36", "r67", "r68", "r69", "r157", "r251", "r252" ], "lang": { "en-us": { "role": { "documentation": "Accumulated increase (decrease) in equity from transactions and other events and circumstances from non-owner sources, attributable to the parent. Excludes net income (loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners.", "label": "Accumulated other comprehensive loss" } } }, "localname": "AccumulatedOtherComprehensiveIncomeMember", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://phbi.com/role/CondensedConsolidatedStatementsOfStockholdersDeficitUnaudited" ], "xbrltype": "domainItemType" }, "us-gaap_AdditionalPaidInCapital": { "auth_ref": [ "r8", "r146" ], "calculation": { "http://phbi.com/role/CondensedConsolidatedBalanceSheets": { "order": 15.0, "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Excess of issue price over par or stated value of the entity's capital stock and amounts received from other transactions involving the entity's stock or stockholders. Includes adjustments to additional paid in capital. Some examples of such adjustments include recording the issuance of debt with a beneficial conversion feature and certain tax consequences of equity instruments awarded to employees. Use this element for the aggregate amount of additional paid-in capital associated with common and preferred stock. For additional paid-in capital associated with only common stock, use the element additional paid in capital, common stock. For additional paid-in capital associated with only preferred stock, use the element additional paid in capital, preferred stock.", "label": "Additional paid-in capital" } } }, "localname": "AdditionalPaidInCapital", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://phbi.com/role/CondensedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_AdditionalPaidInCapitalMember": { "auth_ref": [ "r67", "r68", "r69", "r143", "r144", "r145" ], "lang": { "en-us": { "role": { "documentation": "Excess of issue price over par or stated value of the entity's capital stock and amounts received from other transactions involving the entity's stock or stockholders.", "label": "Additional Paid-In Capital" } } }, "localname": "AdditionalPaidInCapitalMember", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://phbi.com/role/CondensedConsolidatedStatementsOfStockholdersDeficitUnaudited" ], "xbrltype": "domainItemType" }, "us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Adjustments to reconcile net loss to net cash used in operating activities:" } } }, "localname": "AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://phbi.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited" ], "xbrltype": "stringItemType" }, "us-gaap_AmortizationOfDebtDiscountPremium": { "auth_ref": [ "r45", "r57", "r175" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of noncash expense included in interest expense to amortize debt discount and premium associated with the related debt instruments. Excludes amortization of financing costs. Alternate captions include noncash interest expense.", "label": "Unamortized discount" } } }, "localname": "AmortizationOfDebtDiscountPremium", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://phbi.com/role/ConvertibleNotesDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "us-gaap_Assets": { "auth_ref": [ "r64", "r94", "r96", "r100", "r108", "r153", "r158", "r166", "r232", "r241" ], "calculation": { "http://phbi.com/role/CondensedConsolidatedBalanceSheets": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.", "label": "[Assets]", "totalLabel": "Total assets" } } }, "localname": "Assets", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://phbi.com/role/CondensedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_AssetsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Assets" } } }, "localname": "AssetsAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://phbi.com/role/CondensedConsolidatedBalanceSheets" ], "xbrltype": "stringItemType" }, "us-gaap_AssetsCurrentAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Current assets" } } }, "localname": "AssetsCurrentAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://phbi.com/role/CondensedConsolidatedBalanceSheets" ], "xbrltype": "stringItemType" }, "us-gaap_AwardDateAxis": { "auth_ref": [ "r139", "r142" ], "lang": { "en-us": { "role": { "documentation": "Information by date or year award under share-based payment arrangement is granted.", "label": "Award Date [Axis]" } } }, "localname": "AwardDateAxis", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://phbi.com/role/CommonStockDetailsNarrative", "http://phbi.com/role/ConvertibleNotesDetailsNarrative" ], "xbrltype": "stringItemType" }, "us-gaap_AwardDateDomain": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Date or year award under share-based payment arrangement is granted." } } }, "localname": "AwardDateDomain", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://phbi.com/role/CommonStockDetailsNarrative", "http://phbi.com/role/ConvertibleNotesDetailsNarrative" ], "xbrltype": "domainItemType" }, "us-gaap_Cash": { "auth_ref": [ "r14", "r257", "r258" ], "calculation": { "http://phbi.com/role/CondensedConsolidatedBalanceSheets": { "order": 4.0, "parentTag": "us-gaap_Assets", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Excludes cash and cash equivalents within disposal group and discontinued operation.", "label": "Cash", "periodEndLabel": "Cash, end of period", "periodStartLabel": "Cash, beginning of period" } } }, "localname": "Cash", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://phbi.com/role/CondensedConsolidatedBalanceSheets", "http://phbi.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Non-cash investing and financing activities:" } } }, "localname": "CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://phbi.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited" ], "xbrltype": "stringItemType" }, "us-gaap_CashPeriodIncreaseDecrease": { "auth_ref": [], "calculation": { "http://phbi.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of increase (decrease) in cash. Cash is the amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Includes effect from exchange rate changes.", "label": "[Cash, Period Increase (Decrease)]", "totalLabel": "Change in cash" } } }, "localname": "CashPeriodIncreaseDecrease", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://phbi.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_CommitmentsAndContingenciesDisclosureAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Commitments" } } }, "localname": "CommitmentsAndContingenciesDisclosureAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "xbrltype": "stringItemType" }, "us-gaap_CommitmentsAndContingenciesDisclosureTextBlock": { "auth_ref": [ "r121", "r122", "r123", "r124" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for commitments and contingencies.", "label": "11. Commitments" } } }, "localname": "CommitmentsAndContingenciesDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://phbi.com/role/Commitments" ], "xbrltype": "textBlockItemType" }, "us-gaap_CommonStockMember": { "auth_ref": [ "r67", "r68" ], "lang": { "en-us": { "role": { "documentation": "Stock that is subordinate to all other stock of the issuer.", "label": "Common Stock [Member]", "verboseLabel": "Common Stock" } } }, "localname": "CommonStockMember", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://phbi.com/role/CondensedConsolidatedStatementsOfStockholdersDeficitUnaudited" ], "xbrltype": "domainItemType" }, "us-gaap_CommonStockParOrStatedValuePerShare": { "auth_ref": [ "r7" ], "lang": { "en-us": { "role": { "documentation": "Face amount or stated value per share of common stock.", "label": "Common Stock, Par Value", "terseLabel": "Common Stock, Par Value", "verboseLabel": "Common Stock, Par Value" } } }, "localname": "CommonStockParOrStatedValuePerShare", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://phbi.com/role/CondensedConsolidatedBalanceSheetsParenthetical", "http://phbi.com/role/ConvertibleNotesDetailsNarrative", "http://phbi.com/role/PreferredStockDetailsNarrative" ], "xbrltype": "perShareItemType" }, "us-gaap_CommonStockSharesAuthorized": { "auth_ref": [ "r7" ], "lang": { "en-us": { "role": { "documentation": "The maximum number of common shares permitted to be issued by an entity's charter and bylaws.", "label": "Common Stock, Shares Authorized", "verboseLabel": "Common Stock, Shares Authorized" } } }, "localname": "CommonStockSharesAuthorized", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://phbi.com/role/CondensedConsolidatedBalanceSheetsParenthetical", "http://phbi.com/role/PreferredStockDetailsNarrative" ], "xbrltype": "sharesItemType" }, "us-gaap_CommonStockSharesIssued": { "auth_ref": [ "r7" ], "lang": { "en-us": { "role": { "documentation": "Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.", "label": "Common Stock, Shares Issued" } } }, "localname": "CommonStockSharesIssued", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://phbi.com/role/CondensedConsolidatedBalanceSheetsParenthetical" ], "xbrltype": "sharesItemType" }, "us-gaap_CommonStockSharesOutstanding": { "auth_ref": [ "r7", "r129" ], "lang": { "en-us": { "role": { "documentation": "Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.", "label": "Common Stock, Shares Outstanding" } } }, "localname": "CommonStockSharesOutstanding", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://phbi.com/role/CondensedConsolidatedBalanceSheetsParenthetical" ], "xbrltype": "sharesItemType" }, "us-gaap_CommonStockSharesSubscriptions": { "auth_ref": [ "r7", "r128" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Monetary value of common stock allocated to investors to buy shares of a new issue of common stock before they are offered to the public. When stock is sold on a subscription basis, the issuer does not initially receive the total proceeds. In general, the issuer does not issue the shares to the investor until it receives the entire proceeds.", "label": "Common stock subscriptions" } } }, "localname": "CommonStockSharesSubscriptions", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://phbi.com/role/SubsequentEventsDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "us-gaap_CommonStockValue": { "auth_ref": [ "r7" ], "calculation": { "http://phbi.com/role/CondensedConsolidatedBalanceSheets": { "order": 17.0, "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.", "label": "Common stock Authorized: 2,000,000,000 shares, $0.001 par value; 355,129,269 and 95,806,289 shares issued and outstanding, respectively" } } }, "localname": "CommonStockValue", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://phbi.com/role/CondensedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterestAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Comprehensive income (loss)" } } }, "localname": "ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterestAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://phbi.com/role/CondensedConsolidatedStatementsOfOperationsAndComprehensiveIncomeLossUnaudited" ], "xbrltype": "stringItemType" }, "us-gaap_ConversionOfStockAmountConverted1": { "auth_ref": [ "r60", "r61", "r62" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The value of the stock converted in a noncash (or part noncash) transaction. Noncash is defined as transactions during a period that do not result in cash receipts or cash payments in the period. \"Part noncash\" refers to that portion of the transaction not resulting in cash receipts or cash payments in the period.", "label": "Principal amount converted into common stock", "verboseLabel": "Conversion of convertible notes" } } }, "localname": "ConversionOfStockAmountConverted1", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://phbi.com/role/ConvertibleNotesDetailsNarrative", "http://phbi.com/role/DerivativeLiabilitiesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_ConversionOfStockSharesIssued1": { "auth_ref": [ "r60", "r61", "r62" ], "lang": { "en-us": { "role": { "documentation": "The number of new shares issued in the conversion of stock in a noncash (or part noncash) transaction. Noncash is defined as transactions during a period that do not result in cash receipts or cash payments in the period. \"Part noncash\" refers to that portion of the transaction not resulting in cash receipts or cash payments in the period.", "label": "Debt instrument converted amount, shares issued" } } }, "localname": "ConversionOfStockSharesIssued1", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://phbi.com/role/CommonStockDetailsNarrative" ], "xbrltype": "sharesItemType" }, "us-gaap_ConvertibleDebt": { "auth_ref": [ "r5", "r234", "r244" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Including the current and noncurrent portions, carrying amount of debt identified as being convertible into another form of financial instrument (typically the entity's common stock) as of the balance sheet date, which originally required full repayment more than twelve months after issuance or greater than the normal operating cycle of the company.", "label": "Remaining value of convertible notes" } } }, "localname": "ConvertibleDebt", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://phbi.com/role/ConvertibleNotesDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "us-gaap_ConvertibleDebtCurrent": { "auth_ref": [ "r4" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The portion of the carrying value of long-term convertible debt as of the balance sheet date that is scheduled to be repaid within one year or in the normal operating cycle if longer. Convertible debt is a financial instrument which can be exchanged for a specified amount of another security, typically the entity's common stock, at the option of the issuer or the holder.", "label": "Convertible notes" } } }, "localname": "ConvertibleDebtCurrent", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://phbi.com/role/ConvertibleNotesDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "us-gaap_ConvertibleDebtFairValueDisclosures": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Fair value portion of borrowing which can be exchanged for a specified number of another security at the option of the issuer or the holder, for example, but not limited to, the entity's common stock.", "label": "Fair value of convertible notes" } } }, "localname": "ConvertibleDebtFairValueDisclosures", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://phbi.com/role/ConvertibleNotesDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "us-gaap_ConvertibleLongTermNotesPayable": { "auth_ref": [ "r22" ], "calculation": { "http://phbi.com/role/CondensedConsolidatedBalanceSheets": { "order": 11.0, "parentTag": "us-gaap_Liabilities", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Carrying value as of the balance sheet date of long-term debt (with maturities initially due after one year or beyond the operating cycle if longer) identified as Convertible Notes Payable, excluding current portion. Convertible Notes Payable is a written promise to pay a note which can be exchanged for a specified amount of another, related security, at the option of the issuer and the holder.", "label": "Convertible notes, net of unamortized discount of $20,696 and $23,619, respectively (Note 5)" } } }, "localname": "ConvertibleLongTermNotesPayable", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://phbi.com/role/CondensedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_ConvertibleNotesPayable": { "auth_ref": [ "r5", "r234", "r243", "r259" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Including the current and noncurrent portions, carrying value as of the balance sheet date of a written promise to pay a note, initially due after one year or beyond the operating cycle if longer, which can be exchanged for a specified amount of one or more securities (typically common stock), at the option of the issuer or the holder.", "label": "Carrying value of convertible notes" } } }, "localname": "ConvertibleNotesPayable", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://phbi.com/role/ConvertibleNotesDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "us-gaap_ConvertibleNotesPayableCurrent": { "auth_ref": [ "r20" ], "calculation": { "http://phbi.com/role/CondensedConsolidatedBalanceSheets": { "order": 6.0, "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Carrying value as of the balance sheet date of the portion of long-term debt due within one year or the operating cycle if longer identified as Convertible Notes Payable. Convertible Notes Payable is a written promise to pay a note which can be exchanged for a specified amount of another, related security, at the option of the issuer and the holder.", "label": "Convertible notes - current portion, net of unamortized discount of $Nil and $182,012, respectively (Note 5)" } } }, "localname": "ConvertibleNotesPayableCurrent", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://phbi.com/role/CondensedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_ConvertibleNotesPayableMember": { "auth_ref": [ "r4", "r233", "r240", "r259" ], "lang": { "en-us": { "role": { "documentation": "Written promise to pay a note which can be exchanged for a specified quantity of securities (typically common stock), at the option of the issuer or the holder.", "label": "Convertible Notes Payable [Member]" } } }, "localname": "ConvertibleNotesPayableMember", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://phbi.com/role/CommonStockDetailsNarrative" ], "xbrltype": "domainItemType" }, "us-gaap_DebtConversionByUniqueDescriptionAxis": { "auth_ref": [ "r60", "r62" ], "lang": { "en-us": { "role": { "documentation": "Information by description of debt issuances converted in a noncash or part noncash transaction.", "label": "Debt Conversion Description [Axis]" } } }, "localname": "DebtConversionByUniqueDescriptionAxis", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://phbi.com/role/SharePurchaseWarrantsDetails", "http://phbi.com/role/SharePurchaseWarrantsDetails1" ], "xbrltype": "stringItemType" }, "us-gaap_DebtConversionConvertedInstrumentAmount1": { "auth_ref": [ "r60", "r62" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The value of the financial instrument(s) that the original debt is being converted into in a noncash (or part noncash) transaction. \"Part noncash\" refers to that portion of the transaction not resulting in cash receipts or cash payments in the period.", "label": "Debt instrument converted amount" } } }, "localname": "DebtConversionConvertedInstrumentAmount1", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://phbi.com/role/CommonStockDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "us-gaap_DebtConversionNameDomain": { "auth_ref": [ "r60", "r62" ], "lang": { "en-us": { "role": { "documentation": "The name of the original debt issue that has been converted in a noncash (or part noncash) transaction during the accounting period. \"Part noncash\" refers to that portion of the transaction not resulting in cash receipts or cash payments in the period." } } }, "localname": "DebtConversionNameDomain", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://phbi.com/role/SharePurchaseWarrantsDetails", "http://phbi.com/role/SharePurchaseWarrantsDetails1" ], "xbrltype": "domainItemType" }, "us-gaap_DebtDisclosureAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Note and Loan Payable" } } }, "localname": "DebtDisclosureAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "xbrltype": "stringItemType" }, "us-gaap_DebtDisclosureTextBlock": { "auth_ref": [ "r127" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for information about short-term and long-term debt arrangements, which includes amounts of borrowings under each line of credit, note payable, commercial paper issue, bonds indenture, debenture issue, own-share lending arrangements and any other contractual agreement to repay funds, and about the underlying arrangements, rationale for a classification as long-term, including repayment terms, interest rates, collateral provided, restrictions on use of assets and activities, whether or not in compliance with debt covenants, and other matters important to users of the financial statements, such as the effects of refinancing and noncompliance with debt covenants.", "label": "5. Convertible Notes" } } }, "localname": "DebtDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://phbi.com/role/ConvertibleNotes" ], "xbrltype": "textBlockItemType" }, "us-gaap_DebtInstrumentConvertibleBeneficialConversionFeature": { "auth_ref": [ "r131" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of a favorable spread to a debt holder between the amount of debt being converted and the value of the securities received upon conversion. This is an embedded conversion feature of convertible debt issued that is in-the-money at the commitment date.", "label": "Beneficial conversion feature" } } }, "localname": "DebtInstrumentConvertibleBeneficialConversionFeature", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://phbi.com/role/ConvertibleNotesDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "us-gaap_DebtInstrumentFaceAmount": { "auth_ref": [ "r176", "r178" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Face (par) amount of debt instrument at time of issuance.", "label": "Face value of convertible notes" } } }, "localname": "DebtInstrumentFaceAmount", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://phbi.com/role/ConvertibleNotesDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "us-gaap_DebtInstrumentUnamortizedDiscountCurrent": { "auth_ref": [ "r175", "r178" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of debt discount to be amortized within one year or within the normal operating cycle, if longer.", "label": "Convertible Notes, Unamortized Discount, Current" } } }, "localname": "DebtInstrumentUnamortizedDiscountCurrent", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://phbi.com/role/CondensedConsolidatedBalanceSheetsParenthetical" ], "xbrltype": "monetaryItemType" }, "us-gaap_DebtInstrumentUnamortizedDiscountNoncurrent": { "auth_ref": [ "r175", "r178" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of debt discount to be amortized after one year or the normal operating cycle, if longer.", "label": "Convertible Notes, Unamortized Discount, Noncurrent" } } }, "localname": "DebtInstrumentUnamortizedDiscountNoncurrent", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://phbi.com/role/CondensedConsolidatedBalanceSheetsParenthetical" ], "xbrltype": "monetaryItemType" }, "us-gaap_DerivativeAssetFairValueGrossLiability": { "auth_ref": [ "r27", "r30", "r164" ], "calculation": { "http://phbi.com/role/CondensedConsolidatedBalanceSheets": { "order": 5.0, "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Fair value of liability associated with financial asset or other contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset.", "label": "Derivative liabilities (Note 6)" } } }, "localname": "DerivativeAssetFairValueGrossLiability", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://phbi.com/role/CondensedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_DerivativeFairValueOfDerivativeLiability": { "auth_ref": [ "r26", "r29", "r164", "r201" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Fair value, before effects of master netting arrangements, of a financial liability or contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset. Includes liabilities elected not to be offset. Excludes liabilities not subject to a master netting arrangement.", "label": "Fair value of the derivative liability" } } }, "localname": "DerivativeFairValueOfDerivativeLiability", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://phbi.com/role/ConvertibleNotesDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Derivative Liabilities" } } }, "localname": "DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "xbrltype": "stringItemType" }, "us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock": { "auth_ref": [ "r165" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for derivative instruments and hedging activities including, but not limited to, risk management strategies, non-hedging derivative instruments, assets, liabilities, revenue and expenses, and methodologies and assumptions used in determining the amounts.", "label": "6. Derivative Liabilities" } } }, "localname": "DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://phbi.com/role/DerivativeLiabilities" ], "xbrltype": "textBlockItemType" }, "us-gaap_DerivativeLiabilitiesCurrent": { "auth_ref": [ "r28" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Fair value, after the effects of master netting arrangements, of a financial liability or contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset, expected to be settled within one year or normal operating cycle, if longer. Includes assets not subject to a master netting arrangement and not elected to be offset.", "label": "[Derivative Liability, Current]", "periodEndLabel": "Derivative Liability", "periodStartLabel": "Derivative Liability" } } }, "localname": "DerivativeLiabilitiesCurrent", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://phbi.com/role/DerivativeLiabilitiesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DerivativeLossOnDerivative": { "auth_ref": [ "r163" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of decrease in the fair value of derivatives recognized in the income statement.", "label": "Loss on change in fair value of derivative" } } }, "localname": "DerivativeLossOnDerivative", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://phbi.com/role/ConvertibleNotesDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Preferred Stock" } } }, "localname": "DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "xbrltype": "stringItemType" }, "us-gaap_DueToRelatedPartiesCurrent": { "auth_ref": [ "r15", "r65", "r182" ], "calculation": { "http://phbi.com/role/CondensedConsolidatedBalanceSheets": { "order": 8.0, "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Carrying amount as of the balance sheet date of obligations due all related parties. For classified balance sheets, represents the current portion of such liabilities (due within one year or within the normal operating cycle if longer).", "label": "Due to related parties (Note 7)", "verboseLabel": "Due to Related Parties" } } }, "localname": "DueToRelatedPartiesCurrent", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://phbi.com/role/CondensedConsolidatedBalanceSheets", "http://phbi.com/role/RelatedPartyTransactionsDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "us-gaap_EarningsPerShareAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Share Purchase Warrants (Details)" } } }, "localname": "EarningsPerShareAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "xbrltype": "stringItemType" }, "us-gaap_EarningsPerShareBasicAndDiluted": { "auth_ref": [ "r81" ], "lang": { "en-us": { "role": { "documentation": "The amount of net income or loss for the period per each share in instances when basic and diluted earnings per share are the same amount and reported as a single line item on the face of the financial statements. Basic earnings per share is the amount of net income or loss for the period per each share of common stock or unit outstanding during the reporting period. Diluted earnings per share includes the amount of net income or loss for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.", "label": "Basic and diluted loss per share attributable to Pharmagreen Biotech Inc. stockholders" } } }, "localname": "EarningsPerShareBasicAndDiluted", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://phbi.com/role/CondensedConsolidatedStatementsOfOperationsAndComprehensiveIncomeLossUnaudited" ], "xbrltype": "perShareItemType" }, "us-gaap_EffectOfExchangeRateOnCashAndCashEquivalents": { "auth_ref": [ "r167" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of increase (decrease) from the effect of exchange rate changes on cash and cash equivalent balances held in foreign currencies.", "label": "Foreign currency translation gain (loss)" } } }, "localname": "EffectOfExchangeRateOnCashAndCashEquivalents", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://phbi.com/role/CondensedConsolidatedStatementsOfOperationsAndComprehensiveIncomeLossUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations": { "auth_ref": [ "r167" ], "calculation": { "http://phbi.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited": { "order": 20.0, "parentTag": "us-gaap_CashPeriodIncreaseDecrease", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of increase (decrease) from effect of exchange rate changes on cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; held in foreign currencies; including, but not limited to, disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.", "label": "Effect of foreign exchange rate changes on cash" } } }, "localname": "EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://phbi.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_EquityAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Common Stock" } } }, "localname": "EquityAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "xbrltype": "stringItemType" }, "us-gaap_EquityComponentDomain": { "auth_ref": [ "r67", "r68", "r69", "r71", "r76", "r78", "r83", "r109", "r129", "r132", "r143", "r144", "r145", "r147", "r148", "r168", "r169", "r170", "r171", "r172", "r173", "r251", "r252", "r253" ], "lang": { "en-us": { "role": { "documentation": "Components of equity are the parts of the total Equity balance including that which is allocated to common, preferred, treasury stock, retained earnings, etc." } } }, "localname": "EquityComponentDomain", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://phbi.com/role/CondensedConsolidatedStatementsOfStockholdersDeficitUnaudited" ], "xbrltype": "domainItemType" }, "us-gaap_FinancialInstrumentAxis": { "auth_ref": [ "r106", "r107", "r110", "r111", "r112", "r113", "r114", "r115", "r116", "r117", "r118", "r188", "r189", "r190", "r191", "r192", "r193", "r194", "r195", "r196", "r197", "r198", "r199", "r200", "r202", "r203", "r204", "r205", "r206", "r207", "r208", "r209", "r210", "r211", "r212", "r213", "r214", "r215", "r216", "r217", "r218" ], "lang": { "en-us": { "role": { "documentation": "Information by type of financial instrument.", "label": "Financial Instrument Axis" } } }, "localname": "FinancialInstrumentAxis", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://phbi.com/role/DerivativeLiabilitiesDetails1" ], "xbrltype": "stringItemType" }, "us-gaap_GainLossOnDispositionOfIntangibleAssets": { "auth_ref": [ "r57" ], "calculation": { "http://phbi.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited": { "order": 9.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of gain (loss) on sale or disposal of intangible assets.", "label": "Loss on change in fair value of derivative liabilities" } } }, "localname": "GainLossOnDispositionOfIntangibleAssets", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://phbi.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_GainLossOnSaleOfDebtInvestments": { "auth_ref": [ "r57" ], "calculation": { "http://phbi.com/role/CondensedConsolidatedStatementsOfOperationsAndComprehensiveIncomeLossUnaudited": { "order": 9.0, "parentTag": "us-gaap_NonoperatingIncomeExpense", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The difference between the carrying value and the sale price of debt securities, not separately or otherwise categorized as trading, available-for-sale, or held-to-maturity. This element refers to the gain (loss) included in earnings and not to the cash proceeds of the sale.", "label": "Gain (loss) on settlement on convertible notes (Note 5)" } } }, "localname": "GainLossOnSaleOfDebtInvestments", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://phbi.com/role/CondensedConsolidatedStatementsOfOperationsAndComprehensiveIncomeLossUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_GainLossOnSaleOfDerivatives": { "auth_ref": [ "r57", "r238" ], "calculation": { "http://phbi.com/role/CondensedConsolidatedStatementsOfOperationsAndComprehensiveIncomeLossUnaudited": { "order": 10.0, "parentTag": "us-gaap_NonoperatingIncomeExpense", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The difference between the book value and the sale price of options, swaps, futures, forward contracts, and other derivative instruments. This element refers to the gain (loss) included in earnings.", "label": "Gain (loss) on change in fair value of derivative liabilities (Note 6)" } } }, "localname": "GainLossOnSaleOfDerivatives", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://phbi.com/role/CondensedConsolidatedStatementsOfOperationsAndComprehensiveIncomeLossUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_GeneralAndAdministrativeExpense": { "auth_ref": [ "r43" ], "calculation": { "http://phbi.com/role/CondensedConsolidatedStatementsOfOperationsAndComprehensiveIncomeLossUnaudited": { "order": 4.0, "parentTag": "us-gaap_OperatingExpenses", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line.", "label": "General and administrative" } } }, "localname": "GeneralAndAdministrativeExpense", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://phbi.com/role/CondensedConsolidatedStatementsOfOperationsAndComprehensiveIncomeLossUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest": { "auth_ref": [ "r64", "r70", "r94", "r95", "r98", "r99", "r101", "r108", "r151", "r166" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount after tax of income (loss) from continuing operations including portion attributable to the noncontrolling interest.", "label": "[Income (Loss) from Continuing Operations, Net of Tax, Including Portion Attributable to Noncontrolling Interest]", "verboseLabel": "Net loss" } } }, "localname": "IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://phbi.com/role/NatureOfBusinessAndContinuanceOfOperationsDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncomeStatementAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Condensed Consolidated Statements of Operations and Comprehensive Income (Loss) (Unaudited)" } } }, "localname": "IncomeStatementAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "xbrltype": "stringItemType" }, "us-gaap_IncomeTaxesPaidNet": { "auth_ref": [ "r59" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The amount of cash paid during the current period to foreign, federal, state, and local authorities as taxes on income, net of any cash received during the current period as refunds for the overpayment of taxes.", "label": "Income taxes paid" } } }, "localname": "IncomeTaxesPaidNet", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://phbi.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInAccountsAndOtherReceivables": { "auth_ref": [ "r56" ], "calculation": { "http://phbi.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited": { "order": 5.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The increase (decrease) during the reporting period in the amount due from customers for the credit sale of goods and services; includes accounts receivable and other types of receivables.", "label": "[Increase (Decrease) in Accounts and Other Receivables]", "verboseLabel": "Amounts receivable" } } }, "localname": "IncreaseDecreaseInAccountsAndOtherReceivables", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://phbi.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities": { "auth_ref": [ "r56" ], "calculation": { "http://phbi.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited": { "order": 3.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The increase (decrease) during the reporting period in the amounts payable to vendors for goods and services received and the amount of obligations and expenses incurred but not paid.", "label": "Accounts payable and accrued liabilities" } } }, "localname": "IncreaseDecreaseInAccountsPayableAndAccruedLiabilities", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://phbi.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInDueToRelatedParties": { "auth_ref": [ "r56" ], "calculation": { "http://phbi.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited": { "order": 2.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The increase (decrease) during the reporting period in the aggregate amount of obligations to be paid to the following types of related parties: a parent company and its subsidiaries; subsidiaries of a common parent; an entity and trust for the benefit of employees, such as pension and profit-sharing trusts that are managed by or under the trusteeship of the entities' management; an entity and its principal owners, management, or member of their immediate families; affiliates; or other parties with the ability to exert significant influence.", "label": "Due to related parties" } } }, "localname": "IncreaseDecreaseInDueToRelatedParties", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://phbi.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInOperatingCapitalAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Changes in operating assets and liabilities:" } } }, "localname": "IncreaseDecreaseInOperatingCapitalAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://phbi.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited" ], "xbrltype": "stringItemType" }, "us-gaap_IncreaseDecreaseInPrepaidExpense": { "auth_ref": [ "r56" ], "calculation": { "http://phbi.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited": { "order": 4.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The increase (decrease) during the reporting period in the amount of outstanding money paid in advance for goods or services that bring economic benefits for future periods.", "label": "[Increase (Decrease) in Prepaid Expense]", "verboseLabel": "Prepaid expenses and deposits" } } }, "localname": "IncreaseDecreaseInPrepaidExpense", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://phbi.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_InterestAndDividendsPayableCurrent": { "auth_ref": [ "r20" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Sum of the carrying values as of the balance sheet date of (a) interest payable on all forms of debt, including trade payables, that has been incurred, and (b) dividends declared but unpaid on equity securities issued by the entity and outstanding (also includes dividends collected on behalf of another owner of securities that are being held by the entity). Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).", "label": "Accured Interest Payable" } } }, "localname": "InterestAndDividendsPayableCurrent", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://phbi.com/role/NoteAndLoanPayableDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "us-gaap_InterestExpense": { "auth_ref": [ "r39", "r93", "r174", "r177", "r239" ], "calculation": { "http://phbi.com/role/CondensedConsolidatedStatementsOfOperationsAndComprehensiveIncomeLossUnaudited": { "order": 8.0, "parentTag": "us-gaap_NonoperatingIncomeExpense", "weight": -1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of the cost of borrowed funds accounted for as interest expense.", "label": "[Interest Expense]", "negatedLabel": "Interest and finance costs (Note 5)" } } }, "localname": "InterestExpense", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://phbi.com/role/CondensedConsolidatedStatementsOfOperationsAndComprehensiveIncomeLossUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_InterestPaidNet": { "auth_ref": [ "r52", "r54", "r59" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of cash paid for interest, excluding capitalized interest, classified as operating activity. Includes, but is not limited to, payment to settle zero-coupon bond for accreted interest of debt discount and debt instrument with insignificant coupon interest rate in relation to effective interest rate of borrowing attributable to accreted interest of debt discount.", "label": "Interest paid" } } }, "localname": "InterestPaidNet", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://phbi.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_InterestPayableCurrent": { "auth_ref": [ "r2", "r3", "r20" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Carrying value as of the balance sheet date of [accrued] interest payable on all forms of debt, including trade payables, that has been incurred and is unpaid. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).", "label": "Accrued interest payable" } } }, "localname": "InterestPayableCurrent", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://phbi.com/role/AccountsPayableAndAccruedLiabilitiesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Convertible Notes" } } }, "localname": "InvestmentsDebtAndEquitySecuritiesAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "xbrltype": "stringItemType" }, "us-gaap_LegalFees": { "auth_ref": [ "r42" ], "calculation": { "http://phbi.com/role/CondensedConsolidatedStatementsOfOperationsAndComprehensiveIncomeLossUnaudited": { "order": 5.0, "parentTag": "us-gaap_OperatingExpenses", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The amount of expense provided in the period for legal costs incurred on or before the balance sheet date pertaining to resolved, pending or threatened litigation, including arbitration and mediation proceedings.", "label": "Consulting fees (Note 7)" } } }, "localname": "LegalFees", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://phbi.com/role/CondensedConsolidatedStatementsOfOperationsAndComprehensiveIncomeLossUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_Liabilities": { "auth_ref": [ "r19", "r64", "r97", "r108", "r154", "r158", "r159", "r166" ], "calculation": { "http://phbi.com/role/CondensedConsolidatedBalanceSheets": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Sum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future.", "label": "[Liabilities]", "totalLabel": "Total liabilities" } } }, "localname": "Liabilities", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://phbi.com/role/CondensedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_LiabilitiesAndStockholdersEquity": { "auth_ref": [ "r13", "r64", "r108", "r166", "r236", "r248" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.", "label": "Total liabilities and stockholders' deficit" } } }, "localname": "LiabilitiesAndStockholdersEquity", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://phbi.com/role/CondensedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_LiabilitiesAndStockholdersEquityAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Liabilities and Stockholders' Deficit" } } }, "localname": "LiabilitiesAndStockholdersEquityAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://phbi.com/role/CondensedConsolidatedBalanceSheets" ], "xbrltype": "stringItemType" }, "us-gaap_LiabilitiesCurrent": { "auth_ref": [ "r21", "r64", "r108", "r154", "r158", "r159", "r166" ], "calculation": { "http://phbi.com/role/CondensedConsolidatedBalanceSheets": { "order": 13.0, "parentTag": "us-gaap_Liabilities", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.", "label": "[Liabilities, Current]", "totalLabel": "Total current liabilities" } } }, "localname": "LiabilitiesCurrent", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://phbi.com/role/CondensedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_LiabilitiesCurrentAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Current liabilities" } } }, "localname": "LiabilitiesCurrentAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://phbi.com/role/CondensedConsolidatedBalanceSheets" ], "xbrltype": "stringItemType" }, "us-gaap_LineOfCreditFacilityAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Share Purchase Warrants" } } }, "localname": "LineOfCreditFacilityAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "xbrltype": "stringItemType" }, "us-gaap_LoansPayableCurrent": { "auth_ref": [ "r20" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Carrying value as of the balance sheet date of portion of long-term loans payable due within one year or the operating cycle if longer.", "label": "Loans payable" } } }, "localname": "LoansPayableCurrent", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://phbi.com/role/NoteAndLoanPayableDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "us-gaap_LongtermDebtTypeAxis": { "auth_ref": [ "r22" ], "lang": { "en-us": { "role": { "documentation": "Information by type of long-term debt.", "label": "Longterm Debt Type Axis" } } }, "localname": "LongtermDebtTypeAxis", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://phbi.com/role/ConvertibleNotesDetailsNarrative" ], "xbrltype": "stringItemType" }, "us-gaap_LongtermDebtTypeDomain": { "auth_ref": [ "r22", "r126" ], "lang": { "en-us": { "role": { "documentation": "Type of long-term debt arrangement, such as notes, line of credit, commercial paper, asset-based financing, project financing, letter of credit financing. These are debt arrangements that originally required repayment more than twelve months after issuance or greater than the normal operating cycle of the company, if longer." } } }, "localname": "LongtermDebtTypeDomain", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://phbi.com/role/ConvertibleNotesDetailsNarrative" ], "xbrltype": "domainItemType" }, "us-gaap_MinorityInterest": { "auth_ref": [ "r25", "r64", "r108", "r166", "r235", "r247" ], "calculation": { "http://phbi.com/role/CondensedConsolidatedBalanceSheets": { "order": 19.0, "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which is directly or indirectly attributable to that ownership interest in subsidiary equity which is not attributable to the parent (that is, noncontrolling interest, previously referred to as minority interest).", "label": "Non-controlling interest" } } }, "localname": "MinorityInterest", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://phbi.com/role/CondensedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_NatureOfOperations": { "auth_ref": [ "r84", "r92" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for the nature of an entity's business, major products or services, principal markets including location, and the relative importance of its operations in each business and the basis for the determination, including but not limited to, assets, revenues, or earnings. For an entity that has not commenced principal operations, disclosures about the risks and uncertainties related to the activities in which the entity is currently engaged and an understanding of what those activities are being directed toward.", "label": "1. Nature of Business and Continuance of Operations" } } }, "localname": "NatureOfOperations", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://phbi.com/role/NatureOfBusinessAndContinuanceOfOperations" ], "xbrltype": "textBlockItemType" }, "us-gaap_NetCashProvidedByUsedInFinancingActivities": { "auth_ref": [ "r53" ], "calculation": { "http://phbi.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited": { "order": 21.0, "parentTag": "us-gaap_CashPeriodIncreaseDecrease", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.", "label": "[Net Cash Provided by (Used in) Financing Activities]", "totalLabel": "Net cash provided by financing activities" } } }, "localname": "NetCashProvidedByUsedInFinancingActivities", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://phbi.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "FINANCING ACTIVITIES" } } }, "localname": "NetCashProvidedByUsedInFinancingActivitiesAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://phbi.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited" ], "xbrltype": "stringItemType" }, "us-gaap_NetCashProvidedByUsedInOperatingActivities": { "auth_ref": [ "r53", "r55", "r58" ], "calculation": { "http://phbi.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited": { "order": 22.0, "parentTag": "us-gaap_CashPeriodIncreaseDecrease", "weight": 1.0 } }, "lang": { "en-us": { "role": { "documentation": "Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.", "label": "[Net Cash Provided by (Used in) Operating Activities]", "negatedLabel": "Net cash used in operating activities", "totalLabel": "Net cash used in operating activities" } } }, "localname": "NetCashProvidedByUsedInOperatingActivities", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://phbi.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited", "http://phbi.com/role/NatureOfBusinessAndContinuanceOfOperationsDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "OPERATING ACTIVITIES" } } }, "localname": "NetCashProvidedByUsedInOperatingActivitiesAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://phbi.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited" ], "xbrltype": "stringItemType" }, "us-gaap_NetIncomeLoss": { "auth_ref": [ "r0", "r37", "r38", "r40", "r58", "r64", "r70", "r72", "r73", "r74", "r75", "r77", "r78", "r80", "r94", "r95", "r98", "r99", "r101", "r108", "r166", "r237", "r249" ], "calculation": { "http://phbi.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited": { "order": 12.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 }, "http://phbi.com/role/CondensedConsolidatedStatementsOfOperationsAndComprehensiveIncomeLossUnaudited": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.", "label": "[Net Income (Loss) Attributable to Parent]", "terseLabel": "Net loss", "totalLabel": "Net loss", "verboseLabel": "Net loss for the period" } } }, "localname": "NetIncomeLoss", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://phbi.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited", "http://phbi.com/role/CondensedConsolidatedStatementsOfOperationsAndComprehensiveIncomeLossUnaudited", "http://phbi.com/role/CondensedConsolidatedStatementsOfStockholdersDeficitUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_NetIncomeLossAttributableToNoncontrollingInterest": { "auth_ref": [ "r37", "r38", "r77", "r78", "r155", "r161" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of Net Income (Loss) attributable to noncontrolling interest.", "label": "Less: net loss attributable to non-controlling interest" } } }, "localname": "NetIncomeLossAttributableToNoncontrollingInterest", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://phbi.com/role/CondensedConsolidatedStatementsOfOperationsAndComprehensiveIncomeLossUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_NetIncomeLossAttributableToParentDiluted": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The portion of profit or loss for the period, net of income taxes, which is attributable to the parent, and includes adjustments resulting from the assumption that dilutive convertible securities were converted, options or warrants were exercised, or that other shares were issued upon the satisfaction of certain conditions.", "label": "Net loss attributable to Pharmagreen Biotech Inc." } } }, "localname": "NetIncomeLossAttributableToParentDiluted", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://phbi.com/role/CondensedConsolidatedStatementsOfOperationsAndComprehensiveIncomeLossUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact.", "label": "Recently Adopted Accounting Pronouncements" } } }, "localname": "NewAccountingPronouncementsPolicyPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://phbi.com/role/SummaryOfSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_NoncontrollingInterestMember": { "auth_ref": [ "r67", "r68", "r69", "r132", "r149" ], "lang": { "en-us": { "role": { "documentation": "This element represents that portion of equity (net assets) in a subsidiary not attributable, directly or indirectly, to the parent. A noncontrolling interest is sometimes called a minority interest.", "label": "Noncontrolling Interest" } } }, "localname": "NoncontrollingInterestMember", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://phbi.com/role/CondensedConsolidatedStatementsOfStockholdersDeficitUnaudited" ], "xbrltype": "domainItemType" }, "us-gaap_NonoperatingIncomeExpense": { "auth_ref": [ "r44" ], "calculation": { "http://phbi.com/role/CondensedConsolidatedStatementsOfOperationsAndComprehensiveIncomeLossUnaudited": { "order": 12.0, "parentTag": "us-gaap_NetIncomeLoss", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The aggregate amount of income or expense from ancillary business-related activities (that is to say, excluding major activities considered part of the normal operations of the business).", "label": "[Nonoperating Income (Expense)]", "totalLabel": "Total other income (expense)" } } }, "localname": "NonoperatingIncomeExpense", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://phbi.com/role/CondensedConsolidatedStatementsOfOperationsAndComprehensiveIncomeLossUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_NotesIssued1": { "auth_ref": [ "r60", "r61", "r62" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The fair value of notes issued in noncash investing and financing activities.", "label": "Common shares issued for settlement of convertible notes" } } }, "localname": "NotesIssued1", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://phbi.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_NotesPayableCurrent": { "auth_ref": [ "r18" ], "calculation": { "http://phbi.com/role/CondensedConsolidatedBalanceSheets": { "order": 7.0, "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Sum of the carrying values as of the balance sheet date of the portions of long-term notes payable due within one year or the operating cycle if longer.", "label": "Note payable (Note 4)" } } }, "localname": "NotesPayableCurrent", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://phbi.com/role/CondensedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingExpenses": { "auth_ref": [], "calculation": { "http://phbi.com/role/CondensedConsolidatedStatementsOfOperationsAndComprehensiveIncomeLossUnaudited": { "order": 13.0, "parentTag": "us-gaap_NetIncomeLoss", "weight": -1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Generally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Includes selling, general and administrative expense.", "label": "[Operating Expenses]", "totalLabel": "Total expenses" } } }, "localname": "OperatingExpenses", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://phbi.com/role/CondensedConsolidatedStatementsOfOperationsAndComprehensiveIncomeLossUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingExpensesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Expenses" } } }, "localname": "OperatingExpensesAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://phbi.com/role/CondensedConsolidatedStatementsOfOperationsAndComprehensiveIncomeLossUnaudited" ], "xbrltype": "stringItemType" }, "us-gaap_OperatingIncomeLoss": { "auth_ref": [ "r94", "r95", "r98", "r99", "r101" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The net result for the period of deducting operating expenses from operating revenues.", "label": "Net loss before other income (expense)" } } }, "localname": "OperatingIncomeLoss", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://phbi.com/role/CondensedConsolidatedStatementsOfOperationsAndComprehensiveIncomeLossUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Nature of Business and Continuance of Operations" } } }, "localname": "OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "xbrltype": "stringItemType" }, "us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock": { "auth_ref": [ "r1", "r66", "r92", "r162" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for the organization, consolidation and basis of presentation of financial statements disclosure, and significant accounting policies of the reporting entity. May be provided in more than one note to the financial statements, as long as users are provided with an understanding of (1) the significant judgments and assumptions made by an enterprise in determining whether it must consolidate a VIE and/or disclose information about its involvement with a VIE, (2) the nature of restrictions on a consolidated VIE's assets reported by an enterprise in its statement of financial position, including the carrying amounts of such assets, (3) the nature of, and changes in, the risks associated with an enterprise's involvement with the VIE, and (4) how an enterprise's involvement with the VIE affects the enterprise's financial position, financial performance, and cash flows. Describes procedure if disclosures are provided in more than one note to the financial statements.", "label": "Basis of Presentation" } } }, "localname": "OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://phbi.com/role/SummaryOfSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax": { "auth_ref": [ "r31" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount after tax and reclassification adjustments of gain (loss) on foreign currency translation adjustments, foreign currency transactions designated and effective as economic hedges of a net investment in a foreign entity and intra-entity foreign currency transactions that are of a long-term-investment nature.", "label": "Foreign currency translation loss" } } }, "localname": "OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://phbi.com/role/CondensedConsolidatedStatementsOfStockholdersDeficitUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherComprehensiveIncomeLossTaxPortionAttributableToNoncontrollingInterest": { "auth_ref": [ "r151", "r152", "r156" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of tax expense (benefit) allocated to other comprehensive income (loss) attributable to noncontrolling interest.", "label": "Comprehensive loss attributable to Pharmagreen Biotech Inc." } } }, "localname": "OtherComprehensiveIncomeLossTaxPortionAttributableToNoncontrollingInterest", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://phbi.com/role/CondensedConsolidatedStatementsOfOperationsAndComprehensiveIncomeLossUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherIncomeAndExpensesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Other income (expense)" } } }, "localname": "OtherIncomeAndExpensesAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://phbi.com/role/CondensedConsolidatedStatementsOfOperationsAndComprehensiveIncomeLossUnaudited" ], "xbrltype": "stringItemType" }, "us-gaap_OtherLoansPayableCurrent": { "auth_ref": [ "r20" ], "calculation": { "http://phbi.com/role/CondensedConsolidatedBalanceSheets": { "order": 12.0, "parentTag": "us-gaap_Liabilities", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of long-term loans classified as other, payable within one year or the operating cycle, if longer.", "label": "Loan payable (Note 4)" } } }, "localname": "OtherLoansPayableCurrent", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://phbi.com/role/CondensedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherNonoperatingIncomeExpense": { "auth_ref": [ "r46" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of income (expense) related to nonoperating activities, classified as other.", "label": "Original issuance discount on notes" } } }, "localname": "OtherNonoperatingIncomeExpense", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://phbi.com/role/ConvertibleNotesDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "us-gaap_PayablesAndAccrualsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Accounts Payable and Accrued Liabilities" } } }, "localname": "PayablesAndAccrualsAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "xbrltype": "stringItemType" }, "us-gaap_PaymentOfFinancingAndStockIssuanceCosts": { "auth_ref": [ "r51" ], "calculation": { "http://phbi.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited": { "order": 19.0, "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The total of the cash outflow during the period which has been paid to third parties in connection with debt origination, which will be amortized over the remaining maturity period of the associated long-term debt and the cost incurred directly for the issuance of equity securities.", "label": "[Payment of Financing and Stock Issuance Costs]", "negatedLabel": "Financing costs" } } }, "localname": "PaymentOfFinancingAndStockIssuanceCosts", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://phbi.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_PaymentsOfFinancingCosts": { "auth_ref": [ "r51" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The cash outflow for loan and debt issuance costs.", "label": "Financing cost of convertible note" } } }, "localname": "PaymentsOfFinancingCosts", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://phbi.com/role/ConvertibleNotesDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "us-gaap_PlanNameAxis": { "auth_ref": [ "r139", "r142" ], "lang": { "en-us": { "role": { "documentation": "Information by plan name for share-based payment arrangement.", "label": "Plan Name [Axis]" } } }, "localname": "PlanNameAxis", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://phbi.com/role/CommitmentsDetailsNarrative", "http://phbi.com/role/ConvertibleNotesDetailsNarrative" ], "xbrltype": "stringItemType" }, "us-gaap_PlanNameDomain": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Plan name for share-based payment arrangement." } } }, "localname": "PlanNameDomain", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://phbi.com/role/CommitmentsDetailsNarrative", "http://phbi.com/role/ConvertibleNotesDetailsNarrative" ], "xbrltype": "domainItemType" }, "us-gaap_PreferredStockMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Preferred shares may provide a preferential dividend to the dividend on common stock and may take precedence over common stock in the event of a liquidation. Preferred shares typically represent an ownership interest in the company.", "label": "Preferred Stock [Member]", "verboseLabel": "Preferred Stock" } } }, "localname": "PreferredStockMember", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://phbi.com/role/CondensedConsolidatedStatementsOfStockholdersDeficitUnaudited" ], "xbrltype": "domainItemType" }, "us-gaap_PreferredStockParOrStatedValuePerShare": { "auth_ref": [ "r6" ], "lang": { "en-us": { "role": { "documentation": "Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer.", "label": "Preferred Stock, Par Value", "verboseLabel": "Preferred stock par value" } } }, "localname": "PreferredStockParOrStatedValuePerShare", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://phbi.com/role/CondensedConsolidatedBalanceSheetsParenthetical", "http://phbi.com/role/PreferredStockDetailsNarrative" ], "xbrltype": "perShareItemType" }, "us-gaap_PreferredStockSharesAuthorized": { "auth_ref": [ "r6" ], "lang": { "en-us": { "role": { "documentation": "The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws.", "label": "Preferred Stock, Shared Authorized", "verboseLabel": "Preferred stock authorized" } } }, "localname": "PreferredStockSharesAuthorized", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://phbi.com/role/CondensedConsolidatedBalanceSheetsParenthetical", "http://phbi.com/role/PreferredStockDetailsNarrative" ], "xbrltype": "sharesItemType" }, "us-gaap_PreferredStockSharesIssued": { "auth_ref": [ "r6" ], "lang": { "en-us": { "role": { "documentation": "Total number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) issued to shareholders (includes related preferred shares that were issued, repurchased, and remain in the treasury). May be all or portion of the number of preferred shares authorized. Excludes preferred shares that are classified as debt.", "label": "Preferred Stock, Shares Issued" } } }, "localname": "PreferredStockSharesIssued", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://phbi.com/role/CondensedConsolidatedBalanceSheetsParenthetical" ], "xbrltype": "sharesItemType" }, "us-gaap_PreferredStockSharesOutstanding": { "auth_ref": [ "r6" ], "lang": { "en-us": { "role": { "documentation": "Aggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased.", "label": "Preferred Stock, Shares Outstanding" } } }, "localname": "PreferredStockSharesOutstanding", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://phbi.com/role/CondensedConsolidatedBalanceSheetsParenthetical" ], "xbrltype": "sharesItemType" }, "us-gaap_PreferredStockTextBlock": { "auth_ref": [ "r134" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for terms, amounts, nature of changes, rights and privileges, dividends, and other matters related to preferred stock.", "label": "9. Preferred Stock" } } }, "localname": "PreferredStockTextBlock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://phbi.com/role/PreferredStock" ], "xbrltype": "textBlockItemType" }, "us-gaap_PreferredStockValue": { "auth_ref": [ "r6" ], "calculation": { "http://phbi.com/role/CondensedConsolidatedBalanceSheets": { "order": 18.0, "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Aggregate par or stated value of issued nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable preferred shares, par value and other disclosure concepts are in another section within stockholders' equity.", "label": "Preferred stock Authorized: 1,000,000 shares, $0.001 par value; 10,000 and nil shares issued and outstanding, respectively" } } }, "localname": "PreferredStockValue", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://phbi.com/role/CondensedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_PrepaidExpenseAndOtherAssets": { "auth_ref": [], "calculation": { "http://phbi.com/role/CondensedConsolidatedBalanceSheets": { "order": 2.0, "parentTag": "us-gaap_Assets", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets.", "label": "Prepaid expenses and deposits" } } }, "localname": "PrepaidExpenseAndOtherAssets", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://phbi.com/role/CondensedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_PrivatePlacementMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "A private placement is a direct offering of securities to a limited number of sophisticated investors such as insurance companies, pension funds, mezzanine funds, stock funds and trusts.", "label": "Private Placement [Member]" } } }, "localname": "PrivatePlacementMember", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://phbi.com/role/CommonStockDetailsNarrative" ], "xbrltype": "domainItemType" }, "us-gaap_ProceedsFromIssuanceOfCommonStock": { "auth_ref": [ "r48" ], "calculation": { "http://phbi.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited": { "order": 17.0, "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The cash inflow from the additional capital contribution to the entity.", "label": "Proceeds from units issued and issuable for cash", "verboseLabel": "Proceeds from issuance of common stock" } } }, "localname": "ProceedsFromIssuanceOfCommonStock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://phbi.com/role/CommonStockDetailsNarrative", "http://phbi.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_ProceedsFromIssuanceOfConvertiblePreferredStock": { "auth_ref": [ "r48" ], "calculation": { "http://phbi.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited": { "order": 18.0, "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The cash inflow from issuance of preferred stocks identified as being convertible into another form of financial instrument, typically the entity's common stock.", "label": "Proceeds from issuance of convertible notes" } } }, "localname": "ProceedsFromIssuanceOfConvertiblePreferredStock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://phbi.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_ProceedsFromIssuanceOfDebt": { "auth_ref": [ "r49" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The cash inflow during the period from additional borrowings in aggregate debt. Includes proceeds from short-term and long-term debt.", "label": "Proceeds from convertible debt" } } }, "localname": "ProceedsFromIssuanceOfDebt", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://phbi.com/role/ConvertibleNotesDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "us-gaap_ProceedsFromIssuanceOfPreferredStockAndPreferenceStock": { "auth_ref": [ "r48" ], "calculation": { "http://phbi.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited": { "order": 16.0, "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Proceeds from issuance of capital stock which provides for a specific dividend that is paid to the shareholders before any dividends to common stockholders and which takes precedence over common stockholders in the event of liquidation.", "label": "Proceeds from issuance of preferred shares" } } }, "localname": "ProceedsFromIssuanceOfPreferredStockAndPreferenceStock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://phbi.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_ProceedsFromLoanOriginations1": { "auth_ref": [ "r47" ], "calculation": { "http://phbi.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited": { "order": 13.0, "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Cash inflow associated with loan origination (the process when securing a mortgage for a piece of real property) or lease origination.", "label": "Proceeds from loans payable", "verboseLabel": "Proceeds from loan" } } }, "localname": "ProceedsFromLoanOriginations1", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://phbi.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited", "http://phbi.com/role/NoteAndLoanPayableDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "us-gaap_ProceedsFromRelatedPartyDebt": { "auth_ref": [ "r49" ], "calculation": { "http://phbi.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited": { "order": 14.0, "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The cash inflow from a long-term borrowing made from related parties where one party can exercise control or significant influence over another party; including affiliates, owners or officers and their immediate families, pension trusts, and so forth. Alternate caption: Proceeds from Advances from Affiliates.", "label": "Proceeds from related party loans" } } }, "localname": "ProceedsFromRelatedPartyDebt", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://phbi.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_ProfessionalFees": { "auth_ref": [ "r260", "r261" ], "calculation": { "http://phbi.com/role/CondensedConsolidatedStatementsOfOperationsAndComprehensiveIncomeLossUnaudited": { "order": 3.0, "parentTag": "us-gaap_OperatingExpenses", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "A fee charged for services from professionals such as doctors, lawyers and accountants. The term is often expanded to include other professions, for example, pharmacists charging to maintain a medicinal profile of a client or customer.", "label": "Professional fees" } } }, "localname": "ProfessionalFees", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://phbi.com/role/CondensedConsolidatedStatementsOfOperationsAndComprehensiveIncomeLossUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_RelatedPartyDomain": { "auth_ref": [ "r137", "r181", "r182" ], "lang": { "en-us": { "role": { "documentation": "Related parties include affiliates; other entities for which investments are accounted for by the equity method by the entity; trusts for benefit of employees; and principal owners, management, and members of immediate families. It also may include other parties with which the entity may control or can significantly influence the management or operating policies of the other to an extent that one of the transacting parties might be prevented from fully pursuing its own separate interests." } } }, "localname": "RelatedPartyDomain", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://phbi.com/role/CommitmentsDetailsNarrative", "http://phbi.com/role/PreferredStockDetailsNarrative", "http://phbi.com/role/RelatedPartyTransactionsDetailsNarrative" ], "xbrltype": "domainItemType" }, "us-gaap_RelatedPartyTransactionAxis": { "auth_ref": [ "r137", "r181", "r182", "r183" ], "lang": { "en-us": { "role": { "documentation": "Information by type of related party transaction.", "label": "Related Party Transaction [Axis]" } } }, "localname": "RelatedPartyTransactionAxis", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://phbi.com/role/ConvertibleNotesDetailsNarrative" ], "xbrltype": "stringItemType" }, "us-gaap_RelatedPartyTransactionDomain": { "auth_ref": [ "r137" ], "lang": { "en-us": { "role": { "documentation": "Transaction between related party." } } }, "localname": "RelatedPartyTransactionDomain", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://phbi.com/role/ConvertibleNotesDetailsNarrative" ], "xbrltype": "domainItemType" }, "us-gaap_RelatedPartyTransactionDueFromToRelatedParty": { "auth_ref": [ "r65", "r182" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Receivables to be collected from (obligations owed to) related parties, net as of the balance sheet date where one party can exercise control or significant influence over another party; including affiliates, owners or officers and their immediate families, pension trusts, and so forth.", "label": "Amount Owed to Related Party" } } }, "localname": "RelatedPartyTransactionDueFromToRelatedParty", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://phbi.com/role/ConvertibleNotesDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "us-gaap_RelatedPartyTransactionsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Related Party Transactions" } } }, "localname": "RelatedPartyTransactionsAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "xbrltype": "stringItemType" }, "us-gaap_RelatedPartyTransactionsByRelatedPartyAxis": { "auth_ref": [ "r137", "r181", "r183", "r220", "r221", "r222", "r223", "r224", "r225", "r226", "r227", "r228", "r229", "r230", "r231" ], "lang": { "en-us": { "role": { "documentation": "Information by type of related party. Related parties include, but not limited to, affiliates; other entities for which investments are accounted for by the equity method by the entity; trusts for benefit of employees; and principal owners, management, and members of immediate families. It also may include other parties with which the entity may control or can significantly influence the management or operating policies of the other to an extent that one of the transacting parties might be prevented from fully pursuing its own separate interests.", "label": "Related Party Transactions By Related Party Axis" } } }, "localname": "RelatedPartyTransactionsByRelatedPartyAxis", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://phbi.com/role/CommitmentsDetailsNarrative", "http://phbi.com/role/PreferredStockDetailsNarrative", "http://phbi.com/role/RelatedPartyTransactionsDetailsNarrative" ], "xbrltype": "stringItemType" }, "us-gaap_RelatedPartyTransactionsDisclosureTextBlock": { "auth_ref": [ "r179", "r180", "r182", "r184", "r185" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for related party transactions. Examples of related party transactions include transactions between (a) a parent company and its subsidiary; (b) subsidiaries of a common parent; (c) and entity and its principal owners; and (d) affiliates.", "label": "7. Related Party Transactions" } } }, "localname": "RelatedPartyTransactionsDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://phbi.com/role/RelatedPartyTransactions" ], "xbrltype": "textBlockItemType" }, "us-gaap_RepaymentsOfDebt": { "auth_ref": [ "r50" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The cash outflow during the period from the repayment of aggregate short-term and long-term debt. Excludes payment of capital lease obligations.", "label": "Monthly payment of convertible debt" } } }, "localname": "RepaymentsOfDebt", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://phbi.com/role/ConvertibleNotesDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "us-gaap_RetainedEarningsAccumulatedDeficit": { "auth_ref": [ "r9", "r132", "r146", "r246", "r254", "r256" ], "calculation": { "http://phbi.com/role/CondensedConsolidatedBalanceSheets": { "order": 20.0, "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The cumulative amount of the reporting entity's undistributed earnings or deficit.", "label": "Deficit", "negatedLabel": "Accumulated Deficit" } } }, "localname": "RetainedEarningsAccumulatedDeficit", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://phbi.com/role/CondensedConsolidatedBalanceSheets", "http://phbi.com/role/NatureOfBusinessAndContinuanceOfOperationsDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "us-gaap_RetainedEarningsMember": { "auth_ref": [ "r67", "r68", "r69", "r71", "r76", "r78", "r109", "r143", "r144", "r145", "r147", "r148", "r251", "r253" ], "lang": { "en-us": { "role": { "documentation": "The cumulative amount of the reporting entity's undistributed earnings or deficit.", "label": "Retained Earnings (Accumulated Deficit)" } } }, "localname": "RetainedEarningsMember", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://phbi.com/role/CondensedConsolidatedStatementsOfStockholdersDeficitUnaudited" ], "xbrltype": "domainItemType" }, "us-gaap_SalariesAndWages": { "auth_ref": [ "r41" ], "calculation": { "http://phbi.com/role/CondensedConsolidatedStatementsOfOperationsAndComprehensiveIncomeLossUnaudited": { "order": 2.0, "parentTag": "us-gaap_OperatingExpenses", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of expense for salary and wage arising from service rendered by nonofficer employee. Excludes allocated cost, labor-related nonsalary expense, and direct and overhead labor cost included in cost of good and service sold.", "label": "Salaries and wages" } } }, "localname": "SalariesAndWages", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://phbi.com/role/CondensedConsolidatedStatementsOfOperationsAndComprehensiveIncomeLossUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_SaleOfStockNameOfTransactionDomain": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Sale of the entity's stock, including, but not limited to, initial public offering (IPO) and private placement." } } }, "localname": "SaleOfStockNameOfTransactionDomain", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://phbi.com/role/CommonStockDetailsNarrative" ], "xbrltype": "domainItemType" }, "us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of the (a) carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business (accounts payable); (b) other payables; and (c) accrued liabilities. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer). An alternative caption includes accrued expenses.", "label": "Schedule of Accounts Payable and Accrued Liabilities" } } }, "localname": "ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://phbi.com/role/AccountsPayableAndAccruedLiabilitiesTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfDerivativeLiabilitiesAtFairValueTableTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of derivative liabilities at fair value.", "label": "Schedule of Derivative Liability" } } }, "localname": "ScheduleOfDerivativeLiabilitiesAtFairValueTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://phbi.com/role/DerivativeLiabilitiesTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfProductWarrantyLiabilityTableTextBlock": { "auth_ref": [ "r125" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of the changes in the guarantor's aggregate product warranty liability, including the beginning balance of the aggregate product warranty liability, the aggregate reductions in that liability for payments made (in cash or in kind) under the warranty, the aggregate changes in the liability for accruals related to product warranties issued during the reporting period, the aggregate changes in the liability for accruals related to preexisting warranties (including adjustments related to changes in estimates), and the ending balance of the aggregate product warranty liability.", "label": "Schedule of Share Purchase Warrants" } } }, "localname": "ScheduleOfProductWarrantyLiabilityTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://phbi.com/role/SharePurchaseWarrantsTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock": { "auth_ref": [ "r133", "r138" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of warrants or rights issued. Warrants and rights outstanding are derivative securities that give the holder the right to purchase securities (usually equity) from the issuer at a specific price within a certain time frame. Warrants are often included in a new debt issue to entice investors by a higher return potential. The main difference between warrants and call options is that warrants are issued and guaranteed by the company, whereas options are exchange instruments and are not issued by the company. Also, the lifetime of a warrant is often measured in years, while the lifetime of a typical option is measured in months. Disclose the title of issue of securities called for by warrants and rights outstanding, the aggregate amount of securities called for by warrants and rights outstanding, the date from which the warrants or rights are exercisable, and the price at which the warrant or right is exercisable.", "label": "Schedule of Warrants Outstanding" } } }, "localname": "ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://phbi.com/role/SharePurchaseWarrantsTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_SecuredDebtCurrent": { "auth_ref": [ "r4", "r233", "r242" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Carrying value as of the balance sheet date of the portion of long-term, collateralized debt obligations due within one year or the operating cycle, if longer. Such obligations include mortgage loans, chattel loans, and any other borrowings secured by assets of the borrower.", "label": "Promissory Note with unrelated party", "verboseLabel": "Promissory Note with unrelated party" } } }, "localname": "SecuredDebtCurrent", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://phbi.com/role/CommitmentsDetailsNarrative", "http://phbi.com/role/NoteAndLoanPayableDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod": { "auth_ref": [ "r141" ], "lang": { "en-us": { "role": { "documentation": "The number of grants made during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).", "label": "Issued" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://phbi.com/role/SharePurchaseWarrantsDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber": { "auth_ref": [ "r140" ], "lang": { "en-us": { "role": { "documentation": "The number of non-vested equity-based payment instruments, excluding stock (or unit) options, that validly exist and are outstanding as of the balance sheet date.", "label": "[Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Number]", "periodEndLabel": "Ending Balance", "periodStartLabel": "Beginning Balance" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://phbi.com/role/SharePurchaseWarrantsDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_SharesIssued": { "auth_ref": [ "r129" ], "lang": { "en-us": { "role": { "documentation": "Number of shares of stock issued as of the balance sheet date, including shares that had been issued and were previously outstanding but which are now held in the treasury.", "label": "[Shares, Issued]", "periodEndLabel": "Balance, shares", "periodStartLabel": "Balance, shares" } } }, "localname": "SharesIssued", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://phbi.com/role/CondensedConsolidatedStatementsOfStockholdersDeficitUnaudited" ], "xbrltype": "sharesItemType" }, "us-gaap_SharesIssuedPricePerShare": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Per share or per unit amount of equity securities issued.", "label": "Common stock shares issued price per share", "verboseLabel": "Common stock price per share" } } }, "localname": "SharesIssuedPricePerShare", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://phbi.com/role/CommonStockDetailsNarrative", "http://phbi.com/role/SubsequentEventsDetailsNarrative" ], "xbrltype": "perShareItemType" }, "us-gaap_ShortTermDebtTypeAxis": { "auth_ref": [ "r17" ], "lang": { "en-us": { "role": { "documentation": "Information by type of short-term debt arrangement.", "label": "Short Term Debt Type Axis" } } }, "localname": "ShortTermDebtTypeAxis", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://phbi.com/role/CommonStockDetailsNarrative", "http://phbi.com/role/ConvertibleNotesDetailsNarrative", "http://phbi.com/role/NoteAndLoanPayableDetailsNarrative" ], "xbrltype": "stringItemType" }, "us-gaap_ShortTermDebtTypeDomain": { "auth_ref": [ "r15" ], "lang": { "en-us": { "role": { "documentation": "Type of short-term debt arrangement, such as notes, line of credit, commercial paper, asset-based financing, project financing, letter of credit financing." } } }, "localname": "ShortTermDebtTypeDomain", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://phbi.com/role/CommonStockDetailsNarrative", "http://phbi.com/role/ConvertibleNotesDetailsNarrative", "http://phbi.com/role/NoteAndLoanPayableDetailsNarrative" ], "xbrltype": "domainItemType" }, "us-gaap_SignificantAccountingPoliciesTextBlock": { "auth_ref": [ "r66" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for all significant accounting policies of the reporting entity.", "label": "2. Summary of Significant Accounting Policies" } } }, "localname": "SignificantAccountingPoliciesTextBlock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://phbi.com/role/SummaryOfSignificantAccountingPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_StatementEquityComponentsAxis": { "auth_ref": [ "r24", "r67", "r68", "r69", "r71", "r76", "r78", "r83", "r109", "r129", "r132", "r143", "r144", "r145", "r147", "r148", "r168", "r169", "r170", "r171", "r172", "r173", "r251", "r252", "r253" ], "lang": { "en-us": { "role": { "documentation": "Information by component of equity.", "label": "Statement Equity Components [Axis]" } } }, "localname": "StatementEquityComponentsAxis", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://phbi.com/role/CondensedConsolidatedStatementsOfStockholdersDeficitUnaudited" ], "xbrltype": "stringItemType" }, "us-gaap_StatementLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Statement [Line Items]" } } }, "localname": "StatementLineItems", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://phbi.com/role/CommitmentsDetailsNarrative", "http://phbi.com/role/CommonStockDetailsNarrative", "http://phbi.com/role/CondensedConsolidatedStatementsOfStockholdersDeficitUnaudited", "http://phbi.com/role/ConvertibleNotesDetailsNarrative", "http://phbi.com/role/DerivativeLiabilitiesDetails1", "http://phbi.com/role/NoteAndLoanPayableDetailsNarrative", "http://phbi.com/role/PreferredStockDetailsNarrative", "http://phbi.com/role/RelatedPartyTransactionsDetailsNarrative", "http://phbi.com/role/SharePurchaseWarrantsDetails", "http://phbi.com/role/SharePurchaseWarrantsDetails1" ], "xbrltype": "stringItemType" }, "us-gaap_StatementOfCashFlowsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Condensed Consolidated Statements of Cash Flows (Unaudited)" } } }, "localname": "StatementOfCashFlowsAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "xbrltype": "stringItemType" }, "us-gaap_StatementOfFinancialPositionAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Condensed Consolidated Balance Sheets" } } }, "localname": "StatementOfFinancialPositionAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "xbrltype": "stringItemType" }, "us-gaap_StatementOfStockholdersEquityAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Condensed Consolidated Statements of Stockholders' Deficit (Unaudited)" } } }, "localname": "StatementOfStockholdersEquityAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "xbrltype": "stringItemType" }, "us-gaap_StatementTable": { "auth_ref": [ "r67", "r68", "r69", "r83", "r219" ], "lang": { "en-us": { "role": { "documentation": "Schedule reflecting a Statement of Income, Statement of Cash Flows, Statement of Financial Position, Statement of Shareholders' Equity and Other Comprehensive Income, or other statement as needed.", "label": "Statement [Table]" } } }, "localname": "StatementTable", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://phbi.com/role/CommitmentsDetailsNarrative", "http://phbi.com/role/CommonStockDetailsNarrative", "http://phbi.com/role/CondensedConsolidatedStatementsOfStockholdersDeficitUnaudited", "http://phbi.com/role/ConvertibleNotesDetailsNarrative", "http://phbi.com/role/DerivativeLiabilitiesDetails1", "http://phbi.com/role/NoteAndLoanPayableDetailsNarrative", "http://phbi.com/role/PreferredStockDetailsNarrative", "http://phbi.com/role/RelatedPartyTransactionsDetailsNarrative", "http://phbi.com/role/SharePurchaseWarrantsDetails", "http://phbi.com/role/SharePurchaseWarrantsDetails1" ], "xbrltype": "stringItemType" }, "us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities": { "auth_ref": [ "r23", "r129", "r130", "r132" ], "lang": { "en-us": { "role": { "documentation": "Number of shares issued during the period as a result of the conversion of convertible securities.", "label": "Common stock, shares issued upon conversion of convertible shares" } } }, "localname": "StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://phbi.com/role/ConvertibleNotesDetailsNarrative" ], "xbrltype": "sharesItemType" }, "us-gaap_StockIssuedDuringPeriodSharesConversionOfUnits": { "auth_ref": [ "r6", "r7", "r129", "r130", "r132" ], "lang": { "en-us": { "role": { "documentation": "The number of shares issued during the period upon the conversion of units. An example of a convertible unit is an umbrella partnership real estate investment trust unit (UPREIT unit).", "label": "Common Stock Issued upon exercise of the option (in Shares)" } } }, "localname": "StockIssuedDuringPeriodSharesConversionOfUnits", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://phbi.com/role/CommitmentsDetailsNarrative" ], "xbrltype": "sharesItemType" }, "us-gaap_StockIssuedDuringPeriodSharesIssuedForServices": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Number of shares issued in lieu of cash for services contributed to the entity. Number of shares includes, but is not limited to, shares issued for services contributed by vendors and founders.", "label": "Common stock shares issued for services, shares" } } }, "localname": "StockIssuedDuringPeriodSharesIssuedForServices", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://phbi.com/role/CommonStockDetailsNarrative" ], "xbrltype": "sharesItemType" }, "us-gaap_StockIssuedDuringPeriodSharesNewIssues": { "auth_ref": [ "r6", "r7", "r129", "r132" ], "lang": { "en-us": { "role": { "documentation": "Number of new stock issued during the period.", "label": "Issuance of units for cash, shares", "verboseLabel": "Common stock shares issued" } } }, "localname": "StockIssuedDuringPeriodSharesNewIssues", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://phbi.com/role/CommonStockDetailsNarrative", "http://phbi.com/role/CondensedConsolidatedStatementsOfStockholdersDeficitUnaudited" ], "xbrltype": "sharesItemType" }, "us-gaap_StockIssuedDuringPeriodValueConversionOfUnits": { "auth_ref": [ "r24", "r129", "r132" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Value of stock issued during the period upon the conversion of units. An example of a convertible unit is an umbrella partnership real estate investment trust unit (UPREIT unit).", "label": "Common Stock Issued upon exercise of the option, value" } } }, "localname": "StockIssuedDuringPeriodValueConversionOfUnits", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://phbi.com/role/CommitmentsDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "us-gaap_StockIssuedDuringPeriodValueIssuedForServices": { "auth_ref": [], "calculation": { "http://phbi.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited": { "order": 7.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Value of stock issued in lieu of cash for services contributed to the entity. Value of the stock issued includes, but is not limited to, services contributed by vendors and founders.", "label": "Shares issued or issuable for services", "verboseLabel": "Common stock shares issued for services, amount" } } }, "localname": "StockIssuedDuringPeriodValueIssuedForServices", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://phbi.com/role/CommonStockDetailsNarrative", "http://phbi.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_StockIssuedDuringPeriodValueNewIssues": { "auth_ref": [ "r6", "r7", "r129", "r132" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Equity impact of the value of new stock issued during the period. Includes shares issued in an initial public offering or a secondary public offering.", "label": "Issuance of units for cash, amount" } } }, "localname": "StockIssuedDuringPeriodValueNewIssues", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://phbi.com/role/CondensedConsolidatedStatementsOfStockholdersDeficitUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_StockholdersEquity": { "auth_ref": [ "r7", "r11", "r12", "r64", "r105", "r108", "r166" ], "calculation": { "http://phbi.com/role/CondensedConsolidatedBalanceSheets": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.", "label": "[Stockholders' Equity Attributable to Parent]", "periodEndLabel": "Balance, amount", "periodStartLabel": "Balance, amount", "totalLabel": "Total stockholders' deficit" } } }, "localname": "StockholdersEquity", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://phbi.com/role/CondensedConsolidatedBalanceSheets", "http://phbi.com/role/CondensedConsolidatedStatementsOfStockholdersDeficitUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_StockholdersEquityAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Stockholders' deficit" } } }, "localname": "StockholdersEquityAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://phbi.com/role/CondensedConsolidatedBalanceSheets" ], "xbrltype": "stringItemType" }, "us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest": { "auth_ref": [ "r64", "r67", "r68", "r69", "r71", "r76", "r108", "r109", "r132", "r143", "r144", "r145", "r147", "r148", "r149", "r150", "r160", "r166", "r168", "r169", "r173", "r252", "r253" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of stockholders' equity (deficit), net of receivables from officers, directors, owners, and affiliates of the entity, attributable to both the parent and noncontrolling interests. Amount excludes temporary equity. Alternate caption for the concept is permanent equity.", "label": "Total Pharmagreen Biotech Inc. stockholders' deficit" } } }, "localname": "StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://phbi.com/role/CondensedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_StockholdersEquityNoteDisclosureTextBlock": { "auth_ref": [ "r63", "r132", "r134" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for shareholders' equity comprised of portions attributable to the parent entity and noncontrolling interest, including other comprehensive income. Includes, but is not limited to, balances of common stock, preferred stock, additional paid-in capital, other capital and retained earnings, accumulated balance for each classification of other comprehensive income and amount of comprehensive income.", "label": "8. Common Stock" } } }, "localname": "StockholdersEquityNoteDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://phbi.com/role/CommonStock" ], "xbrltype": "textBlockItemType" }, "us-gaap_SubsequentEventsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Subsequent Events" } } }, "localname": "SubsequentEventsAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "xbrltype": "stringItemType" }, "us-gaap_SubsequentEventsTextBlock": { "auth_ref": [ "r186", "r187" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for significant events or transactions that occurred after the balance sheet date through the date the financial statements were issued or the date the financial statements were available to be issued. Examples include: the sale of a capital stock issue, purchase of a business, settlement of litigation, catastrophic loss, significant foreign exchange rate changes, loans to insiders or affiliates, and transactions not in the ordinary course of business.", "label": "12. Subsequent Events" } } }, "localname": "SubsequentEventsTextBlock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://phbi.com/role/SubsequentEvents" ], "xbrltype": "textBlockItemType" }, "us-gaap_SubsidiarySaleOfStockAxis": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Information by type of sale of the entity's stock.", "label": "Sale of Stock [Axis]" } } }, "localname": "SubsidiarySaleOfStockAxis", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://phbi.com/role/CommonStockDetailsNarrative" ], "xbrltype": "stringItemType" }, "us-gaap_SupplementalCashFlowInformationAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Supplemental disclosures:" } } }, "localname": "SupplementalCashFlowInformationAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://phbi.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited" ], "xbrltype": "stringItemType" }, "us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain": { "auth_ref": [ "r106", "r107", "r188", "r189", "r190", "r191", "r192", "r193", "r194", "r195", "r196", "r197", "r198", "r199", "r200", "r202", "r203", "r204", "r205", "r206", "r207", "r208", "r209", "r210", "r211", "r212", "r213", "r214", "r215", "r216", "r217", "r218" ], "lang": { "en-us": { "role": { "documentation": "Instrument or contract that imposes a contractual obligation to deliver cash or another financial instrument or to exchange other financial instruments on potentially unfavorable terms and conveys a contractual right to receive cash or another financial instrument or to exchange other financial instruments on potentially favorable terms." } } }, "localname": "TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://phbi.com/role/DerivativeLiabilitiesDetails1" ], "xbrltype": "domainItemType" }, "us-gaap_UseOfEstimates": { "auth_ref": [ "r85", "r86", "r87", "r88", "r89", "r90", "r91" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles.", "label": "Use of Estimates and Judgments" } } }, "localname": "UseOfEstimates", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://phbi.com/role/SummaryOfSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_WeightedAverageNumberOfSharesOutstandingBasic": { "auth_ref": [ "r79", "r82" ], "lang": { "en-us": { "role": { "documentation": "Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.", "label": "Weighted average number of shares outstanding used in the calculation of net loss per share attributable to Pharmagreen Biotech Inc." } } }, "localname": "WeightedAverageNumberOfSharesOutstandingBasic", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://phbi.com/role/CondensedConsolidatedStatementsOfOperationsAndComprehensiveIncomeLossUnaudited" ], "xbrltype": "sharesItemType" } }, "unitCount": 4 } }, "std_ref": { "r0": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "205", "URI": "http://asc.fasb.org/extlink&oid=109222650&loc=SL51721683-107760" }, "r1": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "205", "URI": "http://asc.fasb.org/topic&trid=2122149" }, "r10": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(30)(a)(4))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r100": { "Name": "Accounting Standards Codification", "Paragraph": "32", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8933-108599" }, "r101": { "Name": "Accounting Standards Codification", "Paragraph": "32", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8933-108599" }, "r102": { "Name": "Accounting Standards Codification", "Paragraph": "41", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e9038-108599" }, "r103": { "Name": "Accounting Standards Codification", "Paragraph": "41", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e9038-108599" }, "r104": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "310", "URI": "http://asc.fasb.org/extlink&oid=121593590&loc=d3e4647-111522" }, "r105": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 4.E)", "Topic": "310", "URI": "http://asc.fasb.org/extlink&oid=27010918&loc=d3e74512-122707" }, "r106": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "320", "URI": "http://asc.fasb.org/extlink&oid=121645371&loc=d3e27232-111563" }, "r107": { "Name": "Accounting Standards Codification", "Paragraph": "5A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "320", "URI": "http://asc.fasb.org/extlink&oid=121645371&loc=SL120269820-111563" }, "r108": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "323", "URI": "http://asc.fasb.org/extlink&oid=114001798&loc=d3e33918-111571" }, "r109": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "326", "URI": "http://asc.fasb.org/extlink&oid=121646688&loc=SL121648383-210437" }, "r11": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(30))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r110": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "326", "URI": "http://asc.fasb.org/extlink&oid=121599337&loc=SL82919244-210447" }, "r111": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "326", "URI": "http://asc.fasb.org/extlink&oid=121599337&loc=SL82919249-210447" }, "r112": { "Name": "Accounting Standards Codification", "Paragraph": "14", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "326", "URI": "http://asc.fasb.org/extlink&oid=121599337&loc=SL82919253-210447" }, "r113": { "Name": "Accounting Standards Codification", "Paragraph": "16", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "326", "URI": "http://asc.fasb.org/extlink&oid=121599337&loc=SL82919258-210447" }, "r114": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "326", "URI": "http://asc.fasb.org/extlink&oid=121599337&loc=SL82919230-210447" }, "r115": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Topic": "326", "URI": "http://asc.fasb.org/extlink&oid=121582814&loc=SL82922888-210455" }, "r116": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Topic": "326", "URI": "http://asc.fasb.org/extlink&oid=121582814&loc=SL82922895-210455" }, "r117": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Topic": "326", "URI": "http://asc.fasb.org/extlink&oid=121582814&loc=SL82922900-210455" }, "r118": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "55", "SubTopic": "30", "Topic": "326", "URI": "http://asc.fasb.org/extlink&oid=121590138&loc=SL82922954-210456" }, "r119": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Topic": "410", "URI": "http://asc.fasb.org/extlink&oid=6392676&loc=d3e7480-110848" }, "r12": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(31))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r120": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "35", "SubTopic": "10", "Topic": "420", "URI": "http://asc.fasb.org/extlink&oid=6394232&loc=d3e17558-110866" }, "r121": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "440", "URI": "http://asc.fasb.org/extlink&oid=121559207&loc=d3e25336-109308" }, "r122": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "440", "URI": "http://asc.fasb.org/extlink&oid=121559207&loc=d3e25336-109308" }, "r123": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "440", "URI": "http://asc.fasb.org/topic&trid=2144648" }, "r124": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "450", "URI": "http://asc.fasb.org/topic&trid=2127136" }, "r125": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "460", "URI": "http://asc.fasb.org/extlink&oid=68068213&loc=d3e12565-110249" }, "r126": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=6802200&loc=SL6230698-112601" }, "r127": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "470", "URI": "http://asc.fasb.org/topic&trid=2208564" }, "r128": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=65888546&loc=d3e21300-112643" }, "r129": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=109259400&loc=d3e21463-112644" }, "r13": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(32))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r130": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=109259400&loc=d3e21475-112644" }, "r131": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=109259400&loc=d3e21538-112644" }, "r132": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.3-04)", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=120397183&loc=d3e187085-122770" }, "r133": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "50", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=6784392&loc=d3e188667-122775" }, "r134": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "505", "URI": "http://asc.fasb.org/topic&trid=2208762" }, "r135": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=121604090&loc=SL49130545-203045" }, "r136": { "Name": "Accounting Standards Codification", "Paragraph": "91", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=121551570&loc=SL49130690-203046-203046" }, "r137": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(n)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920" }, "r138": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5047-113901" }, "r139": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5047-113901" }, "r14": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.1)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r140": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(2)(i)-(ii)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r141": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(2)(iii)(1)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r142": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r143": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333" }, "r144": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(f)(1)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333" }, "r145": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(f)(2)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333" }, "r146": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(g)(2)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333" }, "r147": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(d)(2)", "Topic": "740" }, "r148": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(d)(3)", "Topic": "740" }, "r149": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "810", "URI": "http://asc.fasb.org/extlink&oid=108774443&loc=SL4568447-111683" }, "r15": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.19(a))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r150": { "Name": "Accounting Standards Codification", "Paragraph": "16", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "810", "URI": "http://asc.fasb.org/extlink&oid=108774443&loc=SL4568740-111683" }, "r151": { "Name": "Accounting Standards Codification", "Paragraph": "19", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "810", "URI": "http://asc.fasb.org/extlink&oid=108774443&loc=SL4569616-111683" }, "r152": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "810", "URI": "http://asc.fasb.org/extlink&oid=108774443&loc=SL4569643-111683" }, "r153": { "Name": "Accounting Standards Codification", "Paragraph": "25", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "810", "URI": "http://asc.fasb.org/extlink&oid=116870748&loc=SL6758485-165988" }, "r154": { "Name": "Accounting Standards Codification", "Paragraph": "25", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "810", "URI": "http://asc.fasb.org/extlink&oid=116870748&loc=SL6758485-165988" }, "r155": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)(2)", "Topic": "810", "URI": "http://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684" }, "r156": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(3)", "Topic": "810", "URI": "http://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684" }, "r157": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c),(3)", "Topic": "810", "URI": "http://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684" }, "r158": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(bb)", "Topic": "810", "URI": "http://asc.fasb.org/extlink&oid=121559654&loc=d3e5710-111685" }, "r159": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "810", "URI": "http://asc.fasb.org/extlink&oid=121559654&loc=d3e5710-111685" }, "r16": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.19(a),20,24)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r160": { "Name": "Accounting Standards Codification", "Paragraph": "4I", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Topic": "810", "URI": "http://asc.fasb.org/extlink&oid=120409616&loc=SL4590271-111686" }, "r161": { "Name": "Accounting Standards Codification", "Paragraph": "4J", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Topic": "810", "URI": "http://asc.fasb.org/extlink&oid=120409616&loc=SL4591551-111686" }, "r162": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "810", "URI": "http://asc.fasb.org/topic&trid=2197479" }, "r163": { "Name": "Accounting Standards Codification", "Paragraph": "4A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)(1)", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=121590274&loc=SL5618551-113959" }, "r164": { "Name": "Accounting Standards Codification", "Paragraph": "4B", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a),(c)", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=121590274&loc=SL5624163-113959" }, "r165": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "815", "URI": "http://asc.fasb.org/topic&trid=2229140" }, "r166": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)", "Topic": "825", "URI": "http://asc.fasb.org/extlink&oid=75031198&loc=d3e14064-108612" }, "r167": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "230", "Topic": "830", "URI": "http://asc.fasb.org/extlink&oid=98513438&loc=d3e33268-110906" }, "r168": { "Name": "Accounting Standards Codification", "Paragraph": "17", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Topic": "830", "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32136-110900" }, "r169": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Subparagraph": "(a)", "Topic": "830", "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900" }, "r17": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.19)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r170": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Subparagraph": "(b)", "Topic": "830", "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900" }, "r171": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Subparagraph": "(c)", "Topic": "830", "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900" }, "r172": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Subparagraph": "(d)", "Topic": "830", "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900" }, "r173": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Topic": "830", "URI": "http://asc.fasb.org/extlink&oid=6450520&loc=d3e32583-110901" }, "r174": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "835", "URI": "http://asc.fasb.org/extlink&oid=6450988&loc=d3e26243-108391" }, "r175": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Topic": "835", "URI": "http://asc.fasb.org/extlink&oid=119993939&loc=d3e28541-108399" }, "r176": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Topic": "835", "URI": "http://asc.fasb.org/extlink&oid=119993939&loc=d3e28551-108399" }, "r177": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Topic": "835", "URI": "http://asc.fasb.org/extlink&oid=119993939&loc=d3e28555-108399" }, "r178": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "55", "SubTopic": "30", "Topic": "835", "URI": "http://asc.fasb.org/extlink&oid=114775985&loc=d3e28878-108400" }, "r179": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "850", "URI": "http://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864" }, "r18": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.19,20)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r180": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "850", "URI": "http://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864" }, "r181": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "850", "URI": "http://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864" }, "r182": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "850", "URI": "http://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864" }, "r183": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "850", "URI": "http://asc.fasb.org/extlink&oid=6457730&loc=d3e39603-107864" }, "r184": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "850", "URI": "http://asc.fasb.org/extlink&oid=6457730&loc=d3e39691-107864" }, "r185": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "850", "URI": "http://asc.fasb.org/topic&trid=2122745" }, "r186": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "855", "URI": "http://asc.fasb.org/extlink&oid=6842918&loc=SL6314017-165662" }, "r187": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "855", "URI": "http://asc.fasb.org/topic&trid=2122774" }, "r188": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(2)(i)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719" }, "r189": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(2)(ii)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719" }, "r19": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.19-26)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r190": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(3)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719" }, "r191": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(bb)(1)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719" }, "r192": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(bb)(2)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719" }, "r193": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(bb)(3)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719" }, "r194": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)(1)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719" }, "r195": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)(2)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719" }, "r196": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)(3)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719" }, "r197": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(1)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719" }, "r198": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(2)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719" }, "r199": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(3)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719" }, "r2": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=121566466&loc=d3e6935-107765" }, "r20": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.20)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r200": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719" }, "r201": { "Name": "Accounting Standards Codification", "Paragraph": "4D", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)(2)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=SL51823488-111719" }, "r202": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=66007379&loc=d3e113888-111728" }, "r203": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(a)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=109249958&loc=SL34722452-111729" }, "r204": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "50", "Subparagraph": "(a)(1)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=116651436&loc=d3e122625-111746" }, "r205": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "50", "Subparagraph": "(a)(2)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=116651436&loc=d3e122625-111746" }, "r206": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "50", "Subparagraph": "(a)(3)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=116651436&loc=d3e122625-111746" }, "r207": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "50", "Subparagraph": "(a)(4)(i)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=116651436&loc=d3e122625-111746" }, "r208": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "50", "Subparagraph": "(a)(1)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=116651436&loc=d3e122739-111746" }, "r209": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "50", "Subparagraph": "(a)(2)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=116651436&loc=d3e122739-111746" }, "r21": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.21)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r210": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "50", "Subparagraph": "(a)(3)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=116651436&loc=d3e122739-111746" }, "r211": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "50", "Subparagraph": "(a)(4)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=116651436&loc=d3e122739-111746" }, "r212": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "50", "Subparagraph": "(a)(5)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=116651436&loc=d3e122739-111746" }, "r213": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "50", "Subparagraph": "(a)(6)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=116651436&loc=d3e122739-111746" }, "r214": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "50", "Subparagraph": "(a)(7)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=116651436&loc=d3e122739-111746" }, "r215": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "50", "Subparagraph": "(b)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=116651436&loc=d3e122739-111746" }, "r216": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "50", "Subparagraph": "(e)(1)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=116651436&loc=d3e122739-111746" }, "r217": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "50", "Subparagraph": "(e)(2)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=116651436&loc=d3e122739-111746" }, "r218": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "50", "Subparagraph": "(e)(3)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=116651436&loc=d3e122739-111746" }, "r219": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 11.L)", "Topic": "924", "URI": "http://asc.fasb.org/extlink&oid=6472922&loc=d3e499488-122856" }, "r22": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.22)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r220": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(a)", "Topic": "932", "URI": "http://asc.fasb.org/extlink&oid=68064819&loc=d3e61929-109447" }, "r221": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(b)", "Topic": "932", "URI": "http://asc.fasb.org/extlink&oid=68064819&loc=d3e61929-109447" }, "r222": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(a)", "Topic": "932", "URI": "http://asc.fasb.org/extlink&oid=68064819&loc=d3e62059-109447" }, "r223": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(b)", "Topic": "932", "URI": "http://asc.fasb.org/extlink&oid=68064819&loc=d3e62059-109447" }, "r224": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(a)", "Topic": "932", "URI": "http://asc.fasb.org/extlink&oid=68064819&loc=d3e62395-109447" }, "r225": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(b)", "Topic": "932", "URI": "http://asc.fasb.org/extlink&oid=68064819&loc=d3e62395-109447" }, "r226": { "Name": "Accounting Standards Codification", "Paragraph": "33", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(a)", "Topic": "932", "URI": "http://asc.fasb.org/extlink&oid=68064819&loc=d3e62479-109447" }, "r227": { "Name": "Accounting Standards Codification", "Paragraph": "33", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(b)", "Topic": "932", "URI": "http://asc.fasb.org/extlink&oid=68064819&loc=d3e62479-109447" }, "r228": { "Name": "Accounting Standards Codification", "Paragraph": "35A", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(a)", "Topic": "932", "URI": "http://asc.fasb.org/extlink&oid=68064819&loc=SL6807758-109447" }, "r229": { "Name": "Accounting Standards Codification", "Paragraph": "35A", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(b)", "Topic": "932", "URI": "http://asc.fasb.org/extlink&oid=68064819&loc=SL6807758-109447" }, "r23": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.29-30)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r230": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(c)(1)", "Topic": "932", "URI": "http://asc.fasb.org/extlink&oid=68064819&loc=d3e61872-109447" }, "r231": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(c)(2)", "Topic": "932", "URI": "http://asc.fasb.org/extlink&oid=68064819&loc=d3e61872-109447" }, "r232": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03(11))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878" }, "r233": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03(13))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878" }, "r234": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03(16))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878" }, "r235": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03(22))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878" }, "r236": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03(23))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878" }, "r237": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.9-04(22))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260" }, "r238": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.9-04.13(h))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260" }, "r239": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.9-04.9)", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260" }, "r24": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.29-31)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r240": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(16))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910" }, "r241": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(12))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910" }, "r242": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(16)(a)(1))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910" }, "r243": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(16)(a))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910" }, "r244": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(16))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910" }, "r245": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(23)(a)(3))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910" }, "r246": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(23)(a)(4))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910" }, "r247": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(24))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910" }, "r248": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(25))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910" }, "r249": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.7-04(18))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263" }, "r25": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.31)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r250": { "Name": "Accounting Standards Codification", "Paragraph": "13H", "Publisher": "FASB", "Section": "55", "SubTopic": "40", "Subparagraph": "(b)", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=121639165&loc=SL117783719-158441" }, "r251": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(e)", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=121370832&loc=SL117420844-207641" }, "r252": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(f)(1)", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=121370832&loc=SL117420844-207641" }, "r253": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(f)(2)", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=121370832&loc=SL117420844-207641" }, "r254": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(g)(2)(i)", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=121370832&loc=SL117420844-207641" }, "r255": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(g)(2)(ii)", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=121370832&loc=SL117420844-207641" }, "r256": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(h)(2)", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=121370832&loc=SL117420844-207641" }, "r257": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "45", "SubTopic": "210", "Topic": "946", "URI": "http://asc.fasb.org/extlink&oid=118262064&loc=SL116631418-115840" }, "r258": { "Name": "Accounting Standards Codification", "Paragraph": "21", "Publisher": "FASB", "Section": "45", "SubTopic": "210", "Topic": "946", "URI": "http://asc.fasb.org/extlink&oid=118262064&loc=SL116631419-115840" }, "r259": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.6-04(13))", "Topic": "946", "URI": "http://asc.fasb.org/extlink&oid=120401414&loc=d3e603758-122996" }, "r26": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=51824906&loc=SL20225862-175312" }, "r260": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "45", "SubTopic": "220", "Subparagraph": "(k)", "Topic": "946", "URI": "http://asc.fasb.org/extlink&oid=118262090&loc=SL114874205-224268" }, "r261": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.6-07.2(a),(b),(c),(d))", "Topic": "946", "URI": "http://asc.fasb.org/extlink&oid=120401555&loc=SL114874292-224272" }, "r262": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "310", "Subparagraph": "(SX 210.12-29(Footnote 4))", "Topic": "948", "URI": "http://asc.fasb.org/extlink&oid=120402547&loc=d3e617274-123014" }, "r263": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "360", "Subparagraph": "(SX 210.12-28(Column B))", "Topic": "970", "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024" }, "r264": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "360", "Subparagraph": "(SX 210.12-28(Column C))", "Topic": "970", "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024" }, "r265": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "360", "Subparagraph": "(SX 210.12-28(Column D))", "Topic": "970", "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024" }, "r266": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "360", "Subparagraph": "(SX 210.12-28(Column E))", "Topic": "970", "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024" }, "r267": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "360", "Subparagraph": "(SX 210.12-28(Column F))", "Topic": "970", "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024" }, "r268": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "360", "Subparagraph": "(SX 210.12-28(Column G))", "Topic": "970", "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024" }, "r269": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "360", "Subparagraph": "(SX 210.12-28(Column H))", "Topic": "970", "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024" }, "r27": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=51824906&loc=SL20225862-175312" }, "r270": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "360", "Subparagraph": "(SX 210.12-28(Column I))", "Topic": "970", "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024" }, "r271": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "360", "Subparagraph": "(SX 210.12-28(Footnote 2))", "Topic": "970", "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024" }, "r272": { "Name": "Form 10-Q", "Number": "240", "Publisher": "SEC", "Section": "308", "Subsection": "a" }, "r273": { "Name": "Forms 10-K, 10-Q, 20-F", "Number": "240", "Publisher": "SEC", "Section": "13", "Subsection": "a-1" }, "r274": { "Name": "Regulation 12B", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b-2" }, "r275": { "Name": "Regulation S-T", "Number": "232", "Publisher": "SEC", "Section": "405" }, "r276": { "Name": "Securities Act", "Number": "7A", "Publisher": "SEC", "Section": "B", "Subsection": "2" }, "r28": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=51824906&loc=SL20225862-175312" }, "r29": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=99393222&loc=SL20226000-175313" }, "r3": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=121566466&loc=d3e7018-107765" }, "r30": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=99393222&loc=SL20226003-175313" }, "r31": { "Name": "Accounting Standards Codification", "Paragraph": "10A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=121641772&loc=SL7669646-108580" }, "r32": { "Name": "Accounting Standards Codification", "Paragraph": "10A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=121641772&loc=SL7669646-108580" }, "r33": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=121641772&loc=d3e637-108580" }, "r34": { "Name": "Accounting Standards Codification", "Paragraph": "14", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=121641772&loc=d3e681-108580" }, "r35": { "Name": "Accounting Standards Codification", "Paragraph": "14A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=121641772&loc=SL7669686-108580" }, "r36": { "Name": "Accounting Standards Codification", "Paragraph": "17B", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=121641772&loc=SL34724394-108580" }, "r37": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=121641772&loc=SL7669619-108580" }, "r38": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=121641772&loc=SL7669625-108580" }, "r39": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(210.5-03(11))", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=120395209&loc=SL114868664-224227" }, "r4": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(19))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r40": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03(20))", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=120395209&loc=SL114868664-224227" }, "r41": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03(4))", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=120395209&loc=SL114868664-224227" }, "r42": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03.3)", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=120395209&loc=SL114868664-224227" }, "r43": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03.4)", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=120395209&loc=SL114868664-224227" }, "r44": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03.7)", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=120395209&loc=SL114868664-224227" }, "r45": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03.8)", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=120395209&loc=SL114868664-224227" }, "r46": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03.9)", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=120395209&loc=SL114868664-224227" }, "r47": { "Name": "Accounting Standards Codification", "Paragraph": "12", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3179-108585" }, "r48": { "Name": "Accounting Standards Codification", "Paragraph": "14", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3255-108585" }, "r49": { "Name": "Accounting Standards Codification", "Paragraph": "14", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3255-108585" }, "r5": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(22))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r50": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3291-108585" }, "r51": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3291-108585" }, "r52": { "Name": "Accounting Standards Codification", "Paragraph": "17", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3367-108585" }, "r53": { "Name": "Accounting Standards Codification", "Paragraph": "24", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3521-108585" }, "r54": { "Name": "Accounting Standards Codification", "Paragraph": "25", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3536-108585" }, "r55": { "Name": "Accounting Standards Codification", "Paragraph": "25", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3536-108585" }, "r56": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3602-108585" }, "r57": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3602-108585" }, "r58": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3602-108585" }, "r59": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=121583591&loc=d3e4297-108586" }, "r6": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(28))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r60": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=121583591&loc=d3e4304-108586" }, "r61": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=121583591&loc=d3e4313-108586" }, "r62": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=121583591&loc=d3e4332-108586" }, "r63": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(e)(1))", "Topic": "235", "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690" }, "r64": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(g)(1)(ii))", "Topic": "235", "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690" }, "r65": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08.(k)(1))", "Topic": "235", "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690" }, "r66": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "235", "URI": "http://asc.fasb.org/topic&trid=2122369" }, "r67": { "Name": "Accounting Standards Codification", "Paragraph": "23", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=115929471&loc=d3e21914-107793" }, "r68": { "Name": "Accounting Standards Codification", "Paragraph": "24", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=115929471&loc=d3e21930-107793" }, "r69": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=115929471&loc=d3e21711-107793" }, "r7": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(29))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r70": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)(2)", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=109234566&loc=d3e22499-107794" }, "r71": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)(3)", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=109234566&loc=d3e22499-107794" }, "r72": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=109234566&loc=d3e22694-107794" }, "r73": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=109234566&loc=d3e22694-107794" }, "r74": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=109234566&loc=d3e22583-107794" }, "r75": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=109234566&loc=d3e22595-107794" }, "r76": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=109234566&loc=d3e22644-107794" }, "r77": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=109234566&loc=d3e22658-107794" }, "r78": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=109234566&loc=d3e22663-107794" }, "r79": { "Name": "Accounting Standards Codification", "Paragraph": "10", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=121326447&loc=d3e1448-109256" }, "r8": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(30)(a)(1))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r80": { "Name": "Accounting Standards Codification", "Paragraph": "60B", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=121326447&loc=SL5780133-109256" }, "r81": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=121326447&loc=d3e1337-109256" }, "r82": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=6371337&loc=d3e3550-109257" }, "r83": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "272", "URI": "http://asc.fasb.org/extlink&oid=6828210&loc=d3e70191-108054" }, "r84": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "275", "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e5967-108592" }, "r85": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "275", "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e5967-108592" }, "r86": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "275", "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e5967-108592" }, "r87": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "275", "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6161-108592" }, "r88": { "Name": "Accounting Standards Codification", "Paragraph": "12", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "275", "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6191-108592" }, "r89": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "275", "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6061-108592" }, "r9": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(30)(a)(3))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r90": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "275", "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6132-108592" }, "r91": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "275", "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6143-108592" }, "r92": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "275", "URI": "http://asc.fasb.org/topic&trid=2134479" }, "r93": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8736-108599" }, "r94": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8736-108599" }, "r95": { "Name": "Accounting Standards Codification", "Paragraph": "30", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8906-108599" }, "r96": { "Name": "Accounting Standards Codification", "Paragraph": "30", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8906-108599" }, "r97": { "Name": "Accounting Standards Codification", "Paragraph": "30", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8906-108599" }, "r98": { "Name": "Accounting Standards Codification", "Paragraph": "31", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8924-108599" }, "r99": { "Name": "Accounting Standards Codification", "Paragraph": "32", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8933-108599" } }, "version": "2.1" } ZIP 52 0001477932-21-005724-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0001477932-21-005724-xbrl.zip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�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end